



Cochrane
Library

Cochrane Database of Systematic Reviews

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)

Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, Summerbell CD, Worthington HV, Song F, Hooper L

Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, Summerbell CD, Worthington HV, Song F, Hooper L.

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD003177.

DOI: [10.1002/14651858.CD003177.pub5](https://doi.org/10.1002/14651858.CD003177.pub5).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	17
OBJECTIVES	18
METHODS	18
RESULTS	24
Figure 1.	25
Figure 2.	29
Figure 3.	35
Figure 4.	36
Figure 5.	38
DISCUSSION	46
Figure 6.	51
AUTHORS' CONCLUSIONS	51
ACKNOWLEDGEMENTS	52
REFERENCES	54
CHARACTERISTICS OF STUDIES	84
DATA AND ANALYSES	248
Analysis 1.1. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 1 All-cause mortality (overall) - LCn3.	265
Analysis 1.2. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 2 All-cause mortality -LCn3 - sensitivity analysis (SA) fixed-effect.	266
Analysis 1.3. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 3 All-cause mortality - LCn3 - SA by summary risk of bias.	267
Analysis 1.4. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 4 All-cause mortality - LCn3 - SA by compliance and study size.	268
Analysis 1.5. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 5 All-cause mortality - LCn3 - subgroup by dose.	270
Analysis 1.6. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 6 All-cause mortality - LCn3 - subgroup by replacement.	272
Analysis 1.7. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 7 All-cause mortality - LCn3 - subgroup by intervention type.	274
Analysis 1.8. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 8 All-cause mortality - LCn3 - subgroup by duration.	275
Analysis 1.9. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention.	277
Analysis 1.10. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 10 All-cause mortality - LCn3 - subgroup by statin use.	278
Analysis 1.11. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 11 All-cause mortality - LCn3 - subgroup by baseline TG.	280
Analysis 1.12. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 12 All-cause mortality - LCn3 - subgroup by baseline DM.	281
Analysis 1.13. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 13 Cardiovascular mortality (overall) - LCn3.	283
Analysis 1.14. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 14 CVD mortality - LCn3 - SA fixed-effect.	283
Analysis 1.15. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 15 CVD mortality - LCn3 - SA by summary risk of bias.	284
Analysis 1.16. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 16 CVD mortality - LCn3 - SA by compliance and study size.	285
Analysis 1.17. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 17 CVD mortality - LCn3 - subgroup by dose.	286

Analysis 1.18. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 18 CVD mortality - LCn3 - subgroup by replacement.	288
Analysis 1.19. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 19 CVD mortality - LCn3 - subgroup by intervention type.	289
Analysis 1.20. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 20 CVD mortality - LCn3 - subgroup by duration.	291
Analysis 1.21. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 21 CVD mortality - LCn3 - subgroup by primary or secondary prevention.	292
Analysis 1.22. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 22 CVD mortality - LCn3 - subgroup by statin uses.	293
Analysis 1.23. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 23 CVD mortality - LCn3 - subgroup by baseline TG.	294
Analysis 1.24. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 24 CVD mortality - LCn3 - subgroup by baseline DM.	295
Analysis 1.25. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 25 Cardiovascular events (overall) - LCn3.	297
Analysis 1.26. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 26 CVD events - LCn3 - SA fixed effect.	298
Analysis 1.27. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 27 CVD events - LCn3 - SA by summary risk of bias.	299
Analysis 1.28. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 28 CVD events - LCn3 - SA by compliance and study size.	300
Analysis 1.29. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 29 CVD events - LCn3 - subgroup by dose.	302
Analysis 1.30. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 30 CVD events - LCn3 - subgroup by replacement.	303
Analysis 1.31. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 31 CVD events - LCn3 - subgroup by intervention type.	305
Analysis 1.32. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 32 CVD events - LCn3 - subgroup by duration.	307
Analysis 1.33. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 33 CVD events - LCn3 - subgroup by primary or secondary prevention.	308
Analysis 1.34. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 34 CVD events - LCn3 - subgroup by statin use.	310
Analysis 1.35. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 35 CVD events - LCn3 - subgroup by baseline TG.	311
Analysis 1.36. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 36 CVD events - LCn3 - subgroup by baseline diabetes.	312
Analysis 1.37. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 37 Coronary heart disease mortality (overall) - LCn3.	314
Analysis 1.38. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 38 CHD mortality - LCn3 - SA fixed effect.	315
Analysis 1.39. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 39 CHD mortality - LCn3 - SA by summary risk of bias.	315
Analysis 1.40. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 40 CHD mortality - LCn3 - SA by compliance and study size.	316
Analysis 1.41. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 41 CHD mortality - LCn3 - SA omitting cardiac death.	317
Analysis 1.42. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 42 CHD mortality - LCn3 - subgroup by dose.	318
Analysis 1.43. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 43 CHD mortality - LCn3 - subgroup by replacement.	320
Analysis 1.44. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 44 CHD mortality - LCn3 - subgroup by intervention type.	321
Analysis 1.45. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 45 CHD mortality - LCn3 - subgroup by duration.	322

Analysis 1.46. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 46 CHD mortality - LCn3 - subgroup by primary or secondary prevention.	323
Analysis 1.47. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 47 CHD mortality - LCn3 - subgroup by statin use.	324
Analysis 1.48. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 48 CHD mortality - LCn3 - subgroup by CAD history.	325
Analysis 1.49. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 49 CHD mortality - LCn3 - subgroup by baseline TG.	326
Analysis 1.50. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 50 CHD mortality - LCn3 - subgroup by baseline DM.	327
Analysis 1.51. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 51 Coronary heart disease events (overall) - LCn3.	328
Analysis 1.52. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 52 CHD events - LCn3 - SA fixed effect.	329
Analysis 1.53. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 53 CHD events - LCn3 - SA by summary risk of bias.	330
Analysis 1.54. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 54 CHD events - LCn3 - SA by compliance and study size.	331
Analysis 1.55. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 55 CHD events - LCn3 - subgroup by dose.	333
Analysis 1.56. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 56 CHD events - LCn3 - subgroup by replacement.	334
Analysis 1.57. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 57 CHD events - LCn3 - subgroup by intervention type.	336
Analysis 1.58. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 58 CHD events - LCn3 - subgroup by duration.	337
Analysis 1.59. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 59 CHD events - LCn3 - subgroup by primary or secondary prevention.	338
Analysis 1.60. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 60 CHD events - LCn3 - subgroup by statin use.	339
Analysis 1.61. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 61 CHD events - LCn3 subgroup by CAD history.	341
Analysis 1.62. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 62 CHD events - LCn3 - subgroup by baseline TG.	342
Analysis 1.63. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 63 CHD events - LCn3 - subgroup by baseline DM.	343
Analysis 1.64. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 64 Stroke (overall) - LCn3.	344
Analysis 1.65. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 65 Stroke - LCn3 - SA fixed effect. ...	345
Analysis 1.66. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 66 Stroke - LCn3 - SA by summary risk of bias.	346
Analysis 1.67. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 67 Stroke - LCn3 - SA by compliance and study size.	347
Analysis 1.68. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 68 Stroke - LCn3 - subgroup by stroke type.	348
Analysis 1.69. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 69 Stroke - LCn3 - subgroup by dose.	349
Analysis 1.70. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 70 Stroke - LCn3 - subgroup by replacement.	351
Analysis 1.71. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 71 Stroke - LCn3 - subgroup by intervention type.	353
Analysis 1.72. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 72 Stroke - LCn3 - subgroup by duration.	354
Analysis 1.73. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 73 Stroke - LCn3 - subgroup by primary or secondary prevention.	355
Analysis 1.74. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 74 Stroke - LCn3 - subgroup by statin use.	356

Analysis 1.75. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 75 Stroke - LCn3 - subgroup by baseline TG.	358
Analysis 1.76. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 76 Stroke - LCn3 - subgroup by baseline DM.	359
Analysis 1.77. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 77 Arrhythmia (overall) - LCn3.	360
Analysis 1.78. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 78 Arrhythmia - LCn3 - SA fixed effects.	361
Analysis 1.79. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 79 Arrhythmia- LCn3 - SA by summary risk of bias.	362
Analysis 1.80. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 80 Arrhythmia- LCn3 - SA by compliance and study size.	363
Analysis 1.81. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 81 Arrhythmia - LCn3 - subgroup by new or recurrent.	364
Analysis 1.82. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 82 Arrhythmia - LCn3 - subgroup by fatality.	365
Analysis 1.83. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 83 Arrhythmia - LCn3 - subgroup by dose.	365
Analysis 1.84. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 84 Arrhythmia - LCn3 - subgroup by replacement.	367
Analysis 1.85. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 85 Arrhythmia - LCn3 - subgroup by intervention type.	369
Analysis 1.86. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 86 Arrhythmia - LCn3 - subgroup by duration.	370
Analysis 1.87. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 87 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3.	371
Analysis 1.88. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 88 Arrhythmia - LCn3 - subgroup by statin use.	372
Analysis 1.89. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 89 Arrhythmia - LCn3 - subgroup by baseline TG.	374
Analysis 1.90. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 90 Arrhythmia - LCn3 - subgroup by baseline DM.	375
Analysis 2.1. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 1 MACCEs - LCn3.	391
Analysis 2.2. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 2 Myocardial infarction (overall) - LCn3.	391
Analysis 2.3. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 3 Total MI - LCn3 - SA fixed effects. .	392
Analysis 2.4. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 4 Total MI - LCn3 - SA by summary risk of bias.	393
Analysis 2.5. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 5 Total MI - LCn3 - SA by compliance and study size.	394
Analysis 2.6. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 6 Total MI - LCn3 - subgroup by fatality.	395
Analysis 2.7. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 7 Sudden cardiac death (overall) - LCn3.	396
Analysis 2.8. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 8 Angina - LCn3.	397
Analysis 2.9. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 9 Heart failure - LCn3.	398
Analysis 2.10. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 10 Revascularisation - LCn3.	398
Analysis 2.11. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 11 Peripheral arterial disease - LCn3.	399
Analysis 2.12. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 12 PAD - LCn3 - SA fixed effects. ..	400
Analysis 2.13. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 13 PAD - LCn3 - SA by summary risk of bias.	400
Analysis 2.14. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 14 PAD - LCn3 - SA compliance and study size.	401
Analysis 2.15. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 15 Acute coronary syndrome - LCn3.	401
Analysis 2.16. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 16 Body weight, kg - LCn3.	402

Analysis 2.17. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 17 Weight, kg - LCn3 - SA fixed effects.	402
Analysis 2.18. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 18 Weight, kg - LCn3 - SA by summary risk of bias.	403
Analysis 2.19. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 19 Weight, kg - LCn3 - SA by compliance and study size.	403
Analysis 2.20. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 20 Weight, kg - LCn3 - subgroup by dose.	404
Analysis 2.21. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 21 Weight, kg - LCn3 - subgroup by replacement.	405
Analysis 2.22. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 22 Weight, kg - LCn3 - subgroup by intervention type.	406
Analysis 2.23. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 23 Weight, kg - LCn3 - subgroup by duration.	407
Analysis 2.24. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 24 Weight, kg - LCn3 - subgroup by primary or secondary prevention.	408
Analysis 2.25. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 25 Weight, kg - LCn3 - subgroup by statin use.	409
Analysis 2.26. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 26 Body mass index, kg/m ² - LCn3.	409
Analysis 2.27. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 27 BMI, kg/m ² - LCn3 - SA fixed effects.	410
Analysis 2.28. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 28 BMI, kg/m ² - LCn3 - SA by summary risk of bias.	410
Analysis 2.29. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 29 BMI, kg/m ² - LCn3 - SA by compliance and study size.	411
Analysis 2.30. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 30 BMI, kg/m ² - LCn3 - subgroup by dose.	412
Analysis 2.31. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 31 BMI, kg/m ² - LCn3 - subgroup by replacement.	413
Analysis 2.32. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 32 BMI, kg/m ² - LCn3 - subgroup by intervention type.	414
Analysis 2.33. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 33 BMI, kg/m ² - LCn3 - subgroup by duration.	415
Analysis 2.34. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 34 BMI, kg/m ² - LCn3 - subgroup by primary or secondary prevention.	416
Analysis 2.35. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 35 BMI, kg/m ² - LCn3 - subgroup by statin use.	416
Analysis 2.36. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 36 Other measures of adiposity - LCn3.	417
Analysis 2.37. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 37 Total cholesterol, serum, mmol/L - LCn3.	418
Analysis 2.38. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 38 TC, mmol/L - LCn3 - SA fixed effects.	419
Analysis 2.39. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 39 TC, mmol/L - LCn3 - SA by summary risk of bias.	420
Analysis 2.40. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 40 TC, mmol/L - LCn3 - SA by compliance and study size.	421
Analysis 2.41. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 41 TC, mmol/L - LCn3 - subgroup by dose.	422
Analysis 2.42. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 42 TC, mmol/L - LCn3 - subgroup by replacement.	423
Analysis 2.43. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 43 TC, mmol/L - LCn3 - subgroup by intervention type.	424
Analysis 2.44. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 44 TC, mmol/L - LCn3 - subgroup by duration.	425

Analysis 2.45. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 45 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention.	427
Analysis 2.46. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 46 TC, mmol/L - LCn3 - subgroup by statin use.	428
Analysis 2.47. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 47 Triglycerides, fasting, serum, mmol/L - LCn3.	429
Analysis 2.48. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 48 TG, fasting, mmol/L - LCn3 - SA fixed effects.	429
Analysis 2.49. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 49 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias.	430
Analysis 2.50. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 50 TG, fasting, mmol/L - LCn3 - SA by compliance and study size.	431
Analysis 2.51. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 51 TG, fasting, mmol/L - LCn3 - subgroup by dose.	432
Analysis 2.52. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 52 TG, fasting, mmol/L - LCn3 - subgroup by replacement.	433
Analysis 2.53. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 53 TG, fasting, mmol/L - LCn3 - subgroup by intervention type.	435
Analysis 2.54. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 54 TG, fasting, mmol/L - LCn3 - subgroup by duration.	436
Analysis 2.55. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 55 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention.	437
Analysis 2.56. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 56 TG, fasting, mmol/L - LCn3 - subgroup by statin use.	438
Analysis 2.57. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 57 High-density lipoprotein, serum, mmol/L - LCn3.	439
Analysis 2.58. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 58 HDL, mmol/L - LCn3 - SA fixed effects.	440
Analysis 2.59. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 59 HDL, mmol/L - LCn3 - SA by summary risk of bias.	441
Analysis 2.60. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 60 HDL, mmol/L - LCn3 - SA by compliance and study size.	442
Analysis 2.61. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 61 HDL, mmol/L - LCn3 - subgroup by dose.	443
Analysis 2.62. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 62 HDL, mmol/L - LCn3 - subgroup by replacement.	444
Analysis 2.63. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 63 HDL, mmol/L - LCn3 - subgroup by intervention type.	445
Analysis 2.64. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 64 HDL, mmol/L - LCn3 - subgroup by duration.	446
Analysis 2.65. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 65 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention.	448
Analysis 2.66. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 66 HDL, mmol/L - LCn3 - subgroup by statin use.	449
Analysis 2.67. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 67 Low-density lipoprotein, serum, mmol/L - LCn3.	450
Analysis 2.68. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 68 LDL, mmol/L - LCn3 - SA fixed effects.	450
Analysis 2.69. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 69 LDL, mmol/L - LCn3 - SA by summary risk of bias.	451
Analysis 2.70. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 70 LDL, mmol/L - LCn3 - SA by compliance and study size.	452
Analysis 2.71. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 71 LDL, mmol/L - LCn3 - subgroup by dose.	453
Analysis 2.72. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 72 LDL, mmol/L - LCn3 - subgroup by replacement.	454

Analysis 2.73. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 73 LDL, mmol/L - LCn3 - subgroup by intervention type.	455
Analysis 2.74. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 74 LDL, mmol/L - LCn3 - subgroup by duration.	457
Analysis 2.75. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 75 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention.	458
Analysis 2.76. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 76 LDL, mmol/L - LCn3 - subgroup by statin use.	459
Analysis 3.1. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - LCn3.	461
Analysis 3.2. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - LCn3.	462
Analysis 3.3. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 3 Side effects - LCn3.	463
Analysis 3.4. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - LCn3.	467
Analysis 4.1. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 1 All-cause mortality (overall) - ALA. ...	478
Analysis 4.2. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect.	479
Analysis 4.3. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 3 All-cause mortality - ALA - SA by summary risk of bias.	479
Analysis 4.4. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 4 All-cause mortality - ALA - SA by compliance and study size.	480
Analysis 4.5. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 5 All-cause mortality - ALA - subgroup by dose.	480
Analysis 4.6. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 6 All-cause mortality - ALA - subgroup by replacement.	481
Analysis 4.7. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 7 All cause mortality - ALA - subgroup by intervention type.	482
Analysis 4.8. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 8 All-cause mortality - ALA - subgroup by duration.	483
Analysis 4.9. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 9 All-cause mortality - ALA - subgroup by primary or secondary prevention.	483
Analysis 4.10. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 10 All-cause mortality - ALA - subgroup by statin use.	484
Analysis 4.11. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 11 Cardiovascular mortality (overall) - ALA.	485
Analysis 4.12. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 12 CVD mortality - ALA - SA fixed-effect.	485
Analysis 4.13. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 13 CVD mortality - ALA - SA by summary risk of bias.	485
Analysis 4.14. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 14 CVD mortality - ALA - SA by compliance and study size.	486
Analysis 4.15. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 15 CVD mortality - ALA - subgroup by dose.	486
Analysis 4.16. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 16 CVD mortality - ALA - subgroup by replacement.	487
Analysis 4.17. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 17 CVD mortality - ALA - subgroup by intervention type.	488
Analysis 4.18. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 18 CVD mortality - ALA - subgroup by duration.	489
Analysis 4.19. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 19 CVD mortality - ALA - subgroup by primary or secondary prevention.	489
Analysis 4.20. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 20 CVD mortality - ALA - subgroup by statin uses.	490
Analysis 4.21. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 21 Cardiovascular events (overall) - ALA.	490
Analysis 4.22. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 22 CVD events - ALA - SA fixed-effect. ..	491
Analysis 4.23. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 23 CVD events - ALA - SA by summary risk of bias.	491

Analysis 4.24. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 24 CVD events - ALA - SA by compliance and study size.	492
Analysis 4.25. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 25 CVD events - ALA - subgroup by dose.	492
Analysis 4.26. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 26 CVD events - ALA - subgroup by replacement.	493
Analysis 4.27. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 27 CVD events - ALA - subgroup by intervention type.	494
Analysis 4.28. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 28 CVD events - ALA - subgroup by duration.	495
Analysis 4.29. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 29 CVD events - ALA - subgroup by primary or secondary prevention.	495
Analysis 4.30. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 30 CVD events - ALA - subgroup by statin use.	496
Analysis 4.31. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) - ALA.	497
Analysis 4.32. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 32 CHD mortality - ALA - SA fixed-effect.	497
Analysis 4.33. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 33 CHD mortality - ALA - SA by summary risk of bias.	497
Analysis 4.34. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 34 CHD mortality - ALA - SA by compliance and study size.	498
Analysis 4.35. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 35 CHD mortality - ALA - subgroup by dose.	498
Analysis 4.36. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 36 CHD mortality - ALA - subgroup by replacement.	499
Analysis 4.37. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 37 CHD mortality - ALA - subgroup by intervention type.	500
Analysis 4.38. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 38 CHD mortality - ALA - subgroup by duration.	501
Analysis 4.39. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 39 CHD mortality - ALA - subgroup by primary or secondary prevention.	501
Analysis 4.40. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 40 CHD mortality - ALA - subgroup by statin use.	502
Analysis 4.41. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 41 CHD mortality - ALA - subgroup by CAD history.	503
Analysis 4.42. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 42 Coronary heart disease events (overall) - ALA.	503
Analysis 4.43. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 43 CHD events - ALA - SA fixed-effect. .	504
Analysis 4.44. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 44 CHD events - ALA - SA by summary risk of bias.	504
Analysis 4.45. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 45 CHD events - ALA - SA by compliance and study size.	504
Analysis 4.46. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 46 CHD events - ALA - subgroup by dose.	505
Analysis 4.47. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 47 CHD events - ALA - subgroup by replacement.	506
Analysis 4.48. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 48 CHD events - ALA - subgroup by intervention type.	507
Analysis 4.49. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 49 CHD events - ALA - subgroup by duration.	507
Analysis 4.50. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 50 CHD events - ALA - subgroup by primary or secondary prevention.	508
Analysis 4.51. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 51 CHD events - ALA - subgroup by statin use.	509

Analysis 4.52. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 52 CHD events - ALA - subgroup by CAD history.	509
Analysis 4.53. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 53 Stroke (overall) - ALA.	510
Analysis 4.54. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 54 Stroke - ALA - SA fixed-effect.	510
Analysis 4.55. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 55 Stroke - ALA - SA by summary risk of bias.	511
Analysis 4.56. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 56 Stroke - ALA - SA by compliance and study size.	511
Analysis 4.57. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 57 Stroke - ALA - subgroup by dose. ..	512
Analysis 4.58. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 58 Stroke - ALA - subgroup by replacement.	512
Analysis 4.59. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 59 Stroke - ALA - subgroup by intervention type.	513
Analysis 4.60. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 60 Stroke - ALA - subgroup by duration.	514
Analysis 4.61. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 61 Stroke - ALA - subgroup by primary or secondary prevention.	515
Analysis 4.62. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 62 Stroke - ALA - subgroup by statin use.	515
Analysis 4.63. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 63 Stroke - ALA - subgroup by stroke type.	516
Analysis 4.64. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 64 Arrhythmia (overall) - ALA.	516
Analysis 4.65. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 65 Arrhythmia - ALA - SA fixed-effect. ..	517
Analysis 4.66. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 66 Arrhythmia - ALA - SA by summary risk of bias.	517
Analysis 4.67. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 67 Arrhythmia - ALA - SA by compliance and study size.	518
Analysis 5.1. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 1 MACCEs - ALA.	531
Analysis 5.2. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 2 Myocardial infarction (overall) - ALA.	531
Analysis 5.3. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 3 Total MI - ALA - subgroup by fatality.	531
Analysis 5.4. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 4 Angina - ALA.	532
Analysis 5.5. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 5 Revascularisation - ALA.	532
Analysis 5.6. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 6 Peripheral arterial disease - ALA. ..	533
Analysis 5.7. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 7 Body weight, kg - ALA.	533
Analysis 5.8. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect.	533
Analysis 5.9. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 9 Weight, kg - ALA - SA by summary risk of bias.	533
Analysis 5.10. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 10 Weight, kg - ALA - SA by compliance and study size.	534
Analysis 5.11. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 11 Weight, kg - ALA - subgroup by dose.	534
Analysis 5.12. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 12 Weight, kg - ALA - subgroup by intervention type.	535
Analysis 5.13. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 13 Weight, kg - ALA - subgroup by replacement.	536
Analysis 5.14. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 14 Weight, kg - ALA - subgroup by duration.	536
Analysis 5.15. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 15 Weight, kg - ALA - subgroup by statin use.	537
Analysis 5.16. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 16 Weight, kg - ALA - subgroup by primary or secondary prevention.	538
Analysis 5.17. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 17 Body mass index, kg/m ² - ALA. ..	538
Analysis 5.18. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 18 BMI, kg/m ² - ALA - SA fixed-effect.	538

Analysis 5.19. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 19 BMI, kg/m ² - ALA - SA by summary risk of bias.	539
Analysis 5.20. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 20 BMI, kg/m ² - ALA - SA by compliance and study size.	539
Analysis 5.21. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 21 BMI, kg/m ² - ALA - subgroup by dose.	540
Analysis 5.22. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 22 BMI, kg/m ² - ALA - subgroup by intervention type.	540
Analysis 5.23. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 23 BMI, kg/m ² - ALA - subgroup by replacement.	541
Analysis 5.24. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 24 BMI, kg/m ² - ALA - subgroup by duration.	542
Analysis 5.25. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 25 BMI, kg/m ² - ALA - subgroup by statin use.	542
Analysis 5.26. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 26 BMI, kg/m ² - ALA - subgroup by primary or secondary preventionA.	543
Analysis 5.27. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 27 Other measures of adiposity - ALA.	543
Analysis 5.28. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 28 Total cholesterol, serum, mmol/L - ALA.	544
Analysis 5.29. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 29 TC, mmol/L - ALA - SA fixed-effect.	544
Analysis 5.30. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 30 TC, mmol/L - ALA - SA by summary risk of bias.	544
Analysis 5.31. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 31 TC, mmol/L - ALA - SA by compliance and study size.	545
Analysis 5.32. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 32 TC, mmol/L - ALA - subgroup by dose.	545
Analysis 5.33. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 33 TC, mmol/L - ALA - subgroup by intervention type.	546
Analysis 5.34. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 34 TC, mmol/L - ALA - subgroup by replacement.	547
Analysis 5.35. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 35 TC, mmol/L - ALA - subgroup by duration.	547
Analysis 5.36. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 36 TC, mmol/L - ALA - subgroup by statin use.	548
Analysis 5.37. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 37 TC, mmol/L - ALA - subgroup by primary or secondary prevention.	549
Analysis 5.38. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 38 Triglycerides, fasting, serum, mmol/L - ALA.	549
Analysis 5.39. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 39 TG, fasting, mmol/L - ALA - SA fixed-effect.	549
Analysis 5.40. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 40 TG, fasting, mmol/L - ALA - SA by summary risk of bias.	550
Analysis 5.41. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 41 TG, fasting, mmol/L - ALA - SA by compliance and study size.	550
Analysis 5.42. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 42 TG, fasting, mmol/L - ALA - subgroup by dose.	551
Analysis 5.43. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 43 TG, fasting, mmol/L - ALA - subgroup by intervention type.	551
Analysis 5.44. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 44 TG, fasting, mmol/L - ALA - subgroup by replacement.	552
Analysis 5.45. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 45 TG, fasting, mmol/L - ALA - subgroup by duration.	553
Analysis 5.46. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 46 TG, fasting, mmol/L - ALA - subgroup by statin use.	553

Analysis 5.47. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 47 TG, fasting, mmol/L - ALA - subgroup by primary or secondary prevention.	554
Analysis 5.48. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 48 High-density lipoprotein, serum, mmol/L - ALA.	555
Analysis 5.49. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 49 HDL, mmol/L - ALA - SA fixed-effect.	555
Analysis 5.50. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 50 HDL, mmol/L - ALA - SA by summary risk of bias.	555
Analysis 5.51. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 51 HDL, mmol/L - ALA - SA by compliance and study size.	556
Analysis 5.52. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 52 HDL, mmol/L - ALA - subgroup by dose.	556
Analysis 5.53. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 53 HDL, mmol/L - ALA - subgroup by intervention type.	557
Analysis 5.54. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 54 HDL, mmol/L - ALA - subgroup by replacement.	558
Analysis 5.55. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 55 HDL, mmol/L - ALA - subgroup by duration.	558
Analysis 5.56. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 56 HDL, mmol/L - ALA - subgroup by statin use.	559
Analysis 5.57. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention.	560
Analysis 5.58. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 58 Low-density lipoprotein, serum, mmol/L - ALA.	560
Analysis 5.59. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 59 LDL, mmol/L - ALA - SA fixed-effect.	561
Analysis 5.60. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 60 LDL, mmol/L - ALA - SA by summary risk of bias.	561
Analysis 5.61. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 61 LDL, mmol/L - ALA - SA by compliance and study size.	561
Analysis 5.62. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 62 LDL, mmol/L - ALA - subgroup by dose.	562
Analysis 5.63. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 63 LDL, mmol/L - ALA - subgroup by intervention type.	563
Analysis 5.64. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 64 LDL, mmol/L - ALA - subgroup by replacement.	563
Analysis 5.65. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 65 LDL, mmol/L - ALA - subgroup by duration.	564
Analysis 5.66. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 66 LDL, mmol/L - ALA - subgroup by statin use.	565
Analysis 5.67. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention.	565
Analysis 6.1. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - ALA.	567
Analysis 6.2. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - ALA.	567
Analysis 6.3. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 3 Side effects - ALA.	568
Analysis 6.4. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - ALA.	569
ADDITIONAL TABLES	569
APPENDICES	578
FEEDBACK	589
WHAT'S NEW	591
HISTORY	591
CONTRIBUTIONS OF AUTHORS	592
DECLARATIONS OF INTEREST	592
SOURCES OF SUPPORT	593
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	593

INDEX TERMS	593
-------------------	-----

[Intervention Review]

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Asmaa S Abdelhamid¹, Tracey J Brown¹, Julii S Brainard¹, Priti Biswas², Gabrielle C Thorpe³, Helen J Moore⁴, Katherine HO Deane³, Carolyn D Summerbell⁵, Helen V Worthington⁶, Fujian Song¹, Lee Hooper¹

¹Norwich Medical School, University of East Anglia, Norwich, UK. ²MED/HSC, University of East Anglia, Norwich, UK. ³School of Health Sciences, University of East Anglia, Norwich, UK. ⁴School of Social Sciences, Humanities and Law, Teesside University, Middlesbrough, UK. ⁵Department of Sport and Exercise Sciences, Durham University, Durham, UK. ⁶Cochrane Oral Health, Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Contact address: Lee Hooper, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR4 7TJ, UK. l.hooper@uea.ac.uk.

Editorial group: Cochrane Heart Group

Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 3, 2020.

Citation: Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2020, Issue 3. Art. No.: CD003177. DOI: [10.1002/14651858.CD003177.pub5](https://doi.org/10.1002/14651858.CD003177.pub5).

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3)), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) may benefit cardiovascular health. Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this.

Objectives

To assess the effects of increased intake of fish- and plant-based omega-3 fats for all-cause mortality, cardiovascular events, adiposity and lipids.

Search methods

We searched CENTRAL, MEDLINE and Embase to February 2019, plus ClinicalTrials.gov and World Health Organization International Clinical Trials Registry to August 2019, with no language restrictions. We handsearched systematic review references and bibliographies and contacted trial authors.

Selection criteria

We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation or advice to increase LCn3 or ALA intake, or both, versus usual or lower intake.

Data collection and analysis

Two review authors independently assessed trials for inclusion, extracted data and assessed validity. We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression.

Main results

We included 86 RCTs (162,796 participants) in this review update and found that 28 were at low summary risk of bias. Trials were of 12 to 88 months' duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most trials assessed LCn3

supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet. LCn3 doses ranged from 0.5 g a day to more than 5 g a day (19 RCTs gave at least 3 g LCn3 daily).

Meta-analysis and sensitivity analyses suggested **little or no effect of increasing LCn3 on all-cause mortality** (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.93 to 1.01; 143,693 participants; 11,297 deaths in 45 RCTs; high-certainty evidence), **cardiovascular mortality** (RR 0.92, 95% CI 0.86 to 0.99; 117,837 participants; 5658 deaths in 29 RCTs; moderate-certainty evidence), **cardiovascular events** (RR 0.96, 95% CI 0.92 to 1.01; 140,482 participants; 17,619 people experienced events in 43 RCTs; high-certainty evidence), **stroke** (RR 1.02, 95% CI 0.94 to 1.12; 138,888 participants; 2850 strokes in 31 RCTs; moderate-certainty evidence) or **arrhythmia** (RR 0.99, 95% CI 0.92 to 1.06; 77,990 participants; 4586 people experienced arrhythmia in 30 RCTs; low-certainty evidence). Increasing LCn3 may **slightly reduce coronary heart disease mortality (number needed to treat for an additional beneficial outcome (NNTB) 334**, RR 0.90, 95% CI 0.81 to 1.00; 127,378 participants; 3598 coronary heart disease deaths in 24 RCTs, low-certainty evidence) and **coronary heart disease events (NNTB 167**, RR 0.91, 95% CI 0.85 to 0.97; 134,116 participants; 8791 people experienced coronary heart disease events in 32 RCTs, low-certainty evidence). Overall, effects did not differ by trial duration or LCn3 dose in pre-planned subgrouping or meta-regression. There is little evidence of effects of eating fish.

Increasing ALA intake probably makes **little or no difference to all-cause mortality** (RR 1.01, 95% CI 0.84 to 1.20; 19,327 participants; 459 deaths in 5 RCTs, moderate-certainty evidence), **cardiovascular mortality** (RR 0.96, 95% CI 0.74 to 1.25; 18,619 participants; 219 cardiovascular deaths in 4 RCTs; moderate-certainty evidence), **coronary heart disease mortality** (RR 0.95, 95% CI 0.72 to 1.26; 18,353 participants; 193 coronary heart disease deaths in 3 RCTs; moderate-certainty evidence) and **coronary heart disease events** (RR 1.00, 95% CI 0.82 to 1.22; 19,061 participants; 397 coronary heart disease events in 4 RCTs; low-certainty evidence). However, increased ALA may slightly **reduce risk of cardiovascular disease events (NNTB 500**, RR 0.95, 95% CI 0.83 to 1.07; but RR 0.91, 95% CI 0.79 to 1.04 in RCTs at low summary risk of bias; 19,327 participants; 884 cardiovascular disease events in 5 RCTs; low-certainty evidence), and probably slightly reduces risk of **arrhythmia (NNTB 91**, RR 0.73, 95% CI 0.55 to 0.97; 4912 participants; 173 events in 2 RCTs; moderate-certainty evidence). Effects on **stroke are unclear**.

Increasing LCn3 and ALA had little or no effect on serious adverse events, adiposity, lipids and blood pressure, except increasing LCn3 reduced triglycerides by ~15% in a dose-dependent way (high-certainty evidence).

Authors' conclusions

This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and low-certainty evidence suggests that increasing LCn3 slightly reduces risk of coronary heart disease mortality and events, and reduces serum triglycerides (evidence mainly from supplement trials). Increasing ALA slightly reduces risk of cardiovascular events and arrhythmia.

PLAIN LANGUAGE SUMMARY

Omega-3 intake for cardiovascular disease

Review question

We reviewed randomised trials (where participants have an equal chance of being assigned to either treatment) examining effects of increasing fish- and plant-based omega-3 fats on heart and circulatory disease (called cardiovascular diseases, which include heart attacks and stroke), fatness and blood fats (lipids, including cholesterol, triglycerides, high-density lipoprotein (HDL – 'good' cholesterol) and low-density lipoprotein (LDL – 'bad' cholesterol)).

Background

The main types of omega-3 fats are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both found in fish, and alpha-linolenic acid (ALA) found in plant foods. Many people believe that taking omega-3 supplements reduces risk of heart disease, stroke and death.

Trial characteristics

The evidence is current to February 2019. The review included 86 trials involving 162,796 people. These trials assessed effects of greater omega-3 intake versus lower omega-3 intake for at least a year on heart and circulatory disease. Twenty-eight trials were very trustworthy (well-designed so as not to give biased results). Participants were adults, some with existing illness and some healthy, living in North America, Europe, Australia and Asia. Most EPA and DHA trials provided capsules, few gave oily fish.

Key results

Increasing EPA and DHA has little or no effect on deaths and cardiovascular events (high-certainty evidence) and probably makes little or no difference to cardiovascular death, stroke, or heart irregularities (moderate-certainty evidence). However, increasing EPA and DHA may slightly reduce risk of coronary death and coronary events (low-certainty evidence, coronary events are illnesses of arteries supplying the heart). To prevent one person having a coronary event, 167 people would need to increase their EPA and DHA, and 334 people would need to increase their EPA and DHA to prevent one person dying from coronary disease. EPA and DHA reduce triglycerides by about 15% but do not affect fatness or other lipids (high-certainty evidence).

Eating more ALA (for example, by increasing walnuts or enriched margarine) probably makes little or no difference to all-cause, cardiovascular or coronary deaths or coronary events but probably slightly reduces cardiovascular events and heart irregularities (moderate- or low-certainty evidence). To prevent one person having a coronary event, 500 people would need to increase their ALA, 91 people to prevent one person having arrhythmia.

There is little evidence of effects of eating fish. EPA and DHA reduce triglycerides. EPA, DHA and ALA may be slightly protective of some heart and circulatory diseases.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. High versus low long-chain omega-3 fats for preventing cardiovascular disease and mortality (primary outcomes)

High versus low long-chain omega-3 fats for preventing cardiovascular disease and mortality (primary outcomes)

Patient or population: adults with or without existing CVD

Setting: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high-income economies ([World Bank 2018](#)), but four were carried out in upper-middle-income countries (Argentina, Iran, Turkey and China). No trials took place wholly in low- or low-middle income countries.

Intervention: higher intake of LCn3 fats

Comparison: lower intake of LCn3 fats

The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been oily fish or fish oils as a food, oil, made into a spreading fat, or supplementing another food (such as bread or eggs). Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated fish or algal oils, were also accepted.

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (trials)	Certainty of the evidence (GRADE)	Comments
	Risk with lower LCn3	Risk with higher LCn3				
All-cause mortality – deaths Assessed with number of participants dying of any cause, whether reported as an outcome or a reason for dropout Duration: range 12-88 months	80 per 1000	78 per 1000 (74 to 81)	RR 0.97 (0.93 to 1.01)	143,693 (45 RCTs)	⊕⊕⊕⊕ High ^a	LCn3 fat intake makes little or no difference to risk of all-cause mortality
Cardiovascular mortality – cardiovascular deaths Assessed with deaths from any cardiovascular cause. Where this was not available, we used cardiac death instead where known Duration: range 12-88 months	50 per 1000	46 per 1000 (43 to 49)	RR 0.92 (0.86 to 0.99)	117,837 (29 RCTs)	⊕⊕⊕⊖ Moderate ^b	LCn3 fat intake probably makes little or no difference to risk of cardiovascular death
Cardiovascular events Assessed with number of participants experiencing any cardiovascular event	128 per 1000	123 per 1000 (118 to 129)	RR 0.96 (0.92 to 1.01)	140,482 (43 RCTs)	⊕⊕⊕⊕ High ^c	LCn3 fat intake makes little or no difference to risk of cardiovascular events

Duration: range 12-88 months						
Coronary heart disease mortality – CHD deaths Assessed with coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) Duration: range 12-88 months	29 per 1000	26 per 1000 (24 to 29)	RR 0.90 (0.81 to 1.00)	127,378 (24 RCTs)	⊕⊕⊕⊖ Low ^d	Increasing LCn3 fat intake may slightly reduce CHD mortality (NNTB 334 , 95% CI 200 to infinity; NNTB 1000 for primary prevention; NNTB 200 for secondary prevention)
Coronary heart disease events – CHD events Assessed with number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) Duration: range 12-88 months	68 per 1000	62 per 1000 (58 to 66)	RR 0.91 (0.85 to 0.97)	134,116 (32 RCTs)	⊕⊕⊕⊖ Low ^e	Increasing LCn3 fat intake may slightly reduce the risk of CHD events (NNTB 167 , 95% CI 100 to 500; NNTB 200 for primary prevention; NNTB 143 for secondary prevention)
Stroke Assessed with number of participants experiencing at least 1 fatal or non-fatal, ischaemic or haemorrhagic stroke Duration: range 12-88 months	20 per 1000	21 per 1000 (19 to 23)	RR 1.02 (0.94 to 1.12)	138,888 (31 RCTs)	⊕⊕⊕⊖ Moderate ^f	LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke
Arrhythmias Assessed with number of participants experiencing fatal or nonfatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation Duration: range 12-88 months	57 per 1000	56 per 1000 (52 to 60)	RR 0.99 (0.92 to 1.06)	77,990 (30 RCTs)	⊕⊕⊕⊖ Low ^g	Increasing LCn3 fat intake may make little or no difference to risk of arrhythmia
Harms: bleeding Assessed with number of participants experiencing bleeding events	16 per 1000	18 per 1000 (14 to 22)	RR 1.12 (0.91 to 1.37)	80,147 (11 RCTs)	⊕⊕⊕⊖ Very low ^h	The effect of LCn3 fat intake on bleeding is unclear as the evidence is of very low certainty

Duration: range 12-72 months						
Harms: pulmonary embolus or DVT	5 per 1000	6 per 1000 (2 to 14)	RR 1.15 (0.44 to 2.98)	3546 (5 RCTs)	⊕⊕⊕⊕ Very low ⁱ	The effect of LCn3 fat intake on pulmonary embolus or DVT is unclear as the evidence is of very low certainty
Assessed with number of participants experiencing pulmonary embolus or DVT						
Duration: range 18-36 months						

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CHD: coronary heart disease; **CI:** confidence interval; **CVD:** cardiovascular disease; **DHA:** docosahexaenoic acid; **DVT:** deep vein thrombosis; **EPA:** eicosapentaenoic acid; **IHD:** ischaemic heart disease; **LCn3:** long-chain omega-3; **MI:** myocardial infarction; **RCT:** randomised controlled trial; **RR:** risk ratio.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

^aAll-cause mortality, long-chain omega-3 (LCn3)

- **Risk of bias:** effect size moved closer to no effect (risk ratio (RR) 1.0) when analysis was limited to trials at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger trials. It was further noted by the World Health Organization Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health that although many of the trials had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60% and I^2 reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with cardiovascular disease (CVD) risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** tight confidence intervals, very large numbers of participants took part in long-term randomised controlled trials (RCTs) with consistent results. Given the lack of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. Not downgraded.
- **Publication bias:** the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

^bCardiovascular mortality, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias and with fixed-effect analysis (adding weight to the suggestion of little or no effect) but did not alter when the analyses were limited to trials at low risk of compliance bias or larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60% and I^2 reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** 95% confidence intervals do not exclude important benefits. Downgraded once.
- **Publication bias:** the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

^cCardiovascular events, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias (adding weight to the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60% and I^2 reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** very large numbers of participants took part in long-term RCTs with consistent results. Given the lack of an important effect in this very large set of participants, any effect appears too small to be individually relevant. The 95% confidence intervals excluded important benefits or harms. Not downgraded.
- **Publication bias:** the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

^dCoronary heart disease mortality, LCn3

- **Risk of bias:** effect size more than 8% was retained when analysis was limited to trials at low summary risk of bias, low risk of compliance bias and larger trials. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** large numbers of participants took part in long-term RCTs with consistent results. As 95% confidence intervals did not exclude lack of effect we downgraded once.
- **Publication bias:** the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in the RR would rise. This weakens the suggestion of an effect. Downgraded once.

^eCoronary heart disease events, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias, but increased when limiting trials to those at low risk of compliance problems and larger trials. There was a small protective effect in the main analysis and some sensitivity analyses, but not in sensitivity analyses limiting to RCTs at low summary risk of bias or using fixed-effect analysis. The suggestion of a dose response in meta-regression was lost when [REDUCE-IT 2019](#) data were omitted. We summarised this as suggesting a true effect of around 8%. This is on the borderline of little or no effect and a more than 8% effect. Downgraded twice.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** 95% confidence interval did not include the null. Not downgraded.
- **Publication bias:** no suggestion from the funnel plot of publication bias. Not downgraded.

^fStroke, LCn3

- **Risk of bias:** effect size consistently suggested little or no effect for all sensitivity analyses. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** very large numbers of participants took part in long-term RCTs with consistent results. Given the lack of a statistically significant effect in this very large set of participants any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important harms, we downgraded once.
- **Publication bias:** the funnel plot did not suggest any small trial bias. Not downgraded.

^g**Arrhythmias, LCn3**

- **Risk of bias:** effect size remained similar in most sensitivity analyses, but suggested harm when limited to trials at low summary risk of bias. Downgraded once.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** As 95% confidence intervals of the sensitivity analysis excluding trials at higher risk of bias included both harm and no effect, and there was a statistically significant difference in effect size between trials at low summary risk of bias and other trials, we downgraded once.
- **Publication bias:** funnel plot not interpretable as trials all of a similar size and weight. Not downgraded.

^h**Bleeding, LCn3**

- **Risk of bias:** effect size changed direction (from harmful to protective) when analysis limited to trials at low summary risk of bias. Downgraded once.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals do not exclude large and important benefits or harms. Downgraded twice.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

ⁱ**Pulmonary embolus or DVD, LCn3**

- **Risk of bias:** effect size suggested greater harm when analysis limited to trials at low summary risk of bias. Downgraded once.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals do not exclude large benefits or large harms. Downgraded twice.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

Summary of findings 2. High versus low alpha-linolenic acid omega-3 fats for preventing cardiovascular disease (primary outcomes)

High versus low alpha-linolenic omega-3 fats for preventing cardiovascular disease (primary outcomes)

Patient or population: adults with or without existing CVD

Setting: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high-income economies ([World Bank 2018](#)), but four were carried out in upper-middle-income countries (Argentina, Iran, Turkey and China). No trials took place in low- or low- to middle-income countries.

Intervention: higher intake of ALA

Comparison: lower intake of ALA

The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been refined ALA: linseed (flax); canola (rapeseed);

perilla; purslane; mustard seed; candlenut; stillingia; or walnut, as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content.

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (trials)	Certainty of the evidence (GRADE)	Comments
	Risk with lower ALA	Risk with higher ALA				
All-cause mortality – deaths Assessed with number of participants dying of any cause, whether reported as an outcome or a reason for dropout Duration: range 12-40 months	24 per 1000	24 per 1000 (20 to 28)	RR 1.01 (0.84 to 1.20)	19,327 (5 RCTs)	⊕⊕⊕⊖ Moderate ^a	ALA intake probably makes little or no difference to risk of all-cause mortality
Cardiovascular mortality – cardiovascular deaths Assessed with deaths from any cardiovascular cause. Where this was not available, we used cardiac death instead where known. Duration: range 12-40 months	12 per 1000	12 per 1000 (9 to 15)	RR 0.96 (0.74 to 1.25)	18,619 (4 RCTs)	⊕⊕⊕⊖ Moderate ^b	ALA intake probably makes little or no difference to risk of cardiovascular mortality
Cardiovascular events Assessed with number of participants experiencing any cardiovascular event Duration: range 12-40 months	47 per 1000	45 per 1000 (39 to 50)	RR 0.95 (0.83 to 1.07)	19,327 (5 RCTs)	⊕⊕⊖⊖ Low ^c	Increasing ALA intake may slightly reduce the risk of cardiovascular events. (NNTB 500 , 95% CI 125 to –334; NNTB 500 in primary prevention; NNTB 84 in secondary prevention)
Coronary heart disease mortality – CHD deaths Assessed with: coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) Duration: range 12-40 months	11 per 1000	10 per 1000 (8 to 14)	RR 0.95 (0.72 to 1.26)	18,353 (3 RCTs)	⊕⊕⊕⊖ Moderate ^d	ALA intake probably has little or no effect on risk of CHD mortality
Coronary heart disease events Assessed with number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coro-	21 per 1000	21 per 1000 (17 to 26)	RR 1.00 (0.82 to 1.22)	19,061 (4 RCTs)	⊕⊕⊖⊖ Low ^e	ALA intake may make little or no difference to CHD events

nary syndrome; or angina (stable and unstable) Duration: range 12-40 months						
Stroke Assessed with: number of participants experiencing at least one fatal or non-fatal, ischaemic or haemorrhagic stroke Duration: range 12 to 40 months	2 per 1000	3 per 1000 (2 to 5)	RR 1.15 (0.66 to 2.01)	19,327 (5 RCTs)	⊕⊕⊕⊕ Very low ^f	The effect of ALA intake on stroke is unclear as the evidence is of very low certainty
Arrhythmias Assessed with number of participants experiencing fatal or nonfatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation Duration: range 12-40 months	40 per 1000	29 per 1000 (22 to 39)	RR 0.73 (0.55 to 0.97)	4912 (2 RCTs)	⊕⊕⊕⊕ Moderate ^g	ALA intake probably slightly reduces the risk of arrhythmias. (NNTB 91 , 95% CI 56 to 1000; assessment by primary or secondary prevention not possible)
Harms: bleeding Assessed with number of participants experiencing bleeding events	The effect of ALA intake on bleeding is unclear as no trials reported this outcome.					
Harms: pulmonary embolus or DVT Assessed with number of participants experiencing pulmonary embolus or DVT Duration: 24 months	3 per 1000	1 per 1000 (0 to 23)	RR 0.32 (0.01 to 7.80)	708 (1 RCT)	⊕⊕⊕⊕ Very low ^h	The effect of ALA intake on pulmonary embolus or DVT is unclear as the evidence is of very low certainty

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

ALA: alpha-linolenic acid; **CHD:** coronary heart disease; **CI:** confidence interval; **DVT:** deep vein thrombosis; **IHD:** ischaemic heart disease; **MI:** myocardial infarction; **RCT:** randomised controlled trial; **RR:** risk ratio.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

^aAll-cause mortality, alpha-linolenic acid (ALA)

- **Risk of bias:** there was little or no effect in the main meta-analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with cardiovascular disease (CVD) risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** large numbers of participants took part in long-term RCTs with consistent results. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

^bCardiovascular mortality, ALA

- **Risk of bias:** there was little or no effect in the main analysis, or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** large numbers of participants took part in RCTs in long-term trials with consistent results. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

^cCardiovascular events, ALA

- **Risk of bias:** there was little or no effect in the main analysis, with larger trials and in fixed-effect analysis, and a 9%-10% reduction in risk when data were limited to RCTs at low summary risk of bias or at low risk from compliance problems. Downgraded once.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** As 95% confidence intervals do not exclude important benefits we downgraded once.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

^dCoronary heart disease mortality, ALA

- **Risk of bias:** all sensitivity analyses suggested little or no effect. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** As 95% confidence intervals do not exclude important benefits or harms we downgraded once.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

^eCoronary heart disease events, ALA

- **Risk of bias:** there was little or no effect in the main analyses, in fixed-effect meta-analysis, in larger trials or when limiting to trials at low risk of compliance bias, but some risk reduction (9%) when data were limited to RCTs at low summary risk of bias. Downgraded once.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** as 95% confidence intervals do not exclude important benefits or harms we downgraded once.

- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

fStroke, ALA

- **Risk of bias:** the main analysis, fixed-effect analysis, and larger trials suggest increased risk of stroke with more ALA, but there was little or no effect when data were limited to RCTs at low summary risk of bias, and a suggestion of benefit when limited to trials with low risk of compliance problems. Downgraded twice.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All trials were conducted in high-income countries. Not downgraded.
- **Imprecision:** only 49 participants experienced strokes in the included trials; 95% confidence intervals do not exclude important benefits or harms, downgraded once.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

gArrhythmias, ALA

- **Risk of bias:** increasing ALA reduced the risk of arrhythmia in the main analysis, and also in all sensitivity analyses. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** two trials, which included adults with previous myocardial infarction or successful cardioversion in high-income countries. Not downgraded.
- **Imprecision:** as 95% confidence intervals do not exclude little or no effect we downgraded once.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

hPulmonary embolus or DVD, ALA

- **Risk of bias:** the single trial was not at low summary risk of bias. Downgraded once.
- **Inconsistency:** with one trial no inconsistency. Not downgraded.
- **Indirectness:** healthy men and women, no participants with CVD risk factors or previous CVD; low- and middle-income countries not represented. Not downgraded.
- **Imprecision:** only one event included in a single trial. Downgraded twice.
- **Publication bias:** insufficient trials for funnel plot. Not downgraded.

Summary of findings 3. High versus low omega-3 fats for modification of cardiovascular disease risk factors (adiposity and lipids): key outcomes

High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids)

Patient or population: adults with or without existing CVD

Setting: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high-income economies ([World Bank 2018](#)), but four were carried out in upper-middle income countries. No trials took place in low- or low-middle income countries.

Intervention: higher omega-3 intake (LCn3 or ALA)

Comparison: lower omega-3 intake (LCn3 or ALA)

The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been oily fish; fish oils; linseed (flax), canola (rape-seed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or ALAs, or concentrated fish or algal oils, were also accepted.

Outcomes	Anticipated absolute effects* (95% CI)	Nº of participants	Certainty of the evidence	Comments
----------	--	--------------------	---------------------------	----------

All in trials of 12 to 72 months' duration	Risk with low omega-3	Risk with high omega-3	(trials)	(GRADE)	
Measures of adiposity , LCn3 - weight, kg	Mean body weight was 81.2 kg	MD 0.00 kg lower (0.69 lower to 0.70 higher)	17,000 (14 RCTs)	⊕⊕⊕⊕ High ^a	LCn3 intake makes little or no difference to body weight
Measures of adiposity , LCn3 - BMI, kg/m ²	Mean BMI was 27.3 kg/m ²	MD 0.06 higher (0.14 lower to 0.25 higher)	15,474 (15 RCTs)	⊕⊕⊕⊕ High ^b	LCn3 intake makes little or no difference to BMI
Serum total cholesterol , LCn3 - TC, mmol/L	Mean TC was 5.61 mmol/L	MD 0.01 lower (0.05 lower to 0.03 higher)	38,469 (30 RCTs)	⊕⊕⊕⊕ High ^c	LCn3 intake makes little or no difference to serum TC
Serum triglyceride , LCn3 - fasting TG, mmol/L	Mean TG was 1.59 mmol/L	MD 0.24 lower (0.31 lower to 0.16 lower)	43,998 (27 RCTs)	⊕⊕⊕⊕ High ^d	Increasing LCn3 intake reduces serum TG by about 0.24 mmol/L or 15%
Serum high-density lipoprotein , LCn3 - HDL, mmol/L	Mean HDL was 1.32 mmol/L	MD 0.03 higher (0.01 to 0.05 higher)	46,604 (30 RCTs)	⊕⊕⊕⊕ High ^e	Increasing LCn3 intake has little or no effect on serum HDL
Serum low-density lipoprotein , LCn3 - LDL, mmol/L	Mean LDL was 3.27 mmol/L	MD 0.01 higher (0.01 lower to 0.03 higher)	43,454 (25 RCTs)	⊕⊕⊕⊕ High ^f	LCn3 intake makes little or no difference to serum LDL.
Measures of adiposity , ALA - weight, kg	Mean weight was 80.9 kg	MD 1.49 lower (4.17 lower to 1.18 higher)	664 (4 RCTs)	⊖⊖⊖⊖ Very low ^g	The effect of ALA intake on body weight is unclear as the evidence is of very low certainty
Measures of adiposity , ALA - BMI, kg/m ²	Mean BMI was 27.4 kg/m ²	MD 0.42 lower (1.53 lower to 0.69 higher)	1581 (3 RCTs)	⊖⊖⊖⊖ Very low ^h	The effect of ALA intake on BMI is unclear as the evidence is of very low certainty
Serum total cholesterol , ALA - TC, mmol/L	Mean TC was 5.02 mmol/L	MD 0.09 lower (0.23 lower to 0.05 higher)	2164 (6 RCTs)	⊕⊕⊖⊖ Low ⁱ	ALA intake may make little or no difference to serum TC
Serum triglyceride , ALA - fasting TG, mmol/L	Mean TG was 1.48 mmol/L	MD 0.03 lower (0.11 lower to 0.05 higher)	1776 (6 RCTs)	⊕⊕⊕⊖ Moderate ^j	ALA intake probably makes little or no difference to serum TG
Serum high-density lipoprotein , ALA - HDL, mmol/L	Mean HDL was 1.49 mmol/L	MD 0.02 lower (0.08 lower to 0.03 higher)	1776 (6 RCTs)	⊕⊕⊕⊖ Moderate ^k	ALA intake probably has little or no effect on serum HDL
Serum low-density lipoprotein , ALA - LDL, mmol/L	Mean LDL was 2.88 mmol/L	MD 0.05 lower (0.15 lower to 0.04 higher)	2201 (7 RCTs)	⊕⊕⊕⊖ Moderate ^l	ALA intake probably has little or no effect on serum LDL

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

ALA: alpha-linolenic acid; **BMI:** body mass index; **CI:** confidence interval; **DHA:** docosahexaenoic acid; **EPA:** eicosapentaenoic acid; **HDL:** high-density lipoprotein; **LCn3:** long-chain omega-3 fatty acids; **LDL:** low-density lipoprotein; **MD:** mean difference; **RCT:** randomised controlled trial; **TC:** total cholesterol; **TG:** triglycerides

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

^aMeasures of adiposity, weight, long-chain omega-3 (LCn3)

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I² statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were underrepresented. Not downgraded.
- **Imprecision:** large numbers of participants took part in long-term randomised controlled trials (RCTs) with consistent results; 95% confidence intervals exclude important benefits or harms. Not downgraded.
- **Publication bias:** funnel plot was not interpretable, no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded.

^bMeasures of adiposity, body mass index (BMI), LCn3

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I² statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were underrepresented. Not downgraded.
- **Imprecision:** large numbers of participants took part in long-term RCTs with consistent results. 95% confidence intervals exclude important benefits or harms. Not downgraded.
- **Publication bias:** funnel plot was not interpretable, no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded.

^cLipids, serum total cholesterol, LCn3

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I² statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** the 95% CI excluded important benefits or harms. Not downgraded.
- **Publication bias:** funnel plot did not suggest clear small trial bias. However, we are aware of several trials whose data could not be included; not downgraded.

^dLipids, serum triglycerides, LCn3

- **Risk of bias:** there was a greater than 5% (and statistically significant) effect overall and in all sensitivity analyses, including when data were limited to RCTs at low summary risk of bias. Not downgraded.
- **Inconsistency:** I² statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants took part in long-term RCTs with consistent results. 95% confidence intervals exclude harm and lack of effect. Not downgraded.

- **Publication bias:** funnel plot was not interpretable, but results of fixed-effect and random-effects analyses were similar, suggesting little small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded.

^e**Lipids, high-density lipoprotein (HDL), LCn3**

- **Risk of bias:** the suggested little or no effect (less than 5% increase) in HDL with increased LCn3 was apparent in all sensitivity analyses. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals exclude harms or benefits. Not downgraded.
- **Publication bias:** funnel plot suggested no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded.

^f**Lipids, low-density lipoprotein (LDL), LCn3**

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals excluded important benefits or harms. Not downgraded.
- **Publication bias:** funnel plot did not suggest clear small trial bias, and results of fixed-effect and random-effects analyses were similar. However, we are aware of several trials whose data could not be included. Not downgraded.

^g**Measures of adiposity, weight, alpha-linolenic acid (ALA)**

- **Risk of bias:** no included trials were at low summary risk of bias. Downgraded once.
- **Inconsistency:** I^2 statistic was greater than 60%. Downgraded once.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals included both benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, but effects in fixed-effect and random-effects meta-analysis were different suggesting that small trial bias may be present. We are aware of several trials whose data could not be included. Downgraded once.

^h**Measures of adiposity, BMI, ALA**

- **Risk of bias:** the main analysis and some sensitivity analyses suggested that ALA reduced BMI, but this was not seen when trials were limited to those at low summary risk of bias. Downgraded once.
- **Inconsistency:** I^2 statistic was greater than 60%. Downgraded once.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals include benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, but effects of fixed-effect and random-effects analyses were distinct, suggesting some small trial bias. We are aware of several trials whose data could not be included. Downgraded once.

ⁱ**Lipids, serum total cholesterol, ALA**

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I^2 statistic was greater than 60%. Downgraded once.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** the main analysis included both benefits and harms. Downgraded once.

- **Publication bias:** funnel plot was not interpretable, no clear small trial bias, fixed-effect and random-effects meta-analysis suggested similar effects. We are aware of several trials whose data could not be included. Not downgraded.

/Lipids, serum triglycerides, ALA

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals included benefits. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small trial bias and fixed-effect and random-effects analysis results were similar. We are aware of several trials whose data could not be included. Not downgraded.

^k/Lipids, HDL, ALA

- **Risk of bias:** there was little or no effect in the main analysis and all sensitivity analyses. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** 95% confidence interval includes harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, effects of fixed-effect and random-effects meta-analysis was very similar suggesting lack of small trial bias. We are aware of several trials whose data could not be included. Not downgraded.

/Lipids, LDL, ALA

- **Risk of bias:** little or no effect in main analysis and all sensitivity analyses. Not downgraded.
- **Inconsistency:** I^2 statistic was less than 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** for main analysis 95% confidence interval included benefits. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, effects of fixed-effect and random-effects meta-analysis were similar suggesting no small trial bias. We are aware of several trials whose data could not be included. Not downgraded.

BACKGROUND

Description of the condition

Cardiovascular diseases are disorders of the heart and blood vessels. They comprise cerebrovascular disease (including stroke and transient ischaemic attack), coronary heart disease (including heart attack or myocardial infarction and angina), peripheral arterial disease (diseases of the blood vessels to the arms and legs), deep vein thrombosis and pulmonary embolism (blood clots formed in the legs which can move to the heart and lungs), as well as rheumatic and congenital heart disease (WHO 2017); these last two are not discussed in this review. Globally, 31% of all deaths are due to cardiovascular disease, more than from any other cause (WHO 2017). Of the estimated 17.7 million people who died from cardiovascular diseases in 2015, around 7.4 million were due to coronary heart disease and 6.7 million due to stroke. Of 17 million premature deaths in 2015 caused by non-communicable diseases, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases (WHO 2017).

Description of the intervention

Omega-3 fats (also called $\Omega 3$ or n-3 fats) from fish sources include eicosapentaenoic acid (EPA, or 20:5), docosahexaenoic acid (DHA, 22:6) and docosapentaenoic acid (DPA, 22:5); these are long-chain omega-3 fats (LCn3). Alpha-linolenic acid (ALA or α -linolenic, 18:3) is the short-chain omega-3 fat found in plants and grass-fed meat, which is partially converted to LCn3 fatty acids within our bodies. There is some debate about the effectiveness of this conversion, which may differ depending on whether it is assessed over the short or long term as well as on other dietary factors (Li 1999; Pawlosky 2001). For this reason the effectiveness of ALA may differ from that of the LCn3 fats.

Since Bang and colleagues first suggested that the abundance of omega-3 fatty acids in the diet of the Greenland Inuit people was responsible for their low mortality from ischaemic heart disease (Bang 1972; Bang 1976), there has been considerable interest in the protective role and possible mechanism of action of marine unsaturated fats. This interest has spread to encompass plant seeds and oils rich in ALA, including chia seed, flax (linseed) and rapeseed (canola) oils (Nettleton 1991), their derivatives (e.g. margarines), purslane leaves (Simopoulos 1992), and nuts (especially walnuts).

How the intervention might work

Proposed mechanisms for the protective role of omega-3 fats against cardiovascular diseases include: lowering the blood pressure; altering the lipid profile, especially reduced serum triglyceride concentration; modulating arterial lipoprotein lipase levels; reducing thrombotic tendency; producing anti-inflammatory effects and anti-arrhythmic effects; improving vascular endothelial function and insulin sensitivity; and increasing plaque stability and paraoxonase levels (Bhatnagar 2003; BNF 1999; Calabresi 2004; Chang 2013; Geelen 2004).

Given that most omega-3 fats are ingested in the form of oily fish or fish oil (often fish liver) capsules, reports of high levels of various toxic compounds such as mercury, dioxins and polychlorinated biphenyls (PCBs) in oily fish and fish oils are concerning (Bourdon 2010; FSA 2000; Levine 2005; Liem 1997; MAFF 1998a; SACN COT 2004; USFDA 1995). These are all fat soluble and accumulate over time in the body, so harm may be exhibited only after

long-term fish consumption or supplementation with fish oils. Animal intervention trials and human cohorts who have suffered accidental exposure to dioxins and PCBs suggest that pre-natal exposure may cause sub-fertility problems, and adult exposures may lead to an excess of total cancers (JECFA 2001). Human cohorts exposed to high levels of mercury exhibit neurological problems (USFDA 1995). As many people eat oily fish once or twice a week or take fish oil supplements, it is important to explore the potentially harmful effects of fish-associated omega-3 intake. It is also possible that omega-3 fats themselves may exhibit harm, for example through extension of bleeding times or suppression of normal immune responses (USFDA 2000).

Cardiovascular effects of eating more oily fish may differ from those of taking a fish oil supplement because fish (not fish oil) is a rich source of nutrients including selenium, iodine, zinc, calcium and protein. Fish in the diet may also displace a variety of other foods including sources of saturated or trans fats, so it could alter cardiovascular disease risk in other ways.

Why it is important to do this review

There is a great deal of public belief in the cardiovascular benefits of omega-3 fats. Analysis of US National Health and Nutrition Examination Survey data from 2003 to 2008 suggests that in the USA, adults' mean LCn3 intakes were greater from dietary supplements (0.72 g/d EPA and DHA) than from foods (0.41 g/d, Papanikolaou 2014). But public health advice differs across countries. For example, the National Institute for Health and Clinical Excellence in the UK now encourages fish intake but discourages supplementation: "people with or at high risk of CVD [cardiovascular disease] should be advised to consume at least 2 portions of fish per week, including a portion of oily fish". However, it advises that omega-3 fatty acid compounds "should not be offered for primary or secondary prevention of CVD [cardiovascular disease]" (NICE 2016). The American Heart Association (AHA) also "recommends eating fish (particularly fatty fish) at least two times (two servings) a week". Although the AHA suggests that omega-3 intake via foods is preferable, it is more positive about omega-3 supplements: "those with coronary artery disease may not get enough omega-3 by diet alone. These people may want to talk to their doctor about supplements" (AHA 2016). These recommendations are balanced with a warning about potential excessive bleeding in those taking doses of more than 3 g/d omega-3 fatty acids (presumably LCn3 fats). The AHA have issued updated guidelines on use of omega-3 fats to treat raised triglycerides, suggesting that "prescription n-3 FAs [fatty acids, meaning LCn3] (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents" (Skulas-Ray 2019). Such recommendations, and resulting increased fish consumption, have potentially negative long-term consequences for our marine ecosystems (Brunner 2009).

Epidemiological trials have supported the relationship between high omega-3 intake and lower cardiovascular disease rates (Ballard-Barbash 1987; Burr 1993; Kris-Etherton 2002). However, these associations could be due to other characteristics of people who choose to eat fish. In many societies eating fish is associated with better social status and a health-conscientious life view (Cade 2007), so eating fish is highly confounded by dietary quality, socioeconomic status and other markers of healthy lifestyles. As

an example, the global attributable burden of eating a diet low in seafood omega-3 fats was estimated as 1.1% of global disability-adjusted life-years (DALYs; 95% confidence interval (CI) 0.8 to 1.5), "with 22% of ischaemic heart disease DALYs attributable to low seafood intake" (Engell 2013). The data sources are not described, but when the estimate was derived from randomised controlled trials (RCTs) alone, rather than cohort trials and RCTs combined, the estimated global attributable burden was much smaller, 0.5% (95% CI -0.5 to 1.4). Information concerning cause and effect is more reliably supplied by intervention trials in which participants are randomly allocated to receive fish oil or advice to eat more fish.

Systematic reviews of RCTs have had various findings. A recent version of this review (Abdelhamid 2018a), included 79 long-term RCTs and more than 112,000 participants, finding no effects of omega-3 fats on all-cause mortality or cardiovascular outcomes. Other systematic reviews have suggested a lack of effect for omega-3 fats on all-cause mortality or a variety of cardiovascular diseases (Campbell 2013; Chowdhury 2012; Khoueiry 2013; Kotwal 2012; Kwak 2012; Mariani 2013; Rizos 2012; Zheng 2014). However, some reviews have highlighted particular outcomes or circumstances in which cardiovascular disease prevention was evident: after heart surgery (He 2013), for preventing sudden cardiac death (Zhao 2009), for reducing cardiovascular disease mortality and sudden cardiac death, although with no effect on all-cause mortality (Trikalinos 2012), for cardiovascular disease mortality (Sethi 2016), and for reducing the risk of stroke in women, albeit with no effect on stroke overall (Larsson 2012). Kwak 2012 reported marginal effects on cardiovascular death, though these were lost when a poor-quality trial was removed, and a few others have reported only positive effects in their abstracts (reductions in cardiovascular events, cardiac death and coronary events) (Delgado-Lista 2012). These disparate findings have fuelled both debate and confusion. A recent extensive Agency for Healthcare Research and Quality review meta-analysed risk factors extensively but suggested there was only limited RCT data to assess the effects of omega-3 fats on clinical cardiovascular disease outcomes (Balk 2016). The publication recently of a suite of large-scale and long-term trials of LCn3 (ASCEND 2018; REDUCE-IT 2019; VITAL 2019), has prompted the need to update Abdelhamid 2018a.

This systematic review and meta-analysis aimed to assess the evidence on the effects of omega-3 fats (LCn3 and ALA separately) on all-cause mortality and cardiovascular diseases. It also aimed to assess potentially harmful effects of omega-3 fats or compounds associated with consuming LCn3 fats, such as excessive bleeding. A related review has formally systematically reviewed potential harms such as excessive cancers, rather than simply examining trials included in this review for cancer outcomes (Hanson 2019). We assessed mechanisms of action such as lipid and body weight changes and antiarrhythmic effects as primary or secondary outcomes in this review, and we have systematically reviewed these outcomes in a formal way by including trials that assessed adiposity, lipids and arrhythmic events, even where no cardiovascular disease events occurred or were reported. The World Health Organization (WHO) is currently updating its guidance on polyunsaturated fatty acid (PUFA) intake in adults and children. This is one of a set of systematic reviews commissioned by WHO in order to inform and contribute to the development of updated WHO recommendations. Sister systematic reviews have assessed effects of omega-3, omega-6 and total polyunsaturated

fats on inflammation and inflammatory bowel disease (Thorpe 2017), diabetes and glucose metabolism (Brown 2019), depression and anxiety (Deane 2019), cognition and dementia (Brainard 2019), cancers (Hanson 2019) and functional status (Abdelhamid 2019). Separate reviews assess effects of omega-6 fats and total polyunsaturated fat on mortality and cardiovascular outcome (Abdelhamid 2018b; Hooper 2018), and provide a detailed database of the relevant trials for use by others (Hooper 2019).

The results of this review including GRADE assessments were discussed and reviewed by the WHO Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health as part of WHO's guideline development process.

OBJECTIVES

To assess the effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular events, adiposity and lipids.

The primary review question was, 'Do long-chain omega-3 fats (LCn3, fish-based omega-3 fats) or ALA (plant-based omega-3 fats) alter risk of all-cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart disease events, stroke, arrhythmia, adiposity and lipids?'

Secondary questions include the following.

- If omega-3 fatty acids confer protection:
 - * does protection occur equally in those at low and at high risk of cardiovascular disease?
 - * does protection depend on the dose of omega-3 fats taken per day?
 - * do effects differ between dietary and supplemental omega-3 sources?
 - * does protection depend on trial summary risk of bias?
- Is protection or harm stronger with longer trial duration?
- Are effects of omega-3 fatty acids dependent on baseline triglyceride levels or diabetic status?

The latter was suggested by WHO NUGAG and added post-hoc specifically for this update.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled clinical trials that included diet advice or dietary supplementation to promote omega-3 fatty acid intake versus placebo, no supplementation, usual diet or lower-dose omega-3. One of our outcomes had to be measured and available (through publications or contact with trial authors), and trials had to follow participants for at least 12 months (52 weeks or 360 days). For advice trials, follow-up must have been at least 12 months following advice, and for trials where participants received food or supplementation, provision must have continued for at least 12 months. We accepted randomisation of individuals or of clusters as long as there were at least six clusters randomised.

Careful work by Browning suggests that supplements of EPA and DHA equivalent to one weekly portion of oily fish results in 95% of maximal incorporation by 5 days for EPA in plasma

phosphatidylcholine (95% CI 0 to 18 days) to 273 days for DHA into blood mononuclear cells (95% CI 0 to 670 days; [FISH 2012](#)). While this suggests individual variability, on average all compartments except blood mononuclear cells had equilibrated by 117 days (both EPA and DHA into plasma phosphatidylcholine, plasma cholesteryl esters, plasma nonesterified fatty acids, plasma triglycerides, erythrocytes and platelets). The authors stated, "EPA and DHA reached a maximum in platelets in 3–4 weeks and 1–2 months, respectively, and in blood mononuclear cells in 6–9 months". For this reason we chose 12 months as the minimum duration of intervention, as it allows equilibration of most body compartments with EPA and DHA as well as time for this change in body composition to have some effect on cardiovascular risk or mortality.

In previous reviews of dietary effects on cardiovascular outcomes, we limited trials to at least two years' duration ([Hooper 2015](#)), as the proposed mechanism of effects was via LDL cholesterol, atherosclerosis and its sequelae, and this takes time to develop. The 4S trial showed separation of the survival curves at around two years ([Scandinavian Simvastatin Survival Study Group 1994](#)). Potential mechanisms for effects of PUFAs are broader, including what could be rapid effects on arrhythmias or inflammation, so we decided to include trials of at least 12 months to ensure we did not miss these effects.

Types of participants

Trials in adults (18 years or older, men and women) at any risk of cardiovascular disease (with or without existing cardiovascular disease) were eligible, including those in participants with increased risk of cancer, those undergoing or who have undergone coronary artery bypass grafting or angioplasty, and those with current or previous cardiovascular disease, nephritis in systemic lupus erythematosus, breast cysts, diabetes mellitus, rheumatoid arthritis, multiple sclerosis, psoriasis, hay fever, asthma or ulcerative colitis. Including these populations allows us to understand both development and progression of cardiovascular disease (primary and secondary prevention). We excluded participants who were pregnant or acutely ill (with acute-stage cancer, undergoing heart or renal transplantation, with HIV or AIDS, on haemodialysis, with IgA glomerulonephritis, or any other renal problem except in diabetes).

Types of interventions

The intervention must have been dietary supplementation, a provided diet or advice on diet. The foodstuffs or supplements must have been: oily fish (including mackerel, dogfish, salmon, herring, trout, tuna, sturgeon, stablefish, anchovy, sprat, coho, capelin, sardines, swordfish, sild, pilchard, brisling, menhaden, bloater, whitebait, crab and conger eel); fish oils (made from any of the above or a mixture of fish, or cod liver oil); linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, capsule, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or ALAs, or concentrated fish or algal oils, were also accepted. Supplementation may have been in oil or capsule form or as foodstuffs provided to be consumed by mouth (excluding enteral and parenteral feeds and enemas).

We excluded trials using multiple risk factor interventions on lifestyle factors (such as weight reduction, smoking or physical activity goals), or differential dietary interventions not involving dietary fats, except where that other intervention was a direct replacement for polyunsaturated fats or the effect of diet or supplementation could be separated out from the other interventions.

Trials were eligible if they compared the effect of dietary advice or supplementation to increase omega-3 fats with the usual diet, no advice, no supplementation, placebo or lower-dose omega-3.

Types of outcome measures

Primary outcomes

Primary outcomes included numbers of participants experiencing:

- all-cause mortality (deaths);
- cardiovascular mortality (cardiovascular deaths);
- cardiovascular events (cardiovascular events);
- coronary heart disease mortality (coronary heart disease deaths);
- coronary heart disease events;
- stroke; and
- arrhythmia (atrial fibrillation).

We analysed coronary heart disease using the first of the following to be reported: number of participants experiencing coronary heart disease or coronary events, total myocardial infarction, acute coronary syndrome or angina (stable and unstable). This meant that if trial authors reported coronary heart disease events, we used these in analysis; where trials did not report coronary heart disease events but did report total myocardial infarction, we used that (and so on). Combined cardiovascular events included fatal and non-fatal myocardial infarction, angina, stroke, heart failure, peripheral arterial disease, sudden death and non-scheduled cardiovascular interventions – coronary artery bypass surgery or angioplasty. We included all available outcomes where we could be sure that the same participant was not being counted twice.

At the request of WHO NUGAG Subgroup on Diet and Health, we added coronary heart disease mortality post hoc as a primary outcome. Data used were the first of the following list reported: coronary death, ischaemic heart disease death, fatal myocardial infarction, cardiac death. We only used cardiac death when no other outcomes in this category were available, and we ran a sensitivity analysis omitting cardiac death. The reason for excluding cardiac death in sensitivity analysis was that it goes slightly outside our area of interest, including other causes of death in addition to coronary heart disease, such as cardiomyopathies and congenital and valvular heart diseases. We wanted to include cardiac death in the main analysis as we felt that otherwise we would be missing some important cases of coronary heart mortality, but we decided to exclude it in sensitivity analysis as we were potentially including a few outcomes that coronary heart disease mortality did not encompass.

Secondary outcomes

Secondary outcomes included:

- major adverse cerebrovascular or cardiovascular events (MACCEs) or individual cardiovascular events (total, fatal or non-

fatal myocardial infarction, sudden cardiac death, angina, heart failure, revascularisation, peripheral arterial disease or acute coronary syndrome);

- body weight and other measures of adiposity; and
- lipids (total, LDL or HDL cholesterol and triglycerides).

We defined MACCEs as participants experiencing myocardial infarction, unstable angina, stroke or death. We did not consider trials that did not provide data on all these health events for this outcome.

The review included trials if any of their participants experienced or were assessed for any primary or secondary outcome. These could have been reported in publications (as outcomes or reasons for dropout or adverse events), supplied by trial authors, or which clearly happened even if exact numbers were not available. However, as almost all trials note if a death or cardiovascular event occurs in a trial participant (so all trials assessed for our primary outcomes) we only included trials where at least one event occurred, or where a continuous outcome was measured.

Tertiary outcomes

We extracted the following outcomes where available within included trials.

- Blood pressure
- Serious adverse events (any other reported illnesses)
- Side effects
- Dropouts
- Quality-of-life measures
- Economic costs

We originally intended to assess type 2 diabetes diagnoses, measures of glucose metabolism, cancers, breast cancer, neurocognitive outcomes such as dementia, depression and anxiety within included trials. However, as part of the larger set of reviews we formally systematically reviewed effects of omega-3 fats on type 2 diabetes diagnoses and measures of glucose metabolism (Brown 2019), cancers including breast cancer (Hanson 2019), neurocognitive outcomes such as dementia (Brainard 2019), irritable bowel disease (IBD) and inflammatory factors (Thorpe 2017), depression and anxiety (Deane 2019), and functional outcomes (Abdelhamid 2019), so a partial assessment within this review would be unhelpful and potentially misleading. For this reason we exclude these specific outcomes from our reporting of serious adverse events.

Key outcomes

When the World Health Organization (WHO) NUGAG Subgroup on Diet and Health requested this review update they named the following as key outcomes to inform their planned dietary guidance.

- All-cause mortality
- Cardiovascular disease mortality
- Cardiovascular disease events
- Coronary heart disease mortality
- Coronary heart disease events
- Stroke
- Arrhythmia (atrial fibrillation)

- Serum lipids including total cholesterol, fasting triglycerides, high-density lipoprotein (HDL) and low-density lipoprotein (LDL)
- Measures of adiposity (body weight and body mass index (BMI))

We were not able to make all of these outcomes into primary outcomes (as the number of primary outcomes are restricted for Cochrane Reviews). However, because WHO NUGAG Subgroup on Diet and Health will use these outcomes to underpin guidance, we carried out sensitivity analyses, subgroup analyses and GRADE assessment of certainty of evidence for them, even when they were not primary outcomes.

Search methods for identification of studies

Electronic searches

We searched the following electronic databases on 13 February 2019 to identify reports of relevant randomised clinical trials:

- Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 2) in the Cochrane Library;
- Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 12 February 2019);
- Embase Classic and Embase (Ovid, 1947 to 2019 week 6).

We applied date limits to the terms from the original strategies so that the search included only new records (Appendix 1). The RCT filter for MEDLINE was the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, we applied the terms as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Lefebvre 2011).

Appendix 2 shows the MEDLINE search strategy for the original version of this review (Hooper 2004), Appendix 3 and Appendix 4 show searches used to update the previous version of this review (Abdelhamid 2018a).

For the previous (27 April 2017) update we also ran searches for a new systematic review of the effects of polyunsaturated fats on cardiovascular disease (Abdelhamid 2018b), as well as updating and extending a Cochrane Review of the effects of omega-6 polyunsaturated fats on health outcomes (Hooper 2018). We ran searches for these reviews using the same RCT filters (Appendix 4). The results of these searches were de-duplicated against the omega-3 searches, and all the titles and abstracts assessed as a single set for all three reviews. We created a data set of RCTs that lasted at least six months and compared higher versus lower omega-6, omega-3 or total PUFA in adults. We used this data set as the wider study pool from which we selected included trials for all reviews (Abdelhamid 2018a; Abdelhamid 2018b; Abdelhamid 2019; Brainard 2019; Brown 2019; Deane 2019; Hanson 2019; Hooper 2018; Hooper 2019; Thorpe 2017). We did not repeat these additional searches in 2019.

We also searched two trials registers, ClinicalTrials.gov (clinicaltrials.gov), and the WHO International Clinical Trials Registry Platform (ICTRP, www.who.int/ictip/en), to 31 July 2019 for registry entries for relevant completed and ongoing trials.

Searching other resources

We assessed titles and abstracts retrieved during these electronic searches for relevant RCTs and also relevant systematic reviews.

We handsearched the included trials in all relevant systematic reviews up to April 2017 for new trials and additional publications of included trials. We contacted authors of all large included trials (at least 100 participants) included up to April 2017 and some smaller trials for further trial data, methodological details and references to trials not yet identified, including published, unpublished or ongoing trials.

For all included trials we carefully searched and data-extracted trials registry entries, protocols, supplementary materials, letters, conference abstracts and additional publications to help us locate complete data sets.

Data collection and analysis

Selection of studies

At least two review authors independently assessed titles and abstracts resulting from the electronic and bibliographic searches. We rejected titles and abstracts on initial screen only if the review author could determine from the title and abstract that the article was not a report of a RCT; did not address omega-3 intake (or total polyunsaturated fat or omega-6 fat for the other two reviews); were exclusively in children or young adults (less than 18 years old), pregnant women or the critically ill; were of less than 12 months' duration; or if the intervention was multi-factorial and we could not separate out the effect of dietary fat.

We rejected trials only when it was certain that no primary or secondary outcome events occurred, and none of the secondary outcome risk factors were measured. When we could not reject a title or abstract with certainty, we obtained the full text of the article for further evaluation. We made attempts to obtain full-text translations or evaluations, or both, of all potentially relevant non-English articles.

We used an in/out form to assess full-text papers and trials for inclusion (or otherwise) into the review. We contacted the authors of all potentially included RCTs for further information on trial methodology and outcomes. Two review authors independently decided on inclusion of full-text RCTs, resolving any differences by discussion and, when necessary, in consultation with the review author team.

Data extraction and management

We designed a data extraction form for this review, which each of the review authors tested on a common 'training' trial (SCIMO 1999), and we adapted the form as needed. We extracted data concerning participants, interventions, and outcomes, as described above in the selection criteria section. We extracted dichotomous data from dietary advice trials at the latest point available in the trial (regardless of the amount of reinforcement of the original dietary message), while for supplement trials, we extracted dichotomous data to the point that supplementation or the trial ended, whichever was earlier. We extracted continuous data at the nearest time point to 12 months and also the latest point available in fixed-term trials, but in trials where participants were followed up for varying durations (aside from dropouts), we extracted the participants' data from the first time point following the mean trial duration. We never used data from periods following the end of a trial in meta-analysis.

We also extracted data on risk of bias, assessed using the Cochrane 'Risk of bias' tool, along with data on potential effect modifiers, including existing cardiovascular disease (primary or secondary prevention), trial duration, intensity of intervention (dietary advice, diet provided, supplemental foods, supplements (capsules) and any combination), LCn3 fats or ALA and dose, replacement, medications used (including statins, antihypertensive, antiarrhythmic or antithrombotic medication), fatty acid data (from plasma, platelets or adipose tissue) and smoking status.

For primary and secondary dichotomous outcomes, we extracted numbers of participants experiencing an outcome and total numbers of participants randomised (or in whom the outcome was assessed where known) for each trial arm. For continuous outcomes, we extracted the number of participants assessed, means and standard deviations of the final readings in each treatment arm; we calculated standard deviations from other variance data where appropriate. Where data were available on both change and final readings, we used data on change.

Two review authors independently extracted original reports of trial results. We resolved differences between review authors' results by discussion and, when necessary, in consultation with a third review author or the review author team.

Assessment of risk of bias in included studies

Two review authors independently assessed risk of bias for each included trial, using Cochrane criteria (Higgins 2017), including in the domains of sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; and selective outcome reporting. Additional review-specific criteria included similarity of type and intensity of intervention in both arms (attention) and evidence of appropriate moderate to high compliance (to establish that the intervention group were receiving a different intake of omega-3 fats than the control group). Table 1 presents specific details of how we interpreted these criteria for this review.

In brief, we considered a trial to be at low risk of attention bias when participants were given the same amount of time and attention from trial staff and health professionals whether they were in the intervention or control arms, and at low risk of compliance bias when adherence was assessed, results of that assessment were clearly reported for both intervention and control arms, and where most participants appeared to have taken at least 75% of the intended PUFA dose.

Summary risk of bias

Schulz 1995 found that poorly concealed allocation was associated with a 40% greater effect size, so randomisation and allocation concealment are core issues for all trials. Lack of blinding is associated with bias, though smaller levels of bias than lack of allocation concealment (Savovic 2012), especially in trials with objectively measured outcomes (Wood 2008), such as those we primarily used in our review. Although we originally planned to assess summary risk of bias for all included trials in the same way across the whole set of reviews (Abdelhamid 2018a; Abdelhamid 2018b; Abdelhamid 2019; Brainard 2019; Brown 2019; Deane 2019; Hanson 2019; Hooper 2018; Hooper 2019; Thorpe 2017), we adopted a different approach after discussing the different nature

of supplement trials compared to dietary advice or food provision trials with the WHO NUGAG Subgroup on Diet and Health.

We considered supplement or capsule type trials to be at low summary risk of bias where we judged randomisation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors to be adequate. We considered all other trials to be at moderate or high risk of bias (a single category).

We considered dietary advice or all-food-provided type trials to be at low summary risk of bias where we judged randomisation, allocation concealment, and blinding of outcome assessors to be adequate. We considered all other trials to be at moderate or high risk of bias (a single category).

Measures of treatment effect

We pooled dichotomous data using risk ratios (RR) to describe effect sizes and continuous data using mean differences (MD). Where effects were described by different but comparable measures or scales in different trials, we planned to combine them using standardised mean difference (SMD), but this was not needed in this review.

Unit of analysis issues

We considered that we could reduce patient numbers in cluster-randomised trials to an effective sample size, as described by [Hauck 1991](#), however, we identified no such trials. For combined outcomes (e.g. combined cardiovascular events), we made attempts to add numbers of individuals experiencing specific outcomes within trials, but only where we could be certain that we were not counting individual participants more than once within any one of our review outcome categories.

For trials with intervention arms providing different omega-3 doses, we combined data for the intervention groups for binary outcomes and used higher-dose data versus control for continuous outcomes. We used arms with different doses separately when subgrouping by dose. Where factorial trials ran more than one intervention included in this review ([AlphaOmega - ALA 2010](#); [AlphaOmega - EPA+DHA 2010](#)), we did not pool both comparisons in the same meta-analysis.

Dealing with missing data

We sought trials registry entries and trial protocols to help us assess which trials measured each outcome. Where trials appeared to have collected – but did not report – data, we wrote to trial authors to ask for information. We wrote to authors of all trials that randomised at least 100 participants as well as to those of many smaller trials (although not to all due to limited resources), prioritising our efforts on larger trials that would tend to provide more information to the review. For larger trials where we found no trials registry entry or protocol, we wrote to trial authors to ask whether they had collected information on any outcomes of interest that we had not yet located. Where it was clear that data existed but could not be located to use within the review, we noted this and assessed the potential effect of this missing data on effect sizes narratively.

A recent meta-analysis of effects of omega-3 fats on cardiovascular outcomes, [Aung 2018](#), worked with 10 large RCTs in depth to formulate their outcome data to match precisely between trials. It is difficult as a reviewer to access complex outcomes (such as 'cardiovascular events') where we need to count people

experiencing events, rather than counting events – events are additive, but people experiencing events are not (a participant experiencing a stroke, non-fatal myocardial infarction and angina must be counted as only one person experiencing cardiovascular events, rather than three events). As the review had worked with trial authors to optimise their data, we used data from this review to both fill in missing data (some data had not been previously published) and also to update our data where the data in [Aung 2018](#) differed from previously reported data for any outcome. The trials that this applies to, those included in [Aung 2018](#), were [AlphaOmega - ALA 2010](#); [AlphaOmega - EPA+DHA 2010](#); [AREDS2 2014](#); [DO IT 2010](#); [GISSI-HF 2008](#); [GISSI-P 1999](#); [JELIS 2007](#); [OMEGA 2009](#); [ORIGIN 2012](#); [Risk & Prevention 2013](#); [SU.FOL.OM3 2010](#).

Assessment of heterogeneity

We assessed heterogeneity using the I^2 test and assumed it to be important when I^2 test value was more than 60% ([Higgins 2003](#)).

Assessment of reporting biases

We used funnel plots to assess for evidence of bias for primary outcomes where at least 10 trials contributed to the meta-analysis ([Egger 1997](#)). We also compared effects from random-effects and fixed-effect meta-analyses to understand whether small study effects may be important ([Page 2019](#)), alongside reporting known missing data (above).

Data synthesis

Primary measures of interest were effects of dietary advice or supplementation of fish-based (LCn3) fats, and ALAs, on primary outcomes. We separated out effects of LCn3 and ALA in all analyses and thus present two separate sets of results: one for LCn3 and one for ALA.

We combined treatment/control differences in the outcomes across trials using risk ratios (RR) or mean differences (MD) in random-effects meta-analysis. For combined outcomes (e.g. combined cardiovascular events), we made attempts to add numbers of individuals experiencing specific outcomes within trials, but only where we were certain that we were not counting individual participants more than once within any one of our review outcome categories. However, individuals may have been counted for more than one of the review outcomes (in separate forest plots).

Subgroup analysis and investigation of heterogeneity

We explored the effects of LCn3 and ALA separately on all primary review outcomes and also on key review outcomes where these were secondary outcomes in our review and included at least six trials by subgrouping. The planned subgroup analyses were as follows.

- Type of intervention: dietary advice, supplemental foods (for example margarine fortified with rapeseed, tins of sardines or oils to use in cooking) provided by the trial, supplements (capsules or oils) provided to take as medicine or any combination
- Replacement of saturated fatty acids, mono-unsaturated fatty acids (MUFA), omega-6 fats, fat mixture, carbohydrates or sugars, non-fat or no placebo, or unclear, with LCn3 or ALA
- Primary prevention versus secondary prevention of cardiovascular disease (where trials that recruited participants

for cardiovascular disease at baseline were considered secondary prevention trials, and trials that did not recruit on the basis of cardiovascular disease, so may include some or no people with existing cardiovascular disease, were considered primary prevention trials)

- LCN3 dose: at least 150 mg/d, 250 mg/d, 400 mg/d from all sources including supplements (above or below each threshold); low dose 0.4 g/d to 2.4 g/d, medium dose 2.5 g/d to 4.4 g/d, and high dose ≥ 4.5 g/d of combined LCN3 fats;
- ALA dose: higher versus lower levels of intake (≥ 5 g/d versus < 5 g/d);
- Trial duration: trials with medium follow-up (12 to 23 months), medium follow-up (24 to 47 months) and long follow-up (≥ 48 months)
- Statin use ($< 50\%$ of control group on statins, $\geq 50\%$ of control group on statins, use of statins unclear)
- Baseline LCN3 intake, and baseline ALA intake

There were insufficient data on baseline omega-3 or ALA intake (or intake in control groups, which could have been used as a proxy) to subgroup by baseline omega-3 or ALA intake.

Post-hoc, WHO NUGAG asked us to assess whether effects of omega-3 fats differed by baseline triglyceride or diabetes status. We carried out post-hoc subgroups on primary outcomes whenever the other subgroups were created, including the following.

- Triglyceride status: raised triglycerides at baseline (inclusion criteria relate to triglycerides and mean triglycerides in control group at baseline were > 200 mg/dL or > 2.26 mmol/L) versus normal triglycerides (triglycerides did not relate to inclusion criteria, or mean triglycerides in control group at baseline was < 200 mg/dL or < 2.26 mmol/L)
- Diabetes status: diabetic at baseline (at least half of participants had diabetes) versus diabetes risk factors at baseline (insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis or obesity) versus inclusion criteria that did not relate to diabetic status.

Meta-regression

We used meta-regression to further explore effects of LCN3 dose, ALA dose, omega-6 dose, total PUFA dose (looking for evidence of dose response for each), trial duration, primary or secondary prevention, food or capsule intervention (food included dietary advice and supplemental foods), and risk of bias (summary risk of bias low or moderate to high) on primary outcomes. We performed random-effects meta-regression using the STATA 16 command `meta regress` (Berkley 1995; Sharp 1998): `log(e) risk ratio versus (dose or primary/secondary prevention or type of intervention or risk of bias or duration)`, weighted by the standard error of the `log(e) risk ratio`. Where there were no events in one arm, we added 0.1 to the numbers for both groups (so a trial with 10 people experiencing stroke in one arm but none in the other arm would be entered as 10.1 and 0.1). We analysed all included trials (of at least 12 months' duration) that reported each outcome from this review and its sister reviews (omega-3 trials from this review, omega-6 trials from Hooper 2018, and total PUFA trials from Abdelhamid 2018b). We carried out meta-regression of each variable singly, then a multivariate meta-regression of the three variables with lowest P values in single regression for each outcome. Given that we generally included data from fewer than 40 trials and there were

some missing data for some trials, we did not run meta-regressions with more than three variables at one time.

Sensitivity analysis

We carried out sensitivity analyses on all primary outcomes (regardless of the number of included trials) and on key outcomes that were secondary outcomes in this review.

We used sensitivity analyses to assess robustness of results to:

- trial quality (removing trials at moderate or high summary risk of bias);
- trial size (retaining only trials that randomised at least 100 participants across all trial arms);
- fixed-effect analysis; and
- compliance (retaining only trials where we assessed compliance as conferring low risk of bias).

We tabulated the type and frequency of side effects and adverse effects (with the other extracted data on adverse effects) and compared between different trials and designs.

'Summary of findings' tables

We interpreted outcome data as follows.

1. Is there an effect? (options were 'increased risk', 'decreased risk', or 'little or no effect'). Our main outcome measure was RR so we decided on existence of an effect using RR. RR more than 8% ($RR < 0.92$ or > 1.08) for the highest-certainty evidence suggested increased or decreased risk (otherwise little or no effect). The presence or not of an effect was decided on the RR for the main analysis and sensitivity analyses, the highest-certainty evidence (the main analysis, the sensitivity analyses of trials at low summary risk of bias and at low risk of compliance problems).
2. For continuous outcomes, we considered increasing ALA or LCN3 to have little or no effect unless effect sizes represented at least 5% change from baseline (or 2% in the case of cumulative outcomes such as adiposity).
3. We assessed certainty of evidence using GRADE assessment (GRADE Working Group 2004), for key outcomes. We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it related to the trials that contributed data to the meta-analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 (Higgins 2017), and Chapter 11 (Schünemann 2017), of the *Cochrane Handbook for Systematic Reviews of Interventions*, plus GRADEpro GDT software (GRADEpro GDT). We justified all decisions to downgrade the certainty of trials using footnotes and made comments to aid readers' understanding of the review.
4. Where there was a suggested effect, we assessed the size of effect using the number needed to treat for an additional beneficial outcome (NNTB), number needed to treat for an additional harmful outcome (NNTH) or absolute risk reduction (ARR).

We included three 'Summary of findings' tables: for effects of LCN3 on primary outcomes ([Summary of findings for the main comparison](#)), effects of ALA on primary outcomes ([Summary of](#)

findings 2), and for key outcomes that were not included in the review primary outcomes (measures of adiposity and serum lipids, Summary of findings 3).

RESULTS

Description of studies

Results of the search

During the 2019 update, we assessed a further 2419 publications for inclusion and included another seven trials (Figure 1). We found that six previously ongoing trials had published relevant results (Broutset 2007; DREAM Asbell 2018; ENRGISE 2018; ASCEND 2018; REDUCE-IT 2019; VITAL 2019), so we included them in

the review, and we included a further trial (not previously ongoing, HEARTS 2017). We assessed 29 registry entries from ClinicalTrials.gov and 88 entries from WHO ICTRP, of which seven were newly included as ongoing trials (NCT03806426; EVAPORATE 2016; MTG 2018; NCT03784963; LO-MAPT 2018; POSEIDON 2018; ACTRN12618000761268 2018), and one is awaiting assessment, as it appears to fulfil all inclusion criteria, except that trial duration is unclear (IRCT20100123003140N21). VITAL 2019 had a number of substudies registered with different trial registration numbers, which we included as part of the included VITAL 2019 trial (noted in the Characteristics of included studies), even though most are ongoing. This provided 86 RCTs (over 421 documents) included in this review.

Figure 1. Study flow diagram




Figure 1. (Continued)




Figure 1. (Continued)

duration \geq 12 months and
measuring primary and/or
secondary outcomes.

Of these 86 RCTs, we included 83 in meta-analyses. Three trials clearly collected relevant data but did not report them in a format that we could use in meta-analyses (Gill 2012; Ramirez-Ramirez 2013; Reed 2014; Figure 1).

Using the data provided in Aung 2018, we updated the data for 10 trials already included in this review (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; AREDS2 2014; DO IT 2010; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; OMEGA 2009; ORIGIN 2012; Risk & Prevention 2013; SU.FOL.OM3 2010). This has allowed us to include additional outcomes for some trials, and use updated numbers for others.

Included studies

The 86 included RCTs randomised 162,796 participants, adding 31% to the number of participants with this update (we included 112,059 participants in the previous version of this review, Abdelhamid 2018a). Fifteen trials (16 comparisons) randomised at least 1000 participants (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; ASCEND 2018; AREDS2 2014; DART 1989; DART2 2003; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; Norwegian 1968; OMEGA 2009; ORIGIN 2012; REDUCE-IT 2019; Risk & Prevention 2013; SU.FOL.OM3 2010; VITAL 2019), of which one was a 2x2 factorial trial, which included both interventions (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010). Most of these larger trials assessed effects of LCn3 fats, but two trials/arms assessed effects of ALA (AlphaOmega - ALA 2010; Norwegian 1968).

Participants had cardiovascular disease at baseline in 35 of the trials (secondary prevention), and the remaining 50 trials were of primary prevention, while one was mixed (REDUCE-IT 2019).

Most trials assessed effects of LCn3 fats.

- Sixty-nine trials increased LCn3 intake using supplementary capsules or medicinal oils (ADCS 2010; AFFORD 2013; Ahn 2016; AREDS2 2014; ASCEND 2018; Baldassarre 2006; Bates 1989; Berson 2004; Brox 2001; Caldwell 2011; Derosa 2016; Deslypere 1992; Doi 2014; DO IT 2010; DREAM Asbell 2018; ENRGISE 2018; EPE-A 2014 (as two different doses); EPIC-1 2008; EPIC-2 2008; EPOCH 2014; Erdogan 2007; FAAT 2005; FORWARD 2013; Franzen 1993; Gill 2012; GISSI-HF 2008; GISSI-P 1999; HARP 1995; HEARTS 2017; JELIS 2007; Kumar 2012; Kumar 2013; Lorenz-Meyer 1996; MAPT 2017; MARINA 2011; Mita 2007; NAT2 2013; Nodari 2011 AF; Nodari 2011 HF; Norouzi 2014; Nutristroke 2009; Nye 1990; OFAMI 2001; OMEGA 2009; OPAL 2010; ORIGIN 2012; ORL 2013; Özyaydin 2011; Proudman 2015; Puri 2005; Raitt 2005; Ramirez-Ramirez 2013; REDUCE-IT 2019; Reed 2014; Risk & Prevention 2013; Rossing 1996; Sandhu 2016; SCIMO 1999; seAFOod Hull 2018; Shinto 2014; SHOT 1996; Sianni 2013; SOFA 2006; Sofi 2010; SU.FOL.OM3 2010; Tande 2016; VITAL 2019; WELCOME 2015; Zhang 2017).

- Two trials used supplemented or supplemental foods, either enriched margarine (AlphaOmega - EPA+DHA 2010) or orange juice (FOSTAR 2016) to increase LCn3.
- Four increased LCn3 fats using dietary advice (DART 1989; DART2 2003; DISAF 2003; THIS DIET 2008).
- Three provided some combination of these interventions to increase LCn3 (DIPP 2015; SMART 2013; Weinstock-Guttman 2005).

Doses of LCn3 ranged from 0.5 g/d of EPA and DHA to more than 5 g/d (19 RCTs had a dose of LCn3 < 1 g/d, 27 a dose of 1 to < 2 g/d, 12 of 2 to < 3 g/d, 19 RCTs had a dose of 3 or more g/d LCn3, 1 did not clearly state their dose).

Fewer trials assessed the effects of ALA on health outcomes.

- One trial used supplementary capsules or medicinal oils to increase ALA (Norwegian 1968).
- Seven increased ALA using supplemented or supplemental foods, such as enriched margarine, bread, walnuts or other enriched food products (AlphaOmega - ALA 2010; Broutset 2007; Dodin 2005; FLAX-PAD 2013; HERO 2009; MARGARIN 2002; WAHA 2016).
- One used a combination of these to increase ALA (MENU 2016).

One trial provided an intervention combining LCn3 and ALA as capsules (DIPP 2015). However, trial authors did not state the ALA dose, so we treated the trial as an LCn3 intervention.

Control groups received olive, corn, sunflower oils, other types of fats (including medium-chain triglycerides and fat replicating the composition of an average European diet), other 'inert' or ill-defined substances (liquid paraffin, aluminium hydroxide, 'placebo' not described), different dietary advice or foods without the omega-3 enrichment, or no treatment/no placebo. These control groups or replacements are shown for each key outcome when subgrouping by replacement (for example Analysis 1.6 shows effects of increasing LCn3 on all-cause mortality, grouped by replacement).

The main trial outcome was cardiovascular in 51 trials. Twenty-one trials (22 comparisons) aimed to measure death or cardiovascular events (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; ASCEND 2018; DART 1989; DART2 2003; Doi 2014; FAAT 2005; FLAX-PAD 2013; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; Norwegian 1968; Nye 1990; OFAMI 2001; OMEGA 2009; ORIGIN 2012; REDUCE-IT 2019; Risk & Prevention 2013; SOFA 2006; SU.FOL.OM3 2010; THIS DIET 2008; VITAL 2019).

Thirty-two trials aimed to measure various cardiovascular risk factors or progression of cardiovascular health.

- Atrial fibrillation recurrence or sinus rhythm (AFFORD 2013; Broutset 2007; DISAF 2003; Erdogan 2007; FAAT 2005; FORWARD

2013; Kumar 2012; Kumar 2013; Nodari 2011 AF; Özyaydin 2011; Raitt 2005; Sianni 2013)

- Atherosclerosis progression/regression (Ahn 2016; DO IT 2010; HARP 1995; HEARTS 2017; SCIMO 1999)
- Left ventricular function (Nodari 2011 HF)
- Coronary artery bypass graft patency (SHOT 1996)
- Lipids and other cardiovascular disease risk factors (Brox 2001; Deslypere 1992; Franzen 1993; MARGARIN 2002)
- Diabetes, insulin or glucose-based outcomes (Derosa 2016; Rossing 1996)
- Endothelial function or carotid intima-media thickness (Baldassarre 2006; Gill 2012; MARINA 2011; Mita 2007)
- Body weight and adiposity (HERO 2009; MENU 2016; SMART 2013)

Thirty-five RCTs assessed effects on other health states.

- Cognitive measures (ADCS 2010; EPOCH 2014; MAPT 2017; OPAL 2010; Shinto 2014; WAHA 2016; Zhang 2017)
- Eye health (AREDS2 2014; Berson 2004; DREAM Asbell 2018; NAT2 2013)
- Multiple sclerosis outcomes (Bates 1989; Weinstock-Guttman 2005)
- Cancer or pre-cancer outcomes (DIPP 2015; seAFOod Hull 2018; VITAL 2019)
- Bone health (Dodin 2005)
- Liver health (Caldwell 2011; EPE-A 2014; Sofi 2010; WELCOME 2015)
- Gastrointestinal health (Crohn's; EPIC-1 2008; EPIC-2 2008; Lorenz-Meyer 1996)
- Arthritis outcomes (FOSTAR 2016; Proudman 2015; Reed 2014)
- Functional status (ENRGISE 2018; Nutristroke 2009)
- Neurological function after spinal injury or in Huntington's disease (Norouzi 2014; Puri 2005)
- Safety outcomes and adverse events (ORL 2013; Tande 2016)
- Breast health (Sandhu 2016)
- Inflammatory markers (Ramirez-Ramirez 2013 plus ENRGISE 2018)

Most trials took place in high-income economies (World Bank 2018), but four were in upper-middle-income countries: Argentina (FORWARD 2013), Iran (Norouzi 2014), Turkey (Özyaydin 2011), and

China (Zhang 2017). No trials took place exclusively in low- or low-to middle-income countries. REDUCE-IT 2019 was a multi-centre trial that randomised participants in the USA, Netherlands, Ukraine, Russia, South Africa, Poland, India, Romania, Australia and New Zealand.

We identified a further 25 ongoing trials, which we describe in the table of [Characteristics of ongoing studies](#). At the time of writing this review, all of these trials appear unpublished, and some were recruiting or delivering interventions or had recently been completed, and trial authors were presumably analysing data and writing up results. Others appear overdue for publication, and their status is unclear – they may constitute missing data.

Excluded studies

We read the full texts of over 1000 papers, so the full list of excluded trials is too extensive to add to this review. The main reason for exclusion of full-text papers was duration of less than 12 months (this was often unclear in abstracts, so we collected full-text papers to check).

We initially included several trials into our wider data set that we later excluded (Singh 1992; Singh 1997; Singh 1997; Singh 2002). Their exclusion was due to expressions of concern published by the *BMJ* and *The Lancet* (BMJ 2005; Horton 2005; White 2005). These expressions of concern followed extensive examination of the conduct, results and publication of these trials and questioned the veracity of data behind several trials published by RB Singh. Another trial that would otherwise have been included was retracted and so not included (Matsuyama 2005).

Risk of bias in included studies

We assessed summary risk of bias as low in 28 RCTs (29 comparisons: ADCS 2010; AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; AREDS2 2014; ASCEND 2018; Berson 2004; Caldwell 2011; Derosa 2016; DREAM Asbell 2018; EPOCH 2014; FLAX-PAD 2013; FORWARD 2013; FOSTAR 2016; Lorenz-Meyer 1996; MAPT 2017; MARGARIN 2002; MARINA 2011; NAT2 2013; OMEGA 2009; OPAL 2010; ORIGIN 2012; Proudman 2015; Puri 2005; Reed 2014; SCIMO 1999; SOFA 2006; SU.FOL.OM3 2010; VITAL 2019; WELCOME 2015), and we deemed it to be moderate to high in the remainder. Our definition of low summary risk of bias is in the section [Assessment of risk of bias in included studies](#). Figure 2 itemises risk of bias by domain and trial.

Figure 2. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Attention	Compliance	Other bias
ADCS 2010	+	+	+	+	+	+	+	?	+
AFFORD 2013	?	?	?	?	+	-	+	+	+
Ahn 2016	+	+	?	+	+	?	?	?	-
AlphaOmega - ALA 2010	+	+	+	+	+	-	+	+	+
AlphaOmega - EPA+DHA 2010	+	+	+	+	+	-	+	+	+
AREDS2 2014	+	+	+	+	+	+	+	?	+
ASCEND 2018	+	+	+	+	+	+	+	?	+
Baldassarre 2006	+	?	?	?	+	?	+	+	+
Bates 1989	?	?	+	?	+	-	+	+	+
Berson 2004	+	+	+	+	?	?	+	+	+

Figure 2. (Continued)

Berson 2004	+	+	+	+	?	?	+	+	+
Broutset 2007	?	?	-	-	-	-	?	?	?
Brox 2001	+	+	-	+	-	?	+	+	+
Caldwell 2011	+	+	+	+	+	+	+	?	+
DART 1989	+	?	-	+	+	?	-	?	+
DART2 2003	?	?	-	+	+	?	-	?	+
Derosa 2016	+	+	+	+	+	?	+	?	+
Deslypere 1992	+	+	-	+	+	?	+	+	+
DIPP 2015	+	+	?	+	+	-	+	?	+
DISAF 2003	+	+	-	?	-	-	+	+	-
Dodin 2005	+	?	+	+	+	?	+	+	+
Doi 2014	+	?	-	?	+	-	+	?	+
DO IT 2010	+	?	?	+	+	?	+	+	+
DREAM Asbell 2018	+	+	+	+	+	+	+	+	+
ENRGISE 2018	+	+	+	?	-	-	+	?	+
EPE-A 2014	+	+	+	?	-	+	+	+	+
EPIC-1 2008	+	+	+	?	+	-	+	?	+
EPIC-2 2008	+	+	?	?	-	-	+	?	+
EPOCH 2014	+	+	+	+	?	-	+	?	+
Erdogan 2007	?	?	?	?	?	?	?	?	+
FAAT 2005	+	+	?	+	-	-	+	-	+

Figure 2. (Continued)

FAAT 2005	+	+	?	+	-	-	+	-	+
FLAX-PAD 2013	+	+	+	+	+	-	+	?	+
FORWARD 2013	+	+	+	+	-	+	+	?	+
FOSTAR 2016	+	+	+	+	?	-	+	+	+
Franzen 1993	+	?	?	?	+	?	+	?	+
Gill 2012	?	?	?	?	?	-	?	?	?
GISSI-HF 2008	+	+	?	+	+	?	+	?	+
GISSI-P 1999	+	+	-	+	+	?	+	?	+
HARP 1995	+	?	?	+	+	-	+	+	+
HEARTS 2017	+	?	-	?	-	-	?	?	+
HERO 2009	+	?	-	?	-	?	+	-	+
JELIS 2007	+	+	-	+	+	?	+	?	+
Kumar 2012	?	?	-	-	+	?	?	+	+
Kumar 2013	+	+	-	-	-	+	?	+	-
Lorenz-Meyer 1996	+	+	+	+	-	?	+	?	+
MAPT 2017	+	+	+	+	+	+	+	?	+
MARGARIN 2002	+	+	+	+	+	?	-	+	+
MARINA 2011	+	+	+	+	+	+	+	+	+
MENU 2016	+	?	-	?	+	+	+	+	+
Mita 2007	+	?	-	+	+	?	+	?	+
NAT2 2013	+	+	+	+	+	?	+	+	+

Figure 2. (Continued)

NAT2 2013	+	+	+	+	+	?	+	+	+
Nodari 2011 AF	+	+	?	?	+	?	+	?	+
Nodari 2011 HF	?	?	-	-	?	?	+	+	+
Norouzi 2014	+	?	?	+	+	-	+	?	+
Norwegian 1968	?	?	+	+	+	?	+	?	+
Nutristroke 2009	?	?	?	+	-	?	+	?	+
Nye 1990	?	?	?	+	?	?	+	?	+
OFAMI 2001	?	+	+	+	?	?	+	?	+
OMEGA 2009	+	+	+	+	+	+	+	+	+
OPAL 2010	+	+	+	+	+	-	+	+	+
ORIGIN 2012	+	+	+	+	+	+	+	?	+
ORL 2013	+	+	-	-	+	+	+	+	+
Özaydin 2011	?	?	-	?	+	?	+	?	+
Proudman 2015	+	+	+	+	+	?	+	-	+
Puri 2005	+	+	+	+	-	?	+	?	+
Raït 2005	+	?	?	+	+	-	+	+	+
Ramirez-Ramirez 2013	+	?	+	+	-	-	+	+	+
REDUCE-IT 2019	+	?	+	+	+	+	+	+	-
Reed 2014	+	+	+	+	-	+	+	?	+
Risk & Prevention 2013	+	+	?	+	+	-	?	?	+
Rossing 1996	+	?	+	?	+	?	+	+	+

Figure 2. (Continued)

Rossing 1996	+	?	+	?	+	?	+	+	+
Sandhu 2016	+	?	-	-	+	-	+	?	+
SCIMO 1999	+	+	+	+	?	?	+	+	+
seAFood Hull 2018	+	+	+	+	+	+	+	+	+
Shinto 2014	+	?	+	+	+	+	+	+	+
SHOT 1996	+	?	-	+	+	?	+	+	+
Sianni 2013	?	?	?	?	?	?	?	?	?
SMART 2013	+	+	-	?	+	-	?	-	+
SOFA 2006	+	+	+	+	+	+	+	?	+
Sofi 2010	?	?	?	?	?	?	+	?	+
SU.FOL.OM3 2010	+	+	+	+	+	+	+	+	+
Tande 2016	+	?	+	+	+	?	+	?	+
THIS DIET 2008	+	?	-	+	+	-	+	?	+
VITAL 2019	+	+	+	+	+	+	+	+	+
WAHA 2016	+	+	-	-	+	?	?	+	+
Weinstock-Guttman 2005	?	?	-	?	-	?	+	+	+
WELCOME 2015	+	+	+	+	+	?	+	+	+
Zhang 2017	+	?	+	+	?	+	+	?	?

Allocation

Of the 86 RCTs (87 RCT arms as [AlphaOmega - ALA 2010](#) and [AlphaOmega - EPA+DHA 2010](#) which include the same participants are represented twice) described in the 'Risk of bias' summary (Figure 2), 69 trials (70 arms) described randomisation well enough to merit an assessment of low risk (the remainder were unclear),

and 49 trials (50 arms) described adequate allocation concealment (the remaining 37 were unclear).

Blinding

We considered blinding of participants and personnel to be at low risk of bias in 42 of the 86 trials (43 arms). Lack of blinding of participants put 24 trials at high risk of bias, while the remaining

20 trials were at unclear risk. Blinding of outcome assessors put 57 trials (58 arms) at low risk of detection bias and at seven at high risk; this aspect was unclear in the remainder. We found that 37 trials (38 arms) were at low risk of both performance and detection bias.

Incomplete outcome data

We found that 57 trials (58 arms) were at low risk of attrition bias, 17 at high risk, and the remaining 12 at unclear risk.

Selective reporting

We determined that 22 trials had a pre-published trials registry entry or protocol and reported all planned outcomes appropriately so we considered them at low risk of selective reporting. Twenty-five trials (26 arms) were at high risk of selective reporting, omitting reports on either pre-stated outcomes or time points. We judged the remaining 39 trials to be at unclear risk of reporting bias as we could not find any protocol or prospective trial registry entry (often trials were published prior to trial registration availability).

Other potential sources of bias

We assessed risk of bias due to lack of compliance and attention bias and also noted other sources of bias. We found four trials to be at high risk of compliance bias ([FAAT 2005](#); [HERO 2009](#); [Proudman 2015](#); [SMART 2013](#)), while 37 trials (38 arms) provided evidence of good compliance, and the remaining 45 trials were unclear. We noted a high risk of attention bias in three trials where intervention participants potentially had more dedicated time for dietary advice or follow-up ([DART 1989](#); [DART2 2003](#); [MARGARIN 2002](#)). Eleven trials did not provide enough details to assess so we considered them to be at unclear risk of attention bias ([Ahn 2016](#); [Broutset 2007](#); [Erdogan 2007](#); [Gill 2012](#); [HEARTS 2017](#); [Kumar 2012](#); [Kumar 2013](#); [Risk & Prevention 2013](#); [Sianni 2013](#); [SMART 2013](#); [WAHA 2016](#)), while we thought the remaining 72 trials (73 arms) were at low risk of attention bias. We judged four trials to be at high risk of other potential biases: [Ahn 2016](#) because it is unclear whether it was placebo-controlled, and there was concern over reported standard

deviations; [DISAF 2003](#) because the trial stopped early; [Kumar 2013](#) due to concerns over design; and [REDUCE-IT 2019](#) because some data were presented for opposite arms in different publications. Four trials were at unclear risk due to insufficient methodological detail being provided ([Broutset 2007](#); [Gill 2012](#); [Sianni 2013](#); [Zhang 2017](#)).

Effects of interventions

See: [Summary of findings for the main comparison](#) High versus low long-chain omega-3 fats for preventing cardiovascular disease and mortality (primary outcomes); [Summary of findings 2](#) High versus low alpha-linolenic acid omega-3 fats for preventing cardiovascular disease (primary outcomes); [Summary of findings 3](#) High versus low omega-3 fats for modification of cardiovascular disease risk factors (adiposity and lipids): key outcomes

Primary outcomes

See [Summary of findings for the main comparison](#) for a GRADE summary of our evidence on effects of long-chain omega-3 (LCn3) fats (including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)) on our primary outcomes.


Effects of long-chain omega-3 fats on primary health outcomes

All-cause mortality (LCn3)

High-certainty evidence showed little or no effect of LCn3 on all-cause mortality.

There was little or no effect of increasing LCn3 fats on all-cause mortality, despite 11,297 deaths in more than 143,000 participants (RR 0.97, 95% CI 0.93 to 1.01; $I^2 = 5\%$; [Analysis 1.1](#)). The funnel plot suggested that some small trials with higher numbers of deaths in the intervention group might be missing ([Figure 3](#)), indicating small study bias, though there was almost no difference between random-effects and fixed-effect analysis. If any such missing trials were added back in the RR would rise slightly (towards the null value of 1.0).

Figure 3. Funnel plot of comparison 1. High versus low long-chain omega-3 fats (primary outcomes), outcome 1.3, all-cause mortality, sensitivity analysis by summary risk of bias



Sensitivity analyses using fixed-effect meta-analysis did not alter the lack of effect on all-cause mortality (RR 0.97, 95% CI 0.93 to 1.00; [Analysis 1.2](#)). Removing RCTs not at low summary risk of bias left us with 19 RCTs involving over 75,000 participants, 5579 of whom died, suggesting no effect of LCn3 on mortality (RR 0.99, 95% CI 0.95 to 1.04; $I^2 = 0\%$; [Analysis 1.3](#)). This lack of effect was also evident in sensitivity analyses limited to trials at low risk of compliance bias and to larger trials ([Analysis 1.4](#)).

The lack of effect for LCn3 on mortality did not differ by replacement with MUFA, omega-6 fats or other types of placebo compounds ([Analysis 1.6](#)). There was no suggestion of any dose effect for LCn3 fats on mortality ([Analysis 1.5](#)), and subgroups with RRs further away from 1.00 had wide 95% confidence intervals. The lack of effect did not differ by primary versus secondary prevention ([Analysis 1.9](#)), statin use ([Analysis 1.10](#)), mode of intervention (dietary advice, supplemental foods, or capsules, [Analysis 1.7](#)), baseline triglycerides ([Analysis 1.11](#)) or baseline diabetic status ([Analysis 1.12](#)). While there was some suggestion of a small risk reduction in total mortality with LCn3 in trials with medium to long duration (2 to < 4 years, RR 0.91, 95% CI 0.86 to 0.96) and this subgroup was clearly different from other durations (test for subgroup differences $P = 0.03$), the effect was not evident in shorter (1 to < 2 years) or longer trials (≥ 4 years, RR 1.00, 95% CI 0.96 to 1.05).

Because of the lack of effect in longer trials, we did not assume any duration effects ([Analysis 1.8](#)).

As there was no suggestion of any effect of LCn3 fats on all-cause mortality, we did not carry out meta-regression.


GRADE assessment suggested that the finding of little or no effect of LCn3 on all-cause mortality was supported by high-certainty evidence (not downgraded, [Summary of findings for the main comparison](#)).

Cardiovascular disease mortality (LCn3)

Moderate-certainty evidence suggests that LCn3 fat intake probably makes little or no difference to cardiovascular deaths.

Twenty-nine trials in 117,837 participants, 5658 of whom died of cardiovascular disease, reported on cardiovascular mortality (RR 0.92, 95% CI 0.86 to 0.99; $I^2 = 22\%$; [Analysis 1.13](#)). The funnel plot suggested that some smaller trials with more cardiovascular deaths in the intervention group were missing (some small study bias, [Figure 4](#)). If this were the case then adding the missing trials would increase the RR slightly towards the null (no effect). This was supported by the fixed-effect meta-analysis effect being closer to the null than the random-effects model.

Figure 4. Funnel plot of comparison 1. High vs low long-chain omega-3 fats (primary outcomes), outcome 1.15, cardiovascular disease mortality, sensitivity analysis by summary risk of bias



Fixed-effect meta-analysis suggested little or no effect on cardiovascular disease mortality risk (RR 0.93, 95% CI 0.88 to 0.97; [Analysis 1.14](#)). Sensitivity analyses removing RCTs not at low summary risk of bias left 12 RCTs in 71,019 participants, 2266 of whom died, also suggesting little or no effect of LCn3 on cardiovascular disease mortality (RR 0.95, 95% CI 0.88 to 1.03; $I^2 = 0\%$; [Analysis 1.15](#)). Removing trials not at low risk of compliance bias and retaining only larger trials produced similar effects to the main analysis ([Analysis 1.16](#)).

There were no statistically significant differences between subgroups and no differential effects by replacement ([Analysis 1.18](#)), mode of intervention ([Analysis 1.19](#)), duration ([Analysis 1.20](#)), primary or secondary prevention ([Analysis 1.21](#)), statin use ([Analysis 1.22](#)), omega-3 dose ([Analysis 1.17](#)), baseline triglyceride level ([Analysis 1.23](#)) or diabetes status ([Analysis 1.24](#)). There was no suggestion of a dose-response effect.

Meta-regression to assess effects of LCn3 dose, ALA, omega-6 and total PUFA dose, trial duration, intervention type, primary or secondary prevention and risk of bias (as well as a single multiple regression of the three factors with the smallest P values) showed no association between these factors and risk of cardiovascular mortality (all P values were > 0.2 , [Table 2](#)). We saw no suggestion of dose-response or duration effects.

The suggestion of a marginally protective effect disappeared in trials at low summary risk of bias, the funnel plot suggests that the true risk ratio is slightly higher than the main estimate, and there was no suggestion of dose or duration effects; thus we summarised the evidence as showing little or no effect of LCn3 on cardiovascular disease mortality. GRADE assessment suggested moderate-certainty evidence that LCn3 fat intake probably makes little or no difference to cardiovascular deaths (downgraded once for imprecision).

Combined cardiovascular events (LCn3)

High-certainty evidence suggests that LCn3 intake makes little or no difference to risk of cardiovascular events.

There was little or no effect of increasing LCn3 fats on cardiovascular events (RR 0.96, 95% CI 0.92 to 1.01; $I^2 = 44\%$; [Analysis 1.25](#)). Analyses included 17,619 participants with cardiovascular events in 140,482 participants in 43 trials. The funnel plot suggested that some smaller trials with more participants experiencing cardiovascular events in the intervention group were missing (some small study bias, not shown). If this were the case then adding the missing trials would increase the RR. However effect sizes were the same in fixed-effect and random-effects analyses suggesting any bias is limited.

Sensitivity analyses removing trials at moderate to high risk of bias left 16 trials, including 73,000 participants, 7951 of whom had cardiovascular disease events, with no suggestion of any effect of LCn3 fats (RR 0.98, 95% CI 0.95 to 1.02; $I^2 = 0\%$; [Analysis 1.27](#)). Sensitivity analyses including trials at low risk of compliance bias, at low risk of small study bias and using fixed-effect meta-analysis did not suggest any effect of LCn3 on cardiovascular disease events ([Analysis 1.26](#); [Analysis 1.28](#)).

In subgroup analysis there was no suggestion of a dose-response effect ([Analysis 1.29](#)). Effects did not differ by replacement ([Analysis 1.30](#)), baseline cardiovascular disease risk ([Analysis 1.33](#)), type of intervention ([Analysis 1.31](#)), statin use ([Analysis 1.34](#)), LCn3 dose ([Analysis 1.29](#)), trial duration ([Analysis 1.32](#)), baseline triglycerides ([Analysis 1.35](#)) or baseline diabetic status ([Analysis 1.36](#)), and there were no important differences between subgroups.

Meta-regression suggested a negative relationship between LCn3 dose and risk of cardiovascular disease events ($P = 0.02$), suggesting reduction in cardiovascular disease risk at higher LCn3 doses, as would be expected from a dose response. However, when the single outlying trial [REDUCE-IT 2019](#) (with a large effect size and high dose) was omitted, the P value was 0.997 suggesting no relationship between LCn3 dose and risk of cardiovascular disease events. The effect was also moderated in the multiple regression ($P = 0.07$). Meta-regression did not suggest associations between ALA, omega-6 or total PUFA dose, trial duration, intervention type, primary or secondary prevention, risk of bias or the single multiple regression of the three factors with the smallest P values ([Table 3](#)).

GRADE assessment suggested high-certainty evidence that LCn3 intake makes little or no difference to risk of cardiovascular events (not downgraded).

Coronary heart disease mortality (LCn3)

Low-certainty evidence suggests that increasing LCn3 fat intake may slightly reduce coronary heart mortality (NNTB 334).

Increasing LCn3 fats reduced the risk of coronary heart mortality by 10% (RR 0.90, 95% CI 0.81 to 1.00; $I^2 = 35\%$) in 24 trials reporting 3598 events in more than 127,000 participants ([Analysis 1.37](#)). Sensitivity analyses using a fixed-effect model suggested little or no effect on coronary heart disease mortality (RR 0.92, 95% CI 0.86 to 0.98; [Analysis 1.38](#)).

Retaining only RCTs at low summary risk of bias, meta-analysis of 10 trials with more than 70,000 participants and 1180 coronary heart disease deaths suggested that increasing LCn3 fats reduced coronary heart disease deaths (RR 0.89, 95% CI 0.76 to 1.04; $I^2 = 22\%$; [Analysis 1.39](#)). Sensitivity analyses retaining only trials with low risk of compliance bias suggested a 17% reduction in risk with LCn3, retaining only larger trials suggested a 13% reduction ([Analysis 1.40](#)). The funnel plot suggested that some smaller trials with higher RRs were missing, and if added back these would increase the RR. The presence of such small study bias is supported by the reduction in effect size in fixed-effect compared to random-effects meta-analysis (random-effects meta-analysis weighs information from small trials more heavily).

When we added this outcome we prespecified that we would use the first of the following list reported in any trial: coronary death, ischaemic heart disease death, fatal myocardial infarction and cardiac death. We used cardiac death only when no other outcomes in this category were available, and we ran a sensitivity analysis omitting cardiac death as it potentially includes other causes of death in addition to coronary heart disease, such as cardiomyopathies and congenital and valvular heart diseases (though numbers are likely to be small). Omitting cardiac death resulted in a 19% reduction in coronary heart disease deaths with LCn3 (RR 0.81, 95% CI 0.73 to 0.90, $I^2 = 0\%$, 18 trials including 106,676 participants, [Analysis 1.41](#)).

There were no statistically significant differences between subgroups for LCn3 dose ([Analysis 1.42](#)), type of intervention ([Analysis 1.44](#)), duration ([Analysis 1.45](#)), primary or secondary prevention ([Analysis 1.46](#)), statin use ([Analysis 1.47](#)), baseline coronary artery disease status ([Analysis 1.48](#)), replacement ([Analysis 1.43](#)), baseline triglycerides ([Analysis 1.49](#)) or diabetes status ([Analysis 1.50](#)).

Meta-regression to assess associations between LCn3 dose and risk of coronary heart disease mortality found no relationship ($P = 0.89$, [Table 4](#)). Similarly we saw no relationships between ALA dose, omega-6 dose, total PUFA dose, duration, intervention type, primary or secondary prevention, or risk of bias and coronary heart disease deaths (all P values were > 0.40 , [Table 4](#)). Multiple regression of the three factors with the smallest P value found no factors associated with risk of coronary heart disease deaths. We saw no suggestion of dose or duration effects.

The NNTB is 334 (95% CI 200 to infinity), so 334 people would need to increase their LCn3 intake to prevent one death from coronary heart disease. If we assess NNTB by primary or secondary prevention of cardiovascular disease, people without previous cardiovascular disease (needing primary prevention) have an NNTB of 1000 (95% CI NNTB 334 to NNTB 1000), while those with existing cardiovascular disease have an NNTB of 200 (95% CI NNTB 112 to NNTB 500).


The suggestion of a small protective effect was seen across sensitivity analyses, excepting fixed-effect analysis. We summarised the evidence as indicating that increasing LCn3 reduces coronary heart disease mortality. GRADE assessment suggested low-certainty evidence that LCn3 fat intake may slightly reduce coronary heart mortality (downgraded once for imprecision and once for publication bias).

Coronary heart disease events (LCn3)

Low-certainty evidence suggests that LCn3 fat intake may slightly reduce the risk of coronary heart events (NNTB 167).

The main meta-analysis suggested a 9% reduction in people experiencing coronary heart disease events with higher intake of LCn3 fats (RR 0.91, 95% CI 0.85 to 0.97; $I^2 = 37\%$; 32 trials, 8777 events, 134,116 participants; [Analysis 1.51](#)). The funnel plot did not suggest serious small study bias ([Figure 5](#)), but effect sizes in fixed-effect meta-analysis were slightly smaller.

Figure 5. Funnel plot of comparison 1. High vs low long-chain omega-3 fats (primary outcomes), outcome 1.51, coronary heart disease events (overall)



The size of any effect was reduced in sensitivity analyses using a fixed-effect model (RR 0.93, 95% CI 0.89 to 0.96; [Analysis 1.52](#)) and when we limited trials to those at low summary risk of bias (RR 0.93, 95% CI 0.82 to 1.05, $I^2 = 38\%$, [Analysis 1.53](#)), but increased when analyses were limited to trials with good compliance and to larger trials ([Analysis 1.54](#)).

There were no statistically significant differences between subgroups ([Analysis 1.55](#); [Analysis 1.56](#); [Analysis 1.57](#); [Analysis 1.58](#); [Analysis 1.59](#); [Analysis 1.60](#); [Analysis 1.61](#); [Analysis 1.63](#)), except for subgrouping by baseline triglyceride, where the subgroup of trials with raised triglyceride suggested a greater reduction in coronary heart disease events ([Analysis 1.62](#)).

Meta-regression suggested a negative relationship between LCn3 dose and risk of coronary heart disease events ($P = 0.02$), suggesting reduction in coronary heart disease risk at higher LCn3 doses, as would be expected from a dose response. This was weakened in the single multiple regression of the three factors with the smallest P value ($P = 0.06$). When we omitted the single outlying trial [REDUCE-IT 2019](#), meta-regression no longer suggested any relationship between LCn3 dose and risk of coronary heart disease events ($P = 0.81$). Meta-regression did not suggest associations between ALA, omega-6 or total PUFA dose, trial duration, intervention type, primary or secondary prevention, or risk of bias and risk of coronary heart disease events ([Table 5](#)).

167 people would need to increase their LCn3 intake for one person to avoid a coronary heart disease event (NNTB 167, 95% CI 100 to 500). If we separate this out for people without existing cardiovascular disease the NNTB is 200 for primary prevention (95% CI NNTB 112 to NNTB infinity), and the NNTB is 143 for people with existing cardiovascular disease, secondary prevention, (95% CI NNTB 91 to NNTB 500).

While there was a small protective effect in the main analysis and some sensitivity analyses, but not in sensitivity analyses limiting to RCTs at low summary risk of bias or using fixed-effect analysis, there was also a suggestion of a dose response. We summarised this as suggesting a true effect of around 8%. GRADE assessment suggested low-certainty evidence that increasing LCn3 fat intake may slightly reduce risk of coronary heart events (downgraded twice for risk of bias).

Stroke (LCn3)

Moderate-certainty evidence suggests that LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke.

Increasing intake of LCn3 appears to have little effect on risk of stroke (RR 1.02, 95% CI 0.94 to 1.12; $I^2 = 11\%$; 31 trials reported 2850 strokes; [Analysis 1.64](#)), and the funnel plot did not suggest small study bias (not shown).

Sensitivity analyses removing trials not at low summary risk of bias left 14 trials with 1684 participants experiencing strokes, suggesting

little or no effect of LCn3 fats on stroke (RR 0.99, 95% CI 0.90 to 1.09; $I^2 = 0\%$; [Analysis 1.66](#)). Using fixed-effect meta-analysis and sensitivity analysis removing trials with risk from poor compliance and smaller trials all suggested no effect of increased LCn3 ([Analysis 1.66](#); [Analysis 1.68](#)).

When trials reported stroke type separately, the risk of haemorrhagic stroke was increased (RR 1.23, 95% CI 0.93 to 1.64; $I^2 = 0\%$; 197 participants with events), while ischaemic stroke was unaltered (RR 0.98, 95% CI 0.79 to 1.20; $I^2 = 47\%$; 985 people with events in 10 trials; [Analysis 1.68](#)). Six trials reported only 152 participants experiencing transient ischaemic attack, suggesting a 10% increase in risk but with very wide confidence intervals (transient ischaemic attacks were not included in any other stroke categories; [Analysis 1.68](#)). Subgrouping did not suggest important differences by intervention type, replacement, statin use, trial duration, baseline triglycerides or diabetic status ([Analysis 1.70](#); [Analysis 1.71](#); [Analysis 1.72](#); [Analysis 1.74](#); [Analysis 1.75](#); [Analysis 1.76](#)). Subgrouping by dose suggested important differences in effect at different doses, but there was no pattern to these effects so they were assumed to be spurious ([Analysis 1.69](#)). There was a suggestion of increased stroke risk in people with cardiovascular disease at baseline (RR 1.21, 95% CI 1.05 to 1.40; $I^2 = 0\%$; with differences in effect size between subgroups by primary or secondary prevention, $P = 0.002$; [Analysis 1.73](#)).

Meta-regression to assess effects of LCn3 dose did not find any clear dose response on risk of stroke ($P = 0.12$, [Table 6](#)). Univariate meta-regression suggested that trials of longer duration showed smaller risk ratios (or lower risk, $P = 0.03$), and this effect was retained in the multivariate regression ($P = 0.03$). There were no clear relationships between dose of any PUFA type, risk of bias, or use of food or capsules, and only trial duration remained statistically significant in multivariate meta-regression.

Analyses consistently suggested little or no effect of LCn3 on stroke risk, and there were no dose-response relationships, though there is a possible increase in risk of haemorrhagic stroke with increased LCn3. GRADE assessment suggests moderate-certainty evidence that LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke (downgraded once for imprecision).

Arrhythmia (LCn3)

Low-certainty evidence suggests that LCn3 fat intake may slightly increase the risk of arrhythmia (NNT 1000).

There was little or no effect of LCn3 fats on incidence of new or recurrent (fatal and non-fatal) arrhythmias (RR 0.99, 95% CI 0.92 to 1.06; $I^2 = 44\%$; 4586 events in more than 77,000 participants; [Analysis 1.77](#)). The funnel plot was not interpretable as trials were clustered (not shown), but the effect size moved above 1 in fixed-effect meta-analysis, suggesting that some trials suggesting harm from increased LCn3 may be missing.

Sensitivity analyses removing trials not at low summary risk of bias left 12 trials with 1602 events ($> 41,000$ participants), suggesting a 9% increase in risk of arrhythmia with increased LCn3 (RR 1.09, 95% CI 0.99 to 1.20, $I^2 = 0\%$, [Analysis 1.79](#)). Restricting the analysis to trials at low summary risk of bias removed heterogeneity, and there was a statistically significant difference in effect size between subgroups at low versus moderate to high risk of bias ($P = 0.04$, [Analysis 1.79](#)). Using fixed-effect methodology did not alter the

apparent lack of effect of LCn3 on arrhythmia ([Analysis 1.78](#)), and sensitivity analysis by compliance and trial size also suggested little or no effect of LCn3 on arrhythmia ([Analysis 1.80](#)).

Subgrouping by new or recurrent arrhythmias suggested differences between subgroups, with LCn3 increasing the risk of new arrhythmias and having little or no effect on the risk of recurrent arrhythmia ([Analysis 1.81](#)). There were also statistically significant differences between subgroups by fatality, suggesting that LCn3 increases the risk of fatal arrhythmia, but protects against non-fatal arrhythmia ([Analysis 1.82](#)), primary or secondary prevention, suggesting harm in primary prevention, little or no effect in secondary prevention ([Analysis 1.87](#)) and duration, suggesting little or no effect in trials of up to four years' duration and harm in longer trials ([Analysis 1.86](#)). Subgroup analyses by type of intervention, replacement, statin use, dose and baseline triglyceride did not suggest statistically significant differences between subgroups ([Analysis 1.83](#); [Analysis 1.84](#); [Analysis 1.85](#); [Analysis 1.88](#); [Analysis 1.89](#)). Subgrouping by diabetes status suggested significant differences between subgroups, with little or no effect of increasing LCn3 on arrhythmia for those recruited without specific diabetes risk factors, but increased risk of arrhythmia in those with diabetes risk factors and in those with diabetes at baseline ([Analysis 1.90](#)).

Meta-regression suggested a positive relationship between trial duration and risk ratio, such that longer trials appeared to increase arrhythmia risk ($P = 0.03$; [Table 7](#)). This relationship was lost when we controlled for primary or secondary prevention and ALA dose ($P = 0.42$). There was also a relationship between arrhythmia with primary versus secondary prevention, suggesting greater risk ratio (harm) in primary prevention ($P = 0.03$; [Table 7](#)). There were no other suggested relationships, and neither of these relationships were maintained in multivariate analysis.

Overall, the trials at lower risk of bias, and the longer trials, suggested slight harm from increasing LCn3. This suggests that there may be some harm associated with increasing LCn3 on arrhythmia risk, and fatal arrhythmia, particularly in the longer term and in primary prevention. One thousand people would need to increase their LCn3 intake for one additional person to experience arrhythmia (NNT 1000, 95% CI 200 to -334). GRADE assessment suggested low-certainty evidence that LCn3 fat intake may slightly increase the risk of arrhythmia (downgraded once for risk of bias and once for imprecision).

Effects of alpha-linolenic acid (ALA) on primary health outcomes

See [Summary of findings 2](#) for a summary of our evidence on effects of ALA on our primary outcomes.

As there were fewer than 10 trials for all ALA analyses we did not create or assess funnel plots, though we did run sensitivity analyses and subgroups. We assessed ALA dose-response and duration effects in meta-regression of all included LCn3, ALA, omega-6 and total PUFA trials (but not of ALA trials alone as there were too few trials to carry out meta-regression with any reliability). None of the trials that increased ALA intakes were in participants with raised baseline triglycerides, increased risk of diabetes or diabetes at baseline, so we did not subgroup by baseline triglycerides or diabetic status.

All-cause mortality (ALA)

Moderate-certainty evidence suggests that ALA intake probably makes little or no difference to all-cause mortality.

There was little or no effect of increasing ALA omega-3 fats on all-cause mortality, with 459 deaths in more than 19,000 participants involved in five trials (RR 1.01, 95% CI 0.84 to 1.20; $I^2 = 0\%$; [Analysis 4.1](#)).

Sensitivity analyses removing trials not at low summary risk of bias left three trials with 375 deaths, again suggesting little or no effect (RR 1.02, 95% CI 0.72 to 1.45; $I^2 = 3\%$; [Analysis 4.3](#)). Other sensitivity analyses all suggested little or no effect ([Analysis 4.2](#); [Analysis 4.4](#)).

Subgrouping by ALA dose, trial duration, statin use, replacement, primary or secondary prevention, or intervention type did not result in any significant differences between subgroups ([Analysis 4.5](#); [Analysis 4.6](#); [Analysis 4.7](#); [Analysis 4.8](#); [Analysis 4.9](#); [Analysis 4.10](#)). As there was no suggestion of effect in any subgroup, we did not carry out meta-regression.

GRADE assessment suggested that ALA intake probably makes little or no difference to all-cause mortality (moderate-certainty evidence, downgraded once for imprecision).

Cardiovascular mortality (ALA)

Moderate-certainty evidence suggests that increasing ALA intake probably has little or no effect on cardiovascular mortality.

Four trials contributed data to this outcome. There was little or no effect of increasing ALA omega-3 fats on cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25; $I^2 = 0\%$; [Analysis 4.11](#)), but confidence intervals were very wide. Analyses included 219 cardiovascular disease deaths in more than 18,000 participants. All sensitivity analyses suggested little or no effect of increasing ALA ([Analysis 4.12](#); [Analysis 4.13](#); [Analysis 4.14](#)).

Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, or primary or secondary prevention did not suggest important differences between subgroups ([Analysis 4.15](#); [Analysis 4.16](#); [Analysis 4.17](#); [Analysis 4.18](#); [Analysis 4.19](#); [Analysis 4.20](#)). Meta-regression to assess for effects of ALA dose on cardiovascular mortality did not suggest dose effects ($P = 0.88$; [Table 2](#)).

GRADE assessment suggested that increasing ALA intake probably has little or no effect on cardiovascular mortality (moderate-certainty evidence, downgraded once for imprecision).

Cardiovascular events (ALA)

GRADE assessment suggested low-certainty evidence that increasing ALA intake may slightly reduce the risk of cardiovascular events (NNTB 500).

There was little or no effect on risk of cardiovascular events in five trials with increased ALA intake (RR 0.95, 95% CI 0.83 to 1.07; $I^2 = 0\%$; 884 out of > 19,000 participants experienced at least one cardiovascular event; [Analysis 4.21](#)). Sensitivity analyses removing trials at moderate to high risk of bias left three trials in which 691 of more than 5000 enrolled participants experienced at least one cardiovascular event, suggesting a 9% reduction in risk of cardiovascular disease events with higher ALA (RR 0.91, 95% CI 0.79 to 1.04; $I^2 = 0\%$; [Analysis 4.23](#)). Fixed-effect analysis, and limiting to

larger trials, suggested little or no effect on cardiovascular disease event risk ([Analysis 4.22](#); [Analysis 4.24](#)), while trials at low risk of compliance bias suggested a 10% reduction in risk ([Analysis 4.24](#)).

Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, or primary or secondary prevention did not suggest significant differences between subgroups ([Analysis 4.25](#); [Analysis 4.26](#); [Analysis 4.27](#); [Analysis 4.28](#); [Analysis 4.29](#); [Analysis 4.30](#)). Meta-regression to assess for effects of ALA dose on cardiovascular events did not suggest dose effects ($P = 0.67$; [Table 3](#)).

The NNTB was 500 (95% CI 125 to -334), so 500 people would need to increase their ALA intake to prevent one person experiencing a cardiovascular event. The NNTB for primary prevention was 500 (95% CI 125 to -112), the NNTB for secondary prevention was 84 (95% CI 35 to 143). GRADE assessment suggested that increasing ALA intake may reduce the risk of cardiovascular events by a small amount (low-certainty evidence, downgraded once for risk of bias and once for imprecision).

Coronary heart disease mortality (ALA)

GRADE assessment suggested that increasing ALA intake probably has little or no effect on coronary heart disease mortality.

Three trials reported 193 coronary heart disease deaths in more than 18,000 participants, suggesting little or no effect on coronary heart disease mortality with increased ALA (RR 0.95, 95% CI 0.72 to 1.26; $I^2 = 0\%$; [Analysis 4.31](#)). No sensitivity analyses suggested benefits or harms ([Analysis 4.32](#); [Analysis 4.33](#); [Analysis 4.34](#)).

Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, primary or secondary prevention, or previous history of coronary artery disease did not suggest important differences between subgroups ([Analysis 4.35](#); [Analysis 4.36](#); [Analysis 4.37](#); [Analysis 4.38](#); [Analysis 4.39](#); [Analysis 4.40](#); [Analysis 4.41](#)), and meta-regression did not suggest dose effects ($P = 0.94$; [Table 4](#)).

GRADE assessment suggested that increasing ALA intake probably has little or no effect on coronary heart disease mortality (moderate-certainty evidence, downgraded once for imprecision).

Coronary heart disease events (ALA)

Low-certainty evidence suggests that ALA intake may make little or no difference to coronary heart disease events.

Four trials contributed data to this outcome, with 397 of more than 19,000 participants experiencing at least one coronary heart disease event. There was little or no effect on coronary heart disease risk with increased ALA (RR 1.00, 95% CI 0.82 to 1.22 $I^2 = 2\%$; [Analysis 4.42](#)). Sensitivity analyses using fixed-effect meta-analysis did not alter the lack of effect (RR 1.00, 95% CI 0.82 to 1.21; [Analysis 4.43](#)). Removing trials not at low summary risk of bias left two trials with almost 5000 participants, suggesting a 9% reduction in risk of a coronary heart disease event (RR 0.91, 95% CI 0.71 to 1.15; [Analysis 4.44](#)), though little or no effect was seen when restricting analysis to larger trials or those with better compliance ([Analysis 4.45](#)).

Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, primary or secondary prevention, or previous history of coronary artery disease did not suggest important differences between subgroups ([Analysis 4.46](#); [Analysis 4.47](#); [Analysis 4.48](#); [Analysis 4.49](#); [Analysis 4.50](#); [Analysis 4.51](#); [Analysis](#)

4.52). Meta-regression did not suggest a correlation between ALA dose and coronary heart disease events ($P = 0.18$; [Table 5](#)).

Given the differences in sensitivity analyses, GRADE assessment suggested that ALA intake may make little or no difference to coronary heart disease events (low-certainty evidence, downgraded once for risk of bias and once for imprecision).

Stroke (ALA)

The effect of ALA intake on stroke is unclear, as the evidence is of very low certainty.

Five RCTs included more than 19,000 participants, of whom 51 experienced a stroke, suggesting a 15% increase in stroke risk with increased ALA (RR 1.15, 95% CI 0.66 to 2.01; $I^2 = 0\%$; [Analysis 4.53](#)). Sensitivity analyses removing trials not at low summary risk of bias left three trials with 27 stroke events and no suggestion of effect ([Analysis 4.55](#)). Using a fixed-effect model suggested a 23% increased risk of stroke ([Analysis 4.54](#)), while removing trials at high risk of bias due to compliance suggested a 15% reduction in stroke risk, larger trials suggested a 15% greater stroke risk ([Analysis 4.56](#)).

Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, or primary or secondary prevention did not result in significant differences between subgroups ([Analysis 4.57](#); [Analysis 4.58](#); [Analysis 4.59](#); [Analysis 4.60](#); [Analysis 4.61](#); [Analysis 4.62](#)). When examining data reported by type of stroke, only three trials reported on 28 ischaemic strokes, with no clear effects, and no trials reported haemorrhagic stroke ([Analysis 4.63](#)). Meta-regression did not suggest any relationship between ALA dose and risk of stroke ($P = 0.73$; [Table 6](#)).

The effect of ALA on stroke is unclear as the evidence is of very low certainty (downgraded twice for risk of bias and once for imprecision).

Arrhythmia (ALA)

Moderate-certainty evidence suggested that ALA intake probably slightly reduces the risk of arrhythmias (NNTB 91).

Two trials reported effects of ALA on arrhythmia, with 173 arrhythmias in 4912 participants, suggesting a 27% reduction in arrhythmia but with wide confidence intervals (RR 0.73, 95% CI 0.55 to 0.97, $I^2 = 0\%$, [Analysis 4.64](#)). All sensitivity analyses suggested that ALA reduced arrhythmia ([Analysis 4.65](#); [Analysis 4.66](#); [Analysis 4.67](#)). There was no suggestion of a dose-response relationship between ALA and arrhythmia risk in meta-regression ($P = 0.45$; [Table 7](#)).

The NNTB was 91 (95% CI 56 to 1000) so 91 people would need to increase their ALA intake for one person to avoid experiencing arrhythmia. With only two trials it was not possible to estimate NNTB by primary or secondary prevention. GRADE assessment suggested that ALA intake probably slightly reduces the risk of arrhythmias (moderate-certainty evidence, downgraded once for imprecision).

Secondary outcomes

See [Summary of findings 3](#) for a summary of our evidence on effects of LCn3 fats and ALA on serum lipids and measures of adiposity.

Effects of long-chain omega-3 fats (EPA, DHA and DPA) on secondary health outcomes

We did not carry out sensitivity analyses or subgrouping on secondary outcomes, except for adiposity and lipids, which were key outcomes. We did carry out some post hoc sensitivity analyses to further assess effects of LCn3 on myocardial infarction, to ascertain whether the suggested protection was stable to sensitivity analyses.

Major adverse cerebrovascular or cardiovascular events (LCn3)

Five trials reported on major adverse cerebrovascular or cardiovascular events (MACCEs) in more than 34,000 participants, 4232 of whom suffered from a MACCE, suggesting little or no effect of LCn3 fats (RR 1.03, 95% CI 0.97 to 1.09; $I^2 = 0\%$; [Analysis 2.1](#)).

Myocardial infarction (LCn3)

Twenty-seven trials (> 133,000 participants) reported on total (fatal and non-fatal) myocardial infarction. Meta-analyses suggested that increasing LCn3 fats resulted in a reduction in total myocardial infarction (RR 0.88, 95% CI 0.81 to 0.96; $I^2 = 25\%$; 3992 people experiencing at least one myocardial infarction; [Analysis 2.2](#)). This was confirmed in fixed-effect analysis ([Analysis 2.3](#)), sensitivity analyses limited to trials without compliance problems and to those that randomised at least 100 participants ([Analysis 2.5](#)), but analyses limited to trials at low summary risk of bias suggested little or no effect of LCn3 on myocardial infarction (RR 0.93, 95% CI 0.83 to 1.05; $I^2 = 20\%$; > 71,000 participants in 13 trials reporting on 1885 people experiencing at least one myocardial infarction; [Analysis 2.4](#)). This undermines a true protective effect of LCn3 on myocardial infarction.

We ran subgroup analyses by fatality at the request of the WHO NUGAG Subgroup on Diet and Health, finding no significant difference between fatal and non-fatal myocardial infarction subgroups ($P = 0.20$; [Analysis 2.6](#)).

Sudden cardiac death (LCn3)

There was little or no effect of LCn3 fats on sudden cardiac death (RR 0.93, 95% CI 0.77 to 1.11; $I^2 = 41\%$; 1422 deaths, 14 trials in > 73,000 people; [Analysis 2.7](#)).

Angina (LCn3)

Meta-analysis of 13 trials involving more than 48,000 participants, 2829 of whom reported new or worsening angina, suggested little or no effect of increasing LCn3 fats (RR 0.99, 95% CI 0.92 to 1.06; $I^2 = 0\%$; [Analysis 2.8](#)).

Heart failure (LCn3)

Meta-analysis suggested little or no effect of LCn3 fatty acids on heart failure diagnosis in 17 trials with 4651 people experiencing events (RR 0.94, 95% CI 0.87 to 1.02; $I^2 = 23\%$; [Analysis 2.9](#)). Sensitivity analysis limiting to the seven trials at low summary risk of bias also suggested little or no effect (RR 0.97, 95% CI 0.89 to 1.05; $I^2 = 0\%$; 2017 participants experiencing heart failure). We concluded that there was little or no effect of LCn3 on risk of heart failure.

Revascularisation (LCn3)

Meta-analysis suggested little or no effect of LCn3 fats on revascularisation, all types combined (RR 0.93, 95% CI 0.86 to

1.00; $I^2 = 56\%$; 10,793 participants experiencing revascularisation; [Analysis 2.10](#)).

Peripheral arterial disease (LCn3)

Meta-analysis suggested that LCn3 had little or no effect on risk of peripheral arterial disease (RR 0.95, 95% CI 0.76 to 1.18; $I^2 = 0\%$; 6 trials, 325 events in > 57,000 participants; [Analysis 2.11](#)). Sensitivity analysis, limiting to trials at low summary risk of bias, suggested that increasing LCn3 increased the risk of peripheral arterial disease by 10% ([Analysis 2.13](#)), other sensitivity analyses all suggested little or no effect ([Analysis 2.12](#); [Analysis 2.14](#)). The data suggest that there is little or no effect of LCn3 on risk of peripheral arterial disease.

Acute coronary syndrome (LCn3)

There were limited data on effects of increasing LCn3 fats on acute coronary syndrome (RR 1.19, 95% CI 0.71 to 2.00; $I^2 = 0\%$; 2 trials, 55 events in > 2000 participants; [Analysis 2.15](#)).

Body weight, body mass index (BMI) and other measures of adiposity (LCn3)

Body weight

High-certainty evidence shows that increasing LCn3 intake makes little or no difference to body weight.

Fourteen trials reported on the effect of increasing LCn3 on body weight and were included in meta-analysis, suggesting little or no effect in 17,000 participants (mean difference (MD) 0.00 kg, 95% CI -0.69 to 0.70; $I^2 = 42\%$; [Analysis 2.16](#)). Sensitivity analysis limited to trials at low summary risk of bias, low risk from compliance, larger trials or fixed-effect analysis (not shown) did not alter this lack of effect ([Analysis 2.17](#); [Analysis 2.18](#); [Analysis 2.19](#)).

Subgroup analysis by intervention type, primary or secondary prevention, statin use and trial duration did not suggest important differences between subgroups ([Analysis 2.22](#); [Analysis 2.23](#); [Analysis 2.24](#); [Analysis 2.25](#)). There was a marginally significant difference between dose subgroups ($P = 0.05$; [Analysis 2.20](#)) and increased body weight when participants received very high LCn3 doses (> 4.4 g/d LCn3, MD 1.51 kg, 95% CI 0.28 to 2.75; $I^2 = 0\%$; 2 trials, 261 participants; [Analysis 2.20](#)). Subgrouping by replacement suggested differences between subgroups ($P = 0.001$; [Analysis 2.21](#)), with reduced body weight when LCn3 replaced saturated fatty acids or carbohydrates but increased weight when LCn3 replaced nil or low LCn3 ([Analysis 2.21](#)).

Several trials clearly measured body weight but did not report it in a useable way ([Baldassarre 2006](#); [Caldwell 2011](#); [Deslypere 1992](#); [EPE-A 2014](#); [MARINA 2011](#); [Nutrirstroke 2009](#)). Body weight is commonly measured in healthcare settings, so there may be considerably more missing data than this. The funnel plot was not easily interpretable but small differences in effect size between fixed-effect and random-effects meta-analysis supports the possibility of a small amount of small study bias.

GRADE offers high-certainty evidence that LCn3 intake makes little or no difference to body weight (not downgraded).

Body mass index (BMI)

High-certainty evidence shows that LCn3 intake makes little or no difference to BMI.

Fifteen trials, 13 of which we included in meta-analysis, reported on BMI, suggesting little or no effect of LCn3 on BMI (MD 0.06 kg/m², 95% CI -0.14 to 0.25; $I^2 = 39\%$; > 15,000 participants; [Analysis 2.26](#)). This lack of effect was also apparent in sensitivity analyses limited to trials at low summary risk of bias ([Analysis 2.28](#)), with good compliance or with large trial size ([Analysis 2.29](#)), as well as fixed-effect analysis ([Analysis 2.27](#)). Subgroup analyses by primary or secondary prevention, intervention type, statin use and trial duration did not suggest important differences between subgroups ([Analysis 2.32](#); [Analysis 2.33](#); [Analysis 2.34](#); [Analysis 2.35](#)). There were significant differences between subgroups when subgrouped by replacement, suggesting lower BMI when LCn3 replaced saturated fatty acids or carbohydrate, and increased BMI when LCn3 replaced nil or low LCn3 ($P = 0.02$; [Analysis 2.31](#)). There was also a suggestion that increasing LCn3 increased BMI when the dose was above 2.4 g/d ([Analysis 2.30](#)).

Several trials clearly measured BMI but did not report it in a useable way ([Caldwell 2011](#); [EPE-A 2014](#); [Nutrirstroke 2009](#); [Ramirez-Ramirez 2013](#); [Sofi 2010](#)), suggesting that missing data may be an issue with this outcome. The funnel plot was not interpretable, but effect sizes from random-effects and fixed-effect meta-analysis were similar suggesting minimal small study bias.

GRADE offers high-certainty evidence that LCn3 intake makes little or no difference to BMI (not downgraded).

Other measures of adiposity

Few trials reported on other measures of adiposity (percentage body fat, percentage visceral fat, waist circumference, waist/hip ratio, abdominal circumference and hip circumference) with some suggesting higher adiposity and some lower adiposity in groups with more LCn3 ([Analysis 2.36](#)).

Serum lipids (LCn3)

Several trials clearly measured lipids but did not report them in a way that we could include in our meta-analyses. These included [Baldassarre 2006](#), [Gill 2012](#), [Ramirez-Ramirez 2013](#) and [Reed 2014](#). Further trials assessed but did not report triglycerides ([Ahn 2016](#); [Caldwell 2011](#); [Franzen 1993](#); [Rossing 1996](#)), or HDL and LDL cholesterol ([Franzen 1993](#)). Because of the volume of potentially missing data, small study bias may potentially bias these outcomes.

Serum total cholesterol

High-certainty evidence shows that LCn3 intake makes little or no difference to serum total cholesterol.

Thirty trials provided data on long-term effects of LCn3 fats on serum total cholesterol, suggesting little or no effect in more than 38,000 participants (MD -0.01 mmol/L, 95% CI -0.05 to 0.03, $I^2 = 14\%$; [Analysis 2.37](#)). Sensitivity analyses using a fixed-effect model, or limited to trials at low summary risk of bias, low risk of compliance issues, and larger trials also suggested little or no effect of LCn3 on serum total cholesterol ([Analysis 2.38](#); [Analysis 2.39](#); [Analysis 2.40](#)). Subgrouping by duration, primary or secondary prevention and statin use did not suggest any differential effects of LCn3 ([Analysis 2.44](#); [Analysis 2.45](#); [Analysis 2.46](#)). There were almost significant differences between subgroups by dose but no logical sequence suggesting no true dose-response effect ($P = 0.05$; [Analysis 2.41](#)). There were also subgroup differences for replacement and intervention type but there were no subgroups with changes of at least 5% of baseline ([Analysis 2.42](#); [Analysis 2.43](#)).

GRADE assessment suggests high-certainty evidence that LCN3 intake makes little or no difference to serum total cholesterol (not downgraded).

Serum triglycerides

High-certainty evidence suggests that increasing LCN3 intake reduces serum triglycerides, in a dose-dependent manner, by around 15%.

LCN3 fats significantly reduced serum triglycerides in more than 43,000 participants in 23 trials (MD -0.24 mmol/L, 95% CI -0.31 to -0.16; $I^2 = 48\%$; [Analysis 2.47](#)). This effect was not lost in sensitivity analysis excluding trials at moderate to high risk of bias, those without clear compliance or small trials, or using fixed-effect analysis ([Analysis 2.48](#); [Analysis 2.49](#); [Analysis 2.50](#)). Subgrouping suggested that the reduction of serum triglycerides did not differ between subgroups by primary or secondary prevention, statin use, replacement, intervention type or trial duration ([Analysis 2.52](#); [Analysis 2.53](#); [Analysis 2.54](#); [Analysis 2.55](#); [Analysis 2.56](#)). There was a suggestion of a dose-response relationship with greater reductions in triglycerides at higher LCN3 doses, with significant differences between subgroups ($P = 0.04$; [Analysis 2.51](#)).

GRADE assessment suggests high-certainty evidence that increasing LCN3 intake reduces serum triglycerides in a dose-dependent manner (not downgraded).

HDL cholesterol

High-certainty evidence suggests that LCN3 intake has little or no effect on HDL cholesterol.

Thirty trials including more than 46,000 participants suggested little or no effect (an increase of $< 5\%$) in serum HDL cholesterol with increased LCN3 (MD 0.03 mmol/L, 95% CI 0.01 to 0.05; $P = 0.005$, $I^2 = 50\%$; [Analysis 2.57](#)). The finding of little or no effect was retained in all sensitivity analyses ([Analysis 2.58](#); [Analysis 2.59](#); [Analysis 2.60](#)). There were no significant differences between subgroups in any analysis and no suggestion of a dose-response relationship ([Analysis 2.61](#); [Analysis 2.62](#); [Analysis 2.63](#); [Analysis 2.64](#); [Analysis 2.65](#); [Analysis 2.66](#)).

GRADE assessment suggests high-certainty evidence that LCN3 intake has little or no effect on HDL cholesterol (not downgraded).

LDL cholesterol

GRADE assessment suggests high-certainty evidence that LCN3 intake makes little or no difference to LDL cholesterol.

There was little or no effect of increasing LCN3 on serum LDL cholesterol in over 43,000 participants from 25 trials (MD 0.01 mmol/L, 95% CI -0.01 to 0.03; $I^2 = 0\%$; [Analysis 2.67](#)). This lack of effect did not alter in any sensitivity analysis ([Analysis 2.68](#); [Analysis 2.69](#); [Analysis 2.70](#)). We saw no statistically significant differences between subgroups except for with regard to statin use, where there was a less than 5% increase in LDL cholesterol in nine trials where statin use was low ([Analysis 2.71](#); [Analysis 2.72](#); [Analysis 2.73](#); [Analysis 2.74](#); [Analysis 2.75](#); [Analysis 2.76](#)).

GRADE assessment provides high-certainty evidence that LCN3 intake makes little or no difference to LDL cholesterol (not downgraded).

Effects of ALA on secondary health outcomes

We did not plan any sensitivity or subgroup analyses on secondary outcomes, except for the key outcomes of adiposity and lipids. As fewer than 10 ALA trials were available for these outcomes, we carried out only sensitivity analyses.

Major adverse cerebrovascular or cardiovascular events (ALA)

One trial reported on MACCEs in 110 participants, nine of whom experienced an event. There were insufficient data to suggest any effect of ALA on MACCEs (RR 1.12, 95% CI 0.32 to 3.95; [Analysis 5.1](#)).

Myocardial infarction (ALA)

Three trials reported that 333 out of more than 18,000 participants experienced a fatal or non-fatal myocardial infarction, suggesting little or no effect of ALA on myocardial infarction (RR 1.00, 95% CI 0.76 to 1.32; $I^2 = 26\%$; [Analysis 5.2](#)). We carried out subgroup analyses by fatality at the request of the WHO NUGAG Subgroup on Diet and Health, and these suggested no significant differences between fatal and non-fatal myocardial infarction subgroups ($P = 0.36$; [Analysis 5.3](#)).

Sudden cardiac death (ALA)

No trials assessed effects of ALA on sudden cardiac death.

Angina (ALA)

Two trials assessed the effects of increasing ALA on diagnosis of new or worsening angina (39 of $> 13,000$ participants experienced this). There were insufficient data to suggest any effect of ALA on angina (RR 1.41, 95% CI 0.75 to 2.64; $I^2 = 0\%$; [Analysis 5.4](#)).

Heart failure (ALA)

No trials assessed effects of ALA on heart failure.

Revascularisation (ALA)

Only one trial (3 events in 266 participants) reported on the effects of increased ALA on revascularisation (RR 0.72, 95% CI 0.07 to 7.84; 3 events; [Analysis 5.5](#)) or CABG specifically (RR 0.29, 95% CI 0.01 to 5.93; 2 events; [Analysis 5.5](#)). There were insufficient data to suggest any effect of ALA on revascularisation.

Peripheral arterial disease (ALA)

Meta-analysis suggested no clear effect of ALA on peripheral arterial disease in a single trial (RR 0.25, 95% CI 0.05 to 1.17; 10 of the $> 13,000$ participants experienced peripheral arterial disease; [Analysis 5.6](#)). There were insufficient data to suggest any effect of ALA on the outcome.

Acute coronary syndrome (ALA)

No trials assessed effects of ALA on acute coronary syndrome.

Body weight, body mass index (BMI) and other measures of adiposity (ALA)

The effect of LCN3 intake on body weight and BMI is unclear as the evidence is of very low certainty.

Four trials reported on the effect of ALA on body weight in 664 participants, suggesting some weight reduction in those taking more ALA but with extremely high heterogeneity (MD -1.49 kg, 95% CI -4.17 to 1.18; $I^2 = 73\%$; [Analysis 5.7](#)). Sensitivity analysis using

fixed-effect meta-analysis suggested little or no effect of ALA on body weight ([Analysis 5.8](#)), while no trials were at low summary risk of bias ([Analysis 5.9](#)). Retaining only trials at low risk for compliance bias or only larger trials suggested weight reduction with ALA ([Analysis 5.10](#)). There were no significant differences between subgroups by intervention type, dose, duration, replacement, statin use, or primary or secondary prevention of cardiovascular disease ([Analysis 5.11](#); [Analysis 5.12](#); [Analysis 5.13](#); [Analysis 5.14](#); [Analysis 5.15](#); [Analysis 5.16](#)). GRADE assessment suggests that the effect of ALA intake on body weight is unclear, as the evidence is of very low certainty (downgraded once each for risk of bias, inconsistency, publication bias and imprecision).

Three trials reported on BMI, suggesting a reduction in BMI with increased ALA (MD -0.42 kg/m², 95% CI -1.53 to 0.69 ; $I^2 = 65\%$; 1581 participants; [Analysis 5.17](#)), again with high heterogeneity. Sensitivity analyses using fixed-effect analysis or only retaining trials at low summary risk of bias suggested a small increase in BMI with ALA ([Analysis 5.18](#); [Analysis 5.19](#)), while limiting to trials at low risk of compliance bias or eliminating smaller trials suggested a small reduction in BMI with increased ALA ([Analysis 5.20](#)). There were no statistically significant differences between subgroups differentiated by replacement or statin use ([Analysis 5.23](#); [Analysis 5.25](#)), but there were differences by dose; subgrouping by dose suggested greater reduction of BMI in trials giving more ALA ($P = 0.03$; [Analysis 5.21](#)). All included trials gave supplemental foods ([Analysis 5.22](#)). There were greater reductions in BMI in shorter trials ($P = 0.02$; [Analysis 5.24](#)) and in primary prevention trials ($P = 0.03$; [Analysis 5.26](#)), but the inclusion of [Dodin 2005](#) in any subgroup tended to differentiate that group from the others. GRADE assessment suggests that the effect of ALA intake on BMI is unclear, as the evidence is of very low certainty (downgraded once each for risk of bias, inconsistency, publication bias and imprecision).

One trial reported on visceral adipose tissue, suggesting no clear effect. Three trials reported on waist circumference. Meta-analysis of two of these suggested that increasing ALA resulted in reduced weight circumference (MD -1.59 cm, 95% CI -3.10 to -0.07 ; $I^2 = 0\%$; [Analysis 5.27](#)). However, the single trial that we could not include in the meta-analysis due to lack of information on variance suggested effects in the opposite direction. Sensitivity analyses (only retaining trials at low summary risk of bias, not shown) removed all trials.

Serum lipids (ALA)

Serum total cholesterol

Low-certainty evidence suggests that ALA intake may make little or no difference to serum total cholesterol.

Six trials provided data on the long-term effects of ALA on serum total cholesterol, suggesting that increased ALA intake has little or no effect on total cholesterol, with high heterogeneity (MD -0.09 mmol/L, 95% CI -0.23 to 0.05 ; $I^2 = 63\%$; in > 2000 participants; [Analysis 5.28](#)). The suggestion of little or no effect did not alter in any sensitivity analyses ([Analysis 5.29](#); [Analysis 5.30](#); [Analysis 5.31](#)). All trials provided food supplements ([Analysis 5.33](#)), but subgroup analyses suggested greater (though still small) reductions in total cholesterol in trials of shorter duration ($P = 0.02$; [Analysis 5.35](#)). Other differences between subgroups resulted from effect groups where ALA replacement or statin use was 'unclear' ([Analysis 5.34](#); [Analysis 5.36](#)), or there were no differences ([Analysis 5.32](#); [Analysis 5.37](#)). GRADE assessment suggests low-certainty evidence that ALA

intake may make little or no difference to serum total cholesterol (downgraded once each for imprecision and inconsistency).

Serum triglycerides

Moderate-certainty evidence suggests that increasing ALA intake probably makes little or no difference to serum triglycerides.

There was little or no effect of ALA on serum triglycerides in 1776 participants in six trials (MD -0.03 mmol/L, 95% CI -0.11 to 0.05 ; $I^2 = 0\%$; [Analysis 5.38](#)). There was little or no effect of ALA in sensitivity analysis removing trials of moderate to high risk of bias ([Analysis 5.40](#)), in fixed-effect meta-analysis ([Analysis 5.39](#)), or limiting by compliance bias or trial size ([Analysis 5.41](#)). Subgrouping suggested no important differential effects by dose, duration, replacement, intervention type, statin use, or primary or secondary prevention ([Analysis 5.42](#); [Analysis 5.43](#); [Analysis 5.44](#); [Analysis 5.45](#); [Analysis 5.46](#); [Analysis 5.47](#)). GRADE assessment suggests moderate-certainty evidence that ALA intake probably makes little or no difference to serum triglycerides (downgraded once for imprecision).

HDL cholesterol

Moderate-certainty evidence suggests that ALA probably has little or no effect on HDL cholesterol.

There was little or no effect of ALA on HDL cholesterol in 1776 participants of six trials (MD -0.02 mmol/L, 95% CI -0.08 to 0.03 ; $I^2 = 53\%$; [Analysis 5.48](#)), or in any sensitivity analyses ([Analysis 5.49](#); [Analysis 5.50](#); [Analysis 5.51](#)). A further trial, [WAHA 2016](#), also measured HDL but did not provide data in a useable format for meta-analysis. There were no statistically significant differences between subgroups ([Analysis 5.52](#); [Analysis 5.53](#); [Analysis 5.54](#); [Analysis 5.55](#); [Analysis 5.56](#); [Analysis 5.57](#)). GRADE assessment suggests moderate-certainty evidence that ALA probably has little or no effect on HDL cholesterol (downgraded once for imprecision).

LDL cholesterol

Moderate-certainty evidence suggests that ALA intake probably makes little or no difference to LDL cholesterol.

There was little or no effect of increasing ALA on LDL cholesterol in 2201 participants of seven trials (MD -0.05 mmol/L, 95% CI -0.15 to 0.04 ; $I^2 = 46\%$; [Analysis 5.58](#)), with similar effects in all sensitivity analyses ([Analysis 5.59](#); [Analysis 5.60](#); [Analysis 5.61](#)). Subgrouping suggested no differences in effect by ALA dose or primary or secondary prevention ([Analysis 5.62](#); [Analysis 5.63](#); [Analysis 5.64](#); [Analysis 5.66](#); [Analysis 5.67](#)), but there was a statistically significant difference between trials of longer and shorter duration, though little or no effect in both groups ([Analysis 5.65](#)). GRADE assessment suggests moderate-certainty evidence that ALA intake may make little or no difference to LDL cholesterol (downgraded once for imprecision).

Tertiary outcomes

Effects of long-chain omega-3 fats (EPA, DHA and DPA) on tertiary health outcomes

We extracted these outcomes from trials that we included for other outcomes, so we did not assess them completely or systematically. We did not carry out sensitivity analyses or subgrouping for these outcomes. We are aware of missing data for some of these outcomes, including blood pressure in [Ramirez-Ramirez 2013](#).

Blood pressure (LCn3)

Seventeen included trials (> 35,000 participants) contributed data on effects of LCn3 fats on blood pressure. Meta-analysis suggested little or no effect of LCn3 on systolic (MD 0.01 mmHg, 95% CI -0.31 to 0.34; $I^2 = 0\%$; [Analysis 3.1](#)) or diastolic (MD -0.02 mmHg, 95% CI -0.22 to 0.17; $I^2 = 0\%$; [Analysis 3.1](#)) blood pressure in trials of at least one year.

Serious adverse effects (LCn3)

As part of the larger set of reviews, we formally systematically reviewed effects of omega-3 fats on type 2 diabetes diagnoses, measures of glucose metabolism ([Brown 2019](#)), cancers including breast cancer ([Hanson 2019](#)), neurocognitive outcomes such as dementia ([Brainard 2019](#)), irritable bowel disease (IBD) and inflammatory factors ([Thorpe 2017](#)), depression and anxiety ([Deane 2019](#)), and functional outcomes ([Abdelhamid 2019](#)), so we do not present these outcomes here.

We collected data on the following potentially important health outcomes ([Analysis 3.2](#)).

- Any serious adverse event (RR 1.00, 95% CI 0.94 to 1.06; $I^2 = 0\%$; 3 trials, > 9000 participants, 2668 events).
- Bleeding (RR 1.12, 95% CI 0.91 to 1.37; $I^2 = 44\%$; 11 trials, > 80,000 participants, 1324 events). Assessed as being very low-certainty evidence, so the effect of LCn3 on bleeding is unclear ([Summary of findings for the main comparison](#)).
- Serious gastrointestinal events (RR 1.34, 95% CI 0.64 to 2.80; $I^2 = 22\%$; 3 trials, 774 participants, 49 events).
- Pulmonary embolus or DVT (RR 1.15, 95% CI 0.44 to 2.98; $I^2 = 0\%$; 5 trials, > 3000 participants, 20 events). Assessed as being very low-certainty evidence, so the effect of LCn3 on pulmonary embolus or DVT is unclear ([Summary of findings for the main comparison](#)).
- Progression to advanced age-related macular degeneration (RR 0.96, 95% CI 0.90 to 1.02; 1 trial, > 4000 participants, 2049 events).
- Thrombophlebitis: no data identified
- Urolithiasis: no data identified

Side effects (non-serious, LCn3)

To assess side effects we collected data on the following potential side effects ([Analysis 3.3](#)).

- Withdrawal due to side effects: the data suggest more participants taking LCn3 fats dropped out because of side effects (RR 1.16, 95% CI 0.99 to 1.36; $I^2 = 1\%$; 23 trials, > 16,000 participants, 620 dropouts).
- Increased abdominal pain or discomfort: data suggest an association with higher LCn3 (RR 1.05, 95% CI 0.91 to 1.20; $I^2 = 16\%$; 9 trials, > 41,000 participants, 10,040 events).
- Diarrhoea: the data suggested an increased risk with increased LCn3 (RR 1.02, 95% CI 0.87 to 1.19; $I^2 = 49\%$; 13 trials, > 37,000 participants, 12,303 events).
- Nausea: risk increased with LCn3 (RR 1.20, 95% CI 0.96 to 1.49; $I^2 = 54\%$; 8 trials, > 35,000 participants, 7639 events).
- Any gastrointestinal side effect: risk also appeared to increase with LCn3, albeit with very high heterogeneity (RR 1.10, 95%

CI 0.97 to 1.26; $I^2 = 74\%$; 33 trials, > 895,000 participants, 6651 events).

- Skin problems, including itching or rashes: these were not affected by LCn3 in a meta-analysis with high heterogeneity (RR 1.11, 95% CI 0.52 to 2.37; $I^2 = 68\%$; 9 trials, > 36,000 participants, 293 events).
- Headache or worsening migraine: there were limited data on this outcome (RR 0.85, 95% CI 0.51 to 1.40; $I^2 = 0\%$; 4 trials, 1526 participants, 60 events).
- Reflux: there were limited data (RR 1.23, 95% CI 0.79 to 1.91; $I^2 = 32\%$; 3 trials, > 8000 participants, 282 events).
- Joint, lumbar and muscle pain: meta-analysis of data from three trials suggested that LCn3 had little or no effect on such pain (RR 0.95, 95% CI 0.74 to 1.23; > 27,000 participants, 989 people experienced pain).
- All side effects: there was no suggestion that LCn3 increased or decreased all side effects combined in a meta-analysis with very high heterogeneity (RR 1.01, 95% CI 0.95 to 1.08; $I^2 = 79\%$; 14 trials, > 39,000 participants, 9863 people with at least one side effect).

Dropouts (LCn3)

Included trials reported 6643 dropouts in over 56,000 participants in 35 trials, suggesting no difference in dropout rates between intervention and control arms (RR 0.97, 95% CI 0.90 to 1.04; $I^2 = 28\%$; [Analysis 3.4](#)).

Quality of life, economic costs (LCn3)

We found no data on quality-of-life outcomes or economic costs.

Effects of ALA on tertiary health outcomes

We extracted these outcomes from trials that we included for other outcomes, so we did not assess them completely or systematically. We did not carry out sensitivity analyses or subgrouping for these outcomes.

Blood pressure (ALA)

Four included trials (1671 participants) contributed data on effects of ALA on blood pressure. Meta-analysis suggested little or no effect of ALA on systolic (MD -0.87 mmHg, 95% CI -4.48 to 2.75; $I^2 = 58\%$; [Analysis 6.1](#)) or diastolic (MD -1.42 mmHg, 95% CI -4.40 to 1.57; $I^2 = 74\%$; [Analysis 6.1](#)) blood pressure in trials of at least one year. The heterogeneity in these results reflect a single trial, [FLAX-PAD 2013](#), that showed large diastolic and systolic blood pressure effects. The other (larger) trials did not suggest such effects.

Serious adverse effects (ALA)

As part of the larger set of reviews we formally systematically reviewed effects of omega-3 fats on type 2 diabetes diagnoses and measures of glucose metabolism ([Brown 2019](#)), cancers including breast cancer ([Hanson 2019](#)), neurocognitive outcomes such as dementia ([Brainard 2019](#)), irritable bowel disease (IBD) and inflammatory factors ([Thorpe 2017](#)), depression and anxiety ([Deane 2019](#)), and functional outcomes ([Abdelhamid 2019](#)), so we do not present these outcomes here.

We collected data on the following potentially important health outcomes ([Analysis 6.2](#)).

- Any serious adverse event: no data identified
- Bleeding: no data identified
- Serious gastrointestinal effects: no data identified
- Pulmonary embolus or DVT: only one event was identified in a single trial, so there were insufficient data to assess effects. GRADE assessment suggested very low-certainty evidence (downgraded once for risk of bias and twice for imprecision ([Summary of findings 2](#)).
- Progression to advanced age-related macular degeneration: no data identified
- Thrombophlebitis: there were insufficient data to assess effects (RR 1.59, 95% CI 0.72 to 3.51; 1 trial, > 13,000 participants, 26 events).
- Urolithiasis: there were insufficient data to assess effects (RR 0.80, 95% CI 0.47 to 1.36; 1 trial, > 13,000 participants, 54 events).

Side effects (non-serious, ALA)

To assess potential side effects, we collected data on the following ([Analysis 6.3](#)).

- Dropouts due to side effects: data suggested that ALA increased the risk of withdrawal, although there was high heterogeneity (RR 2.10, 95% CI 0.66 to 6.71; $I^2 = 62\%$; 5 trials, > 3000 participants, 68 events).
- Abdominal pain or discomfort: no data identified
- Diarrhoea: a single trial identified 10 participants with diarrhoea, suggesting a higher risk of diarrhoea with greater ALA intake (RR 3.82, 95% CI 0.82 to 17.88).
- Nausea: there were insufficient data to assess effects of ALA (RR 6.29, 95% CI 0.33 to 118.93; 1 trial, 110 participants, 3 events).
- Any gastrointestinal side effect: there were insufficient data to assess effects of ALA (RR 2.06, 95% CI 0.62 to 6.80; $I^2 = 58\%$; 4 trials, > 3000 participants, 49 events). The high heterogeneity suggests that gastrointestinal side effects may be collected in different ways in different trials.
- Skin problems, including itching or rashes: no data identified
- Headache or worsening migraine: no data identified
- Reflux: no data identified
- All side effects combined: no data identified

Dropouts (ALA)

Included trials reported 558 dropouts in over 3000 participants in six trials, suggesting slightly similar dropout rates in participants taking higher and lower ALA (RR 1.08, 95% CI 0.92 to 1.25; $I^2 = 0\%$; [Analysis 6.4](#)).

Quality of life, economic costs (ALA)

We found no data on quality of life outcomes or economic costs.

DISCUSSION

Summary of main results

We included 86 randomised controlled trials (162,796 participants), of which 28 were at low summary risk of bias (randomisation, allocation concealment, selection and detection bias all at low risk for supplementation trials; randomisation, allocation concealment and detection bias all at low risk for dietary advice trials). This compares to 79 RCTs including 112,059 participants, of which

25 were at low summary risk of bias in the previous review ([Abdelhamid 2018a](#)). Trials of 12 to 88 months' duration included adults at varying levels of cardiovascular risk, mainly in high-income countries. Most trials assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet.

Pooled trial results suggested there is probably little or no effect of increasing LCn3 fats on risk of all-cause mortality, cardiovascular deaths, cardiovascular events, stroke or arrhythmias (moderate- and high-certainty evidence). But in this update we found low-certainty evidence suggesting that increasing LCn3 intake may reduce coronary heart disease mortality (NNTB 334) and coronary heart disease events (NNTB 167). These are small effects and have not been apparent in the more limited data sets of the past.

Limiting LCn3 analyses to trials at low summary risk of bias moved the effect size towards 1.0 (the null value) for most primary outcomes except coronary heart disease mortality and arrhythmia. We found no suggestion of dose responses in subgrouping but there were suggestions of dose response by LCn3 dose in meta-regression for cardiovascular disease events and coronary heart disease events. These results apply to supplemental LCn3 intake. We did not see important differences in LCn3 trials between those providing oily fish (dietary source) or EPA/DHA capsules (supplemental source), but as few trials provided whole fish health effects may differ.

Increasing ALA intake suggested moderate- and low-certainty evidence of little or no effect on all-cause mortality, cardiovascular mortality, coronary heart disease mortality or events, but low-certainty evidence suggested a small protection from cardiovascular events (NNTB 500) and moderate-certainty evidence, protection from arrhythmia (NNTB 91). Effects on stroke were unclear. Data were more limited than for LCn3, and there were too few trials for informative funnel plots or subgroup analyses. These suggested that benefits of ALA need to be considered with caution, as effects were small, and few trials addressed the outcomes.

Meta-analyses suggested little or no effect of increasing LCn3 fats intake on secondary outcomes: major adverse cerebrovascular or cardiovascular events, fatal or non-fatal myocardial infarction, or both, sudden cardiac death, new or worsening angina, heart failure, revascularisation, peripheral arterial disease or acute coronary syndrome. There were very limited data on effects of ALA on these outcomes.

High-certainty evidence suggested that increasing LCn3 has little or no effect on measures of adiposity (body weight or BMI), but effects of ALA on measures of adiposity were unclear as the evidence was of very low-certainty. High-certainty evidence shows that increasing LCn3 reduces serum triglycerides by ~15% in a dose-dependent manner, but moderate-certainty evidence suggests little or no effect of ALA on triglycerides. High-certainty evidence showed no effect of increasing LCn3 on total, HDL or LDL cholesterol in these long-term trials, while moderate- and low-certainty evidence suggested little or no effect of increasing ALA on these lipids. Within the included trials we assessed effects on blood pressure, serious adverse effects, side effects and dropouts. There was no suggestion that blood pressure or risk of adverse events such as bleeding differed by LCn3 or ALA intake. Thus, proposed mechanisms for omega-3 activity, including lowering of blood pressure, reduced

thrombotic tendency and anti-arrhythmic effects are not apparent in long-term trials of adult humans, but LCn3 does lower serum triglyceride levels.

The review has provided some answers for its secondary questions.

- If omega-3 fatty acids confer protection:
 - * does protection occur equally in those at low and at high risk of cardiovascular disease? There is no evidence of differential effects on mortality or cardiovascular health by primary or secondary cardiovascular disease prevention, except in the case of LCn3 and arrhythmia, where there is a suggestion of harm in primary prevention, little or no effect in secondary prevention. However, because the underlying risk of an event is different in primary and secondary prevention the NNTB differs in these two groups. For example, in assessing the effects of LCn3 on coronary heart disease mortality the NNTB is 334 (95% CI 200 to infinity), so 334 people would need to increase their LCn3 intake to prevent one death from coronary heart disease. If we assess NNTB by primary or secondary prevention of cardiovascular disease, people without previous cardiovascular disease (needing primary prevention) have an NNTB of 1000 (95% CI NNTB 334 to NNTB 1000), while those with existing cardiovascular disease have an NNTB of 200 (NNTB 91 to NNTB 500). When assessing effects of LCn3 on coronary heart disease events, the NNTB overall is 167 (95% CI 100 to 500), while the NNTB is 200 for primary prevention (95% CI NNTB 112 to NNTB infinity) and 143 for people with existing cardiovascular disease, secondary prevention (NNTB 143, 95% CI NNTB 91 to NNTB 500).
 - * does protection depend on the dose of omega-3 fats taken per day? We ran subgroup analyses for primary and key outcomes and meta-regression for primary outcomes but found no evidence of differential effects by LCn3 or ALA dose on any outcomes except LCn3 on serum triglycerides, cardiovascular disease events and coronary heart disease events, where there were statistically significantly greater reductions with higher LCn3 dose.
 - * do effects differ between dietary and supplemental omega-3 sources? We assessed this question by looking for statistically significant differences between subgroups but found no evidence of differential effects by dietary or supplemental LCn3 or ALA sources. However, few of the LCn3 trials advised or gave fish, most gave supplemental fish oils, so our ability to assess effects of eating more oily whole fish are limited.
 - * does protection depend on trial summary risk of bias? Some analyses suggested a protective effect of LCn3 fats, but these effects disappeared when analyses were limited to trials at low summary risk of bias. The stronger trials with higher internal validity suggested few or no effects of LCn3 on mortality or most cardiovascular disease outcomes, but effects of LCn3 were greater for coronary heart disease mortality and arrhythmia when limited to the trials at low summary risk of bias. On the other hand, for all-cause mortality, cardiovascular disease mortality and events and coronary heart disease mortality and events, ALA trials at low summary risk of bias suggested greater protection with higher ALA than in the main analysis (including trials of all levels of summary risk of bias).

- Is protection or harm stronger with longer trial duration? In subgroup analyses for primary and key outcomes and in meta-regression for primary outcomes, there was no evidence that longer trials increased the effect of LCn3 or ALA. The exceptions were effects of LCn3 on stroke (where trials of longer duration showed smaller risk ratios, or lower risk) and arrhythmia (where the risk of arrhythmia was higher in longer trials).
- Are effects of omega-3 fatty acids dependent on baseline triglyceride levels or diabetic status? In subgroup analyses for primary outcomes we found no evidence that increasing LCn3 had different effects in trials with higher baseline triglycerides or with diabetes or diabetes risk factors, however few trials had raised triglycerides or diabetes at baseline so the assessment was not well powered. The exception was when assessing coronary heart disease events, where the subgroup of three trials with raised triglyceride suggested a greater reduction in coronary heart disease events ([Analysis 1.62](#)), this effect relied on [REDUCE-IT 2019](#). No trials of increased ALA had raised baseline triglycerides or diabetes, so effects could not be assessed for ALA.

Overall completeness and applicability of evidence

We searched very carefully to find all trials relevant to this review and located 86 trials randomising 162,796 participants to higher and lower omega-3 fats (LCn3 or ALA) for at least 12 months.

To reduce selection bias, we contacted authors of trials that appeared to have randomised appropriate participants to appropriate intervention and comparator but may not have published relevant outcomes (to April 2017). If trial authors had assessed any of our outcomes, we requested data and included the trial. This enabled us to include several additional trials. We also contacted authors of all included trials that randomised at least 100 participants (and most smaller trials to April 2017) to request data on any further outcomes (as well as on methodological issues) that may have been recorded but not reported. We tried to contact 72 of the 86 included trials (all except [Baldassarre 2006](#); [HERO 2009](#); [Mita 2007](#); [Nutrystroke 2009](#); [Özaydin 2011](#); [Shinto 2014](#); [Sofi 2010](#); and the newly added trials [ASCEND 2018](#); [Broutset 2007](#); [DREAM Asbell 2018](#); [ENRGISE 2018](#); [HEARTS 2017](#); [REDUCE-IT 2019](#); [VITAL 2019](#)). This allowed us to collect useful additional data on outcomes such as deaths and cardiovascular events that we would not have had access to otherwise. For all trials we carefully searched out and data extracted trials registry entries, protocols, supplementary materials, letters, conference abstracts and additional publications to help us locate additional data.

Most of our newly included trials were previously ongoing. We have detailed 25 remaining ongoing trials, of which seven are newly ongoing, that appear to be unpublished at the time of writing ([Characteristics of ongoing studies](#)). We have labelled these trials as ongoing, although some appear overdue for publication, and their status is unclear – they may constitute missing data. We tried to contact authors of all 'overdue' ongoing trials, and some stated that publications are forthcoming; others did not reply. We suspect that if trial authors have not published outcomes, it is likely that any protective health effects did not reach statistical significance. Given that existing trials suggest no effects of omega-3 fats on cardiovascular health outcomes, any missing data may not affect outcomes greatly; however, for completeness we would prefer to include all available data.

Post hoc, we followed advice to assess differences in effects between EPA and DHA within the review. However, most LCn3 trials provided or advised changes resulting in increased intakes of both EPA and DHA (as in natural fish oil), though in different ratios. Only three trials provided data on DHA only ([ADCS 2010](#); [Berson 2004](#); [Zhang 2017](#)), and six provided data on EPA only ([Doi 2014](#); [JELIS 2007](#); [Mita 2007](#); [Nye 1990](#); [Puri 2005](#); [REDUCE-IT 2019](#)). Unfortunately, for any single outcome, only two or three of these trials were represented, so our ability to assess differential effects of the DHA-only and EPA-only interventions was very limited, and we have not presented these analyses or attempted to draw any information from them.

Quality of the evidence

[Figure 2](#) displays risk of bias of included trials. Of the 86 RCTs, 28 were at low summary risk of bias (at low risk of selection bias, performance bias and detection bias, plus low risk of performance bias in supplemental trials). We assessed the validity of evidence in meta-analyses by running sensitivity analyses that removed trials not at low summary risk of bias. Funnel plots for LCn3 trials suggested that there may be missing trials for all primary outcomes except stroke and arrhythmia, and in all cases adding such trials back in would move effect sizes closer to no effect (RR 1.0). This lack of effect in the trials at lowest risk of bias (with suggestions of effect in trials at moderate to high risk of bias) supported our interpretation of lack of effect of LCn3 fats on many of our primary outcomes.

However, the increased numbers of trials, of longer trials and of greater numbers of people randomised within included trials (up by 31% in this review from the previous iteration, [Abdelhamid 2018a](#)), has increased our power to see small effects of increasing LCn3. We pre-stated that effect sizes needed to be greater than 8% (RR < 0.92 or > 1.08) to suggest an important effect. Effect sizes of 9% or 10% are still small, and for the outcomes that have reached this level of effectiveness in this review NNTBs are still very large. The effects of LCn3 and ALA we are seeing on cardiovascular diseases and triglycerides are small.

Potential biases in the review process

Potential adverse effects include cancers and neurological problems associated with polychlorinated biphenyls (PCBs) or mercury in fish oils, and bleeds associated with reductions in clotting (see [How the intervention might work](#)). We have collated any data on bleeds, including haemorrhagic stroke, in this review, though we did not ask trial authors specifically for additional data on these outcomes. Unfortunately there were insufficient data on serious harms (bleeding and pulmonary embolism or deep vein thrombosis) to assess these potential harms. We have not collated data on cancers ([Hanson 2019](#)), and neurological problems ([Brainard 2019](#)), within this review but have formally systematically reviewed them elsewhere. This approach is preferable to including data on these outcomes from within included trials, which would be incomplete and potentially underpowered to show important effects.

One problem with cardiovascular disease outcomes is that they are collected together in a variety of ways, depending on the trial. For example, in assessing coronary heart disease mortality, we prespecified that we would include the first of the following list reported in any trial: coronary death, ischaemic heart disease

death, fatal myocardial infarction, cardiac death. Each included trial collates outcome data in its own way, so we had to adapt to this in our analysis. One way to get around this problem would be to ask trial authors to go back to their original datasets to assess outcomes in a single prespecified way. This was done by a recent meta-analysis that included only 10 trials but was able to formulate their outcome data to match between trials ([Aung 2018](#)). In doing this they were able to include data on outcomes that we were not able to access. For example, numbers of coronary heart disease deaths for [GISSI-HF 2008](#) have risen considerably in this version of the review, as we were able to include data on coronary heart disease deaths from a greater range of sources than were previously published: sudden cardiac deaths, deaths due to ventricular arrhythmias, and heart failure in patients with coronary heart disease, myocardial infarction, or deaths occurring after coronary revascularisation or heart transplant. Their data are also richer with regard to summing people with events (rather than numbers of events). Numbers of events are relatively easy to extract from published papers, but are not additive across composite endpoints such as cardiovascular disease events or coronary heart disease events (as a single individual may have experienced a stroke and a heart attack as well as onset of angina, but should be counted once only within any one composite outcome - counting events would lead to their inclusion twice in coronary heart disease events and three times for cardiovascular disease events). For that reason previous versions of this review have been conservative in the data we have used, but use of the [Aung 2018](#) data has allowed more data inclusion. The next section discusses similarities and differences between this review and [Aung 2018](#), but their findings were highly similar. For example, effects of LCn3 on coronary heart disease mortality, our meta-analytic estimate of effect of LCn3 was RR 0.90, (95% CI 0.81 to 1.00; $I^2 = 35\%$) in 24 trials reporting 3598 coronary heart disease deaths ([Analysis 1.37](#)), while theirs was RR 0.93 (95% CI 0.83 to 1.03) in 10 trials reporting 2695 coronary heart disease deaths.

While we tried hard to locate all available trials and collect additional outcome data where possible, there was evidence from funnel plots of some small study bias. Some smaller trials showing increased risk of cardiovascular disease outcomes with omega-3 fats may be missing from some of the meta-analyses. If these trials were replaced they would tend to increase risk ratios. This suggests that there is some underlying small study bias within the review.

Underlying risks vary from trial to trial. For example, the risk of death in [GISSI-HF 2008](#) was 28% in people with heart failure at baseline, but less than 4% in the healthy population recruited to [VITAL 2019](#). Despite this there was little suggestion of heterogeneity between trials ($I^2 = 5\%$; [Analysis 1.1](#)). Where there have been suggestions of effects we have translated these into benefits or harms in both higher- and lower-risk populations to clarify.

Given that the many LCn3 trials at moderate to high risk of bias appear to be inflating any protective effects, and that small trial bias is also inflating any protective effects, it is justified to view with skepticism the occasional suggestion of a protective effect. We do see some protective effects, but they are small. Given the very large number of subgroup analyses we carried out, it is also important to treat the occasional subgroup analysis that throws up a statistically significant difference between subgroups very cautiously.

A secondary question asked by this review was about differential effects of dietary and supplemental LCn3 fats. LCn3 interventions included dietary advice (advice to eat more oily fish), supplemental foods (LCn3 fats incorporated into other foods such as margarine) and supplements or capsules (by far the greatest proportion of trials). Dietary fish is likely to have different health effects, as it may take the place of less healthy foods in the diet (leading to reduced saturated fat intake, for example) and provides many nutrients in addition to omega-3 fats (such as protein, selenium, iodine, calcium, magnesium, etc.). There were only four LCn3 dietary advice trials with event data (DART 1989; DART2 2003; DISAF 2003; THIS DIET 2008), and two of these also provided fish oil capsules when participants did not want to eat more fish (DART 1989; DART2 2003). We found no statistically significant differences between dietary advice subgroups and supplemental foods or capsule subgroups for primary outcomes. This may mean that health effects between the two types of intervention are not different, but it is likely that our analysis was underpowered to see any such differences if they exist.

Population LCn3 status varies widely across the world, from over 8% of fatty acids in Japan, Scandinavia and other areas with non-Westernised dietary patterns to less than 4% in North, South and Central America; Europe; the Middle East; Southeast Asia; and Africa (Stark 2016). We hypothesised that additional LCn3 might have greater health effects in people whose usual LCn3 intake was relatively low, but unfortunately we were not able to ascertain baseline LCn3 intake or status for most of our included trials. However, most of the included trials were carried out in areas of the world with lower LCn3 status, so we would expect to see effects of increasing LCn3 in most included trials if such effects exist.

Agreements and disagreements with other studies or reviews

One potential difference between the findings of this review and some other trials and reviews is our running sensitivity analyses assessing effects exclusively in trials at low summary risk of bias. This clarified the lack of effect of LCn3 fats on stroke, which otherwise appeared slightly harmful. On the other hand, these sensitivity analyses suggested protective effects of LCn3 on coronary heart disease mortality and ALA on cardiovascular events. The effectiveness or lack of effectiveness of LCn3 on coronary heart disease events is harder to call. The main analysis suggests a 9% reduction in coronary heart disease events, but sensitivity analyses limiting trials to those at low summary risk of bias, or fixed-effect analysis suggested 7% and 8% reductions, while limiting to trials with low risk of compliance problems or to larger trials suggested reductions of 16% and 11% respectively. We have suggested that this implies that LCn3 does slightly reduce risk of coronary heart disease events, but the interpretation that there was little or no effect is also logical.

There was no suggestion that blood pressure or risk of adverse events such as bleeding differed by LCn3 or ALA intake. This suggests that possible mechanisms for omega-3 activity, including lowering of blood pressure, reduced thrombotic tendency and anti-arrhythmic effects are not important in most adults, though LCn3 does lower serum triglyceride levels. We did not systematically review blood pressure data so may have missed a few long-term trials (though not many) – missing data from included trials is likely to be a bigger issue. Of the 15 included trials that reported blood pressure outcomes, nine reported numbers of hypertensive

participants at baseline, ranging from 5% in MARINA 2011 to 79% of participants in ORIGIN 2012. Effects did not differ by proportions of hypertensive participants ($I^2 = 0\%$ for both systolic and diastolic blood pressure; Analysis 3.1).

Nearly 20 years ago, the GISSI-P 1999 trial suggested that LCn3 had its primary effects in reducing sudden cardiac death. However, the forest plot clearly shows that subsequent trials have not seen this effect individually or in aggregate (Analysis 2.7).

The scope of this review is similar to that of the extensive Agency for Healthcare Research and Quality review (Balk 2016), so we have compared our results with theirs. Given that our review included 86 RCTs randomising more than 162,000 participants, who experienced over 11,000 deaths and more than 5000 cardiovascular disease deaths, we were surprised to read that Balk and colleagues characterised the body of evidence as having "limited data ... from RCTs on the effect of n-3 FA on clinical CVD [cardiovascular disease] outcomes" (Balk 2016). This appears to be because the Balk review excluded RCTs of people with non-cardiovascular disease and non-diabetes-related diseases at baseline, while we included them. While Balk 2016 excluded some trials that we included, it did not include any trials providing all-cause mortality data that we excluded. This meant that in analysing effects on all-cause mortality, Balk 2016 included 18 RCTs randomising 81,027 participants experiencing 8480 deaths, while we included more than 143,000 participants randomised to high or low LCn3 or ALA experiencing 11,297 deaths. Balk 2016 excluded trials that we included, such as AREDS2 2014, a high-quality trial with 368 deaths in more than 4000 participants with age-related macular degeneration. This sort of population appeared ideal to us for assessment of omega-3 fats on primary prevention of cardiovascular disease, as these people tend to be elderly but there is no clear reason why omega-3 fats would affect cardiovascular disease differently in this population than in other older adults at usual cardiovascular disease risk.


Despite these slight differences in approach, we obtained very similar effect estimates to Balk 2016. We meta-analysed effects of LCn3 and ALA trials, finding an RR for all-cause mortality of 0.97 (95% CI 0.93 to 1.01; $I^2 = 5\%$), compared to a pooled RR for all-cause mortality of 0.97 (95% CI 0.92 to 1.03) in Balk 2016. While that review seldom pooled their results, we can compare our results with theirs where they did. Despite our slightly different inclusion criteria, our results are very comparable (Table 8).

A recent individual meta-analysis of 10 large trials in almost 78,000 people at high risk of cardiovascular disease found no associations of LCn3 with coronary heart disease mortality (RR 0.93, 99% CI 0.83 to 1.03), nonfatal myocardial infarction (RR 0.97, 99% CI 0.87 to 1.08), coronary heart disease events (RR 0.96, 95% CI 0.90 to 1.01) or major vascular events (RR 0.97, 95% CI 0.93 to 1.01; Aung 2018). Aung 2018 included individual patient data from the participants of large, long trials (randomising at least 500 participants and following them for at least one year) (AlphaOmega - EPA+DHA 2010; AREDS2 2014; DO IT 2010; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; OMEGA 2009; ORIGIN 2012; Risk & Prevention 2013; SU.FOL.OM3 2010), and this review includes all these trials. Their review had the advantage of being able to ensure that they had complete and equivalent data for all of their key outcomes from all the trials, reducing the risk of publication bias (and this review has incorporated some of their data to improve and extend our data

set), but the disadvantage of missing all the data from many large LCn3 trials such as [DART 1989](#), [DART2 2003](#), [FORWARD 2013](#), [MAPT 2017](#), [SHOT 1996](#) and [SOFA 2006](#), all LCn3 trials randomising at least 500 participants. It also missed large trials of LCn3 in lower-risk participants such as [OPAL 2010](#), and large trials of ALA such as [MARGARIN 2002](#), [Norwegian 1968](#) and [WAHA 2016](#), as well as all the smaller trials. However, though taking different approaches, the numerical results of this review and [Aung 2018](#) are also very similar ([Table 8](#)). [Aung 2018](#) has been updated with data from the three largest recent trials ([ASCEND 2018](#); [REDUCE-IT 2019](#); [VITAL 2019](#)), published as [Hu 2019](#). This review, [Balk 2016](#), [Aung 2018](#) and [Hu 2019](#) addressed the analysis of the data in slightly different ways, creating sensitivity analyses for each other. The fact that they came to similar numerical conclusions reassures us that our conclusions are solidly based. However, the risk ratios for coronary heart disease mortality and events have fallen in this update of the review and crossed the line to suggest small beneficial effects of LCn3.

Cardiovascular diseases and cancers are both major non-communicable killers, so overall assessment of the utility of increasing omega-3 fats will depend on effects on both sets of outcomes. [Figure 6](#) summarises the information on absolute effects of LCn3 and ALA on cardiovascular and cancer outcomes (focusing on outcomes where risk ratios were < 0.92 or > 1.08). The cancer data come from a sister review ([Hanson 2019](#)). Combining data from the two reviews suggests that for every 1000 men increasing their intake of LCn3, three will avoid dying from coronary heart disease, six will avoid a coronary heart disease event, one will avoid the diagnosis of arrhythmia and three additional men will be diagnosed with prostate cancer. Similarly, for every 1000 men increasing their intake of ALA two will avoid a cardiovascular disease event and 11 will avoid diagnosis of arrhythmia but three additional men will be diagnosed with prostate cancer ([Figure 6](#)). These small negative effects on cancer outcomes for men attenuate the small beneficial effects of LCn3 and ALA on cardiovascular outcomes.

Figure 6. Assessment of health effects across cancers and cardiovascular outcomes. Bars above zero suggest the number of people who would benefit out of 1000 people consuming more long-chain omega-3 (LCn3) or alpha-linolenic acid (ALA), bars below zero suggest the number of people who would be harmed out of 1000 people consuming more LCn3 or ALA. Cardiovascular disease (CVD) data are from this review, cancer data from a sister review ([Hanson 2019](#)). CHD: coronary heart disease.



AUTHORS' CONCLUSIONS

Implications for practice

We found high-certainty evidence that long-chain omega-3 fats (LCn3) do not have important positive or negative effects on mortality or cardiovascular events and moderate-certainty evidence that they have little or no effect on cardiovascular disease mortality, stroke or arrhythmia in primary or secondary prevention. However, we found low-certainty evidence that LCn3 slightly reduces risk of coronary heart disease mortality (number needed to treat for an additional beneficial outcome (NNTB) 334, NNTB 200 in secondary prevention, NNTB 1000 in primary prevention), and coronary heart disease events (NNTB 167, NNTB 143 in secondary prevention, NNTB 200 in primary prevention). As these effects

are very small (and numbers needed to treat for an additional benefit high), supplemental LCn3 fats are probably not useful for preventing or treating cardiovascular disease. LCn3 fats can help to reduce serum triglycerides, though they do not appear to affect body fatness or other lipid fractions.

An NNTB of 167 means that 167 people will need to take LCn3 supplements for around four years each so that one of those people avoids a coronary heart disease event. The other 166 people receive no benefit. Similarly, an NNTB of 334 means that 334 people need to take LCn3 supplements for around four years each for one person to avoid death from coronary heart disease, the other 333 people do not benefit.

How does an NNTB of 143 or 500 compare with effective medications in cardiovascular disease prevention? Could we compare, for example, with the use of statins in secondary prevention of myocardial infarction or ezetimibe added to statins after acute coronary syndrome? In the 4S trial ([Scandinavian Simvastatin Survival Study Group 1994](#)), 8% of the participants taking simvastatin died, and 12% of those taking the placebo died, a difference of 4%, so the NNTB was 25. Twenty-five people needed to take simvastatin for around five years to prevent one person dying. Most of us decide to take statins post-myocardial infarction. Ten-year NNTBs for statins in primary prevention when used according to appropriate guidance are around 30, to prevent one case of atherosclerotic cardiovascular disease ([Mortensen 2019](#)). The IMPROVE-IT trial showed that giving ezetimibe in addition to statin to 50 people with acute coronary syndrome for seven years each prevents one person from having a cardiovascular event ([Turgeon 2015](#)).

Individuals may make differing decisions about whether an NNTB of 143 is useful. Perhaps NNTBs should be noted on fish oil supplement packages: "If 143 people with existing cardiovascular disease take this supplement for 5 years each then one of those 143 people will avoid a coronary event (such as a heart attack). If 1000 people without existing cardiovascular disease take this supplement for 5 years each then one person will avoid dying from coronary heart disease". Then each of us could decide whether this is the way we wish to spend our money, on omega-3 supplements or a different cardiovascular treat such as a pair of running shoes, healthy fruit or fish, or a relaxation class.

Most evidence on LCn3 fats came from trials of capsules of fish oil or eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) mixtures. While we did not see important differences between trials of supplemental capsules and trials of oily fish, there were few trials of oily fish. Fish and seafood are nutrient-dense and rich in a variety of other nutrients (such as vitamin D, calcium, iodine, selenium) so are useful foods even without cardiovascular benefits. In light of the evidence in this review it would be appropriate to review official recommendations supporting supplemental LCn3 fatty acid intake.

We found low-certainty evidence that increasing ALA may slightly reduce risk of cardiovascular disease events (NNTB 500) and moderate-certainty evidence that increasing ALA probably reduces risk of arrhythmia (NNTB 91). However, there is probably little or no effect on all-cause or cardiovascular mortality, coronary heart disease mortality or coronary heart disease events (low- and moderate-certainty evidence). As with LCn3, effects of ALA were very small; 91 people would need to increase their ALA intake to prevent one person developing arrhythmia, and 500 would need to take more ALA to prevent one person experiencing a cardiovascular disease event. We found no evidence that ALA affected adiposity or serum lipids. Trials of ALA gave ALA-rich or enriched foods such as walnuts or ALA-enriched margarine.

Implications for research

There are several large ongoing trials of supplemental LCn3 fats (see [Characteristics of ongoing studies](#), and large parts of [VITAL 2019](#) are ongoing). We suggest that given the minimal protective effects suggested for omega-3 fats in the large number of trials to date, no further trials should be initiated until the ongoing trials have reported. Ongoing and completed trials should make data on baseline LCn3 intake, and details of deaths, cardiovascular

outcomes, lipids, adiposity and blood pressure available, as well as other key health outcomes, regardless of their primary outcomes.

Further large and high-certainty trials of ALA carried out in lower- and higher-income countries, and that assess baseline ALA intake and use biomarkers to assess compliance would be helpful to clarify the cardiovascular effects of ALA. Similarly trials of dietary fish would be helpful.

ACKNOWLEDGEMENTS

The wider set of reviews, including this one, were carried out by the Polyunsaturated Fats and Health (PUFAH) group. PUFAH includes Asmaa Abdelhamid, Zoya Ahmed, Sarah MA Ajabnoor, Fai K AlAbdulghafoor, Lena Al-Khudairy, Priti Biswas, Julii Suzanne Brainard, Charlene Bridges, Tracey J Brown, Katherine HO Deane, Daisy H Donaldson, Sarah Hanson, Lee Hooper, Oluseyi F Jimoh, Nicole Martin, Katie Maas, Helen J Moore, Alex T O'Brien, Karen Rees, Ruksana Sivakaran, Fujian Song, Carolyn D Summerbell, Gabrielle C Thorpe, Xia Wang, Ailsa Welch, Lauren Winstanley, and Helen V Worthington.

The review authors thank all of the authors of primary trials who kindly provided us with the best set of data available, including: D Kromhout, Wageningen University ([AlphaOmega - ALA 2010](#); [AlphaOmega - EPA+DHA 2010](#)); Emily Chew, NIH ([AREDS2 2014](#)); J Brox, University Hospital of North Norway ([Brox 2001](#)); C Argo, University of Virginia ([Caldwell 2011](#)); ML Burr, University of Wales and A Ness, University of Bristol ([DART 1989](#); [DART2 2003](#)); G Derosa and P Maffioli, University of Pavia ([Derosa 2016](#)); PNM Demacker, University Hospital Nijmegen ([Deslypere 1992](#)); S Tokudome, National Institute of Health and Nutrition, Japan ([DIPP 2015](#)); R Harrison, University of Manchester, UK ([DISAF 2003](#)); G Einvik, Akershus University Hospital and H Arnesen, Oslo University Hospital ([DO IT 2010](#)); S Dodin, Université Laval ([Dodin 2005](#)); D Schoenfeld, Harvard Medical School ([FAAT 2005](#)); A Macchia, Fundacio'n GESICA ([FORWARD 2013](#)); C Hill, the Queen Elizabeth Hospital ([FOSTAR 2016](#)); D Franzen, Universität zu Köln ([Franzen 1993](#)); P Bauer, Medical University of Vienna ([Lorenz-Meyer 1996](#)); WJ Bemelmans, National Institute for Public Health and the Environment, Bilthoven ([MARGARIN 2002](#)); T Sanders, King's College, London ([MARINA 2011](#)); E Souied, Hôpital intercommunal de Créteil, France ([NAT2 2013](#)); D Nilsen, University of Bergen, Norway ([OFAMI 2001](#)); S Schneider, Institut für Herzinfarktforschung, Germany ([OMEGA 2009](#)); A Dangour, London School of Hygiene & Tropical Medicine ([OPAL 2010](#)); M James, Royal Adelaide Hospital, Australia ([Proudman 2015](#)); R Zurier, University of Massachusetts Medical School ([Reed 2014](#)); C Roncaglioni and I Marzona, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Italy ([Risk & Prevention 2013](#)); A Manni, Penn State College of Medicine, USA ([Sandhu 2016](#)); C von Schacky, Ludwig Maximilians University, Munich, Germany ([SCIMO 1999](#)); L Tapsell, M Batterham and E Neale, University of Wollongong, Australia ([SMART 2013](#)); P Galan, Université Paris ([SU.FOL.OM3 2010](#)); K Tande, Calanus AS, Norway ([Tande 2016](#)); K Tuttle, Sacred Heart Medical Center, Spokane ([THIS DIET 2008](#)); J Sabaté, Loma Linda University, California ([WAHA 2016](#)); E Scorletti, University of Southampton, UK ([WELCOME 2015](#)).

Thanks also to the authors who replied but were not able to provide further details or confirmed no relevant outcomes, including: S Jebb, University of Oxford ([FISH 2012](#)); R Holman, University of Oxford ([AFORRD 2010](#)); J Quinn, Oregon Health & Science University

([ADCS 2010](#)); D Bates, Royal Victoria Infirmary, Newcastle on Tyne and R Dworkin, University of Rochester, UK ([Bates 1989](#)); E Berson, Harvard Medical School, USA ([Berson 2004](#)); A Sanyal, Virginia Commonwealth University, USA ([EPE-A 2014](#)); G Pierce, St. Boniface Hospital Research Centre, Canada ([FLAX-PAD 2013](#)); H Gerstein, McMaster University, Canada ([ORIGIN 2012](#)); B Puri, Imperial College London ([Puri 2005](#)); M Raitt, Oregon Health & Science University, USA ([Raitt 2005](#)); J Eritsland, Oslo University Hospital, Norway ([SHOT 1996](#)); and I Brouwer, Vrije Universiteit Amsterdam, the Netherlands ([SOFA 2006](#)).

Warm thanks and appreciation to the authors of the first review who did not continue as authors in the review update, including Roger A Harrison, Andrew Ness, Nigel E Capps, George Davey Smith, Shah BJ Ebrahim and Rudolph A Riemersma. Acknowledgements for the earlier version of this systematic review, which we have built on to create the current review: our thanks to Julian Higgins, who was involved in the design of the review, along with Theresa Moore and Margaret Burke from Cochrane Heart. Also to Charlotte C Hammer for help with German translation for [Franzen 1993](#).

REFERENCES

References to studies included in this review

ADCS 2010 {published data only}

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* 2010;**304**(17):1903-11.

AFFORD 2013 {published data only}

* Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. *Journal of the American College of Cardiology* 2014;**64**(14):1441-8.

Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al. Multicentre trial of fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress: the atrial fibrillation fish oil research study. *Canadian Journal of Cardiology* 2013;**1**:S383.

Ahn 2016 {published data only}

Ahn J, Park SK, Park TS, Kim JH, Yun E, Kim SP, et al. Effect of n-3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. *Korean Circulation Journal* 2016;**46**(4):481-9. [PUBMED: 27482256]

AlphaOmega - ALA 2010 {published and unpublished data}

Brouwer IA, Geleijnse JM, Klaassen VM, Smit LA, Giltay EJ, De Goede J, et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. *PLOS ONE* 2013;**8**(12):e81519.

Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. *European Heart Journal* 2012;**33**(13):1582-8.

Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2011;**1**:S512.

Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2012;**8**(4):278-87.

Geleijnse JM, Giltay EJ, Schouten EG, De Goede J, Oude Griep LM, Teitsma-Jansen AM, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. *American Heart Journal* 2010;**159**(4):539-46. [DOI: [10.1016/j.ahj.2009.12.033](https://doi.org/10.1016/j.ahj.2009.12.033)]

Giltay EJ, Geleijnse JM, Heijboer AC, De Goede J, Oude Griep LM, Blankenstein MA, et al. No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. *International Journal of Andrology* 2012;**35**(5):680-7.

Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. *American Journal of Clinical Nutrition* 2011;**94**(6):1442-50.

Hoogveen E, Gemen E, Geleijnse M, Kusters R, Kromhout D, Giltay E. Effects of n-3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. *Nephrology Dialysis Transplantation* 2012;**27**:ii64.

Hoogveen EK, Geleijnse JM, Kromhout D, Giltay EJ. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. *European Journal of Preventive Cardiology* 2014;**21**(11):1429-36.

Hoogveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. *Clinical Journal of The American Society of Nephrology: CJASN* 2014;**9**(10):1676-83.

Kromhout D, Geleijnse JM, De Goede J, Oude Griep LM, Mulder BJ, De Boer MJ, et al. N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. *Diabetes Care* 2011;**34**(12):2515-20.

* Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. *New England Journal of Medicine* 2010;**363**(18):2015-26.

AlphaOmega - EPA+DHA 2010 {published and unpublished data}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Brouwer IA, Geleijnse JM, Klaassen VM, Smit LA, Giltay EJ, De Goede J, et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. *PLOS ONE* 2013;**8**(12):e81519.

Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. *European Heart Journal* 2012;**33**(13):1582-8.

Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2011;**1**:S512.

Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2012;**8**(4):278-87.

Geleijnse JM, Giltay EJ, Schouten EG, De Goede J, Oude Griep LM, Teitsma-Jansen AM, et al. Effect of low doses of n-3

fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. *American Heart Journal* 2010;**159**(4):539-46. [DOI: [10/1016/j.ahj.2009.12.033](https://doi.org/10.1016/j.ahj.2009.12.033)]

Giltay EJ, Geleijnse JM, Heijboer AC, De Goede J, Oude Griep LM, Blankenstein MA, et al. No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. *International Journal of Andrology* 2012;**35**(5):680-7.

Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. *American Journal of Clinical Nutrition* 2011;**94**(6):1442-50.

Hoozeveen E, Gemen E, Geleijnse M, Kusters R, Kromhout D, Giltay E. Effects of N-3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. *Nephrology Dialysis Transplantation* 2012;**27**:ii64.

Hoozeveen EK, Geleijnse JM, Kromhout D, Giltay EJ. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. *European Journal of Preventive Cardiology* 2014;**21**(11):1429-36.

Hoozeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. *Clinical Journal of The American Society of Nephrology: CJASN* 2014;**9**(10):1676-83.

Kromhout D, Geleijnse JM, De Goede J, Oude Griep LM, Mulder BJ, De Boer MJ, et al. N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. *Diabetes Care* 2011;**34**(12):2515-20.

* Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. *New England Journal of Medicine* 2010;**363**(18):2015-26.

AREDS2 2014 {published and unpublished data}

Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA* 2013;**309**(19):2005-15. [PUBMED: 23644932]

Age-Related Eye Disease Study, Chew EY, Clemons TE, SanGiovanni JP, Danis RP, Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. *JAMA Ophthalmology* 2014;**132**(2):142-9.

Age-Related Eye Disease Study, Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E, et al. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. *JAMA Ophthalmology* 2013;**131**(7):843-50.

Age-Related Eye Disease Study, Huynh N, Nicholson BP, Agron E, Clemons TE, Bressler SB, et al. Visual acuity after cataract surgery in patients with age-related macular degeneration: age-

related eye disease study 2 report number 5. *Ophthalmology* 2014;**121**(6):1229-36.

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

* Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, et al. Writing Group for the AREDS Research Group. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA Internal Medicine* 2014;**174**(5):763-71.

Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, Group AREDS Research. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). *Ophthalmology* 2012;**119**(11):2282-9.

Chew EY, Clemons TE. In reply: making sense of the evidence from the age-related eye disease study 2 randomized clinical trial. *JAMA Ophthalmology* 2014;**132**(8):1031-2.

Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PS, et al. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. *JAMA* 2015;**314**(8):791-801.

ASCEND 2018 {published data only}

* ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. *New England Journal of Medicine* 2018;**379**(16):1540-50. [DOI: [10.1056/NEJMoa1804989](https://doi.org/10.1056/NEJMoa1804989)]

Bowman L, Aung T, Haynes R, Armitage J. ASCEND: design and baseline characteristics of a large randomised trial in diabetes. *Diabetes* 2012;**61**:A556-7.

NCT00135226. ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes - a randomized 2x2 factorial study of aspirin versus placebo, and of omega-3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005).

Baldassarre 2006 {published data only}

Baldassarre D, Amato M, Eligini S, Barbieri SS, Mussoni L, Frigerio B, et al. Effect of n-3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double-blind pilot study in primary prevention. *Annals of Medicine* 2006;**38**(5):367-75. [DOI: [10.1080/07853890600852880](https://doi.org/10.1080/07853890600852880)]

Bates 1989 {published data only}

Bates DA, Carlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry* 1989;**52**(1):18-22.

Berson 2004 {published data only}

* Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. *Archives of Ophthalmology* 2004;**122**(9):1297-305.

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. *Archives of Ophthalmology* 2004;**122**(9):1306-14.

Broutset 2007 {published data only}

Lanzmann-Petithory D, Broutset J-P, Flammang D, Sorain F, Combe N, LaBelle RS, et al. Prevention of atrial fibrillation recurrence with an α -linolenic acid enriched diet: a randomized study. *Journal of Clinical Lipidology* 2007;**1**(5):524, abstract 439.

NCT00410020. Arrhythmia prevention with an alpha-linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha-linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006).

Brox 2001 {published and unpublished data}

Brox J, Olausson K, Osterud B, Elvevoll EO, Bjornstad E, Brattebog G, et al. A long-term seal- and cod-liver-oil supplementation in hypercholesterolemic subjects. *Lipids* 2001;**36**(1):7-13.

Caldwell 2011 {published data only}

Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. *Journal of Hepatology* 2015;**62**(1):190-7. [PUBMED: 25195547]

* Caldwell SH, Argo CK, Henry TD, Lackner C, Pramoongjago P, Weltman AL, et al. Dissociated histological and metabolic effects of omega-3 (3000 mg/d) versus placebo with both exercise and diet in a double-blind randomized controlled trial of NASH. *Journal of Hepatology* 2011; Vol. 54, issue Supplement 1:S8.

DART 1989 {published and unpublished data}

Burr ML, Fehily AM. Fatty fish and heart disease: a randomized controlled trial. *World Review of Nutrition and Dietetics* 1991;**66**:306-12.

Burr ML, Fehily AM. Fish and the heart. *Lancet* 1989;**ii**:1451-2.

* Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* 1989;**2**(8666):757-61.

Burr ML, Fehily AM, Rogers S, Welsby E, King S, Sandham S. Diet and reinfarction trial (DART): design, recruitment, and compliance. *European Heart Journal* 1989;**10**(6):558-67.

Burr ML, Holliday RM, Fehily AM, Whitehead PJ. Haematological prognostic indices after myocardial infarction: evidence from

the diet and reinfarction trial (DART). *European Heart Journal* 1992;**13**(2):166-70.

Burr ML, Sweetnam PM, Fehily AM. Diet and reinfarction. *European Heart Journal* 1994;**15**(8):1152-3.

Fehily AM, Vaughan-Williams E, Shiels K, Williams AH, Horner M, Bingham G, et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). *Journal of Human Nutrition and Dietetics* 1991;**4**:33-42.

Fehily AM, Vaughan-Williams E, Shiels K, Williams AH, Horner M, Bingham G, et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). *Journal of Human Nutrition & Dietetics* 1989;**2**:4235.

Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction Trial (DART). *European Journal of Clinical Nutrition* 2002;**56**(6):512-8.

Ness AR, Whitley E, Burr ML, Elwood PC, Smith GD, Ebrahim S. The long-term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. *Journal of Human Hypertension* 1999;**13**(11):729-33.

DART2 2003 {published and unpublished data}

Burr ML. Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. *Proceedings of the Nutrition Society* 2007;**66**(1):9-15. [PUBMED: 17343767]

* Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. *European Journal of Clinical Nutrition* 2003;**57**(2):193-200.

Burr ML, Dunstan FD, George CH. Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. *Journal of Membrane Biology* 2005;**206**(2):155-63. [PUBMED: 16456725]

Ness AR, Ashfield-Watt PA, Whiting JM, Smith GD, Hughes J, Burr ML. The long-term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. *Journal of Human Nutrition and Dietetics* 2004;**17**:1-3.

Ness AR, Gallacher JE, Bennett PD, Gunnell DJ, Rogers PJ, Kessler D, et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. *Nutritional Neuroscience* 2003;**6**(1):63-5.

Derosa 2016 {published and unpublished data}

Derosa G, Cicero AF, D'Angelo A, Borghi C, Maffioli P. Effects of n-3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. *BioFactors (Oxford, England)* 2016;**42**(3):316-22. [PUBMED: 27040503]

Deslypere 1992 {published and unpublished data}

Blok WL, Deslypere JP, Demacker PN, Van der Ven-Jongekrijg J, Hectors MP, Van der Meer JW, et al. Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish

oil for 1 year. *European Journal of Clinical Investigation* 1997;**27**(12):1003-8. [PUBMED: 9466128]

* Deslypere JP. Influence of supplementation with n-3 fatty acids on different coronary risk factors in men: a placebo controlled study. *Verhandelingen - Koninklijke Academie voor Geneeskunde van België* 1992;**54**(3):189-216. [PUBMED: 1413984]

Katan MB, Deslypere JP, Van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. *Journal of Lipid Research* 1997;**38**(10):2012-22. [PUBMED: 9374124]

DIPP 2015 {published and unpublished data}

* Tokudome S, Kuriki K, Yokoyama Y, Sasaki M, Joh T, Kamiya T, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. *Prostaglandins Leukotrienes and Essential Fatty Acids* 2015;**94**:1-11. [PUBMED: 25451556]

Tokudome S, Yokoyama Y, Kamiya T, Seno K, Okuyama H, Kuriki K, et al. Rationale and study design of dietary intervention in patients polypectomized for tumors of the colorectum. *Japanese Journal of Clinical Oncology* 2002;**32**(12):550-3. [PUBMED: 12578906]

DISAF 2003 {published and unpublished data}

Harrison RA. Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]. Manchester (UK): Faculty of Medicine, Dentistry, Nursing and Pharmacy, 2005.

Harrison RA, Elton P. From pies to pilchards: dietary assistants increase consumption of oil rich fish. *Journal of Epidemiology and Community Health* 2000;**Suppl**:6.

Harrison RA, Elton PJ. Can an oil-rich fish diet improve treatment outcomes following cardioversion for atrial fibrillation? A randomised controlled trial. Study design and compliance. *International Society for the Study of Fatty Acids and Lipids (ISSFAL)*; 2002 May; Montreal, Canada. 2002.

Harrison RA, Elton PJ. Is there a role for long-chain omega3 or oil-rich fish in the treatment of atrial fibrillation?. *Medical Hypotheses* 2005;**64**(1):59-63. [PUBMED: 15533612]

* Harrison RA, Purnell P, Elton PJ. Using community-based dietary assistants to increase the intake of oil-rich fish among older people. *European Journal of Public Health* 2003;**13**(Suppl 1):105.

Harrison RA, Suresh V, Purnell B, Roberts C, Houghton P, Miller J, et al. Can oil-rich fish sustain normal sinus rhythm after cardioversion for atrial fibrillation? An RCT (DISAF). Author supplied data 29 September 2010.

Dodin 2005 {published data only}

Dodin S, Cunnane SC, Masse B, Lemay A, Jacques H, Asselin G, et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-

controlled trial. *Nutrition (Burbank, Los Angeles County, Calif.)* 2008;**24**(1):23-30. [PUBMED: 17981439]

* Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism* 2005;**90**(3):1390-7. [PUBMED: 15613422]

Doi 2014 {published data only}

Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, et al. Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary syndrome. *European Heart Journal* 2014;**35**(Abstract Suppl):1156.

* Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. *International Journal of Cardiology* 2014;**176**(3):577-82. [PUBMED: 25305703]

Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsukuda S, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. *International Journal of Cardiology* 2017;**228**:173-9. [DOI: [10.1016/j.ijcard.2016.11.105](https://doi.org/10.1016/j.ijcard.2016.11.105)]

Nosaka K, Miyoshi T, Okawa K, Tsukuda S, Sogo M, Nishibe T, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. *Journal of the American College of Cardiology* 2016;**67**:573.

DO IT 2010 {published and unpublished data}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Berstad P, Seljeflot I, Veierod MB, Hjerkin EM, Arnesen H, Pedersen JI. Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. *Clinical Science* 2003;**105**(1):13-20.

Eid HM, Arnesen H, Hjerkin EM, Lyberg T, Ellingsen I, Seljeflot I. Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. *Nutrition & Metabolism* 2006;**3**:4.

Eid HM, Arnesen H, Hjerkin EM, Lyberg T, Ellingsen I, Seljeflot I. Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. *Nutrition and Metabolism* 2006;**3**:1-10.

Einvik G, Ekeberg O, Klemsdal TO, Sandvik L, Hjerkin EM. Physical distress is associated with cardiovascular events in

a high risk population of elderly men. *BMC Cardiovascular Disorders* 2009;**9**:14. [PUBMED: 19331677]

Einvik G, Ekeberg O, Lavik JG, Ellingsen I, Klemsdal TO, Hjerkin EM. The influence of long-term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. *Journal of Psychosomatic Research* 2010;**68**(6):567-72.

* Einvik G, Klemsdal TO, Sandvik L, Hjerkin EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. *European Journal of Cardiovascular Prevention & Rehabilitation* 2010;**17**(5):588-92.

Ellingsen I, Hjerkin EM, Arnesen H, Seljeflot I, Hjermann I, Tonstad S. Follow-up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. *European Journal of Clinical Nutrition* 2006;**60**(3):378-85.

Furenes EB, Seljeflot I, Solheim S, Hjerkin EM, Arnesen H, Furenes EB. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. *Scandinavian Journal of Clinical and Laboratory Investigation* 2008;**68**(3):177-84.

Hjerkin EM, Abdelnoor M, Breivik L, Bergengen L, Ellingsen I, Seljeflot I, et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. *European Journal of Cardiovascular Prevention & Rehabilitation* 2006;**13**(3):325-33.

Hjerkin EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann I, Sandvik L, et al. Influence of long-term intervention with dietary counselling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. *American Journal of Clinical Nutrition* 2005;**81**(3):583-9.

Lindman AS, Pedersen JI, Hjerkin EM, Arnesen H, Veierod MB, Ellingsen I, et al. The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. *Thrombosis and Haemostasis* 2004;**91**(6):1097-104.

Troset M, Arnesen H, Hjerkin EM, Seljeflot I. Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. *Metabolism: Clinical and Experimental* 2009;**58**(11):1543-9.

Troset M, Seljeflot I, Weiss TW, Klemsdal TO, Hjerkin EM, Arnesen H. Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome. *Atherosclerosis* 2010;**209**(2):337-9.

DREAM Asbell 2018 {published data only}

Asbell PA, Maguire MG, Peskin E, Bunya VY, Kuklinski EJ. Dry Eye Assessment and Management (DREAM) Study: study design

and baseline characteristics. *Contemporary Clinical Trials* 2018;**71**:70-9. [DOI: <https://doi.org/10.1016/j.cct.2018.06.002>]

NCT02128763. Dry eye assessment and management study (DREAM). clinicaltrials.gov/ct2/show/NCT02128763 (first received 1 May 2014).

* The Dry Eye Assessment and Management Study Research Group. n-3 fatty acid supplementation for the treatment of dry eye disease. *New England Journal of Medicine* 2018;**378**(18):1681-90. [DOI: [10.1056/NEJMoa1709691](https://doi.org/10.1056/NEJMoa1709691)]

ENRGISE 2018 {published data only}

Cauley JA, Manini TM, Lovato L, Talton J, Anton SD, Domanchuk K, et al. ENRGISE Investigators. The enabling reduction of low-grade inflammation in seniors (ENRGISE) pilot study: screening methods and recruitment results. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 2018;**74**(8):1296-302. [DOI: [10.1093/gerona/gly204](https://doi.org/10.1093/gerona/gly204)]

Manini TM, Anton SD, Beavers DP, Cauley JA, Espeland MA, Fielding RA, et al. ENRGISE pilot study investigators. Enabling reduction of low-grade inflammation in seniors pilot study: concept, rationale, and design. *Journal of the American Geriatrics Society* 2017;**65**:1961-68. [DOI: [10.1111/jgs.14965](https://doi.org/10.1111/jgs.14965)]

NCT02676466. The ENRGISE pilot study (ENRGISE) [The ENRGISE (enabling reduction of low-grade inflammation in seniors) pilot study]. clinicaltrials.gov/ct2/show/NCT02676466 (first received 8 February 2016).

* Pahor M, Anton SD, Beavers DP, Cauley JA, Fielding RA, Kritchevsky SB, et al. for the ENRGISE study investigators. Effect of losartan and fish oil on plasma IL-6 and mobility in older persons. the ENRGISE pilot randomized clinical trial. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 2018;**74**(10):1612-19. [DOI: [10.1093/gerona/gly277](https://doi.org/10.1093/gerona/gly277)]

EPE-A 2014 {published and unpublished data}

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. *Gastroenterology* 2014;**147**(2):377-84.e1. [PUBMED: 24818764]

EPIC-1 2008 {published and unpublished data}

Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. *JAMA* 2008;**299**(14):1690-7.

EPIC-2 2008 {published and unpublished data}

Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. *JAMA* 2008;**299**(14):1690-7.

EPOCH 2014 {published and unpublished data}

Danthiir V, Burns NR, Nettelbeck T, Wilson C, Wittert G. The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on

cognitive ageing and wellbeing in cognitively healthy older adults. *Nutrition Journal* 2011;**10**:117. [PUBMED: 22011460]

* Danthiir V, Hosking D, Burns NR, Wilson C, Nettelbeck T, Calvaresi E, et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n-3 fatty acids. *Journal of Nutrition* 2014;**144**(3):311-20. [PUBMED: 24353345]

Erdogan 2007 {published data only}

* Erdogan A, Bayer M, Kollath D, Greiss H, Voss R, Neumann T, et al. Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. *Heart Rhythm* 2007;**4**(5):S185-6.

Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, et al. Beneficial effects of intravenously administered n-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. *Thoracic and Cardiovascular Surgeon* 2009;**57**:276-80. [DOI: [10.1055/s-0029-1185301](https://doi.org/10.1055/s-0029-1185301)]

Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. *Journal of the American Heart Association* 2013;**2**(1):e005033.

FAAT 2005 {published and unpublished data}

Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. *Circulation* 2005;**112**(18):2762-8.

FLAX-PAD 2013 {published data only (unpublished sought but not used)}

Caligiuri SP, Aukema HM, Ravandi A, Guzman R, Dibrov E, Pierce GN. Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha-linolenic acid-induced inhibition of soluble epoxide hydrolase. *Hypertension* 2014;**64**(1):53-9. [PUBMED: 24777981]

Caligiuri SP, Rodriguez-Leyva D, Aukema HM, Ravandi A, Weighell W, Guzman R, et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. *Hypertension* 2016;**68**(4):1031-8. [PUBMED: 27528063]

Edel A, Rodriguez-Leyva D, Weighell W, La Vallee R, Aliani M, Guzman R, et al. Flaxseed lignan metabolites elicit antihypertensive effects in PAD patients in the FLAX-PAD trial. *Annals of Nutrition and Metabolism* 2013;**63**:1339.

* Edel AL, Rodriguez-Leyva D, Maddaford TG, Caligiuri SP, Austria JA, Weighell W, et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol-lowering medications alone in patients with peripheral artery disease. *Journal of Nutrition* 2015;**145**(4):749-57. [PUBMED: 25694068]

Leyva DR, Zahradka P, Ramjiawan B, Guzman R, Aliani M, Pierce GN. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-

PAD randomized controlled trial. *Contemporary Clinical Trials* 2011;**32**(5):724-30. [PUBMED: 21616170]

Pierce GN, Edel AL, LaVallee R, Caligiuri S, Aukema H, Ravandi A, et al. The use of dietary flaxseed to promote cardiovascular health. *Acta Physiologica* 2014;**211**:15.

Pierce GN, Rodriguez-Leyva D, Edel A, Guzman R, Aliani M. The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease. *Cardiology (Switzerland)* 2013;**126**:201.

Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. *Hypertension* 2013;**62**(6):1081-9. [PUBMED: 24126178]

FORWARD 2013 {published and unpublished data}

Macchia A, Grancelli H, Varini S, Nul D, Ferrante D, Mariani J, et al. Late-breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. *Circulation* 2012;**126**:2780-1.

* Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. *Journal of the American College of Cardiology* 2013;**61**(4):463-8. [PUBMED: 23265344]

Macchia A, Varini S, Grancelli H, Nul D, Laffaye N, Ferrante D, et al. The rationale and design of the FORomegaARD trial: a randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. *American Heart Journal* 2009;**157**(3):423-7. [PUBMED: 19249410]

FOSTAR 2016 {published and unpublished data}

Chen JS, Hill CL, Lester S, Ruediger CD, Battersby R, Jones G, et al. Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial. *Osteoporosis International* 2016;**27**(5):1897-905. [PUBMED: 26694596]

Hill C, Lester SE, Jones G. Response to 'Low-dose versus high-dose fish oil for pain reduction and function improvement in patients with knee osteoarthritis' by Chen et al. *Annals of the Rheumatic Diseases* 2016; Vol. 75, issue 1:e8. [PUBMED: 26662278]

* Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. *Annals of the Rheumatic Diseases* 2016;**75**(1):23-9. [PUBMED: 26353789]

Franzen 1993 {published and unpublished data}

Franzen D. A prospective, randomized, and double-blind trial on the effect of fish oil on the incidence of restenosis following PTCA. *Catheterization and Cardiovascular Diagnosis* 1993;**28**(4):301-10.

* Franzen D, Geisel J, Hopp HW, Oette K, Hilger HH. Long-term effects of low dosage fish oil on serum lipids and lipoproteins [Langzeiteffekte von niedrigdosiertem fischöl auf serumlipide und lipoproteine]. *Medizinische Klinik* 1993;**88**(3):134-8.

Gill 2012 {published data only}

Gill EA, Chen MA, Paramsothy P, Fish B, Isquith D, Thirumalai A, et al. Omega-3 fatty acids effects on carotid IMT in metabolic syndrome. *Circulation* 2014;**130**:A1269. Abstract no. 12697.

* Gill EA, Chen MA, Thirumalai A, Fish B, Paramsothy P. Omega-3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. *Journal of Clinical Lipidology* 2012;**6**:278-9.

GISSI-HF 2008 {published data only}

Aleksova A, Masson S, Maggioni AP, Lucci D, Fabbri G, Beretta L, et al. N-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. *European Journal of Heart Failure* 2013;**15**(11):1289-95.

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Canepa M, Temporelli PL, Rossi A, Gonzini L, Nicolosi GL, Staszewsky L, et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI-Heart Failure trial. *European Journal of Heart Failure* 2016;**18**:442-3.

Cowie MR, Cure S, Bianic F, McGuire A, Goodall G, Tavazzi L. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. *European Journal of Heart Failure* 2011;**13**(6):681-9. [DOI: [10.1093/eurjhf/hfr023](https://doi.org/10.1093/eurjhf/hfr023)]

Finzi A, Barlera S, Serra DM, Rossi MG, Ruggeri A, Mezzani A, et al. Antiarrhythmic effects of n-3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI-HF trial. *European Heart Journal* 2009;**30**:279.

Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. *American Heart Journal* 2011;**161**(2):338-43. [DOI: [10.1016/j.ahj.2010.10.032](https://doi.org/10.1016/j.ahj.2010.10.032)]

Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. *European Journal of Heart Failure* 2010;**12**(12):1345-53.

* GISSI-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**(9645):1223-30. [DOI: [10.1016/S01406736\(08\)61239-8](https://doi.org/10.1016/S01406736(08)61239-8)]

La Rovere MT, Barlera S, Staszewsky L, Mezzani A, Midi P, Marchioli R, et al. Effect of n-3PUFA on heart rate variability. Data from the GISSI-HF Holter substudy. *Circulation* 2011;**124**(21 Suppl 1):A14829.

La Rovere MT, Pinna GD, Maestri R, Barlera S, Bernardinangeli M, Veniani M, et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. *European Journal of Heart Failure* 2012;**14**(12):1410-9.

La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, et al. n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. *Heart Rhythm* 2013;**10**(2):226-32.

Latini R, Masson S, Tacconi M, Bernasconi R, Dragani L, Milani V, et al. Circulating levels of n-3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI-HF trial. *European Heart Journal* 2011;**32**:919.

Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. *European Heart Journal* 2009;**30**(19):2327-36.

Marchioli R, Aldegheri MP, Borghese L, Franzosi MG, Latini R, Marfisi RM, et al. Time course analysis of the effect of n-3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI-HF trial. *European Heart Journal* 2009;**30**:165.

Marchioli R, Cucchi G, Gualco A, Franzosi MG, Levantesi G, Maggioni AP, et al. Time course analysis of the effect of n-3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI-HF trial. *European Heart Journal* 2009;**30**:432.

Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi RM, Minneci C, et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI-Heart failure Trial. *European Heart Journal* 2009;**30**:1026.

Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi RM, Nicolosi GL, et al. Effect of n-3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI-heart failure trial. *European Heart Journal* 2009;**30**:426.

Marchioli R, Franzosi MG, Levantesi G, Marfisi RM, Maggioni AP, Nicolosi GL, et al. Effect of n-3 PUFA according to fish intake: preliminary results of GISSI-Heart Failure. *European Heart Journal* 2009;**30**:707.

Marchioli R, Levantesi G, Silletta MG, Barlera S, Bernardinangeli M, Carbonieri E, et al. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. *Expert Review of Cardiovascular Therapy* 2009;**7**(7):735-48.

Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. *Circulation. Heart Failure* 2010;**3**(1):65-72.

Masson S, Marchioli R, Mozaffarian D, Bernasconi R, Milani V, Dragani L, et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. *American Heart Journal* 2013;**165**(2):208-15.

Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. *American Heart Journal* 2010;**160**(2):286-93. [DOI: [10.1016/j.ahj.2010.05.015](https://doi.org/10.1016/j.ahj.2010.05.015)]

Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *European Journal of Heart Failure* 2004;**6**(5):635-41. [DOI: [10.1016/j.ejheart.2004.03.001](https://doi.org/10.1016/j.ejheart.2004.03.001)]

GISSI-P 1999 {published data only}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F, GISSI-Prevenzione I. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. *Pharmacoeconomics* 2001;**19**(4):411-20.

* GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 1999;**354**:447-55.

Marchioli R. Treatment with n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione Trial. *European Heart Journal Supplements* 2001;**3**(Suppl D):D85-D97.

Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio DD, Franzosi MG, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 2002;**105**:1897-903.

Marchioli R, Di Pasquale A. The biochemical, pharmacological and epidemiological reference picture of the GISSI-Prevenzione. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. *Giornale Italiano di Cardiologia* 1993;**23**(9):933-64.

Marchioli R, Valagussa F. The results of the GISSI-Prevenzione trial in the general framework of secondary prevention. *European Heart Journal* 2000;**21**(12):949-52.

HARP 1995 {published and unpublished data}

Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial.

Annals of Internal Medicine 1996;**125**(7):529-40. [PUBMED: 8815751]

Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. *Lancet* 1994;**344**(8931):1182-6. [PUBMED: 7934538]

* Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis. *Journal of the American College of Cardiology* 1995;**25**(7):1492-8.

HEARTS 2017 {published data only}

* Alfaddagh A, Elajami TK, Ashfaq H, Saleh M, Bistran BR, Welty FK. Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. *Journal of the American Heart Association* 2017;**6**(12):e006981. [DOI: [10.1161/JAHA.117.006981](https://doi.org/10.1161/JAHA.117.006981)]

Alfaddagh A, Elajami TK, Welty FK. Abstract 16294: Omega-3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease. *Circulation* 2016;**134**:A16294.

Alfaddagh A, Mohebbi D, Elajami TK, Saleh M, Welty FK. Abstract 17391: Omega-3 fatty acid index $\geq 4\%$ prevents progression of coronary artery plaque in non-diabetic subjects on statin therapy. *Circulation* 2017;**136** (Suppl 1):A17391.

Alfaddagh A, Welty FK. Abstract 17689: Omega-3 fatty acid supplementation reduces inflammation and improves physical function in patient with coronary artery disease. American Heart Association Conference. 2015:circ.ahajournals.org/content/132/Suppl_3/A17689.short.

Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK. Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease. *Journal of the American Heart Association* 2017;**6**(7):e004740. [DOI: [10.1161/JAHA.116.004740](https://doi.org/10.1161/JAHA.116.004740)]

Elajami TK, Alfaddagh A, Welty FK. Abstract 16353: Triglyceride reduction with omega-3 fatty acids is associated with regression of coronary plaque volume in subjects with coronary artery disease on maximal statin therapy. *Circulation* 2016;**134**:A16353.

Lakshminarayan DK, Elajami TK, Soliman M, Alfaddagh A, Welty FK. Omega-3 fatty acids supplementation attenuates the progression of microalbuminuria in diabetics with coronary artery disease. *Circulation* 2015;**132**:A15530.

HERO 2009 {published and unpublished data}

Tan SY. Dietary Manipulation and Weight Management [PhD thesis]. Wollongong, Australia: University of Wollongong, 2010.

* Tapsell LC, Batterham MJ, Teuss G, Tan SY, Dalton S, Quick CJ, et al. Long-term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes.

European Journal of Clinical Nutrition 2009;**63**(8):1008-15. [PUBMED: 19352378]

JELIS 2007 {published data only}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. *European Journal of Heart Failure* 2006;**8**(1):105-10. [DOI: [10.1016/j.ejheart.2005.12.003](https://doi.org/10.1016/j.ejheart.2005.12.003)]

Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. *Circulation Journal* 2010;**74**(7):1451-7. [DOI: [10.1253/circj.CJ-09-0520](https://doi.org/10.1253/circj.CJ-09-0520)]

Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. Relationships between plasma fatty acid composition and coronary artery disease. *Journal of Atherosclerosis and Thrombosis* 2011;**18**(2):99-107. [PUBMED: 21099130]

Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. *Journal of Atherosclerosis and Thrombosis* 2012;**19**(7):673-9. [PUBMED: 22653220]

Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Secondary prevention analysis from JELIS. *Circulation Journal* 2009;**73**(7):1283-90.

Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis* 2009;**206**(2):535-9. [DOI: [10.1016/j.atherosclerosis.2009.03.029](https://doi.org/10.1016/j.atherosclerosis.2009.03.029)]

Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y, JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. *Circulation Journal* 2010;**74**(3):510-7. [DOI: [10.1253/circj.CJ-09-0746](https://doi.org/10.1253/circj.CJ-09-0746)]

Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis* 2008;**200**(1):135-40. [DOI: [10.1016/j.atherosclerosis.2008.06.003](https://doi.org/10.1016/j.atherosclerosis.2008.06.003)]

Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients:

subanalysis of the JELIS trial. *Stroke* 2008;**39**(8):2052-8. [DOI: [10.1161/STROKEAHA.107.509455](https://doi.org/10.1161/STROKEAHA.107.509455)]

Yamanouchi D, Komori K. Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. *Circulation Journal* 2010;**74**(7):1298-9. [DOI: [10.1253/circj.CJ-10-0449](https://doi.org/10.1253/circj.CJ-10-0449)]

* Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* 2007;**369**(9567):1090-8.

Yokoyama M, Origasa H, for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). *American Heart Journal* 2003;**146**:613-20.

Kumar 2012 {published data only (unpublished sought but not used)}

Kumar S, Sutherland F, Morton JB, Lee G, Morgan J, Wong J, et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. *Heart Rhythm* 2012;**9**(4):483-91. [DOI: [10.1016/j.hrthm.2011.11.034](https://doi.org/10.1016/j.hrthm.2011.11.034)]

Kumar 2013 {published data only (unpublished sought but not used)}

Kumar S, Sutherland F, Stevenson I, Lee JM, Garg ML, Sparks PB. Effects of long-term omega-3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. *International Journal of Cardiology* 2013;**168**(4):3812-7. [PUBMED: 23890856]

Lorenz-Meyer 1996 {published and unpublished data}

Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. *Scandinavian Journal of Gastroenterology* 1996;**31**(8):778-85.

MAPT 2017 {published data only}

* Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurology* 2017;**16**:377-89. [DOI: [10.1016/S1474-4422\(17\)30040-6](https://doi.org/10.1016/S1474-4422(17)30040-6)]

Barreto PdS, Rolland Y, Cesari M, Dupuy C, Andrieu S, Vellas B, for the MAPT Study Group. Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. *Age and Ageing* 2017;**47**(2):281-8. [DOI: [10.1093/ageing/afx164](https://doi.org/10.1093/ageing/afx164)]

Carrie I, Van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, et al. Recruitment strategies for

preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). *Journal of Nutrition, Health & Aging* 2012;**16**(4):355-9.

Delrieu J, Andrieu S, Pahor M, Cantet C, Cesari M, Ousset PJ, et al. Neuropsychological profile of "cognitive frailty" subjects in MAPT study. *Journal of Prevention of Alzheimer's Disease* 2016;**3**(3):151-9. [DOI: [10.14283/jpad.2016.94](https://doi.org/10.14283/jpad.2016.94)]

Delrieu J, Payoux P, Hitzel A, Peiffer S, Abellan Van Kan G, Gillette S, et al. Multidomain Alzheimer's disease preventive trial: florbetapir ancillary study. *Alzheimer's and Dementia* 2011;**1**:S419.

Fougere B, Barreto PD, Goisser S, Soriano G, Guyonnet S, Andrieu S, et al. Red blood cell membrane omega-3 fatty acid levels and physical performance: cross-sectional data from the MAPT study. *Clinical Nutrition* 2017 Apr 12 [Epub ahead of print]:1-4. [DOI: [10.1016/j.clnu.2017.04.005](https://doi.org/10.1016/j.clnu.2017.04.005)]

Gillette S. The Multidomain Alzheimer Preventive Trial (MAPT): a new approach for the prevention of Alzheimer's disease. *Alzheimer's & Dementia* 2009;**5**:4-02-05:145.

Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. *Alzheimer's & Dementia* 2009;**5**(2):114-21.

Gillette-Guyonnet S, Vellas B, Andrieu S, Dupuy C, Carrié I. MAPT study: a 3-year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects-rationale, design and baseline data. *Alzheimer's & Dementia* 2011;**1**:S97-8.

Vellas B, Carrié I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. *Journal of Prevention of Alzheimers Disease* 2014;**1**(1):13-22.

Vellas B, Carrié I, Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT (Multi-domain Alzheimer's Prevention Trial): results at 36 months. *Alzheimer's & Dementia* 2015;**1**:331.

Vellas B, Touchon J, Weiner M. MAPT (Multidomain Alzheimer Preventive Trial) imaging (MRI, FDG-PET, amyloid-PET) data. *Journal of Nutrition, Health and Aging* 2012;**16**(9):812-5.

MARGARIN 2002 {published data only (unpublished sought but not used)}

Bemelmans WJ, Broer J, De Vries JH, Hulshof KF, May JF, Meyboom-De Jong B. Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. *Public Health Nutrition* 2000;**3**(3):273-83.

* Bemelmans WJ, Broer J, Feskens EJ, Smit AJ, Muskiet AJ, Lefrandt JD, et al. Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha-linolenic enriched Groningen dietary intervention (MARGARIN) study. *American Journal of Clinical Nutrition* 2002;**75**:221-7.

Bemelmans WJ, Lefrandt JD, Feskens EJ, Broer J, Tervaert JW, May JF, et al. Change in saturated fat intake is associated with progression of carotid and femoral intima-media thickness, and with levels of soluble intercellular adhesion molecule-1. *Atherosclerosis* 2002;**163**(1):113-20.

Bemelmans WJ, Lefrandt JD, Feskens EJ, Van Haelst PL, Broer J, Meyboom-de Jong B, et al. Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. *European Journal of Clinical Nutrition* 2004;**58**(7):1083-9.

Bemelmans WJ, Muskiet FA, Feskens EJ, De Vries JH, Broer J, May JF, et al. Associations of alpha-linolenic acid and linoleic acid with risk factors for coronary heart disease. *European Journal of Clinical Nutrition* 2000;**54**(12):865-71.

Siero FW, Broer J, Bemelmans WJ, Meyboom-de Jong BM. Impact of group nutrition education and surplus value of Prochaska based stage-matched information on health-related cognitions and on Mediterranean nutrition behaviour. *Health Education Research* 2000;**15**(5):635-47.

MARINA 2011 {published and unpublished data}

Al-Hilal M, Alsaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA, et al. Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. *Journal of Lipid Research* 2013;**54**(2):542-51. [PUBMED: 23160180]

AlSaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA, O'Dell SD. Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. *Journal of Nutrition* 2014;**144**(3):267-72. [PUBMED: 24401815]

Alsaleh A, Crepostnaia D, Maniou Z, Lewis FJ, Hall WL, Sanders TA, et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. *Journal of Nutrition* 2013;**143**(7):1021-7. [PUBMED: 23658423]

Hall WL, Hay G, Maniou Z, Seed PT, Chowienzyk PJ, Sanders TA. Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial. *International Journal of Cardiology* 2013;**168**:4439-42.

Pinto AM, Hall WL, Sanders TAB. Effect of low doses of long chain n-3 PUFA intake on daytime heart rate variability: results from the MARINA study. *European Journal of Preventive Cardiology* 2015;**1**:S146.

Sanders TA, Chowienzyk PJ, Hall W, Lewis F, Seed P, Maniou Z, et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report 2011.

* Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienzyk PJ. Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. *American Journal of Clinical Nutrition* 2011;**94**(4):973-80. [PUBMED: 21865334]

MENU 2016 {published data only (unpublished sought but not used)}

Le T, Flatt SW, Natarajan L, Pakiz B, Quintana EL, Heath DD, et al. Effects of diet composition and insulin resistance status on plasma lipid levels in a weight loss intervention in women. *Journal of the American Heart Association* 2016;**5**(1):e002771. [DOI: [10.1161/JAHA.115.002771](https://doi.org/10.1161/JAHA.115.002771)]

* Rock CL, Flatt SW, Pakiz B, Quintana EL, Heath DD, Rana BK, et al. Effects of diet composition on weight loss, metabolic factors and biomarkers in a 1-year weight loss intervention in obese women examined by baseline insulin resistance status. *Metabolism* 2016;**65**(11):1605-13. [DOI: [10.1016/j.metabol.2016.07.008](https://doi.org/10.1016/j.metabol.2016.07.008)]

Mita 2007 {published data only}

Mita T, Watada H, Ogihara T, Nomiya T, Ogawa O, Kinoshita J, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. *Atherosclerosis* 2007;**191**(1):162-7.

NAT2 2013 {published data only}

Merle BM, Benlian P, Puche N, Bassols A, Delcourt C, Souied EH. Circulating omega-3 fatty acids and neovascular age-related macular degeneration. *Investigative Ophthalmology & Visual Science* 2014;**55**(3):2010-9. [PUBMED: 24557349]

Merle BM, Richard F, Benlian P, Puche N, Delcourt C, Souied EH. CFH Y402H and ARMS2 A69S polymorphisms and oral supplementation with docosahexaenoic acid in neovascular age-related macular degeneration patients: the NAT2 study. *PLoS One* 2015;**10**(7):e0130816. [PUBMED: 26132079]

Querques G, Merle BM, Pumariega NM, Benlian P, Delcourt C, Zourdani A, et al. Dynamic drusen remodelling in participants of the nutritional AMD treatment-2 (NAT-2) randomized trial. *PLOS ONE* 2016;**11**(2):e0149219. [PUBMED: 26901353]

* Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the nutritional AMD treatment 2 study. *Ophthalmology* 2013;**120**(8):1619-31. [PUBMED: 23395546]

Nodari 2011 AF {published data only}

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. N-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. *Circulation* 2011;**124**(10):1100-6. [PUBMED: 21844082]

Nodari 2011 HF {published and unpublished data}

NCT01223703. PUFAs and left ventricular function in heart failure (CS-PUFA-02) [Effects of n-3 polyunsaturated fatty acids (PUFAs) on left ventricular function and functional capacity in patients with dilated cardiomyopathy]. clinicaltrials.gov/ct2/show/NCT01223703 (first received 19 October 2010).

Nodari S, Triggiani M, Berlinghieri N, Milesi G, Foresti A, Gheorghiade M, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in heart failure patients. *European Heart Journal* 2010;**31**:850.

* Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. *Journal of the American College of Cardiology* 2011;**57**(7):870-9.

Nodari S, Triggiani M, Campia U, Zhao L, Manerba A, Milesi G, et al. Plasma levels of n-3 polyunsaturated fatty acids and risk of hospitalization in patients with non-ischemic cardiomyopathy. *Circulation* 2012;**126**(21 Suppl 1):A17431.

Norouzi 2014 {published data only}

* Norouzi Javidan A, Sabour H, Latifi S, Abrishamkar M, Soltani Z, Shidfar F, et al. Does consumption of polyunsaturated fatty acids influence on neurorehabilitation in traumatic spinal cord-injured individuals? A double-blinded clinical trial. *Spinal Cord* 2014;**52**(5):378-82. [PUBMED: 24637568]

Sabour H, Norouzi Javidan A, Latifi S, Shidfar F, Heshmat R, Emami Razavi SH, et al. Omega-3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: a double-blinded randomized clinical trial. *Journal of Spinal Cord Medicine* 2015;**38**(5):599-606. [PUBMED: 25096818]

Norwegian 1968 {published data only}

Natvig H. The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettstoffer hyppigheten av hjerteinfarkt M.M.]. *Tidsskrift for Den Norske Lægeforening* 1967;**87**(11):1033-41.

* Natvig H, Borchgrevink CF, Dedichen J, Owren PA, Schiotz EH, Westlund K. A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965-66. *Scandinavian Journal of Clinical and Laboratory Investigation* 1968;**105**(Suppl):1-20.

Nutristroke 2009 {published data only}

Garbagnati F, Cairella G, De Martino A, Multari M, Scognamiglio U, Venturiero V, et al. Is antioxidant and n-3 supplementation able to improve functional status in post-stroke patients? Results from the Nutristroke Trial. *Cerebrovascular Diseases* 2009;**27**(4):375-83. [DOI: [10.1159/000207441](https://doi.org/10.1159/000207441)]

Nye 1990 {published data only}

Ilsey CD, Nye ER, Sutherland W, Ram J, Ablett MB. Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty. *Australian & New Zealand Journal of Medicine* 1987;**17**:559.

* Nye ER, Ablett MB, Robertson MC, Ilsey CD, Sutherland WH. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. *Australian and New Zealand Journal of Medicine* 1990;**20**(4):549-52.

OFAMI 2001 {published and unpublished data}

Aarsetoy H, Brugger-Andersen T, Hetland O, Grundt H, Nilsen DW. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following

acute myocardial infarction. *Thrombosis and Haemostasis* 2006;**95**(2):329-36.

Grundt H, Hetland O, Nilsen DW. Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n-3 polyunsaturated fatty acids. *Thrombosis and Haemostasis* 2003;**89**(4):752-9.

Grundt H, Nilsen DW, Hetland O, Mansoor MA. Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. *Clinical Nutrition* 2004;**23**(4):491-500.

Grundt H, Nilsen DW, Mansoor MA, Hetland O, Nordoy A. Reduction in homocysteine by n-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. *Pathophysiology of Haemostasis and Thrombosis* 2003;**33**(2):88-95.

Grundt H, Nilsen DW, Mansoor MA, Nordoy A. Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids (PUFAs) following an acute myocardial infarction. *European Journal of Clinical Nutrition* 2003;**57**(6):793-800.

Naesgaard PA, Grundt H, Brede C, Nilsen DW. The effect on vitamin D levels of long-term high-dose treatment with a concentrated omega-3 compound (Omacor/Lovaza) in patients hospitalized with a myocardial infarction. *Circulation* 2014;**130**(Suppl 2):A17245.

* Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. *American Journal of Clinical Nutrition* 2001;**74**(1):50-6.

Poenitz V, Grundt H, Bottazzi B, Cuccovillo I, Mantovani A, Nilsen DW. Pentraxin 3 is uninfluenced by high doses of concentrated omega-3 fatty acids administered for 12 months following an acute myocardial infarction. *Circulation* 2012;**126**(21 Suppl 1):A13464.

OMEGA 2009 {published and unpublished data}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation* 2010;**122**(21):2152-9. [DOI: [10.1161/CIRCULATIONAHA.110.948562](https://doi.org/10.1161/CIRCULATIONAHA.110.948562)]

Rauch B, Schiele R, Schneider S, Gohlke H, Diller F, Gottwik M, et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study. *Cardiovascular Drugs Therapy* 2006;**20**(5):365-75. [DOI: [10.1007/s10557-006-0495-6](https://doi.org/10.1007/s10557-006-0495-6)]

Zimmer R, Riemer T, Rauch B, Schneider S, Schiele R, Gohlke H, et al. Effects of 1-year treatment with highly purified omega-3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. *Journal of Clinical Psychiatry* 2013;**74**(11):e1037-45. [PUBMED: 24330904]

OPAL 2010 {published and unpublished data}

* Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. *American Journal of Clinical Nutrition* 2010;**91**(6):1725-32.

Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. *Journal of Nutrition, Health & Aging* 2009;**13**(3):198-202.

Dangour AD, Allen E, Elbourne D, Fletcher AE, Neveu MM, Uauy R, et al. N-3 fatty acids and retinal function. *Ophthalmology* 2013;**120**(3):643. [DOI: [dx.doi.org/10.1016/j.ophtha.2012.09.043](https://doi.org/10.1016/j.ophtha.2012.09.043)]

Dangour AD, Clemens F, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. *Nutrition Journal* 2006;**5**:20.

ISRCTN72331636. The OPAL Study: older people and n-3 long-chain polyunsaturated fatty acids. www.isrctn.com/ISRCTN72331636 (first received 27 April 2004). [ISRCTN72331636]

ORIGIN 2012 {published data only}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Bordeleau L, Yakubovich N, Dagenais G, Rosenstock J, Ryden LE, Spinaz G, et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. *Diabetes* 2013;**62**:A72.

Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang Yu P, et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. *Diabetes Care* 2014;**37**(5):1360-6.

Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hancu N, et al. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). *Diabetes Care* 2013;**36**(9):2466-74.

Maggioni AP, Fabbri G, Bosch J, Dyal L, Ryden LE, Gerstein HC, et al. Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. *European Heart Journal* 2013;**34**:352.

* Origin Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *New England Journal of Medicine* 2012;**367**(4):309-18.

Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). *American Heart Journal* 2008;**155**(1):26-32, 32.

Origin Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *New England Journal of Medicine* 2012;**367**(4):319-28.

Punthakee Z, Gerstein HC, Bosch J, Tyrwhitt J, Jung H, Lee SF, et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINE). *Diabetes Care* 2016;**39**(5):709-16.

ORL 2013 {published data only}

* Tatsuno I, Saito Y, Kudou K, Ootake J. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. *Journal of Clinical Lipidology* 2013;**7**(6):615-25. [PUBMED: 24314359]

Tatsuno IT, Saito YS, Kudou KK, Otake JO, Minamide YM. Effects of long-term treatment with omega-3 polyunsaturated fatty acids (Lotriga) on atherogenic lipoproteins in hypertriglyceridemia: results from a phase 3 randomized, open-label, 1-year study. *European Heart Journal* 2013;**34**:768.

Özaydin 2011 {published data only}

Özaydin M, Erdoğan D, Tayyar S, Uysal BA, Doğan A, Içli A, et al. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. *Anadolu Kardiyoloji Dergisi* 2011;**11**(4):305-9. [DOI: [10.5152/akd.2011.080](https://doi.org/10.5152/akd.2011.080)]

Proudman 2015 {published and unpublished data}

Proudman S, Spargo L, Hall C, McWilliams L, Lee A, Maureen R, et al. Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose. *Internal Medicine Journal* 2012;**42**(Suppl 1):2-3.

* Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ. Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis. *British Journal of Nutrition* 2015;**114**(6):885-90. [PUBMED: 26283657]

Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. *Annals of the Rheumatic Diseases* 2015;**74**(1):89-95. [PUBMED: 24081439]

Puri 2005 {published data only}

Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: a

double-blind, randomized, placebo-controlled trial. *Neurology* 2005;**65**(2):286-92.

Raitt 2005 {published data only}

Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. *JAMA* 2005;**293**(23):2884-91.

Ramirez-Ramirez 2013 {published data only}

* Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-Moises F, Torres-Sanchez ED, Sorto-Gomez TE, et al. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. *Oxidative Medicine and Cellular Longevity* 2013;**2013**:709493. [DOI: [10.1155/2013/709493](https://doi.org/10.1155/2013/709493)]

Sorto-Gomez TE, Ortiz GG, Pacheco-Moises FP, Torres-Sanchez ED, Ramirez-Ramirez V, Macias-Islas MA, et al. Effect of fish oil on glutathione redox system in multiple sclerosis. *American Journal of Neurodegenerative Disease* 2016;**5**(2):145-51.

REDUCE-IT 2019 {published data only}

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, et al. REDUCE-IT Investigators. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. *Clinical Cardiology* 2017;**40**(3):138-48.

* Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *New England Journal of Medicine* 2019;**380**:11-22. [DOI: [10.1056/NEJMoa1812792](https://doi.org/10.1056/NEJMoa1812792)]

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. *Journal of the American College of Cardiology* 2019;**73**(22):2791-802.

NCT01492361. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE-IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011).

Reed 2014 {published and unpublished data}

Oleandzki BC, Leung K, Van Buskirk S, Reed G, Zurier RB. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. *Evidence-based Complementary and Alternative Medicine : ECAM* 2011;**2011**:827286.

* Reed GW, Leung K, Rossetti RG, Vanbuskirk S, Sharp JT, Zurier RB. Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial. *Evidence-based Complementary and Alternative Medicine : ECAM* 2014;**2014**:857456.

Risk & Prevention 2013 {published and unpublished data}

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Rischio and Prevenzione Investigators. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. *Trials* 2010;**11**(1):68.

* Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, et al. N-3 fatty acids in patients with multiple cardiovascular risk factors. *New England Journal of Medicine* 2013;**368**(19):1800-8.

Visentin G, Risk & Prevention Study Group. Towards evidence-based practice via practice-based evidence: the Italian experience. *Family Practice* 2008;**25**(Suppl 1):i71-4.

Rossing 1996 {published and unpublished data}

Myrup B, Rossing P, Jensen T, Parving H-H, Holmer G, Gram J, et al. Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. *Scandinavian Journal of Clinical & Laboratory Investigation* 2001;**61**(5):349-56.

* Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving HH. Fish oil in diabetic nephropathy. *Diabetes Care* 1996;**19**(11):1214-9.

Sandhu 2016 {published data only}

* Sandhu N, Schetter SE, Liao J, Hartman TJ, Richie JP, McGinley J, et al. Influence of obesity on breast density reduction by omega-3 fatty acids: evidence from a randomized clinical trial. *Cancer Prevention Research* 2016;**9**(4):275-82. [PUBMED: 26714774]

Signori C, DuBrock C, Richie JP, Prokopczyk B, Demers LM, Hamilton C, et al. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. *European Journal of Clinical Nutrition* 2012;**66**(8):878-84. [PUBMED: 22669332]

SCIMO 1999 {published and unpublished data}

Angerer P, Kothny W, Stork S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. *Cardiovascular Research* 2002;**54**(1):183-90.

* von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 1999;**130**(7):554-62.

von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. *Lipids* 2001;**36**(Suppl):S99-102.

seAFOod Hull 2018 {published data only}

Hull MA, Sandell AC, Montgomery AA, Logan RF, Clifford GM, Rees CJ, et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. *Trials [Electronic Resource]* 2013;**14**:237.

* Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2x2 factorial trial. *Lancet* 2018;**392**(10164):2583-94. [DOI: [10.1016/S0140-6736\(18\)31775-6](https://doi.org/10.1016/S0140-6736(18)31775-6)]

Shinto 2014 {published data only}

NCT00090402. Fish oil and alpha lipoic acid in treating Alzheimer's Disease [Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease]. clinicaltrials.gov/ct2/show/NCT00090402 (first received 24 August 2004). [CENTRAL: NCT00090402]

* Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. *Journal of Alzheimer's Disease* 2014;**38**(1):111-20. [PUBMED: 24077434]

SHOT 1996 {published and unpublished data}

Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M. Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation. *Scandinavian Journal of Clinical and Laboratory Investigation* 1995;**55**(4):295-300.

* Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. *American Journal of Cardiology* 1996;**77**(1):31-6.

Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of supplementation with n-3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study. *European Heart Journal* 1994;**15**:29.

Eritsland J, Arnesen H, Seljeflot I, Hostmark AT. Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease. *American Journal of Clinical Nutrition* 1995;**61**(4):831-6.

Eritsland J, Arnesen H, Seljeflot I, Kierulf P. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. *Blood Coagulation & Fibrinolysis* 1995;**6**(1):17-22.

Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H. Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. *Fibrinolysis* 1994;**8**(2):120-5.

Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H, Torjesen PA. Long-term effects of n-3 fatty acids on serum lipids and

glycaemic control. *Scandinavian Journal of Clinical and Laboratory Investigation* 1994;**54**(4):273-80.

Eritsland J, Seljeflot I, Arnesen H, Abdelnoor M. Long-term effects of fish oil supplementation in patients with coronary artery disease: influence on lipoproteins, coagulation and fibrinolysis. *Thrombosis Research* 1992;**65**:75.

Eritsland J, Seljeflot I, Arnesen H, Abdelnoor M. Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. *Thrombosis and Haemostasis* 1993;**69**:1065.

Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kierulf P. Effect of long-term, moderate-dose supplementation with omega-3 fatty acids on monocyte procoagulant activity and release of interleukin-6 in patients with coronary artery disease. *Thrombosis Research* 1995;**77**(4):337-46.

Sianni 2013 {published data only}

Sianni A, Matsoukis I, Ganotopoulou A, Paraskevas P, Asimis A, Tsivilis N, et al. Effect of omega 3 fatty acids in patients with hypertension and atrial fibrillation. *Clinical Nutrition* 2013;**32**:S70-1.

SMART 2013 {published and unpublished data}

Anil S, Charlton KE, Tapsell LC, Probst Y, Ndanuko R, Batterham MJ. Identification of dietary patterns associated with blood pressure in a sample of overweight Australians. *Journal of Human Hypertension* 2016;**30**(11):672-8. [DOI: [10.1038/jhh.2016.10](https://doi.org/10.1038/jhh.2016.10)]

Tapsell LC, Batterham MJ, Charlton KE. Effect of dietary restriction and n-3 PUFA supplementation on insulin resistance in obese adults. *FASEB Journal* 2010;**24**:733.9.

* Tapsell LC, Batterham MJ, Charlton KE, Neale EP, Probst YC, O'Shea JE, et al. Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial. *BMC Public Health* 2013;**13**:1231. [PUBMED: 24369765]

Zhang Q, O'Shea JE, Thorne RL, Tapsell LC, Batterham M, Charlton KE. Baseline characteristics of volunteers in the smart clinical trial: associations between habitual physical activity and lifestyle disease risk factors. *Nutrition and Dietetics* 2010;**67**(Suppl 1):67-8.

SOFA 2006 {published and unpublished data}

Brouwer IA, Katan MB, Schouten EG, Camm AJ, Hauer RN, Wever EF, et al. Rationale and design of a clinical trial on n-3 fatty acids and cardiac arrhythmia (SOFA). *Annals of Nutrition & Metabolism* 2001;**45**(Suppl 1):79.

Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF, Zock PL, Morris C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. *European Heart Journal* 2009;**30**(7):820-6.

* Brouwer IA, Zock PL, Camm AJ, Böcker D, Hauer RN, Wever EF, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. *JAMA* 2006;**295**(22):2613-9.

Brouwer IA, Zock PL, Wever EF, Hauer RN, Camm AJ, Böcker D, et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA. *European Journal of Clinical Nutrition* 2003;**57**:1323-30.

Sofi 2010 {published data only}

Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. *International Journal of Food Sciences and Nutrition* 2010;**61**(8):792-802. [PUBMED: 20465434]

SU.FOL.OM3 2010 {published and unpublished data}

Ahluwalia N, Blacher J, Szabo De Edelenyi F, Faure P, Julia C, Hercberg S, et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. *Atherosclerosis* 2013;**228**(2):478-84.

Andreeva VA, Galan P, Torres M, Julia C, Hercberg S, Kesse-Guyot E. Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUPplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial. *American Journal of Clinical Nutrition* 2012;**96**(1):208-14.

Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. *American Journal of Clinical Nutrition* 2011;**94**(1):278-86.

Andreeva VA, Latache C, Hercberg S, Briancon S, Galan P, Kesse-Guyot E. B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. *PloS One* 2014;**9**(1):e84844.

Andreeva VA, Touvier M, Kesse-Guyot E, Julia C, Galan P, Hercberg S. B vitamin and/or omega-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial. *Archives of Internal Medicine* 2012;**172**(7):540-7.

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Blacher J, Czernichow S, Paillard F, Ducimetiere P, Hercberg S, Galan P, et al. Cardiovascular effects of B-vitamins and/or n-3 fatty acids: the SU.FOL.OM3 trial. *International Journal of Cardiology* 2013;**167**(2):508-13.

Blacher J, Safar ME, Ly C, Szabo De Edelenyi F, Hercberg S, Galan P. Blood pressure variability: cardiovascular risk integrator or independent risk factor. *Journal of Human Hypertension* 2015;**29**(2):122-6.

Fezeu LK, Laporte F, Kesse-Guyot E, Andreeva VA, Blacher J, Hercberg S, et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. *PLOS ONE* 2014;**9**(4):e92548.

Galan P, Briançon S, Blacher J, Czernichow S, Hercberg S. The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. *Trials* 2008;**9**:35. [DOI: [10.1186/1745-6215-9-35](https://doi.org/10.1186/1745-6215-9-35)]

Galan P, Briançon S, Blacher J, Czernichow S, Hercberg S. The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. *Sang Thrombose Vaisseaux* 2009;**21**(4):207-13.

Galan P, Briançon S, Blacher J, Czernichow S, Hercberg S. The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga-3 dans la prévention de la récurrence de pathologies ischémiques]. *Sang Thrombose Vaisseaux* 2009;**21**(4):207-13.

* Galan P, Kesse-Guyot E, Czernichow S, Briançon S, Blacher J, Hercberg S, SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* 2010;**341**:c6273. [DOI: [10.1136/bmj.c6273](https://doi.org/10.1136/bmj.c6273)]

Galan P, de Bree A, Mennen L, Potier de Courcy G, Preziosi P, Bertrais S, et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. *Journal of Nutrition, Health and Aging* 2003;**7**(6):428-35.

Kesse-Guyot E, Peneau S, Hercberg S, Galan P, Vogt L, Escande M, et al. Thirteen-year prospective study between fish consumption, long-chain N-3 fatty acids intakes and cognitive function. *Journal of Nutrition, Health and Aging* 2011;**15**(2):115-20.

Szabo De Edelenyi F, Vergnaud AC, Ahluwalia N, Julia C, Hercberg S, Blacher J, et al. Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD. *British Journal of Nutrition* 2012;**107**(6):921-7.

Vesin C, Galan P, Gautier B, Czernichow S, Hercberg S, Blacher J. Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?. *European Journal of Cardiovascular Prevention and Rehabilitation* 2010;**17**(5):541-8.

de Bree A, Mennen LI, Hercberg S, Galan P. Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases. *European Journal of Clinical Nutrition* 2004;**58**(5):732-44.

Tande 2016 {published and unpublished data}

Tande KS, Vo TD, Lynch BS. Clinical safety evaluation of marine oil derived from *Calanus finmarchicus*. *Regulatory Toxicology and Pharmacology* 2016;**80**:25-31. [PUBMED: 27233921]

THIS DIET 2008 {published and unpublished data}

Packard DP, Milton JE, Shuler LA, Short RA, Tuttle KR. Implications of chronic kidney disease for dietary treatment of cardiovascular disease. *Journal of Renal Nutrition* 2006;**16**(3):259-68.

* Tuttle KR, Shuler LA, Packard DP, Milton JE, Daratha KB, Bibus DM, et al. Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). *American Journal of Cardiology* 2008;**101**(11):1523-30. [PUBMED: 18489927]

VITAL 2019 {published data only}

Bassuk SS, Manson JE, Lee IM, Cook NR, Christen WG, Bubes VY, et al. Baseline characteristics of participants in the Vitamin D and omega-3 trial (VITAL). *Contemporary Clinical Trials* 2016;**47**:235-43.

Gold DR, Litonjua AA, Carey VJ, Manson JE, Buring JE, Lee IM, et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. *Contemporary Clinical Trials* 2016;**47**:185-95.

Gold DR, Luttmann-Gibson H, Litonjua AA, Friedenber G, Gordon D, Lee IM, et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega-3 trial. *American Journal of Respiratory and Critical Care Medicine* 2014;**189**:D44 COPD.

Kang JH, Grodstein F, Manson JAE. Cognitive substudy of the vitamin d and omega-3 trial (VITAL-COG): design of a large randomized trial of omega-3 and vitamin D supplements in relation to cognitive change. *Alzheimer's & Dementia* 2015;**1**:608.

LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE, Manson JE. VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and Omega-3 Trial (VITAL). *Contemporary Clinical Trials* 2015;**41**:259-68.

Manson JA. Vitamin D and cancer and cardiovascular disease: ready for prime time?. *Menopause* 2010;**17**(6):1215.

Manson JE. Vitamin D and the heart: why we need large-scale clinical trials. *Cleveland Clinic Journal of Medicine* 2010;**77**(12):903-10.

Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, et al. The VITamin D and Omega-3 Trial (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. *Contemporary Clinical Trials* 2012;**33**(1):159-71.

* Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. *New England Journal of Medicine* 2019;**380**:23-32. [DOI: [10.1056/NEJMoa1811403](https://doi.org/10.1056/NEJMoa1811403)]

NCT01169259. Vitamin D and omega-3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010).

Pradhan AD, Manson JE. Update on the vitamin D and omega-3 trial (VITAL). *Journal of Steroid Biochemistry & Molecular Biology* 2016;**155**(Pt B):252-6.

WAHA 2016 {published and unpublished data}

Bitok E, Jaceldo-Siegl K, Rajaram S, Serra-Mir M, Roth I, Feitas-Simoes T, et al. Favourable nutrient intake and displacement with long-term walnut supplementation among elderly: results of a randomised trial. *British Journal of Nutrition* 2017;**118**(3):201-9. [DOI: [10.1017/S0007114517001957](https://doi.org/10.1017/S0007114517001957)]

Bitok E, Rajaram S, Ros E. Does a daily walnut supplement given for a year result in body weight gain?. *FASEB Journal* 2016; Vol. 30:1157.5.

Huey L, Bitok E, Kazzi N. Dietary compliance of walnut or no walnut intake in a 1-year randomized intervention trial among free-living elderly in the Walnuts and Healthy Aging Study (WAHA). *FASEB Journal* 2016; Vol. 30:1157.10.

Rajaram S, Valls-Pedret C, Cofan M, Sabate J, Serra-Mir M, Perez-Heras AM, et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. *Frontiers in Aging Neuroscience* 2017;**8**:333. [PUBMED: 28119602]

* Ros E, Rajaram S, Sala-Vila A, Serra-Mir M, Valls-Pedret C, Cofan M, et al. Effect of a 1-year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. *FASEB Journal* 2016; Vol. 30, issue 1 Suppl:293.4.

Weinstock-Guttman 2005 {published data only}

Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with n-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 2005;**73**:397-404. [DOI: [10.1016/j.plefa.2005.05.024](https://doi.org/10.1016/j.plefa.2005.05.024)]

WELCOME 2015 {published and unpublished data}

Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. *Atherosclerosis* 2016;**246**:13-20. [PUBMED: 26748347]

Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2014;**34**(6):1155-61. [PUBMED: 24743428]

Byrne CD, Targher G. Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease.

Gastroenterology 2016; Vol. 150, issue 1:7-10. [PUBMED: 26602219]

Clough GF, McCormick KG, Scorletti E, Bhatia L, Calder PC, Griffin MJ, et al. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex evaluation of fatty liver and cardiovascular markers in NAFLD with Omacor therapy trial (WELCOME) trial. *Diabetologia* 2016;**59**(7):1422-9. [PUBMED: 27106721]

Hodson L, Bhatia L, Scorletti E, Smith DE, Jackson NC, Shojaei-Moradie F, et al. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. *European Journal of Clinical Nutrition* 2017;**71**(8):973-9. [PUBMED: 28294174]

McCormick KG, Scorletti E, Bhatia L, Calder PC, Griffin MJ, Clough GF, et al. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. *Diabetologia* 2015;**58**(8):1916-25. [PUBMED: 26021488]

McCormick KG, Scorletti ES, Bhatia L, Calder PC, Griffin MJ, Clough GF, et al. Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n-3 fatty acids. *Diabetic Medicine* 2015;**32**(S1):99.

Scorletti E, Bhatia B, McCormick KG, Clough GF, Nash K, Hodson L, et al. Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study. *Diabetic Medicine* 2014;**31**:1.

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. *Contemporary Clinical Trials* 2014;**37**(2):301-11. [PUBMED: 24556343]

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. *Contemporary Clinical Trials* 2014;**38**(1):156.

* Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study. *Hepatology (Baltimore, MD)* 2014;**60**(4):1211-21. [PUBMED: 25043514]

Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG, Burdge GC, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. *Journal of Hepatology* 2015;**63**(6):1476-83. [PUBMED: 26272871]

Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes

and its complications. *Journal of Clinical Endocrinology and Metabolism* 2013;**98**(2):483-95. [PUBMED: 23293330]

Zhang 2017 {published data only (unpublished sought but not used)}

Zhang Y-P, Rujuan M, Qing L, Wu T, Ma F. Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial. *Journal of Alzheimer's Disease* 2016;**55**(2):497-507.

References to studies excluded from this review

Alekseeva 2000 {published data only}

Alekseeva RI, Sharafetdinov K, Plotnikova OA, Meshcheriakova VA, Mal'tsev GI, Kulakova SN. Effects of a diet including linseed oil on clinical and metabolic parameters in patients with type 2 diabetes mellitus. *Voprosy Pitaniia* 2000;**69**(6):32-5.

Baleztena 2015 {published data only}

* Baleztena Gurrea J, Ruiz-Canela M, Pardo M, Castellanos MC, Gozalo MJ, Añorbe T, et al. Utility of heavy food supplement in omega-3 fatty acids in the prevention of dementia, in relation to the basal nutritional level, in people of advanced age: randomized multicenter study. *Revista Española de Geriátria y Gerontología* 2015;**50**:1-49.

Bes-Rastrollo M, Baleztena J, Aguirre I, Ruiz-Canela M. Utility of a rich food supplement omega-3 fatty acids in the prevention of dementia, in relation to baseline nutritional level, in people with advanced age: multicentre randomised study [Complemento alimenticio rico en ácidos grasos omega-3 en la prevención de la demencia: estudio aleatorizado multicéntrico]. *Nutrición Clínica en Medicina* 2015;**9**(1):38.

Belch 1988 {published data only}

Belch JJ, Ansell D, Madhok R, O'Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. *Annals of the Rheumatic Diseases* 1988;**47**(2):96-104.

Belluzzi 1996 {published and unpublished data}

Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *New England Journal of Medicine* 1996;**334**(24):1557-60.

Berthoux 1992 {published data only}

Berthoux FC, Guerin C, Burgard G, Berthoux P, Alamartine E. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. *Transplantation Proceedings* 1992;**24**(6):2578-82.

Borchgrevink 1966 {published and unpublished data}

Borchgrevink CF, Berg KJ, Skaga E, Skjaeggstad O, Stormorken H. Effect of linseed oil on platelet adhesiveness and bleeding time in patients with coronary heart disease. *Lancet* 1965;**ii**:980-2.

* Borchgrevink CF, Skaga E, Berg KJ, Skjaeggstad O. Absence of prophylactic effect of linolenic acid in patients with coronary heart disease. *Lancet* 1966;**2**(456):187-9.

Busnach 1998 {published data only}

Busnach G, Stragliotto E, Minetti E, Perego A, Brando B, Broggi ML, et al. Effect of N-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study. *Journal of Nephrology* 1998;**11**(2):87-93.

CANN 2015 {unpublished data only}

NCT02525198. The cognitive ageing nutrition and neurogenesis trial (CANN) [A randomised controlled trial in 'at risk' humans investigating the cognitive benefits of a combined flavonoid/fatty acid intervention and underlying mechanisms of action: the Cognitive Aging Nutrition and Neurogenesis 8CANN) trial]. clinicaltrials.gov/ct2/show/NCT02525198 (first received 17 August 2015).

Cappelli 1997 {published data only}

Cappelli P, Di LL, Stuard S, Ballone E, Albertazzi A. N-3 polyunsaturated fatty acid supplementation in chronic progressive renal disease. *Journal of Nephrology* 1997;**10**(3):157-62.

CARES 2015 {published data only}

ISRCTN10431469. Changes in brain function among individuals with a mild memory impairment (CARES). www.isrctn.com/ISRCTN10431469 (first received 21 December 2015). [ISRCTN10431469]

Cheng 1990a {published data only}

Cheng A, Bustami M, Norell MS, Mitchell AG, Ilsey CDJ. The effect of omega-3 fatty acids on restenosis after coronary angioplasty. *European Heart Journal* 1990;**11**:368.

Cheng 1990b {published data only}

Cheng IK, Chan PC, Chan MK. The effect of fish oil dietary supplement on the progression of mesangial IgA glomerulonephritis. *Nephrology, Dialysis, Transplantation* 1990;**5**:241-16.

Clark 1993 {published data only}

Clark WF, Parbtani A, Naylor CD, Levinton CM, Muirhead N, Spanner E, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. *Kidney International* 1993;**44**(1):75-86.

Clark 1994 {published data only}

Clark WF, Parbtani A. Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. *American Journal of Kidney Diseases* 1994;**23**(5):644-7.

Clark 2001 {published data only}

Clark WF, Kortas C, Heidenheim AP, Garland J, Spanner E, Parbtani A. Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study. *Journal of the American College of Nutrition* 2001;**20**(2 Suppl):143-8. [PUBMED: 11349937]

Clausen 1989 {published data only}

Clausen J, Nielsen SA, Kristensen M. Biochemical and clinical effects of an antioxidative supplementation of geriatric patients. A double blind study. *Biological Trace Element Research* 1989;**20**(1-2):135-51.

Diskin 1990 {published data only}

Diskin CJ, Thomas CE, Zellner CP, Lock S, Tanja J. Fish oil to prevent intimal hyperplasia and access thrombosis. *Nephron* 1990;**55**(4):445-7.

Donadio 1994 {published data only}

Donadio JJ, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. *New England Journal of Medicine* 1994;**331**:1194-9.

Doyle 2001 {published data only}

Doyle W, Srivastava A, Crawford MA, Bhatti R, Brooke Z, Costeloe KL. Inter-pregnancy folate and iron status of women in an inner-city population. *British Journal of Nutrition* 2001;**86**(1):81-7.

Dry 1991 {published and unpublished data}

Dry J, Vincent D. Effect of a fish oil diet on asthma: results of a 1-year double-blind study. *International Archives of Allergy and Applied Immunology* 1991;**95**(2-3):156-7.

Ezaki 1999 {published data only}

Ezaki O, Takahashi M, Shigematsu T, Shimamura K, Kimura J, Ezaki H, et al. Long-term effects of dietary alpha-linolenic acid from perilla oil on serum fatty acids composition and on the risk factors of coronary heart disease in Japanese elderly subjects. *Journal of Nutritional Science and Vitaminology* 1999;**45**(6):759-72.

Feher 2005 {published data only}

Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. *Ophthalmologica* 2005;**219**(3):154-66. [PUBMED: 15947501]

FISH 2012 {published data only (unpublished sought but not used)}

* Browning LM, Walker CG, Mander AP, West AL, Madden J, Gambell JM, et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. *American Journal of Clinical Nutrition* 2012;**96**(4):748-58. [PUBMED: 22932281]

Walker CG, Browning LM, Mander AP, Madden J, West AL, Calder PC, et al. Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. *British Journal of Nutrition* 2014;**111**(4):679-89. [PUBMED: 24063767]

Walker CG, Browning LM, Stecher L, West AL, Madden J, Jebb SA, et al. Fatty acid profile of plasma NEFA does not reflect

adipose tissue fatty acid profile. *British Journal of Nutrition* 2015;**114**(5):756-62. [PUBMED: 26205910]

Walker CG, West AL, Browning LM, Madden J, Gambell JM, Jebb SA, et al. The pattern of fatty acids displaced by EPA and DHA following 12 months supplementation varies between blood cell and plasma fractions. *Nutrients* 2015;**7**(8):6281-93. [PUBMED: 26247960]

Fonolla 2009 {published data only}

Fonolla J, Lopez-Huertas E, Machado FJ, Molina D, Alvarez I, Marmol E, et al. Milk enriched with "healthy fatty acids" improves cardiovascular risk markers and nutritional status in human volunteers. *Nutrition* 2009;**25**(4):408-14. [PUBMED: 19084376]

Fonolla-Joya 2016 {published data only}

Fonolla J, Diaz-Ropero M, Geerlings A, Marti J, Lopez-Huertas E. Daily intake of a dairy drink enriched with omega-3 (EPA +DHA) and oleic acid improves cardiovascular markers in healthy postmenopausal women. *Atherosclerosis Supplements* 2010;**11**(2):58.

Fonolla J, Diaz-Ropero P, Marti JL, Rodriguez-Martinez C, Lopez-Huertas E. Daily intake of a low lactose dairy drink enriched with omega-3 (EPA+DHA), oleic acid and calcium improves nutritional and bone status in healthy postmenopausal women. *Clinical Nutrition* 2011;**6**(1):86.

* Fonolla-Joya J, Reyes-García R, García-Martín A, López-Huertas E, Muñoz-Torres M. Daily intake of milk enriched with n-3 fatty acids, oleic acid, and calcium improves metabolic and bone biomarkers in postmenopausal women. *Journal of the American College of Nutrition* 2016;**35**(6):529-36. [DOI: [10.1080/07315724.2014](https://doi.org/10.1080/07315724.2014)]

Franzen 1989 {published data only}

Franzen D, Hopp HW, Schanwell M, Hilger HH. Long-term effect of fish oil and olive oil on plasma lipids in patients with CHD. *Zeitschrift fur Kardiologie* 1989;**78**(Suppl 4):28.

Galarraga 2008 {published data only}

Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as a non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. *Rheumatology* 2008;**47**(5):665-9. [DOI: [10.1093/rheumatology/ken024](https://doi.org/10.1093/rheumatology/ken024)]

Gapparova 2000 {published data only}

Gapparova KM, Pogosheva AV, Kulakova SN, Tutel'ian VA. Effects of omega-3 polyunsaturated fatty acids of vegetable and animal origin on clinical and metabolic indicators and the intensity of lipid peroxidation in patients with ischemic heart disease and impaired carbohydrate tolerance. *Voprosy Pitaniia* 2000;**69**(1-2):46-9.

Gazso 1992 {published data only}

Gazso A, Horrobin D, Sinzinger H. Influence of omega-3 fatty acids on the prostaglandin-metabolism in healthy volunteers and patients suffering from PVD. *Agents and Actions. Supplements* 1992;**37**:151-6.

Geusens 1994 {published data only}

Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. *Arthritis and Rheumatism* 1994;**37**(6):824-9.

Gogos 1998 {published data only}

Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. *Cancer* 1998;**82**(2):395-402.

Greatrex 2000 {published data only}

Greatrex JC, Drasdo N, Dresser K. Scotopic sensitivity in dyslexia and requirements for DHA supplementation. *Lancet* 2000;**355**(9213):1429-30.

Griffin 1999 {published data only}

Griffin BA, Minihane AM, Furlonger N, Chapman C, Murphy M, Williams D, et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. *Clinical Science* 1999;**97**(3):269-76.

Hamazaki 1984 {published data only}

Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. *Lancet* 1984;**1**(8384):1017-8.

Hansen 1996 {published data only}

Hansen GV, Nielsen L, Kluger E, Thysen M, Emmertsen H, Stengaard PK, et al. Nutritional status of Danish rheumatoid arthritis patients and effects of a diet adjusted in energy intake, fish-meal, and antioxidants. *Scandinavian Journal of Rheumatology* 1996;**25**(5):325-30.

Harris 1991 {published data only}

Harris WS, Windsor SL, Dujovne CA. Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. *Journal of the American College of Nutrition* 1991;**10**(3):220-7.

Hashimoto 2012 {published data only}

Hashimoto M, Yamashita K, Kato S, Tamai T, Matsumoto I, Tanabe Y, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function in elderly people with very mild dementia in Japan. *Alzheimer's and Dementia* 2011;**1**:S610-1.

* Hashimoto M, Yamashita K, Kato S, Tamai T, Tanabe Y, Mitarai M, et al. Beneficial effects of daily dietary omega-3 polyunsaturated fatty acid supplementation on age related cognitive decline in elderly Japanese with very mild dementia: a 2-year randomized, double-blind, placebo-controlled trial. *Journal of Aging Research & Clinical Practice* 2012;**1**(3):193-201.

Hashimoto 2016 {published data only}

Hashimoto M, Kato S, Tanabe Y, Katakura M, Mamun AA, Ohno M, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing

homes. *Geriatrics & Gerontology International* 2017;**17**(2):330-7. [PUBMED: 26822516]

Hawthorne 1992 {published and unpublished data}

Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. *Gut* 1992;**33**(7):922-8.

Hogg 1995 {published data only}

Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. *American Journal of Kidney Diseases* 1995;**26**(5):792-6.

HOPE epilepsy 2012 {published data only}

NCT01744275. High dose omega 3 fatty acids supplementation in patients with epilepsy: the HOPE-Epilepsy trial. clinicaltrials.gov/ct2/show/NCT01744275 (first received 6 December 2012).

Huang 1996 {published data only}

Huang YC, Jessup JM, Forse RA, Flickner S, Pleskow D, Anastopoulos HT, et al. N-3 fatty acids decrease colonic epithelial cell proliferation in high-risk bowel mucosa. *Lipids* 1996;**31**:S313-7.

Huang 2008 {published and unpublished data}

Huang LL, Coleman HR, Kim J, de Monasterio F, Wong WT, Schleicher RL, et al. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. *Investigative Ophthalmology & Visual Science* 2008;**49**(9):3864-9.

InTrePad 2013 {published data only}

ACTRN12613000034730. Intervention of testosterone & fish oil as a possible strategy for the prevention of Alzheimer's disease. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363372 (first received 14 January 2013).

ISRCTN38354847 {published data only}

ISRCTN38354847. A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy. www.isrctn.com/ISRCTN38354847 (first received 3 February 2003).

Junker 1990 {published data only}

Junker L, Engel S, Berger I, Barleben H. Serum enzymes in grade I hypertensive patients before and following a change in nutrition in relation to polyene acid and electrolyte content. *Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete* 1990;**45**(11):323-4.

Kachorovskii 1977 {published data only}

Kachorovskii BV, Zhoglo FA, Zaverbnyi MI. Total lipid content in the blood after using fish oil in natural and emulsified forms. *Farmatsiia* 1977;**26**(5):86.

Kanorskii 2007 {published data only}

Kanorskii SG, Bodrikova VV, Kanorskaia Iu S. Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation. *Kardiologiia* 2007;**47**(12):39-44.

Karlsson 1998 {published data only}

Karlsson J, Hesselius G, Nygard B, Ronneberg R. Plasma omega-3 fatty acids before and after nutritional therapy. *Journal of Nutritional & Environmental Medicine* 1998;**8**(1):25-34.

Kaul 1992 {published and unpublished data}

Kaul U, Sanghvi S, Bahl VK, Dev V, Wasir HS. Fish oil supplements for prevention of restenosis after coronary angioplasty. *International Journal of Cardiology* 1992;**35**(1):87-93.

Khan 2003 {published and unpublished data}

Khan F, Elherik K, Bolton-Smith C, Barr R, Hill A, Murrie I, Belch JJF. The effects of dietary fatty acid supplementation on endothelial function and vascular tone in healthy subjects. *Cardiovascular Research* 2003;**59**(4):955-62.

Konya 2000 {published data only}

Konya E, Tsuji H, Umekawa T, Kurita T, Iguchi M. Effect of ethyl icosapentate on urinary calcium and oxalate excretion. *International Journal of Urology* 2000;**7**(10):361-5.

Kremer 1995 {published data only}

Kremer JM, Lawrence DA, Petrillo GF, Litts LL, Mullaly PM, Rynes RI, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. *Arthritis and Rheumatism* 1995;**38**(8):1107-14.

Kruger 1998 {published data only}

Kruger MC, Coetzer H, de Winter R, Gericke G, Van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging (Milan, Italy)* 1998;**10**(5):385-94.

Kurabayashi 2000 {published data only}

Kurabayashi T, Okada M, Tanaka K. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group. *Obstetrics and Gynecology* 2000;**96**(4):521-8.

Lau 1993 {published and unpublished data}

Lau CS, McMahon H, Morley KD, Belch JJF. Effects of Maxepa on non-steroidal anti-inflammatory drug useage in patients with mild rheumatoid arthritis. *British Journal of Rheumatology* 1991;**30**:137.

* Lau CS, Morley KD, Belch JJ. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis: a double-blind placebo controlled study. *British Journal of Rheumatology* 1993;**32**(11):982-9.

Leaf 1995 {published data only}

Leaf DA, Connor WE, Barstad L, Sexton G. Incorporation of dietary n-3 fatty acids into the fatty acids of human adipose tissue and plasma lipid classes. *American Journal of Clinical Nutrition* 1995;**62**(1):68-73.

Lee 2010 {published and unpublished data}

Lee TK, Clandinin MT, Hébert M, MacDonald IM. Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial. *Canadian Journal of Ophthalmology* 2010;**45**(5):514-9.

Leng 1998 {published data only}

Leng GC, Lee AJ, Fowkes FG, Jepson RG, Horrobin D, Lowe GD, et al. Randomised controlled trial of y-linolenic and eicosapentaenoic acid in peripheral vascular disease. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 1997;**57**(2):218.

* Leng GC, Lee AJ, Fowkes FG, Jepson RG, Lowe GD, Skinner ER, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. *Clinical Nutrition* 1998;**17**(6):265-71.

LipidiDiet 2016 {published data only}

Freund-Levi Y, Visser PJ, Kivipelto M, Wieggers RL, Hartmann T, Soininen H. The Lipididiet study: rationale and study design. *Alzheimer's & Dementia* 2012;**1**:602.

* Soininen H, Visser PJ, Kivipelto M, Van Hees A, Rouws C, Hartmann T. A clinical trial investigating the effects of Souvenaid in prodromal Alzheimer's disease: progress and baseline characteristics of the Lipididiet study. *Neurobiology of Aging* 2014;**35**:S20.

Visser PJ, Soininen H, Kivipelto M, Freund-Levi Y, Kamphuis P, Wieggers RL, et al. A randomized controlled trial investigating the effects of Souvenaid in prodromal Alzheimer's disease: baseline characteristics of the LipidiDiet study. *Alzheimer's & Dementia* 2013;**9**(4 Suppl):669-70. [DOI: [dx.doi.org/10.1016/j.jalz.2013.05.1381](https://doi.org/10.1016/j.jalz.2013.05.1381)]

Loeschke 1996 {published and unpublished data}

Loeschke K, Ueberschaer B, Pietsch A, Gruber E, Ewe K, Wiebecke B, et al. N-3 fatty acids only delay early relapse of ulcerative colitis in remission. *Digestive Diseases and Sciences* 1996;**41**(10):2087-94.

LUTEGA 2013 {published data only}

Arnold C, Winter L, Frohlich K, Jentsch S, Dawczynski J, Jahreis G, et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. *JAMA Ophthalmology* 2013;**131**(5):564-72. [PUBMED: 23519529]

* Dawczynski J, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J. Long term effects of lutein, zeaxanthin and omega-3-LC-PUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. *Graefes Archive for Clinical and Experimental Ophthalmology* 2013;**251**(12):2711-23. [PUBMED: 23695657]

Lyon Diet Heart 1994 {published data only}

* De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. [Erratum appears in *Lancet* 1995 Mar 18;345(8951):738]. *Lancet* 1994;**343**(8911):1454-9. [DOI: [10.1016/S0140-6736\(94\)92580-1](https://doi.org/10.1016/S0140-6736(94)92580-1)]

De Lorgeril M, Salen P, Caillat-Vallet E, Hanauer MT, Barthelemy JC, Mamelle N. Control of bias in dietary trial to prevent coronary recurrences: the Lyon Diet Heart Study. *European Journal of Clinical Nutrition* 1997;**51**(2):116-22.

De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriment. *Journal of the American College of Cardiology* 1996;**28**(5):1103-8.

De Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P, Mamelle N. Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. *Archives of Internal Medicine* 1998;**158**(11):1181-7.

De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;**99**(6):779-85.

De Lorgeril M, Salen P, Spodick DH. Does a Mediterranean dietary pattern prolong survival?. *Cardiology Review* 1999;**16**(12):30-4.

Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N, et al. Cretan Mediterranean diet for prevention of coronary heart disease. *American Journal of Clinical Nutrition* 1995;**61**(6 Suppl):1360S-7S.

Maachi 1995 {published data only}

Maachi K, Berthou P, Burgard G, Alamartine E, Berthou F. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy. *Transplantation Proceedings* 1995;**27**(1):846-9.

Macsai 2008 {published data only}

Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Transactions of the American Ophthalmological Society* 2008;**106**:336-56. [PUBMED: 19277245]

Mansel 1990 {published data only}

Mansel RE, Harrison BJ, Melhuish J, Sheridan W, Pye JK, Pritchard G, et al. A randomized trial of dietary intervention with essential fatty acids in patients with categorized cysts. *Annals of the New York Academy of Sciences* 1990;**586**:288-94.

Mantzaris 1996 {published data only}

Mantzaris GJ, Archavlis E, Zografos C, Petraki K, Spiliades C, Triantafyllou G. A prospective, randomized, placebo-controlled

study of fish oil in ulcerative colitis. *Hellenic Journal of Gastroenterology* 1996;**9**(2):138-41.

Mate-Jimenez 1991 {published and unpublished data}

Mate J, Castanos R, Garcia-Semaniego J, Pajares JM. Does dietary fish oil maintain the remission of Crohn's disease: a study case control. *Gastroenterology* 1991;**100**:A228.

Matsuyama 2005 {published and unpublished data}

Matsuyama W, Mitsuyama H, Watanabe M, Oonakahara K, Higashimoto I, Osame M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. *Chest* 2005;**128**(6):3817-27.

Middleton 2002 {published data only}

Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. *Alimentary Pharmacology & Therapeutics* 2002;**16**(6):1131-5. [PUBMED: 12030955]

MoodFOOD 2016 {published data only}

Roca M, Kohls E, Gili M, Watkins E, Owens M, Hegerl U, et al. Prevention of depression through nutritional strategies in high-risk persons: rationale and design of the MoodFOOD prevention trial. *BMC Psychiatry* 2016;**16**(1):192.

NAYAB 2017 {published data only}

Qurashi I, Chaudhry IB, Khoso AB, Farooque S, Lane S, Husain MO, et al. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol. *Trials* 2017;**18**(1):524.

NCT01235533 {unpublished data only}

NCT01235533. Fish oil supplementation in late-life depression. clinicaltrials.gov/ct2/show/NCT01235533 (first received 5 November 2010).

NCT01784042 {published data only}

NCT01784042. Dietary energy restriction and omega-3 fatty acids on mammary tissue [Effect of dietary energy restriction and omega-3 fatty acids on mammary tissue and systemic biomarkers of breast cancer risk]. clinicaltrials.gov/ct2/show/NCT01784042 (first received 5 February 2013).

NU-AGE 2014 {published data only}

Berendsen A, Santoro A, Pini E, Cevenini E, Ostan R, Pietruszka B, et al. Reprint of: a parallel randomized trial on the effect of a healthful diet on inflammaging and its consequences in European elderly people: design of the NU-AGE dietary intervention study. *Mechanisms of Ageing and Development* 2014;**136**:14-21.

* Santoro A, Pini E, Scurti M, Palmas G, Berendsen A, Brzozowska A, et al. Combating inflammaging through a Mediterranean whole diet approach: the NU-AGE project's conceptual framework and design. *Mechanisms of Ageing and Development* 2014;**136-137**:3-13.

NutriMEMO 2014 {published data only}

Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M, Smith P, et al. Effects of omega3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. *BMC Geriatrics* 2014;**14**:74.

OFAMS 2012 {published data only}

Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. *Archives of Neurology* 2012;**69**(8):1044-51. [PUBMED: 22507886]

Okuda 1996 {published data only}

Okuda Y, Mizutani M, Ogawa M, Sone H, Asano M, Asakura Y, et al. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. *Journal of Diabetes and its Complications* 1996;**10**(5):280-7.

OLIVE 1998 {published data only}

Colquhoun DM, Hicks BJ, Somerset S. Rationale and design of the "OLIVE" study (comparison of an olive oil enriched to a low fat diet intervention study using vascular endpoints). *Atherosclerosis* 1997;**134**(1-2):326-27.

* Colquhoun DM, Somerset S, Glasziou PP, Richards D, Weyers J. Comparison of an olive oil enriched diet to a low fat diet intervention study using vascular endpoints: assessed by repeat quantitative angiography (OLIVE study). *Australian Journal of Nutrition and Dietetics* 1998;**55**(Suppl 4):S24-9.

Oslo DIET HEART 1970 {published data only}

* Leren P. The Oslo diet-heart study. Eleven year report. *Circulation* 1970;**42**:935-42.

Leren P. The effect of a cholesterol lowering diet in male survivors of myocardial infarction. (A controlled clinical trial). *Nordisk Medicin* 1967;**77**(21):658-61.

Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. *Acta Medica Scandinavica* 1966;**466**(Suppl):1-92.

Leren P. The effect of plasma-cholesterol-lowering diet in male survivors of myocardial infarction. A controlled clinical trial. *Bulletin of the New York Academy of Medicine* 1968;**44**:1012-20.

Pogozheva 1997 {published data only}

Pogozheva AV, Rozanova IA, Sorokovoi KV, Karagodina ZV, Levachev MM. Lipid peroxidation in patients with ischemic heart disease, hyperlipidemia and/or hypertension while polyunsaturated omega-3 fatty acids of plant and animal origin were in their diet. *Voprosy Pitaniia* 1997;**4**:32-5.

Pogozheva 2000 {published data only}

Pogozheva AV, Tutel'ian VA, Gapparova KM, Trushina EN, Miagkova MA. The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity

in patients with ischemic heart disease and a disordered carbohydrate tolerance. *Voprosy Pitaniia* 2000;**69**(4):33-5.

Puri 2008 {published and unpublished data}

Moher D, Weeks L, Ocampo M, Seely D, Sampson M, Altman DG, et al. Describing reporting guidelines for health research: a systematic review. *Journal of Clinical Epidemiology* 2011;**64**(7):718-42. [DOI: [10.1016/j.jclinepi.2010.09.013](https://doi.org/10.1016/j.jclinepi.2010.09.013)]

* Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. *Journal of International Medical Research* 2008;**36**:896-905.

Quazi 1994 {published data only}

Quazi S, Mohiduzzaman M, Mostafizur RM, Keramat AS. Effect of hilsa (*Tenualosa ilisha*) fish in hypercholesterolemic subjects. *Bangladesh Medical Research Council Bulletin* 1994;**20**(1):1-7.

Sacks 1994 {published data only}

He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. Seven-year incidence of hypertension in a cohort of middle-aged African Americans and whites. *Hypertension* 1998;**31**(5):1130-5.

Meilahn EN, Kuller LH, Kiss JE, Sacks FM. Coagulation parameters among healthy adults taking fish oil versus placebo. *Arteriosclerosis* 1990;**10**:916A.

* Sacks FM, Hebert P, Appel LJ, Borhani NO, Applegate WB, Cohen JD, et al. Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention. *Journal of Hypertension* 1994;**12**(2):209-13.

Sacks FM, Hebert P, Appel LJ, Borhani NO, Applegate WB, Cohen JD, et al. The effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the trials of hypertension prevention. *Journal of Hypertension. Supplement* 1994;**12**(7):S23-31.

Satterfield S, Borhani NO, Whelton P, Goodwin L, Brinkmann C, Charleston J, et al. Recruitment for phase I of the Trials of Hypertension Prevention. *American Journal of Preventive Medicine* 1993;**9**(4):237-43.

Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, phase I. *JAMA* 1992;**267**(9):1213-20.

Whelton PK, Kumanyika SK, Cook NR, Cutler JA, Borhani NO, Hennekens CH, et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. *American Journal of Clinical Nutrition* 1997;**65**(2 Suppl):652S-60S.

Saynor 1988 {published data only}

Saynor R, Gillott T. Fish oil and plasma fibrinogen. *BMJ* 1988;**297**:1196.

Saynor 1992 {published data only}

Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. *Lipids* 1992;**27**(7):533-8.

Selvais 1995 {published and unpublished data}

Selvais PL, Ketelslegers JM, Buyschaert M, Hermans MP. Plasma endothelin-1 immunoreactivity is increased following long-term dietary supplementation with omega-3 fatty acids in microalbuminuric IDDM patients. *Diabetologia* 1995;**38**:253.

Shimizu 1995 {published and unpublished data}

Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. *Diabetes Research and Clinical Practice* 1995;**28**(1):35-40.

Singh 1992 {published data only}

Singh RB, Fedacko J, Vargova V, Pella D, Niaz MA, Ghosh S. Effect of low W-6/W-3 fatty acid ratio Paleolithic style diet in patients with acute coronary syndromes: a randomized, single blind, controlled trial. *World Heart Journal* 2012;**4**(1):71-84.

* Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh S, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. *BMJ* 1992;**304**:1015-9.

Singh 1997 {published and unpublished data}

Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4. *Cardiovascular Drugs and Therapy* 1997;**11**(3):485-91.

Singh 2002 {published data only}

Pella D, Dubnov G, Singh RB, Sharma R, Berry EM, Manor O. Effects of an Indo-Mediterranean diet on the omega-6/omega-3 ratio in patients at high risk of coronary artery disease: the Indian paradox. *World Review of Nutrition and Dietetics* 2003;**92**:74-80.

* Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. *Lancet* 2002;**360**(9344):1455-61.

Tariq 1989 {published data only}

Tariq T, Close C, Dodds R, Viberti GC, Lee T, Vergani D. The effect of fish-oil on the remission of type 1 (insulin-dependent) diabetes in newly diagnosed patients. *Diabetologia* 1989;**32**(10):765.

Terano 1999 {published and unpublished data}

Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. *Lipids* 1999;**34**:S345-6.

Tomer 2001 {published data only}

Tomer A, Kasey S, Connor WE, Clark S, Harker LA, Eckman JR. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. *Thrombosis & Haemostasis* 2001;**85**(6):966-74.

Torjesen 1997 {published data only}

Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. *Diabetes Care* 1997;**20**(1):26-31.

VSDR 2015 {published data only}

Roig-Revert MJ, Lleo-Perez A, Zanon-Moreno V, Vivar-Llopis B, Marin-Montiel J, Dolz-Marco R, et al. Enhanced oxidative stress and other potential biomarkers for retinopathy in type 2 diabetics: beneficial effects of the nutraceutical supplements. *BioMed Research International* 2015;**2015**:408180. [DOI: <http://dx.doi.org/10.1155/2015/408180>; PUBMED: 26618168]

Wheaton 2010 {published and unpublished data}

Wheaton DH, Hoffman DR, Locke KG, Watkins RB, Birch DG. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. *Archives of Ophthalmology* 2010;**121**(9):1269-78.

Yasui 2001 {published data only}

Yasui T, Tanaka H, Fujita K, Iguchi M, Kohri K. Effects of eicosapentaenoic acid on urinary calcium excretion in calcium stone formers. *European Urology* 2001;**39**(5):580-5.

Zinger 1987 {published data only}

Zinger P, Berger I, Liuk K, Taube K, Naumann E. Changes in arterial pressure, serum lipids and thromboxane B2 after using a diet with various levels of eicosapentaenoic acid in patients with hypertension. *Klinicheskaia Meditsina* 1987;**65**(1):62-4.

References to studies awaiting assessment
IRCT20100123003140N21 {published data only}

IRCT20100123003140N21. Effect of omega 3 fatty acids supplement on inflammatory factors (IL-1 β , IL-6, TNF- α , IL-10) and lipid profile in Parkinson disease. en.irct.ir/trial/29861 (added to register 18 April 2017).

References to ongoing studies
AC Omega3 2014 {published data only}

ACTRN12614000732684. The Aboriginal cardiovascular omega-3 randomised controlled trial [The effect of omega-3 supplementation on adverse cardiovascular (CV) events among Indigenous Australians with stable coronary artery disease: A randomized controlled trial Query!]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366337 (first received 10 July 2014).

ACTRN12618000761268 2018 {published data only}

ACTRN12618000761268. A 56 week, double-blind, randomised study to evaluate the efficacy of testosterone, with and without

DHA supplementation on cerebral amyloid load in known brain amyloid-PET positive men with subjective memory complaints. www.anzctr.org.au/ACTRN12618000761268.aspx (added to register 7 May 2018).

AFORRD 2010 {published and unpublished data}

Farmer AJ, Oke J, Hardeman W, Tucker L, Sutton S, Kinmonth A-L, et al. The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study. *Diabetes Research and Clinical Practice* 2016;**120**:56-64. [DOI: [10.1016/j.diabres.2016.07.004](https://doi.org/10.1016/j.diabres.2016.07.004)]

Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA, et al. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. *Diabetologia* 2009;**52**(1):50-9.

* Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. *Atherosclerosis* 2010;**213**(2):512-7.

Bartold 2010 {published data only}

* ACTRN12610000594022. Fish oil as adjunct therapy for periodontitis [Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335470 (first received 23 July 2010).

Park B. Impact of omega-3 fatty acids on periodontal inflammation (PhD thesis). University of Adelaide digital.library.adelaide.edu.au/dspace/bitstream/2440/92351/3/02whole.pdf 2015.

Beyond Aging Project 2015 {published data only}

ACTRN12610000032055. The Beyond Ageing Project: a selective prevention trial using novel pharmacotherapies in an older age cohort at risk for depression Query! [In older adults (60+ years) at risk for depression, can sertraline and/or omega-3 fatty acids compared with a placebo, reduce or prevent depressive symptoms, incidence of new cases of depression and/or cognitive decline]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=308413 (first received 22 October 2009).

* Cockayne NL, Duffy SL, Bonomally R, English A, Amminger PG, Mackinnon A, et al. The Beyond Ageing Project Phase 2: a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial. *Trials* 2015;**16**:247.

Chandrakala 2010 {published data only (unpublished sought but not used)}

* Chandrakala G, Arpana G, Rao PV. Long-term effects of a reduced fat diet intervention in pre-diabetes. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando (FL). 2010; Vol. professional.diabetes.org/meeting/scientific-sessions/70th-scientific-sessions-2010:195-PO.

Chandrakala G, Arpana G, Sreenivas T, Rao PV. Low-fat (< 20%) diets prevent type 2 diabetes mellitus. *Diabetes* 2012;**61**:A190.

ChiCTR-TRC-12002014 {published data only}

ChiCTR-TRC-12002014. Influence of different source of n-3 fatty acid on plasma lipid in moderately hypercholesterolemia subject and the valid dosage. www.chictr.org.cn/hvshowproject.aspx?id=2374 (first received 3 May 2015).

DO HEALTH {published data only}

Do-Health. DO-HEALTH trial web site. do-health.eu/wordpress (accessed prior to 10 May 2018).

* NCT01745263. DO-HEALTH / vitamin D3 - omega3 - home exercise - healthy ageing and longevity trial (DO-HEALTH). clinicaltrials.gov/ct2/show/NCT01745263 (first received 10 December 2012).

EVAPORATE 2016 {published data only}

NCT02926027. Effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy (EVAPORATE). clinicaltrials.gov/ct2/show/NCT02926027 (first posted 6 October 2016).

LO-MAPT 2018 {published data only}

NCT03691519. Prevention of cognitive decline in older adults with low DHA/EPA index in red blood cells (LO-MAPT). clinicaltrials.gov/show/NCT03691519 (added to registry 1 October 2018).

MAPT PLUS {published data only}

NCT01513252. Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT-PLUS). clinicaltrials.gov/ct2/show/NCT01513252 (first received 20 January 2012).

MTG 2018 {published data only}

NCT03448185. Improving betabolic health in patients with diastolic dysfunction (MTG). clinicaltrials.gov/ct2/show/NCT03448185 (first posted 28 February 2018).

NCT00010868 {published data only}

NCT00010868. Omega-3 fatty acids in bipolar disorder [Omega-3 fatty acids in bipolar disorder prophylaxis]. clinicaltrials.gov/ct2/show/NCT00010868 (first received 5 February 2001).

NCT00309439 {published data only}

NCT00309439. ALA and prostate cancer [Studies of serum PSA to help resolve the current implication of alpha-linolenic acid (ALA) and prostate cancer]. clinicaltrials.gov/ct2/show/NCT00309439 (first received 31 March 2006).

NCT02211560 {published data only}

NCT02211560. Investigating a phosphatidylserine based dietary approach for the management of mild cognitive impairment [A, multi-center, double-blind, randomized, placebo-controlled study for the efficacy of phosphatidylserine in mild cognitive impairment (MCI)]. clinicaltrials.gov/ct2/show/NCT02211560 (first received 7 August 2014).

NCT02295059 {published data only}

NCT02295059. Omega 3 fatty acids and ERPR(-)HER2(+/-) breast cancer prevention [Omega-3 fatty acids and ERPR(-) and HER-2/Neu(+/-) breast cancer prevention]. clinicaltrials.gov/ct2/show/NCT02295059 (first received 20 November 2014).

NCT02719327 {published data only}

NCT02719327. Brain amyloid and vascular effects of eicosapentaenoic acid (BRAVE-EPA) [Impact of icosapent ethyl on Alzheimers disease biomarkers in preclinical adults]. clinicaltrials.gov/ct2/show/NCT02719327 (first received 25 March 2016).

NCT03784963 {published data only}

NCT03784963. Efficacy of omega-3 fatty acid therapy in preventing gastrointestinal bleeding in patients with CF-LVAD. clinicaltrials.gov/ct2/show/NCT03784963 (first posted 24 December 2018).

NCT03806426 {published data only}

NCT03806426. Effect of EPA-FFA on polypectomy in familial adenomatous polyposis. clinicaltrials.gov/show/NCT03806426 (first received January 2019).

OMEMI 2014 {published data only}

* Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M, Smith P, et al. Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. *BMC Geriatrics* 2014;**14**:74.

Laake K, Seljeflot I, Schmidt EB, Myhre P, Tveit A, Arnesen H, et al. Serum fatty acids, traditional risk factors, and comorbidity as related to myocardial injury in an elderly population with acute myocardial infarction. *Journal of Lipids* 2016;**2016**:4945720. [dx.doi.org/10.1155/2016/4945720]

NCT01841944. Omega-3 fatty acids in elderly patients with acute myocardial infarction (OMEMI) [Giving omega-3 fatty acids to elderly patients diagnosed with acute myocardial infarction to investigate the effect on cardiovascular morbidity and mortality]. clinicaltrials.gov/ct2/show/NCT01841944 (first received 29 April 2013).

POSEIDON 2018 {published data only}

NCT03406897. Pilot study of omega-3 and vitamin D in high-dose in type I diabetic patients (POSEIDON). clinicaltrials.gov/show/NCT03406897 (added to register 28 January 2018).

Shinto 2015 {published data only}

Bowman LG, Silbert CL, Dodge HH, Lahna D, Hagen K, Murchison FC, et al. Randomized trial of marine n-3 polyunsaturated fatty acids for the prevention of cerebral small vessel disease and inflammation in aging (PUFA Trial): rationale, design and baseline results. *Nutrients* 2019;**11**(4):735. [DOI: [10.3390/nu11040735](https://doi.org/10.3390/nu11040735)]

NCT01953705. n-3 PUFA for vascular cognitive aging [Omega 3 PUFA for the vascular component of age-related cognitive decline]. clinicaltrials.gov/ct2/show/NCT01953705 (first received 1 October 2013).

* Shinto L, Silbert LC, Dodge HH, Quinn JF, Howieson D, Kaye J, et al. Omega 3 fatty acids for the prevention of vascular cognitive aging: methods and rationale for a phase II trial. *Alzheimer's & Dementia* 2015;**11**(7):610.

STRENGTH 2015 {published data only}

EudraCT 2014-001069-28. A long-term outcomes study to assess statin residual risk reduction with EpaNova in high cardiovascular risk patients with hypertriglyceridemia (STRENGTH). www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001069-28 (first received 10 February 2015).

SUPERIORSVG 2010 {published data only}

Deb S, Singh SK, de Souza D, Chu MW, Whitlock R, Meyer SR, on behalf of The, Superior SVG Study Investigators. SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-centre randomized control trial, NCT01047449). *Journal of Cardiothoracic Surgery* 2019;**14**:85. [DOI: [10.1186/s13019-019-0887-x](https://doi.org/10.1186/s13019-019-0887-x)]

* NCT01047449. Improving the results of heart bypass surgery using new approaches to surgery and medication (SUPERIORSVG) [Surgical and pharmacological novel interventions to improve overall results of saphenous vein graft patency in coronary artery bypass grafting surgery: an international multi-center randomized controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01047449 (first received 13 January 2010).

UMIN000012825 {published data only}

UMIN000012825. Effect of polyunsaturated fatty acids on vascular healing process in hyper-cholesterolemic patients with acute coronary syndrome. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014981 (first received 1 February 2015).

Additional references
Abdelhamid 2018b

Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 7. [DOI: [10.1002/14651858.CD012345.pub2](https://doi.org/10.1002/14651858.CD012345.pub2)]

Abdelhamid 2019

Abdelhamid A, Hooper L, Sivakaran R, Hayhoe RP, Welch A. The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. *Calcified Tissue International* 2019;**105**:353-72. [DOI: <https://doi.org/10.1007/s00223-019-00584-3>]

AHA 2016

American Heart Association. Fish and Omega-3 Fatty Acids. www.heart.org/HEARTORG/HealthyLiving/HealthyEating/HealthyDietGoals/Fish-and-Omega-3-Fatty-Acids_UCM_303248_Article.jsp#.WhfuRzenzIU (accessed 24 November 2017).

Aung 2018

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225-34. [DOI: [10.1001/jamacardio.2017.5205](https://doi.org/10.1001/jamacardio.2017.5205)]

Balk 2016

Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, et al. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16-E002-EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: [10.23970/AHRQEPERTA223](https://doi.org/10.23970/AHRQEPERTA223)]

Ballard-Barbash 1987

Ballard-Barbash R, Callaway CW. Marine fish oils: role in prevention of coronary artery disease. *Mayo Clinic Proceedings* 1987;**62**:113-8.

Bang 1972

Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic West Coast Eskimos. *Acta Medica Scandinavica* 1972;**192**:85-94.

Bang 1976

Bang HO, Dyerberg J, Hjorne N. The composition of food consumed by Greenland Eskimos. *Acta Medica Scandinavica* 1976;**200**:69-73.

Berkley 1995

Berkley CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. *Statistics in Medicine* 1995;**14**:395-411.

Bhatnagar 2003

Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. *International Journal of Clinical Practice* 2003;**57**(4):305-14.

BMJ 2005

BMJ editors. Expression of concern. *BMJ* 2005;**331**:266. [DOI: [10.1136/bmj.331.7511.266](https://doi.org/10.1136/bmj.331.7511.266)]

BNF 1999

British Nutrition Foundation. N-3 fatty acids and health. London: British Nutrition Foundation; 1999. Briefing paper.

Bourdon 2010

Bourdon JA, Bazinet TM, Arnason TT, Kimpe LE, Blais JM, White PA. Polychlorinated biphenyls (PCBs) contamination and aryl hydrocarbon receptor (AhR) agonist activity of omega-3 polyunsaturated fatty acid supplements: implications for daily intake of dioxins and PCBs. *Food and Chemical Toxicology* 2010;**48**(11):3093-7.

Brainard 2019

Brainard J, Jimoh OF, Deane K, Biswas P, Donaldson D, Maas K, et al. Omega-3, omega-6 and total polyunsaturated fat for

cognition and dementia: systematic review and meta-analysis of RCTs. submitted 2019.

Brown 2019

Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, the PUFAH Group. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2019;**366**:l4697. [DOI: [http://dx.doi.org/10.1136/bmj.l4697](https://doi.org/10.1136/bmj.l4697)]

Brunner 2009

Brunner EJ, Jones PJ, Friel S, Bartley M. Fish, human health and marine ecosystem health: policies in collision. *International Journal of Epidemiology* 2009;**38**(1):93-100. [DOI: [10.1093/ije/dyn157](https://doi.org/10.1093/ije/dyn157)]

Burr 1993

Burr ML. Fish and ischaemic heart disease. *World Review of Nutrition and Dietetics* 1993;**72**:49-60.

Cade 2007

Cade JE, Burley VJ, Greenwood DC, UK Women's Cohort Study Steering Group. The UK Women's Cohort Study: comparison of vegetarians, fish-eaters and meat-eaters. *Public Health Nutrition* 2007;**7**(7):871-8. [DOI: [10.1079/PHN2004620](https://doi.org/10.1079/PHN2004620)]

Calabresi 2004

Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. *Metabolism* 2004;**53**(2):153-8.

Campbell 2013

Campbell A, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. *Cochrane Database of Systematic Reviews* 2013, Issue 7. [DOI: [10.1002/14651858.CD003833.pub4](https://doi.org/10.1002/14651858.CD003833.pub4)]

Chang 2013

Chang CL, Deckelbaum RJ. Omega-3 fatty acids: mechanisms underlying "protective effects" in atherosclerosis. *Current Opinion in Lipidology* 2013;**24**(4):345-50. [DOI: [10.1097/MOL.0b013e3283616364](https://doi.org/10.1097/MOL.0b013e3283616364)]

Chowdhury 2012

Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. *BMJ* 2012;**345**(7881):e6698.

Deane 2019

Deane KH, Jimoh OF, Biswas P, O'Brien AT, Hanson S, Abdelhamid AS, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta-analysis of randomised trials. *British Journal of Psychiatry* 2019;**online**:1-8. [DOI: [10.1192/bjp.2019.234](https://doi.org/10.1192/bjp.2019.234)]

Delgado-Lista 2012

Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. *British Journal of Nutrition* 2012;**107**(Suppl 2):S201-13.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. *BMJ* 1997;**315**:629-34.

Engell 2013

Engell RE, Sanman E, Lim SS, Mozaffarian D. Seafood omega-3 intake and risk of coronary heart disease death: an updated meta-analysis with implications for attributable burden. *Lancet* 2013;**381**(Special Issue):S45. [DOI: [10.1016/S0140-6736\(13\)61299-4](https://doi.org/10.1016/S0140-6736(13)61299-4)]

FSA 2000

Food Standards Agency UK. Dioxins and PCBs in the UK diet: 1997 total diet study samples. Food Surveillance Information Sheet. Number 4/00; 2000. [FSIS 4/00]

Geelen 2004

Geelen A, Brouwer IA, Zock PL, Katan MB. Antiarrhythmic effects of n-3 fatty acids: evidence from human studies. *Current Opinion in Lipidology* 2004;**15**:25-30.

GRADE Working Group 2004

GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**(7454):1490.

GRADEpro GDT [Computer program]

McMaster University (developed by Evidence Prime, Inc). GRADEpro GDT. Version accessed 30 September 2017. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc), 2015.

Hanson 2019

Hanson S, Thorpe G, Winstanley L, Abdelhamid AS, Hooper L. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials. *British Journal of Cancer* 2020. [DOI: [10.1038/s41416-020-0761-6](https://doi.org/10.1038/s41416-020-0761-6)]

Hauck 1991

Hauck WW, Gilliss CL, Donner A, Gortner S. Randomisation by cluster. *Nursing Research* 1991;**40**(6):356-8.

He 2013

He Z, Yang L, Tian J, Yang K, Wu J, Yao Y. Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. *Canadian Journal of Cardiology* 2013;**29**(2):196-203.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2017

Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), *Cochrane Handbook for Systematic Reviews of Interventions* version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.

Hooper 2015

Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database of Systematic Reviews* 2015, Issue 6. [DOI: [10.1002/14651858.CD011737](https://doi.org/10.1002/14651858.CD011737)]

Hooper 2018

Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard JS, Brown TJ, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 7. [DOI: [10.1002/14651858.CD011094.pub3](https://doi.org/10.1002/14651858.CD011094.pub3)]

Hooper 2019

Hooper L, Abdelhamid AS, Brainard J, Deane KH, Song F, the PUFAH Group. Creation of a database to assess effects of omega-3, omega-6 and total polyunsaturated fats on health: methodology for a set of systematic reviews. *BMJ Open* 2019;**9**:e029554. [DOI: [10.1136/bmjopen-2019-029554](https://doi.org/10.1136/bmjopen-2019-029554)]

Horton 2005

Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. *Lancet* 2005;**366**(9483):354-6. [DOI: [10.1016/S0140-6736\(05\)67006-7](https://doi.org/10.1016/S0140-6736(05)67006-7)]

Hu 2019

Hu Y, Hu FB, Manson J. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127477 participants. *Journal of the American Heart Association* 2019;**8**:e013543. [DOI: [10.1161/JAHA.119.013543](https://doi.org/10.1161/JAHA.119.013543)]

JECFA 2001

Joint FAO/WHO Expert Committee on Food Additives. Summary of the fifty-seventh meeting of JECFA, 2001. apps.who.int/iris/bitstream/handle/10665/42578/WHO_TRS_909.pdf?sequence=1.

Khoueiry 2013

Khoueiry G, Abi Rafeh N, Sullivan E, Saiful F, Jaffery Z, Kenigsberg DN, et al. Do omega-3 polyunsaturated fatty acids reduce risk of sudden cardiac death and ventricular arrhythmias? A meta-analysis of randomized trials. *Heart & Lung* 2013;**42**(4):251-6.

Kotwal 2012

Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. *Circulation. Cardiovascular Quality and Outcomes* 2012;**5**(6):808-18.

Kris-Etherton 2002

Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee of the American Heart Association. Fish consumption, fish oil, omega 3 fatty acids, and cardiovascular disease. *Circulation* 2002;**106**:2747-57.

Kwak 2012

Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Archives of Internal Medicine* 2012;**172**(9):686-94.

Larsson 2012

Larsson SC, Orsini N, Wolk A. Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. *European Journal of Epidemiology* 2012;**27**(12):895-901.

Lefebvre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Levine 2005

Levine KE, Levine MA, Weber FX, Hu Y, Perlmutter J, Grohse PM. Determination of mercury in an assortment of dietary supplements using an inexpensive combustion atomic absorption spectrometry technique. *Journal of Automated Methods & Management in Chemistry* 2005;**2005**(4):211-6.

Li 1999

Li D, Sinclair A, Wilson A, Nakkote S, Kelly F, Abedin L, et al. Effect of dietary alpha-linolenic acid on thrombotic risk factors in vegetarian men. *American Journal of Clinical Nutrition* 1999;**69**:872-82.

Liem 1997

Liem AK, Theelen RM. *Dioxins: Chemical Analysis, Exposure and Risk Assessment*. Utrecht: Universiteit Utrecht, 1997. [ISBN 90 393 2012 8]

MAFF 1998A

MAFF UK. Concentrations of metals and other elements in marine fish and shellfish. Food Surveillance Information Sheet no.151; 1998. [FSIS 151]

Mariani 2013

Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. *Journal of the American Heart Association* 2013;**2**(1):e005033.

Mortensen 2019

Mortensen MB, Nordestgaard BG. Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat. *JAMA Cardiology* [Epub ahead of print] 2019. [DOI: [10.1001/jamacardio.2019.3665](https://doi.org/10.1001/jamacardio.2019.3665)]

Nettleton 1991

Nettleton JA. Omega-3 fatty acids: comparison of plant and seafood sources in human nutrition. *Journal of the American Dietetic Association* 1991;**91**:331-7.

NICE 2016

NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification clinical guideline [CG181]. www.nice.org.uk/guidance/cg181 July 2014, last updated September 2016.

Page 2019

Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. Draft version (29th January 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). *Cochrane Handbook for Systematic Reviews of Interventions*. London: Cochrane, 2019.

Papanikolaou 2014

Papanikolaou Y, Brooks J, Reider C, Fulgoni VL. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003–2008. *Nutrition Journal* 2014;**13**:31. [DOI: [10.1186/1475-2891-13-31](https://doi.org/10.1186/1475-2891-13-31)]

Pawlosky 2001

Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. *Journal of Lipid Research* 2001;**42**:1257-65.

Rizos 2012

Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA* 2012;**308**(10):1024-33.

SACN COT 2004

Scientific Advisory Committee on Nutrition, Committee on Toxicity. Advice on fish consumption: benefits & risks. London, United Kingdom: Her Majesty's Stationary Office, 2004.

Savovic 2012

Savovic J, Jones H, Altman D, Harris R, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technology Assessment* 2012;**16**:1-82.

Scandinavian Simvastatin Survival Study Group 1994

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;**344**(8934):1383-9.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**:408-12.

Schünemann 2017

Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Akl E, et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing 'Summary of findings' tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), *Cochrane Handbook for Systematic Reviews of Interventions* version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.

Sethi 2016

Sethi A, Bajaj A, Khosla S, Arora RR. Statin use mitigate the benefit of omega-3 fatty acids supplementation: a meta-regression of randomized trials. *American Journal of Therapeutics* 2016;**23**(3):e737-48.

Sharp 1998

Sharp S. Meta-analysis regression. *Stata Technical Bulletin* 1998;**42**:16-22.

Simopoulos 1992

Simopoulos AP, Norman HA, Gillaspie JE, Duke JA. Common purslane: a source of omega-3 fatty acids and antioxidants. *Journal of the American College of Nutrition* 1992;**11**(4):374-82.

Skulas-Ray 2019

Skulas-Ray AC, Wilson PW, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. *Circulation* 2019;**140**:e673-e691. [DOI: [10.1161/CIR.0000000000000709](https://doi.org/10.1161/CIR.0000000000000709)]

Stark 2016

Stark KD, Van Elswyk ME, Higgins R, Weatherford CA, Salem N Jr. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. *Progress in Lipid Research* 2016;**63**:132-52. [DOI: [10.1016/j.plipres.2016.05.001](https://doi.org/10.1016/j.plipres.2016.05.001)]

Thorpe 2017

Thorpe G, Ajabnoor S, Ahmed Z, Abdelhamid A, Hooper L. Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. *PROSPERO* 2017;www.crd.york.ac.uk/prospere/display_record.php?RecordID=68704:CRD42017068704.

Trikalinos 2012

Trikalinos TA, Moorthy D, Chung M, Yu WW, Lee J, Lichtenstein AH, et al. Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations. *Journal of Clinical Epidemiology* 2012;**65**(1):16-29.

Turgeon 2015

Turgeon RD, Zarnke KB, Allan GM. Does ezetimibe modify clinical outcomes?. *Canadian Family Physician Medecin de Famille Canadien* 2015;**61**(3):251. [PMC4369637]

USFDA 1995

US Food, Drug Administration. What you need to know about mercury in fish and shellfish. www.fda.gov/food/foodborneillnesscontaminants/metals/ucm351781.htm (accessed May 2018).

USFDA 2000

US Food, Drug Administration. Center for Food Safety and Applied Nutrition, Office of Nutritional Products. Labeling, and dietary supplements: letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease (docket No. 91N-0103). www.fda.gov/Food/LabelingNutrition/ucm073992.htm#cardio 2004.

White 2005

White C. Suspected research fraud: difficulties of getting at the truth. *BMJ* 2005;**331**(7511):281-8. [DOI: [10.1136/bmj.331.7511.281](https://doi.org/10.1136/bmj.331.7511.281)]

WHO 2017

World Health Organization. Cardiovascular Diseases (CVDs). Fact sheets; May 2017. www.who.int/mediacentre/factsheets/fs317/en (accessed 24 November 2017).

Wood 2008

Wood L, Egger M, Gluud LL, Schulz K, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008;**336**:601-5.

World Bank 2018

World Bank. World Bank Country and Lending Groups - country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 3 April 2018).

Zhao 2009

Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. *Annals of Medicine* 2009;**41**(4):301-10.

Zheng 2014

Zheng T, Zhao J, Wang Y, Liu W, Wang Z, Shang Y, et al. The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: a meta-analysis. *Clinical Biochemistry* 2014;**47**(6):369-77.

References to other published versions of this review

Abdelhamid 2018a

Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 11. [DOI: [10.1002/14651858.CD003177.pub4](https://doi.org/10.1002/14651858.CD003177.pub4)]

Hooper 2004

Hooper L, Harrison RA, Summerbell CD, Moore H, Worthington HV, Ness A, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2004, Issue 4. [DOI: [10.1002/14651858.CD003177.pub2](https://doi.org/10.1002/14651858.CD003177.pub2)]

Hooper 2006

Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. *BMJ* 2006;**322**:752. [DOI: [10.1136/bmj.38755.366331.2F](https://doi.org/10.1136/bmj.38755.366331.2F)]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

ADCS 2010

Methods	<p>Alzheimer's Disease Cooperative Study (ADCS)</p> <p>RCT, parallel, (n-3 DHA vs n-6 LA), 18 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Individuals with mild to moderate Alzheimer's disease</p> <p>N: 238 intervention, 164 control</p> <p>Level of risk for CVD: low</p> <p>Men: 52.9% intervention, 40.2% control</p> <p>Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control</p> <p>Age range: unclear</p> <p>Smokers: 24.4% intervention, 21.9% control</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: cholinesterase inhibitor, memantine</p> <p>Medications taken by 20%-49% of those in the control group: none</p> <p>Medications taken by some, but < 20% of the control group: none</p> <p>Location: USA</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: DHA vs omega-6</p> <p>Intervention: 2 × 1 g algal-derived DHA capsules (Neuromins)/d for a total daily dose of 2 g, each capsule contain 45%-55% of DHA and does not contain EPA (950 mg soft-gel capsules, which contain approximately 510 mg DHA). Dose: +DHA 1.02 g/d</p> <p>Control: 2 × 1 g placebo capsules/d (made up of corn or soy oil)</p> <p>Compliance: measured by pill counts at every visit</p> <p>Length of intervention: 18 months</p>
Outcomes	<p>Main trial outcome: change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR)</p> <p>Dropouts: 67 intervention, 40 control (discontinued treatment but included in main analyses)</p>

ADCS 2010 (Continued)

Available outcomes: mortality, measures of cognition, baseline and change in plasma DHA, adverse events

Response to contact: no data provided

Notes

Trial funding; quote: "grant U01-AG10483 from the National Institute on Aging. The National Institute on Aging was not otherwise involved in the design and conduct of the study, or in the analysis of data or preparation of the manuscript". "The placebo and DHA study drugs were provided by Martek Biosciences. Martek also provided plasma and cerebrospinal fluid measurements of FAs, as well as partial financial support for the magnetic resonance imaging sub study. (Martek Biosciences produces nutritional supplements from cultivated fungi and microalgae). Martek employees participated in design of the study and in revision of the manuscript, but were not involved in data management or data analysis." (Quinn 2010, p. 1910).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was achieved with a centralised interactive voice response system, using a block design with a block size of 5 (3 in the DHA group and 2 in the placebo group).
Allocation concealment (selection bias)	Low risk	Randomisation was achieved with a centralised interactive voice response system, using a block design with a block size of 5 (3 in the DHA group and 2 in the placebo group).
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo capsules (made up of corn or soy oil) were identical in appearance. The adequacy of blinding was assessed by questionnaires completed by caregivers, trial co-ordinators, and site physicians.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The adequacy of blinding was assessed by questionnaires completed by caregivers, trial co-ordinators, and site physicians with results showing no difference between groups and the majority did not know.
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis. At 12 months data were available for > 80%
Selective reporting (reporting bias)	Low risk	Prospectively registered February 2007, trial started February 2007, completed May 2009. Primary outcomes were rate of change in ADAS-Cog11 and CDR-SOB, which are both reported in main report. NPI and ADL were secondary outcomes also reported.
Attention	Low risk	Both trial arms had the same follow-up and care.
Compliance	Unclear risk	Measured by pill count at every visit. 28% intervention and 24% control discontinued supplement with a minority discontinuing due to adverse events. A further 8% were excluded for < 80% compliance in both intervention and control arms.
Other bias	Low risk	None noted

AFFORD 2013

Methods

Multi-centre study to evaluate the effect of n-3 FAs on arrhythmia recurrence in atrial fibrillation (AFFORD)

AFFORD 2013 (Continued)

RCT, parallel, (n-3 EPA + DHA vs n-6), 12 months

Summary risk of bias: moderate or high

Participants	<p>People with symptomatic paroxysmal or persistent AF</p> <p>N: 165 intervention, 172 control (Analysed, intervention: 153 control: 163)</p> <p>Level of risk for CVD: high</p> <p>Men: 69% intervention, 65% control</p> <p>Mean age in years (SD): 60 (12) intervention, 62 (13) control</p> <p>Age range: not reported</p> <p>Smokers: not reported</p> <p>Hypertension: 45% intervention, 42% control</p> <p>Medications taken by at least 50% of those in the control group: oral anticoagulant</p> <p>Medications taken by 20%-49%: beta-blockers, ACE inhibitors, ARBs</p> <p>Medications taken by some, but < 20%: none</p> <p>Location: Canada</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (fish oil)</p> <p>Comparison: EPA + DHA vs omega-6 safflower oil</p> <p>Intervention: 4 × 1 g enteric-coated fish oil capsules/d (1.6 g/d EPA + 0.8 g/d DHA, Genuine Health, Toronto, Ontario, Canada). Dose: +2.4 g/d EPA + DHA,</p> <p>Control: 4 × 1 g matching placebo capsules, 4 g/d safflower oil</p> <p>Compliance: omega-3 index increased in intervention group, but not control, over the trial</p> <p>Duration of intervention: 6-16 months</p>
Outcomes	<p>Main trial outcome: AF recurrence</p> <p>Dropouts: 21 intervention, 19 control</p> <p>Available outcomes: all-cause mortality, stroke, AF recurrence, TIA, CV events, CRP (not usable)</p> <p>Response to contact: no</p>
Notes	<p>We contacted trial authors about QoL, resource use and dietary habits</p> <p>Trial funding: Canadian Institutes for Health Research and the Heart and Stroke Foundation of Quebec</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"[R]andomised"
Allocation concealment (selection bias)	Unclear risk	Not described

AFFORD 2013 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as double-blind, but blinding not described or tested
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	An independent events committee adjudicated AF recurrences, bleeding, strokes, TIAs, and deaths, but unclear if blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Participant flow well described. ITT analysis
Selective reporting (reporting bias)	High risk	NCT01235130 registered July 2010, recruitment March 2009-March 2012, follow-up finished December 2012. Results published 2014, but no data on QoL, resource utilisation, or dietary habits (stated in registry) found
Attention	Low risk	No problem with attention bias
Compliance	Low risk	Omega-3 index measured
Other bias	Low risk	None noted

Ahn 2016

Methods	RCT, parallel, (EPA + DHA + statins vs statins), 12 months Summary risk of bias: moderate to high
Participants	Statin-treated coronary artery disease (CAD) patients undergoing percutaneous coronary intervention N: 38 intervention, 36 control Level of risk for CVD: high Men: 63.2% intervention, 72.2% control Mean age in years (SD): 59.6 (9.1) intervention, 60.7 (0.8) [sic] control Age range: unclear Smokers: 36.8% intervention, 58.3% control Hypertension: 50% in both groups Medications taken by at least 50% of those in the control group: aspirin, clopidogrel, ACE inhibitors/ARB, beta-blockers, atorvastatin Medications taken by 20%-49% of those in the control group: cilostazol Medications taken by some, but < 20% of the control group: rosuvastatin, nitrates, calcium antagonists Location: South Korea Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs nil

Ahn 2016 (Continued)

Intervention: 3 g of ω -3 PUFA containing 1395 mg of EPA and 1125 mg of DHA/d. No further details.
Dose: +2.52 g/d EPA + DHA

Control: unclear whether control group were given placebo or only statins

Compliance: unclear how it was measured but reported good compliance with no numbers

Length of intervention: 12 months

Outcomes	<p>Main trial outcome: change in atherosclerotic burden</p> <p>Dropouts: none</p> <p>Available outcomes: lipids (TG reported as median, IQR so not used), atheroma volume, neointimal volume index</p> <p>Response to contact: no</p>
Notes	Trial funding: the trial was supported by clinical research grant from Pusan National University Hospital

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Simple randomisation was carried out using random number tables to assign each participant to the intervention or control group
Allocation concealment (selection bias)	Low risk	Participants were assigned randomisation numbers sequentially on recruitment to the trial, and the randomisation codes were retained by the clinical research co-ordinator.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The personnel responsible for randomisation as well as those performing laboratory measurements were blinded to the randomisation assignments.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported
Selective reporting (reporting bias)	Unclear risk	No protocol or trial register entry found
Attention	Unclear risk	No details
Compliance	Unclear risk	No details on how it was measured and no FA levels reported
Other bias	High risk	It's unclear whether the trial was placebo-controlled or the control group had no intervention. Also, some of the SDs appear to be incorrectly reported.

AlphaOmega - ALA 2010

Methods	RCT, (n-3 ALA vs MUFA), 40 months
---------	-----------------------------------

AlphaOmega - ALA 2010 (Continued)

Summary risk of bias: low

Participants	<p>60-80 year-olds with previous MI</p> <p>N: 1197 ALA intervention, 1236 control (1212 ALA + EPA/DHA intervention group)</p> <p>Level of risk for CVD: high</p> <p>Men: 77.9% intervention, 78.7% control</p> <p>Mean age in years (SD): 69.0 (5.6) intervention, 68.9 (5.6) control</p> <p>Age range: 60-80 years</p> <p>Smokers: 17.4% intervention, 18% control</p> <p>Hypertension: unclear</p> <p>Medications taken by at least 50% of those in the control group: lipid-lowering medication, antihypertensives, antithrombotics</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: antiarrhythmic drugs, antidiabetic drugs</p> <p>Location: the Netherlands</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplementary margarine</p> <p>Comparison: ALA vs MUFA</p> <p>Intervention 20 g/d enriched margarine incorporating: 2 g ALA. 8 × 250 g margarine tubs delivered every 12 weeks. Dose: average achieved +1.9 g/d ALA</p> <p>Control: 20 g/d margarine. No additional n-3 PUFAs. Identical margarine (oleic acid) placebo</p> <p>Compliance: unused margarine tubs were returned- daily intakes of margarine and n-3 FAs were calculated on the basis of the amount unused. Adherence was measured by levels of FAs in plasma cholesterol esters, margarine and questionnaires. 90.5% of participants adhered to the protocol and consumed 20.6 (SD 2.8) g/d of margarine.</p> <p>Length of intervention: 40 months</p>
Outcomes	<p>Main trial outcome: CVD events</p> <p>Dropouts: 91 died, 98 discontinued intervention, 93 died, 93 discontinued control</p> <p>Available outcomes: deaths, MI, CVD events, ventricular arrhythmia, incident CVD</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>The trial has 3 intervention arms (ALA margarine, EPA/DHA margarine, mixture of the 2 interventions). This table represents the ALA-only intervention. Outcome data are used for the ALA group where reported separately or for the combined (ALA arm, ALA + EPA/DHA arm)</p> <p>Trial funding: Netherlands Heart Foundation, National Institutes of Health and Unilever R&D (latter provided unrestricted grant for distribution of trial margarines)</p>
Risk of bias	
Bias	<p>Authors' judgement</p> <p>Support for judgement</p>

AlphaOmega - ALA 2010 (Continued)

Random sequence generation (selection bias)	Low risk	On the computer by a random number generator before the start of the trial
Allocation concealment (selection bias)	Low risk	Trial author confirmed allocation was concealed from clinicians/ researchers
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The 4 types of margarine were "similar in taste, texture and colour". A trained test panel did not perceive a fishy taste or odour. Randomisation tables were stored safely under supervision.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation tables were stored safely under supervision. There was an independent statistician for data analysis. Quote: "Events were coded by three members of the end-point adjudication committee who were unaware of the identity of the patient, the identity of the treating physician and the patients assigned study group".
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were followed up for events, computerised linkage with municipal registries. 2531 participants were only followed up for baseline anthropometric and medical measurements.
Selective reporting (reporting bias)	High risk	Sudden cardiac death endpoint omitted. Registered in August 2005, recruitment was from 2002-2006. Outcomes papers published in 2010
Attention	Low risk	All participants appear to have had similar frequency and quantity of attention and follow-up
Compliance	Low risk	Unused margarine tubs were returned; daily intakes of margarine and n-3 FAs were calculated on the basis of the amount unused. Adherence was measured by levels of FAs in plasma cholesteryl esters, margarine and questionnaires. 90.5% of participants adhered to the protocol and consumed 20.6 (SD 2.8) g/d of margarine
Other bias	Low risk	None noted

AlphaOmega - EPA+DHA 2010

Methods	RCT, (EPA + DHA vs MUFA), 40 months Summary risk of bias: low
Participants	60-80 year-olds with previous MI N: 1192 EPA/DHA intervention, 1236 control (1212 ALA + EPA/DHA intervention group) Level of risk for CVD: high Men: 78.1% intervention, 78.7% control Mean age in years (SD): 69.1 (5.6) intervention, 68.9 (5.6) control Age range: 60-80 years Smokers: 16.8%, intervention, 18% control Hypertension: unclear

AlphaOmega - EPA+DHA 2010 (Continued)

Medications taken by at least 50% of those in the control group: lipid-lowering medication, antihypertensives, antithrombotics

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: antiarrhythmic drugs, antidiabetic drugs

Location: the Netherlands

Ethnicity: not reported

Interventions	<p>Type: supplementary margarine</p> <p>Comparison 1: EPA + DHA vs MUFA</p> <p>Intervention: 20 g/d enriched margarine incorporating 400 mg EPA-DHA (240 mg EPA and 160 mg DHA). Dose: average achieved 376 mg/d EPA + DHA Control: 20 g/d margarine. No additional n-3 PUFAs. Identical margarine (oleic acid) placebo</p> <p>Compliance: unused margarine tubs were returned; daily intakes of margarine and n-3 FAs were calculated on the basis of the amount unused. Adherence was measured by levels of FAs in plasma cholesterol esters, margarine and questionnaires. 90.5% of participants adhered to the protocol.</p> <p>Length of intervention: 40 months</p>
Outcomes	<p>Main trial outcome: CVD events</p> <p>Dropouts: 95 died, 119 discontinued intervention, 93 died, 93 discontinued control</p> <p>Available outcomes: deaths, MI, CVD events, ventricular arrhythmia, incident CVD</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>The trial has 3 intervention arms (ALA margarine, EPA/DHA margarine, mixture of the 2 interventions). This table represents the EPA/DHA only intervention. Outcome data is used for the EPA/DHA group where available or for the combined (EPA/DHA arm, EPA/DHA + ALA arm)</p> <p>Trial funding: Netherlands Heart Foundation, National Institutes of Health and Unilever R&D (latter provided unrestricted grant for distribution of trial margarines)</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	On the computer by a random number generator before the start of the trial
Allocation concealment (selection bias)	Low risk	Author confirmed allocation was concealed from clinicians/ researchers
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The 4 types of margarine were "similar in taste, texture and colour". A trained test panel did not perceive a fishy taste or odour. Randomisation tables were stored safely under supervision.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation tables were stored safely under supervision. There was an independent statistician for data analysis. Quote: "Events were coded by three members of the end-point adjudication committee who were unaware of the identity of the patient, the identity of the treating physician and the patients assigned study group".
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were followed up for events computerised linkage with municipal registries. 2531 participants were only followed up for baseline anthropometric and medical measurements.

AlphaOmega - EPA+DHA 2010 *(Continued)*

Selective reporting (reporting bias)	High risk	Sudden cardiac death endpoint omitted. Registered from August 2005, recruitment was from 2002-2006. Outcomes papers published in 2010
Attention	Low risk	All participants appear to have had similar frequency and quantity of attention and follow-up
Compliance	Low risk	Unused margarine tubs were returned; daily intakes of margarine and n-3 FAs were calculated on the basis of the amount unused. Adherence was measured by levels of FAs in plasma cholesteryl esters, margarine and questionnaires. 90.5% of participants adhered to the protocol and consumed 20.6 (SD 2.8) g/d margarine
Other bias	Low risk	None noted

AREDS2 2014

Methods	<p>Age-Related Eye Disease Study 2 (AREDS2)</p> <p>RCT, parallel, 2 × 2 factorial (n-3 EPA + DHA vs nil) also randomised to lutein and zeaxanthin vs nil), 5 years</p> <p>Summary risk of bias: low</p>
Participants	<p>People aged 50-85 years at high risk of progression to advanced age-related macular degeneration (AMD)</p> <p>N: 2147 intervention (1068 DHA/EPA, 1079 DHA/EPA + lutein/zeaxanthin), 2056 control (1012 placebo, 1044 lutein/zeaxanthin)</p> <p>Level of risk for CVD: low (however ~20% had previous CV event)</p> <p>Men: intervention 42.1%, control 44.4%</p> <p>Age in years: intervention median 74.6 (IQR 11.1), control median 74 (IQR 11.1)</p> <p>Age range: 68-79 years</p> <p>Smokers: intervention 6.3%, control 7.2%</p> <p>Hypertension: unclear</p> <p>Medications taken by at least 50% of those in the control group: multivitamins</p> <p>Medications taken by 20%-49% of those in the control group: cholesterol-lowering drugs, aspirin</p> <p>Medications taken by some, but < 20% of the control group: NSAID, paracetamol</p> <p>Location: USA</p> <p>Ethnicity: white 96.5% intervention, 96.6% control; Hispanic: 2.6 intervention, 1.3 control</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention 350 mg/d DHA plus 650 mg/d EPA added to the standard AREDS supplement of Vitamin C (500 mg/d), Vitamin E (440 IU/d), beta-carotene (15 mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/d). Dose: +1 g/d EPA + DHA</p> <p>Control: standard AREDS supplement of Vitamin C (500 mg/d), Vitamin E (400IU/d), beta-carotene (15 mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/d).</p>

AREDS2 2014 (Continued)

Compliance: assessed by pill count. 84% of participants in each group took at least 75% of trial medications

Length of intervention: 60 months

Outcomes	<p>Main trial outcome: development of advanced AMD</p> <p>Dropouts: intervention 200 died, 165 discontinued, 80 were lost to follow-up; control 168 died, 140 discontinued, 61 were lost to follow-up</p> <p>Available outcomes: deaths, CV death, MI, stroke, angina, heart failure, revascularisation, cognition, eye health, (trial authors provided data on diabetes diagnosis, depression diagnosis, breast cancer)</p> <p>Response to contact: yes (data provided)</p>
Notes	Trial funding: National Eye Institute/National Institutes of Health, Department of Health and Human Services

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "random block design was implemented using the AREDS2 Advantage Electronic Data Capture system by the AREDS2 Coordinating Center"
Allocation concealment (selection bias)	Low risk	Each treatment was assigned 5 bottle numbers. Bottle numbers were issued via an electronic randomisation system for each participant once trial eligibility was verified. The assigned bottle number was used to distribute the trial treatment(s). AREDS2 Co-ordinating centre personnel involved in creating the randomisation system had access to the bottle number/treatment assignments.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Participants, investigators, study coordinators, and all other study personnel are masked to treatment assignment". However, no information was given regarding the taste, smell, or appearance of the active or placebo capsules.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The co-ordinating centre randomly assigned the event to a trial adjudicator, who made the final determination of these trial endpoints through review of the medical records and applying the endpoint criterion defined a priori. All adjudicators were masked to trial assignment.
Incomplete outcome data (attrition bias) All outcomes	Low risk	< 20% attrition over 5 years, balanced reasons for dropouts
Selective reporting (reporting bias)	Low risk	Outcomes in trials registry entry appear to all be reported (NCT00345176). Entry received June 2006, recruitment September 2006–October 2012
Attention	Low risk	Participants, investigators, trial co-ordinators, and all other trial personnel are masked to treatment assignment, so attention bias not feasible
Compliance	Unclear risk	Assessed by pill count. 84% of participants in each group took at least 75% of trial medications
Other bias	Low risk	None noted

ASCEND 2018

Methods	<p>A Study of Cardiovascular Events in Diabetes (ASCEND)</p> <p>RCT, parallel, 2 × 2 factorial (n-3 EPA + DHA vs MUFA) also randomised to aspirin vs placebo), median 7.4 years</p> <p>Summary risk of bias: low</p>
Participants	<p>People with diabetes, without apparent vascular disease (94% of participants in both arms had type 2 DM, TG unclear)</p> <p>N: 7740 intervention, 7740 control (ITT so 7740 in each arm analysed)</p> <p>Level of risk for CVD: moderate (DM)</p> <p>Men: intervention 62.6%, control 62.6%</p> <p>Age in years (SD): intervention 63.3 (9.2), control 63.3 (9.2)</p> <p>Age range: 40+ years</p> <p>Smokers: intervention 8.3%, control 8.3%</p> <p>Hypertension: intervention 61.6%, control 61.6%</p> <p>Medications taken by at least 50% of those in the control group: statins, metformin, ACE inhibitors or ARBs</p> <p>Medications taken by 20%-49% of those in the control group: aspirin, insulin, sulphonylurea, calcium channel blockers</p> <p>Medications taken by some, but < 20% of the control group: NSAID, thiazolidinedione, beta-blockers, thiazide or related diuretics, PPI</p> <p>Location: UK</p> <p>Ethnicity: white 96.5% intervention, 96.5% control</p> <p>Indian/Pakistani/Bangladeshi 1.2% intervention, 1.2% control</p> <p>African/Caribbean 0.9% intervention, 0.9% control</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 840 mg/d EPA+DHA (460 mg/d EPA plus 380 mg/d DHA) as 1 capsule daily, provided by Mylan, Solvay and Abbott</p> <p>Arm 1: omega-3 (1 g/d: 0.41 g EPA, 0.34 g DHA) and placebo tablets for aspirin</p> <p>Arm 3: omega-3 (1 g/d) and aspirin (100 mg/d)</p> <p>Control: 1 capsule/d of olive oil provided by Mylan, Solvay and Abbott</p> <p>Arm 2: aspirin (100 mg/d) and olive oil placebo capsule</p> <p>Arm 4: olive oil placebo and placebo tablets for aspirin</p> <p>Compliance: assessed through posted questionnaires, suggesting 77% compliance in intervention group, 76% in control. 10% also took over-the-counter fish oil.</p> <p>Length of intervention: mean 7.4 years</p>
Outcomes	<p>Main trial outcome: serious vascular events (first of MI, stroke, TIA or vascular death)</p> <p>Dropouts: intervention 2879 stopped taking meds for some reason, but were included in analysis; control 2938 stopped taking meds, but were included in analysis</p>

ASCEND 2018 (Continued)

Available outcomes: deaths, CV death, MI, stroke, heart failure, revascularisation, AF, diabetes complications, cancer diagnosis, breast cancer, prostate cancer (and other types of cancer), TIA, IBD, dementia, depressive disorders, anxiety, suicidal and injurious behaviour, Parkinson's disease, body weight, serum cholesterol, HDL cholesterol, HbA1c

Response to contact: not yet attempted

Notes

NCT00135226

Trial website: ascend.medsci.ox.ac.uk; rum.ctsu.ox.ac.uk/ascend

Trial funding: British Heart Foundation, medications provided by Mylan, Solvay and Abbott

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using minimisation
Allocation concealment (selection bias)	Low risk	Almost no direct contact with trial personnel - all via questionnaires and GP appointments, central randomisation appears to follow consent
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding of participants, care providers, investigators and outcome assessors stated in trials register. This appears feasible given the dispersed design with mainly postal contact.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes self-reported (questionnaire) but investigated by masked adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis
Selective reporting (reporting bias)	Low risk	Prospective trial registration (registered August 2005, recruitment June 2005-July 2011), and all outcomes in register reported (plus extensive adverse event list)
Attention	Low risk	Almost no contact that could differ between groups
Compliance	Unclear risk	All information was via questionnaires, so unclear
Other bias	Low risk	None noted

Baldassarre 2006

Methods

RCT, (n-3 EPA + DHA vs MUFA), 24 months

Summary risk of bias: moderate or high

Participants

45-70-year-olds with combined hyperlipoproteinaemia (mean baseline TG > 3 mmol/L)

N: 32 intervention, 32 control

Level of risk for CVD: moderate

Baldassarre 2006 (Continued)

Men: 29% intervention, 29% control

Mean age in years (SD): 53.7 (7.2) intervention, 53.7 (6.9) control

Age range: 45-70 years (inclusion)

Smokers: 28.1% intervention, 28.1% control

Hypertension: none (exclusion criteria)

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported (participants on HRT, anti-hypertensive drugs, lipid-lowering drugs, or who smoked > 10 cigarettes were excluded)

Location: Italy

Ethnicity: not reported

Interventions	<p>Type: capsules</p> <p>Comparison: LCn3 vs MUFA</p> <p>Intervention: 1 g × 6 soft gelatin capsules/d of FA mixture (19% EPA), 13% DHA, 19% palmitic acid, 18% oleic acid, 2% LA and 29% other minor components) providing 1.08 g/d EPA, 0.72 g/d DHA, 0.01 g/d tocopherol acetate, divided to 3 doses. Dose: 1.8 g/d EPA + DHA</p> <p>Control: 1 g × 6 opaque identical soft gelatin capsules/d of olive oil divided in 3 doses</p> <p>Compliance: assessed by counting returned capsules at each visit and by measuring EPA and DHA levels at month 24</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: carotid atherosclerosis measures</p> <p>Dropouts: 2 intervention, 5 control</p> <p>Available outcomes: deaths (nil), MI (lipids, weight, BP and heart rate reported but not in a usable format; lipid data were presented at various times without clear numerical data, suggesting falls in TGs in the intervention but not control arms, and rises in LDL and HDL cholesterol in intervention but not control arms. For the other outcomes the text states "a rise in body weight (+ 3%, $P < 0.01$) was observed at the end of the study in both groups. Blood pressure and heart rate were unchanged". Effects on IMT and platelets also reported but not used)</p> <p>Response to contact: not yet attempted</p>
Notes	<p>Trial funding: supported by Institut De Recherche Pierre Fabre, Departement Recherche Clinique</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	An appropriate software was used to obtain 2 groups balanced for sex, age and smoking
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias)	Unclear risk	Double-blind and placebo capsules were opaque and identical-looking to intervention. However no information provided on capsules taste or smell

Baldassarre 2006 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	All dropouts are accounted for. "One patient left the study after 3 months because he moved to another city and was therefore excluded from statistical analyses. Two patients were excluded because of major deviation from the protocol during the follow-up (anti-hypertensive assumption) and four because of non-compliance on the basis of returning capsules (compliance < 70%). The final analysed group included 57 patients (30 on active treatment)."
Selective reporting (reporting bias)	Unclear risk	No protocol or trial register record
Attention	Low risk	Both groups had the same contact and number of visits.
Compliance	Low risk	Pill count, we know they excluded 4/64 who returned > 70% of capsules. So 60/64 had > 70% compliance with significant increase in serum EPA and DHA in the intervention group.
Other bias	Low risk	None noted

Bates 1989

Methods	RCT, parallel, (n-3 EPA + DHA vs MUFA), 24 months Summary risk of bias: moderate or high
Participants	People with MS N: 155 intervention, 157 control (analysed, intervention: 145 control: 147) Level of risk for CVD: low Men: 34.2% intervention, 30.6% control Mean age in years (SD): 34.0 (6.6) intervention, 33.7 (6.3) control Age range: not reported but 16-45 years inclusion criteria Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: not reported Location: UK Ethnicity: not reported
Interventions	Type: supplement (fish oil capsule) Comparison: EPA + DHA vs MUFA

Bates 1989 (Continued)

Intervention: 20 × 0.5 g/d capsules MaxEPA fish body oil (10 g/d fish oil providing 1.71 g/d EPA + 1.14 g/d DHA +10 IU/d vitamin E), plus all advised to reduce animal fat and ensure plentiful omega-6 fats.
Dose: +2.85 g/d EPA + DHA

Control: 20 × 0.5 g/d capsules olive oil (10 g/d olive oil), plus all advised to reduce animal fat and ensure plentiful omega-6 fats. All capsules contained 0.5 IU vit E and 100 ppm dodecyl gallate to minimise peroxide formation

Compliance: serum EPA and DHA rose in intervention group but fell in controls

Duration of intervention: 24 months (5 years mentioned but outcomes not reported)

Outcomes	<p>Main trial outcome: MS progress</p> <p>Dropouts: 10 intervention, 10 control</p> <p>Available outcomes: all-cause mortality, progress of MS, rate of MS relapse</p> <p>Response to contact: yes (no data provided)</p>
Notes	Trial funding: Multiple Sclerosis Society of Great Britain and Northern Ireland, but Marfleet Refining provided fish oil and placebo capsules

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomised"
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Paper states research was "double blind" and control capsules "had the same appearance and flavour as the fish oil capsules and were packed and dispensed in identical fashion"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low risk at reported time points
Selective reporting (reporting bias)	High risk	No protocol or trials registration entries found. Study was intended to run for 5 years, but outcomes only appear to be reported for the first 2 years.
Attention	Low risk	Unlikely as each had capsules
Compliance	Low risk	Serum EPA and DHA rose in intervention group but fell in controls
Other bias	Low risk	Not noted

Berson 2004

Methods	RCT, parallel, (n-3 DHA vs n-6 LA), 48 months
---------	---

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Berson 2004 (Continued)

Summary risk of bias: low

Participants	<p>People with retinitis pigmentosa aged 18-55 years</p> <p>N: 221 randomised overall, analysed 105 intervention, 103 control</p> <p>Level of risk for CVD: low</p> <p>Men: 48% intervention, 54% control</p> <p>Mean age in years (SD): 37.8 (6.5) intervention, 36.0 (7.2) control</p> <p>Age range: unclear (18-55 inclusion criterion)</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: vitamin A</p> <p>Medications taken by 20%-49% of those in the control group: multivitamins</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: USA</p> <p>Ethnicity: unclear (6% of the trial population were minorities)</p>
Interventions	<p>Type: supplement (DHA capsules)</p> <p>Comparison: DHA vs omega-6</p> <p>Intervention: 6 × 500 mg capsules/d of DHA (1.2 g/d DHA plus 1.8 g vegetable oil) plus < 0.0006 mg/d tocopherols plus 15,000 IU retinyl palmitate (vitamin A). Dose: +1.2 g/d DHA</p> <p>Control: 6 × 500 mg capsules/d of soy and corn oils (half each) with 120 mg/d ALA, plus < 0.0006 mg/d tocopherols plus 15000 IU retinyl palmitate (vitamin A)</p> <p>Compliance: 92% of capsules taken by both intervention and control groups (assessed by monthly calendars). Plasma DHA much higher in intervention than control</p> <p>Length of intervention: 48 months</p>
Outcomes	<p>Main trial outcome: retinal degeneration</p> <p>Dropouts: 5 or 6 intervention, 7 or 8 control</p> <p>Available outcomes: mortality, cancer diagnoses, lipids, eyesight</p> <p>Response to contact: yes (no data provided)</p>
Notes	<p>Trial funding: National Eye Institute and Foundation Fighting Blindness</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random numbers
Allocation concealment (selection bias)	Low risk	Random numbers available only to programmer who provided assignments to data manager, all staff in contact with participants were masked to group assignment

Berson 2004 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	States that all staff in contact with participants were masked to group assignment, as were participants. However no information was provided regarding the taste, smell and appearance of the active and placebo capsules
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All assessments were performed blind to trial allocation. Each ocular examination was performed without review of previous records. All serum samples were analysed without knowledge of treatment group assignment.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Numbers of dropouts and reasons for dropouts not stated. 221 participants randomised, data presented on 208 participants
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found
Attention	Low risk	Staff in contact with participants were masked, so unable to bias time, etc
Compliance	Low risk	92% of capsules taken by both intervention and control groups (assessed by monthly calendars), Plasma DHA much higher in intervention than control
Other bias	Low risk	None noted

Broutset 2007

Methods	RCT, parallel, (ALA vs unclear), 12 months Summary risk of bias: moderate to high
Participants	People aged 18-77 years with successful AF electrical cardioversion N: 98 randomised overall, analysed 40 intervention, 35 control Level of risk for CVD: high Men: % unclear, but both sexes enrolled Mean age in years (SD): unclear Age range: unclear (18-77 inclusion criterion) Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: France Ethnicity: unclear
Interventions	Canola margarine and oil, rich in ALA, vs a conventional diet (control), for 1 year Type: enriched foods (canola margarine and oil rich in ALA) Comparison: ALA vs unclear

Broutset 2007 (Continued)

Intervention: ALA dose of canola margarine and oil unclear

Control: conventional diet (ALA dose unclear)

Compliance: not reported

Duration of intervention: 12 months

Outcomes	Main trial outcome: length of time to first recurrence of AF Dropouts: 98 recruited, 75 analysed, 23 dropouts, unclear which arms Available outcomes: AF recurrence Response to contact: yes (no data provided)
Notes	NCT00410020, registered December 2006 Checked for updates and publications, 2 August 2019. 2007 abstract found (no further publication)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Allocation stated as randomised in trials register, but no method provided
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Trials register suggests open-label trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Trials register suggests open-label trial
Incomplete outcome data (attrition bias) All outcomes	High risk	98 recruited, 75 analysed (23% dropout) over 12 months
Selective reporting (reporting bias)	High risk	Only 1 of the several outcomes and analyses in trials register reported
Attention	Unclear risk	Unclear
Compliance	Unclear risk	Unclear
Other bias	Unclear risk	None noted

Brox 2001

Methods	RCT, parallel, 3 arms (n-3 EPA + DHA from cod liver vs n-3 EPA + DHA from seal oil vs nil), 14 months Summary risk of bias: moderate or high
Participants	People with moderate hypercholesterolaemia (mean baseline TG 204 mg/dL)

Brox 2001 (Continued)

N: 40 seal oil, 40 cod liver oil, 40 control (numbers analysed vary by outcome)

Level of risk for CVD: moderate (dyslipidaemia)

Men: 53% seal oil, 50% cod liver oil, 48% control

Mean age in years: 53.2 seal oil, 55.0 cod liver oil, 55.8 control

Age range: 43-66 years

Smokers: unclear

Hypertension: unclear

Medications taken by at least 50% of those in the control group: none allowed

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Norway

Ethnicity: not reported

Interventions	<p>Type: supplement (oil)</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention: intervention: seal oil – 15 mL/d (2.6 g, 1.1 g/d EPA + 1.5/d DHA) (total n-3 3.9 g/d, total PUFA 4.2 g/d); SO dose: EPA + DHA 2.6 g/d</p> <p>Cod liver oil – 15 mL/d (3.3 g, 1.5 g/d EPA + 1.8 g/d DHA) (total n-3 4.1 g/d, total PUFA 4.35 g/d); cod liver oil dose: EPA + DHA 3.3 g/d</p> <p>Control: nil, no supplement</p> <p>Compliance: serum omega-3 FAs, rose from around 1 mmol/L to 2.4 (seal oil), 2.1 (cod liver oil) and 1.2 mmol/L (control)</p> <p>Length of intervention: 14 months</p>
Outcomes	<p>Main trial outcome: serum lipids</p> <p>Dropouts: 8 seal oil, 2 cod liver oil, 1 control</p> <p>Available outcomes: total and CV deaths, MI, combined CV events, lipids, adverse events</p> <p>Response to contact: yes (author provided methodological details)</p>
Notes	<p>Data of 2 intervention groups combined for dichotomous outcomes and cod liver oil vs control data used for continuous outcomes</p> <p>Trial funding: the trial was supported by the programme Medical Research in Finnmark County, University of Tromsø</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	J Brox stated (personal communication, January 2017): "The randomization of the 120 participants was done by first generating 3 groups (seal oil, cod liver oil, control), then giving each participant a number (1-120), 'putting all the numbers into the same hat' and blindly drawing one number at the time from the hat. The first 40 numbers (1-40) were allocated to the seal oil group, the

Brox 2001 (Continued)

		next 40 numbers (41-80) to the cod liver oil group and the rest (81-120) were allocated to the control group."
Allocation concealment (selection bias)	Low risk	J Brox stated (personal communication, January 2017): "The researcher/clinician who invited the participants had no knowledge of to which group the participants would be allocated."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "controls were aware – not given a supplement"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	J Brox stated (personal communication, 2003): "All the persons involved in the drawing & analysing of blood were unaware of treatment. The technicians analysing the blood did not have any personal contact with the participants except K. Olaussen who did the FA analysis ... she only had access to the sample numbers not names and code. The participants did not know their number (says elsewhere that K Olaussen did not know allocations). The only outcome assessor was J Brox who did not have personal contact with participants, randomising, collecting results or analysing process." "The only assessor was J Brox who did not have any personal contact with the participants, had nothing to do with the randomising or analysing process, or the collecting of results."
Incomplete outcome data (attrition bias) All outcomes	High risk	Control group 3 dropouts, seal oil group 10 dropouts, cod liver oil 3 dropouts. So substantial differences in rates of dropouts between the groups
Selective reporting (reporting bias)	Unclear risk	No trial protocol or trials register entry was found
Attention	Low risk	No suggestion of differential attention
Compliance	Low risk	Serum omega-3 FAs, rose from around 1 mmol/L to 2.4 (seal oil), 2.1 (cod liver oil) and 1.2 mmol/L (control)
Other bias	Low risk	No further bias noted

Caldwell 2011

Methods	RCT, parallel, (n-3 EPA + DHA vs n-6 LA), 12 months Summary risk of bias: low
Participants	Participants with non-cirrhotic NASH (53% obese, mean 3.1 metabolic syndrome criteria, 35% diabetic, mean TG 191 mg/dL) N: 20 intervention, 21 control (analysed 17 intervention, 17 control) Level of risk for CVD: moderate Men: 35.3% intervention, 41.2% control Mean age in years (SD): 46.4 (12.1) intervention, 47.2 (12) control Age range: 25-72 years Smokers: not reported Hypertension: not reported

Caldwell 2011 (Continued)

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: USA

Ethnicity: intervention, 100% white, control 94.% white, 5.9% other

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs omega-6</p> <p>Intervention: 3 × 1 g fish oil capsules/d (Nordic Natural) for a total 2.1 g/d n-3, each capsule contained 70% of n-3 (1050 mg EPA, 750 mg DHA + 300 mg other n-3). Dose: 1.8 g/d EPA + DHA</p> <p>Control: 3 × 1 g/d identical placebo (soybean) capsules containing 8% fish oils</p> <p>Both groups had dietary counselling on caloric intake and physical activity</p> <p>Compliance: unclear (measured n-6-n-3 ratio due to its link to hepatic lipid composition)</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: NASH activity score</p> <p>Dropouts: 3 intervention, 3 control</p> <p>Available outcomes: lipids (TG too unbalanced at baseline to use), measures of adiposity (weight, BMI, visceral fat – all unbalanced at baseline so not used), fasting glucose, insulin, HOMA-IR, QUICKI (also NASH progression, hepatic fat, ALT, VO₂ max, activity level, markers of cell injury, adiponectin not used)</p> <p>Response to contact: yes, change data supplied for BMI and body weight, confirmed no deaths, CV events, diabetes, depression, breast cancer or IBD diagnoses</p>
Notes	<p>Data on: BMI, weight, visceral fat, TG and glucose were not used as they were different between groups at baseline.</p> <p>Trial funding: trial was supported by NIH NCCAM Grant 5R21AT2901-2 and 5 M01 RR00847. Trial medication and identical appearing placebo was provided at no charge by Nordic Natural. RBC phospholipid profile was performed by Metamatrix (www.metamatrix.com). M30, M65, adiponectin, and IGFBP-1 electro chemiluminescence assays were performed by Wellstat Diagnostics (www.wellstatdiagnostics.com).</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised to n-3 or placebo using a stratified block 1:1 randomisation scheme. An independent biostatistician generated the randomisation list which was confidentially forwarded to the Investigational pharmacy
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All staff and participants were blinded to therapy assignment throughout the trial period. Both capsules were identical. However no information provided on capsules' taste or smell

Caldwell 2011 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded for main outcome
Incomplete outcome data (attrition bias) All outcomes	Low risk	15% dropouts explained and equal in both groups
Selective reporting (reporting bias)	Low risk	The trial was prospectively registered
Attention	Low risk	Both groups had the same attention
Compliance	Unclear risk	No details on compliance measurement
Other bias	Low risk	None noted

DART 1989

Methods	<p>Diet And Reinfarction Trial (DART) – oily fish advice (or capsule) arm</p> <p>RCT – parallel, 2 × 2 × 2 factorial (n-3 EPA + DHA vs nil or fat advice vs not, oily fish advice (or capsule) vs not, dietary fibre advice vs not)), 2 years</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Men recovering from MI</p> <p>N: 1015 intervention, 1018</p> <p>Level of risk for CVD: high (post-MI)</p> <p>Men: 100%</p> <p>Mean age, SD: 56.7 intervention, 56.4 control (SDs not stated)</p> <p>Age range: unclear</p> <p>Smokers: 61.7% intervention, 62.2% control</p> <p>Hypertension: 22.7% intervention, 24.6% control</p> <p>Medications taken by at least 50% of those in the control group: none reported</p> <p>Medications taken by 20%-49%: beta-blockers, other antihypertensives, antianginals</p> <p>Medications taken by some, but < 20%: anticoagulant, aspirin/antiplatelet, digoxin/antiarrhythmic</p> <p>Location: UK</p> <p>Ethnicity: not stated</p>
Interventions	<p>Type: dietary advice (to eat more oily fish)</p> <p>Comparison: EPA + DHA vs SFA + MUFA (by dietary achievement below)</p> <p>Intervention: advised to eat at least 2 weekly portions of 200-400 g fatty fish (mackerel, herring, kipper, pilchard, sardine, salmon, trout). If this was not possible, given MaxEPA capsules, 3/d (0.5 g EPA/d). 191/883 participants were taking MaxEPA at 2 years. Advice was reinforced 3-monthly. Dose: aimed for 0.5 g/d EPA</p>

DART 1989 (Continued)

Control: no such dietary advice or capsules

Compliance: 7-day weighed food diary of a random subsample indicated intake of 2.5 g/week EPA intervention, 0.8 g/week EPA control

Dietary achievements

Total fat intake, percentage of energy (%E) (through trial): control 35 (SD 6), intervention 31 (SD 7) (MD -4.00, 95% CI -4.57 to -3.43); significant reduction

Saturated fat intake, %E (through trial): control 15 (SD 3), intervention 11 (SD 3), (MD -4.00, 95% CI -4.26 to -3.74); significant reduction

PUFA intake (through trial), %E: control 7 (SD unclear), intervention 9 (SD unclear), (MD 2.00, 95% CI 1.57 to 2.43 assuming SDs of 5) significant increase

PUFA n-3 intake: EPA, control 0.6 (SD 0.7) g/week, intervention 2.4 (SD 1.4) g/week

PUFA n-6 intake: not reported

MUFA intake (through trial), %E: control 13 (SD unclear), intervention 11 (SD unclear) (MD -2.00, 95% CI -2.43 to -1.57 assuming SDs of 5); significant reduction

CHO intake (through trial), %E: control 44 (SD 6), intervention 46 (SD 7) (MD 2.00, 95% CI 1.43 to 2.57); significant increase

Protein intake (through trial), %E: control 17 (SD 4), intervention 18 (SD 4) (MD 1.00, 95% CI 0.65 to 1.35); significant increase

Trans fat intake: not reported

Length of intervention: 24 months

Outcomes	<p>Main trial outcome: total mortality, reinfarction, CHD death</p> <p>Dropouts: none for mortality</p> <p>Available outcomes: total and CV deaths, MI, CHD events, lipids, BP, cancer deaths</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>Some of each group were also advised on low-fat and high-PUFA and/or high-fibre diets, all participants who smoked were advised to stop and all with a BMI > 30 kg/m² were given weight-reduction advice, regardless of randomisation arm. The low fat high PUFA comparison was included in the omega-6 review.</p> <p>Trial funding: by the Welsh Scheme for the Development of Health and Social Research, the Welsh Heart Foundation and the Health Promotion, Research Trust. Seven Seas Health Care and Duncan Flockhart provided MaxEpa capsules</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomised" confirmed by trial author
Allocation concealment (selection bias)	Unclear risk	Pre-prepared, sequentially numbered envelopes opened by dietitian (unclear if envelopes were opaque)
Blinding of participants and personnel (performance bias)	High risk	Blinding of dietary advice (or lack of it) is not possible

DART 1989 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors were not aware of trial allocation (Prof Burr stated he did not know assignments)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Hospital notes and death registers were flagged to catch all outcome data
Selective reporting (reporting bias)	Unclear risk	No trial protocol or trials register entry was found
Attention	High risk	More attention was paid to those given dietary advice
Compliance	Unclear risk	7-day weighed food diary of a random sub-sample indicated intake of 2.5 g/week EPA intervention, 0.8 g/week EPA control
Other bias	Low risk	None noted

DART2 2003

Methods	Diet and Angina Randomised Trial (DART2) RCT, 2 × 2, (oily fish or capsules n-3 EPA + DHA vs nil, also no specific advice, also fruit, vegetables and oats vs no specific advice), 3-9 years Summary risk of bias: moderate or high
Participants	Men treated for angina N: 1571 intervention, 1543 control (all analysed for events) Control level of risk for CVD: high Men: 100% Mean age in years (SD): 61.1 (NR) intervention, 61.1 (NR) control Age range: unclear Smokers: 25% intervention, 23% control Hypertension: 49% intervention, 47% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49%: lipid-lowering, beta-blockers Medications taken by some, but < 20% of the control group: not reported Location: UK Ethnicity: not reported
Interventions	Type: dietary advice (to eat more oily fish or take fish oil capsules) Comparison: EPA + DHA vs unclear (not total fat, SFA or alcohol, presumably CHO and/or protein but not clear)

DART2 2003 (Continued)

Intervention: most (1109) advised to eat at least 2 weekly portions of fatty fish or take MaxEPA capsules, 3/d (0.5 g EPA/d). But 462 participants were sub-randomised to receive only fish oil capsules, not dietary fish advice. Dose: aimed for 0.5 g/d EPA.

Control: non-specific sensible eating advice that did not include either of the interventions

Compliance: postal dietary questionnaire suggested dietary EPA intake increased by 2.4 g/week intervention, 0.2 g/week control

Dietary achievements

Total fat intake, (change from baseline to 6 months): control -8.6 g/d (SD 20.9), intervention -5.2 (g/d SD 21.4) (MD 3.4 g/d)

Saturated fat intake, (change from baseline to 6 months): control -3.5 g/d (SD 9.3), intervention -2.8 g/d (SD 9.4), (MD 0.7 g/d)

PUFA intake (change from baseline to 6 months): control -1.6 g/d (SD 5.4), intervention -0.1 g/d (SD 5.8) (MD 1.5 g/d)

PUFA n-3 intake (change from baseline to 6 months): EPA, control 0.12 g/week (SD 0.73), intervention 2.65 g/week (SD 1.35) (MD 2.53 g/week)

PUFA n-6 intake: not reported

MUFA intake: not reported

CHO intake: not reported

Protein intake: not reported

Trans fat intake: not reported

Duration of intervention: 36-108 months

Outcomes	Main trial outcome: total mortality Dropouts: none for mortality Available outcomes: total and CV deaths, sudden death, stroke, heart failure, cancer deaths Response to contact: yes (data provided)
Notes	Some of each group were also advised on high fruit, vegetables and oat diets, and those who received neither fish nor fruit advice received 'non-specific' dietary advice. All those whose BMI > 30 kg/m ² in both groups received weight reduction advice. Trial funding: probably British Heart Foundation, Seven Seas Ltd, Novex Pharma Ltd and the Fish Foundation (these were acknowledged)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly allocated"
Allocation concealment (selection bias)	Unclear risk	Pre-prepared sequentially numbered enveloped opened by dietitian (unclear if envelopes were opaque)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Dietary advice, so not possible for participants to be blinded to intervention

DART2 2003 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors were not aware of trial allocation (Prof Burr stated he did not know assignments)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Hospital notes and death registers were flagged to catch all outcome data
Selective reporting (reporting bias)	Unclear risk	No trial protocol was found, or trials registry entry
Attention	High risk	More attention was paid to those given dietary advice
Compliance	Unclear risk	Postal dietary questionnaire suggested dietary EPA intake increased by 2.4 g/week intervention, 0.2 g/week control
Other bias	Low risk	None noted

Derosa 2016

Methods	RCT, parallel, (n-3 PUFA capsules vs placebo), 18 months Summary risk of bias: low
Participants	White overweight/obese people with IFG or IGT (mean baseline TG 182 mg/dL) N: 138 intervention, 143 control (analysed 128 intervention, 130 control) Level of risk for CVD: low Men: 50.72% intervention, 48.95% control Mean age in years (SD): 53.4 (11.2) intervention, 54.8 (12.1) control Age range: unclear Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: Italy Ethnicity: white
Interventions	Type: capsule (n-3 PUFA) Comparison: EPA + DHA vs CHO + SFA Intervention: 3 × 1 g capsule/d n-3 PUFAs (ethylic esters, each 1-g capsule of n-3 PUFAs contains highly concentrated ethyl esters of omega-3 FAs, primarily EPA, and DHA in the proportion of 0.9–1.5). Dose: unclear (approx 2-3 g/d) Control: placebo (a capsule containing sucrose, mannitol and mineral salts, magnesium stearate (a saturated fat) and silicon dioxide, used as anti-caking agents)

Derosa 2016 (Continued)

Both groups were given diet advice to follow a controlled-energy diet based on AHA recommendations (50% of calories from carbohydrates, 30% from fat (6% saturated), and 20% from proteins, with a maximum cholesterol content of 300 mg/d and 35 g/d of fibre). Individuals were also encouraged to increase their physical activity by walking briskly for 20-30 min, 3-5 times per week, or by cycling

Compliance: measured by counting the number of pills returned at the time of specified clinic visits

Length of intervention: 18 months

Outcomes	<p>Main trial outcome: insulin resistance</p> <p>Dropouts: 23 across arms (no details on groups but stated that there were no differences between groups)</p> <p>Available outcomes: mortality, CV mortality, CHD event, stroke, combined CVD events, MI, AF, weight, BMI, lipids, DM</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>Trial funding: "The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties"</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was done using a drawing of envelopes containing randomisation codes prepared by a statistician.
Allocation concealment (selection bias)	Low risk	Trial author stated that allocation was concealed from clinicians and researchers, but no methodology provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Both n-3 PUFAs and placebo were supplied as identical, opaque, white capsules in coded bottles to ensure the blind status of the trial. However no information provided on capsules' taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	A copy of the code was provided only to the person performing the statistical analysis
Incomplete outcome data (attrition bias) All outcomes	Low risk	An ITT analysis was conducted for participants who received 1 dose of trial medication
Selective reporting (reporting bias)	Unclear risk	No trial registry or protocol found
Attention	Low risk	No difference reported
Compliance	Unclear risk	Measured by counting the number of pills returned at the time of specified clinic visits
Other bias	Low risk	None noted

Deslypere 1992

Methods	<p>RCT 4 arms, (n-3 EPA + DHA (3 different doses) vs MUFA), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Healthy monks</p> <p>N: 14 high-, 15 medium-, 15 low-dose intervention, 14 control</p> <p>Level of risk for CVD: low</p> <p>Men: 100%</p> <p>Mean age in years (SD): 56.2 (16.5) (not reported by arm)</p> <p>Age range: 21-87</p> <p>Smokers: none</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported (no medications influencing lipid metabolism or NSAIDs were allowed)</p> <p>Location: the Netherlands</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: capsules</p> <p>Comparison: LCn3 vs MUFA</p> <p>Intervention 9 capsules (9 g vol)/d, of which 3, 6 or 9 were fish oil (Labaz, Brussels, Belgium) and any remainder were placebo (providing respectively 1.12; 2.24 or 3.37 g n-3 FA/day). Dose: 1.12 g/d; 2.24 g/d or 3.37 g/d EPA + DHA)</p> <p>Control: 9 placebo capsules made up of olive oil (Puget Marseille, France) and Palmoil (Loders-Kroklaan Wormerveen, the Netherlands) with the same SFA, cholesterol and vitamin E as the fish oil capsules</p> <p>Compliance: assessed by counting remaining capsules every 2 months and by measuring EPA concentration. Excellent compliance reported and shown by the EPA concentration results</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: effect on coronary risk factors</p> <p>Dropouts: none</p> <p>Available outcomes: deaths (nil), CVD events (nil), lipids, BP, HbA1c, weight (measured but only text suggests "no significant changes in the anthropometric parameters (weight, length, waist, hip and thigh circumferences) during the trial"), IL-6, TNF-alpha and several IL-1s (IL-6 reported as below detection range, for the others there was "no significant difference between the two treatment groups at any point in time")</p> <p>Response to contact: yes</p>
Notes	<p>Trial funding: capsules supplied by Labaz (Brussels Belgium). The placebo capsules contained olive oil (Puget) and palm oil (Loders-Kroklaan, Wormerveer). Financial support by Sanofi-Labaz</p> <p>Data entered for high-fish-oil versus placebo groups</p>

Deslypere 1992 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote (trial author correspondence): "The manufacturer provided envelopes containing numbers corresponding with boxes of capsules. For each enrolled subject, random envelope was opened."
Allocation concealment (selection bias)	Low risk	Allocation concealed from all this way
Blinding of participants and personnel (performance bias) All outcomes	High risk	Although double-blind, the fishy taste of the active treatment was not matched (trial author states that the fishy taste was clear in the intervention capsules)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Trial authors confirmed outcome assessors were unaware until afterwards
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registry record
Attention	Low risk	No difference between groups
Compliance	Low risk	Significant difference in EPA concentration
Other bias	Low risk	None noted

DIPP 2015

Methods	Dietary Intervention for Patients Polypectomized for tumours of the colorectum (DIPP) RCT, parallel, 2 arms (n-3 EPA + DHA + n-3 ALA vs unclear), 24 months Summary risk of bias: moderate or high
Participants	People previously polypectomised for colorectal tumours N: 104 intervention, 101 control Level of risk for CVD: low Men: 73.1% intervention, 74.3% control Mean age in years (SD): 58.3 (9.5) intervention, 59.7 (8.9) control Age range: 35-75 Smokers: 65.4% intervention, 61.4% control Hypertension: not reported Medications taken by at least 50% of those in the control group: supplements

DIPP 2015 (Continued)

Medications taken by 20%-49% of those in the control group: none

Medications taken by some, but < 20% of the control group: oral contraceptive pills

Location: Japan

Ethnicity: not reported

Interventions	<p>Type: advice + supplement (fish oil capsules)</p> <p>Comparison: EPA + DHA + ALA vs unclear</p> <p>Intervention: advice to reduce total fat intake, decrease consumption of n-6 PUFAs, increase intake of n-3 PUFAs from fish/marine foods, increase intake of n-3 PUFAs from perilla oil rich in ALA, take 8 capsules of fish oil/d (equivalent to 96 mg/d of EPA and 360 mg/d of DHA). Dose: 456 mg/d EPA + DHA and unknown dose of ALA</p> <p>Control: advice to decrease intake of fats/oils as a whole</p> <p>Compliance: measured via semi-quantitative food frequency questionnaire, plasma FA concentrations, FA compositions in the membranes of red blood cells and the sigmoid colon. Reported satisfactorily high compliance with protocol in both groups but no figures provided</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: number and size of colorectal tumours</p> <p>Dropouts: 3 intervention, 5 control</p> <p>Available outcomes: all-cause mortality, dietary intake, plasma FAs, lipids, side effects, glucose</p> <p>Response to contact: yes (methodological details provided)</p>
Notes	<p>Trial funding: all were either government or charity grants</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly allocated using random digit number for allocation of participants
Allocation concealment (selection bias)	Low risk	Author confirmed "Allocation information was blinded to clinicians and researchers"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	From the 2015 paper, "The attending physicians as well as the participants were blinded to the assignment information". However in the discussion section they say "complete participant blinding could not have been achieved because free living participants might have exchanged information on their dietary intervention, say in the hospital waiting room". Author confirmed blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "physicians, including colonoscopists, a scientist who conducted blood and specimen analyses, and pathologists were blinded"
Incomplete outcome data (attrition bias) All outcomes	Low risk	All those randomised were accounted for

DIPP 2015 (Continued)

Selective reporting (reporting bias)	High risk	The researchers chose not to report data on the number, size and pathological type of the colorectal tumours as they said they would in the trials register. They reported more outcomes in the paper than initially stated. UMIN000000461 Registered 3 August 2006, recruitment completed 1 March 2007
Attention	Low risk	Participants were given equal follow-up
Compliance	Unclear risk	Reported satisfactorily high compliance with protocol was noted in both groups but no figures
Other bias	Low risk	None noted

DISAF 2003

Methods	Dietary Intervention Study for AF (DISAF) RCT, parallel, 2 arms (n-3 EPA + DHA vs unclear), 12 months Summary risk of bias: moderate or high
Participants	People presenting for 1st treatment of acute/persistent AF or flutter, confirmed by ECG N: intervention 201, control 206 Level of risk for CVD: high (people with AF) Men: intervention 64.7%, control 63.6% Mean age in years (SD): intervention 67.7 (9.4), control 68.7 (9.5) Age range: unclear Smokers: intervention 10.9%, control 12.1% Hypertension: intervention 48.2%, control 40.8% Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: antiarrhythmics, antithrombotics Medications taken by some, but < 20% of the control group: not reported Location: UK Ethnicity: white British
Interventions	Type: dietary advice Comparison: EPA + DHA vs unclear Intervention: dietary assistants gave advice and support to eat 2-3 portions of oily fish/week (providing up to 10 g LCn3/ week), plus 2-3 portions of fruit and vegetables/d. Dose: 1.4 g/d EPA + DHA Control: dietary assistants gave advice and support to eat 2-3 portions of fruit and vegetables/d. No other health/lifestyle given as part of the trial Compliance: assessed red blood cell FAs and found some increases in EPA and DHA in intervention compared to control (no further intake data)

DISAF 2003 (Continued)

Length of intervention: 12 months

Outcomes	Main trial outcome: sinus rhythm after 12 months Dropouts: unclear Available outcomes: deaths, AF recurrence Response to contact: yes (data provided)
Notes	Trial funding: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was by phone to an independent randomisation office, which used pre-printed random number tables
Allocation concealment (selection bias)	Low risk	Randomisation was by phone to an independent randomisation office, which used pre-printed random number tables
Blinding of participants and personnel (performance bias) All outcomes	High risk	Dietary advice was clear, so allocation known by participants
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear
Incomplete outcome data (attrition bias) All outcomes	High risk	Some discrepancies between papers, reasons unclear
Selective reporting (reporting bias)	High risk	ISRCTN16448451 registered 23 January 2004, recruitment from 1 July 1998-1 July 2002; some secondary outcomes were not reported
Attention	Low risk	Intervention (advice to eat more oil-rich fish, fruit and vegetables) and control (advice to eat more fruit and vegetables) groups appeared to be given equivalent time and attention
Compliance	Low risk	Assessed red blood cell FAs and found some increases in EPA and DHA in intervention compared to control
Other bias	High risk	The trial was stopped early

DO IT 2010

Methods	Diet and Omega-3 Intervention Trial on atherosclerosis (DO IT) Randomisation: RCT, parallel, 2 × 2 factorial, (n-3 DHA + EPA vs n-6 LA also dietary advice intervention), 36 months Summary risk of bias: moderate or high
Participants	Elderly men with longstanding dyslipidaemia or hypertension (a subset of Oslo Diet heart trial) (mean baseline TG 1.8 mmol/L)

DO IT 2010 (Continued)

N: intervention 282 (140 n-3 capsules + 142 n-3 capsules and dietary advice), control 281 (142 placebo capsules + 139 placebo capsules and dietary advice)

Level of risk for CVD: moderate

Men: intervention 100%, control 100%

Mean age in years (SD): intervention 70.4 (2.9), control 69.7 (3.0) years

Age range: 64-76 years

Smokers: intervention 35%, control 33%

Hypertension: intervention 29%, control 27%

Medications taken by at least 50% of those in the control group: none

Medications taken by 20%-49% of those in the control group: statins and acetylsalicylic acid

Medications taken by some, but < 20% of the control group: β -blockers, ACE inhibitors and nitrates

Location: Norway

Ethnicity: not reported

Interventions	<p>Type: supplement/capsule (also dietary advice as the factorial intervention)</p> <p>Comparison: EPA + DHA vs omega-6</p> <p>Intervention: 2 \times 2 capsules/d including 2.4 g/d of omega-3 PUFA (Pikazol, 0.84 g/d EPA plus 0.48 g/d DHA plus 8.4 mg/d tocopherols). Dose: 1.32 g/d EPA + DHA</p> <p>Control: 2 \times 2 capsules/d including 4 g/d corn oil (2.24 g/d linoleic, 1.28 g/d oleic acid, 16 mg/d tocopherols)</p> <p>Compliance: pharmacy records suggested that > 90% of supplements were taken, and plasma EPA and DHA were raised in intervention compared to control participants.</p> <p>Duration of intervention: 36 months</p>
Outcomes	<p>Main trial outcome: atherosclerosis progression</p> <p>Dropouts: intervention 14 died, 20 others discontinued, control 24 died, 18 others discontinued</p> <p>Available outcomes: mortality, CV deaths, CHD events, CV events, MI, stroke, diabetes, glucose, lipids, cancer diagnosis, cancer deaths, sudden death, BMI (waist circumference reported as median, IQR)</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>The other 2 \times 2 intervention was dietary counselling to increase both omega-3 and omega-6 fats as well as fruit and vegetables.</p> <p>Trial funding: Norwegian Cardiovascular Council, Norwegian retail company RIMI, vegetable oil and margarine supplied by the Norwegian food company Mills DA and placebo capsules by LUBE</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Permuted block randomisation, no clear mechanism provided
Allocation concealment (selection bias)	Unclear risk	No details provided

DO IT 2010 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Capsules of fish oil or placebo taken, but unclear whether blinded and if so, how well or successfully
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Mortality data were supplied from the Norwegian Cause of Death Registry, and all clinical events were confirmed by hospital records and verified by an independent cardiologist"
Incomplete outcome data (attrition bias) All outcomes	Low risk	No attrition as deaths and events collected from centralised register
Selective reporting (reporting bias)	Unclear risk	Trials registry entry submitted after the outcomes papers were published
Attention	Low risk	No suggestion of attention bias between verum and placebo supplement arms
Compliance	Low risk	Pharmacy records suggested that > 90% of supplements were taken, and plasma EPA and DHA were raised in intervention compared to control participants
Other bias	Low risk	None noted

Dodin 2005

Methods	RCT, parallel, (n-3 ALA vs unclear), 12 months Summary risk of bias: moderate or high
Participants	Healthy menopausal women N: 101 intervention, 98 control (analysed, intervention: 85 control: 94) Level of risk for CVD: low Men: 0% intervention, 0% control Mean age in years (SD): 54.0 (4.0) intervention, 55.4 (4.5) control Age range: 49-65 Smokers: 8% intervention, 6% control Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: Canada Ethnicity: French Canadian
Interventions	Type: food supplement (flaxseed) Comparison: ALA vs unclear (probably includes lipids, CHO and protein, but not clear)

Dodin 2005 (Continued)

Intervention: 40 g/d flaxseed incorporated into diets (providing 21,071 g total lignans, 180 calories, 16 g lipids (57% ALA), and 11 g total dietary fibre). Dose: 9.1 g/d ALA

Control: 40 g/d wheat germ incorporated into diets (providing 196 g total lignans, 144 calories, 4 g lipids (6.9% ALA), and 6 g total dietary fibre)

Compliance: 1st morning urine collection was performed at randomisation and at month 12 to measure urinary lignin levels. In addition, trial participants recorded their daily intake of seeds on diary cards and were asked to return unused bread and packages of seeds at each visit. Good compliance reported

Duration of intervention: 12 months

Outcomes	<p>Main trial outcome: bone mineral density</p> <p>Dropouts: 26 intervention, 17 control (but 13/17 had an endpoint evaluation)</p> <p>Available outcomes: weight, BMI, QoL, BP, lipids, glucose, adverse events, dietary intake, plasma FAs</p> <p>Response to contact: yes</p>
Notes	<p>Trial authors replied to tell us that there were no deaths or CV events during the trial</p> <p>Trial funding: not reported</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The randomisation schedule was prepared by the clinical unit of the research centre using computer-generated randomisation in blocks of 4-8
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Low risk	<p>Participants, investigators, staff, and statisticians were blinded to dietary assignments for the duration of the trial.</p> <p>Quote: "a local baker prepared loaves of bread. Each week, the loaves of bread were delivered in sealed, opaque unmarked wrappers to the Department of Food and Nutrition Sciences at Laval University. The seeds were ground up and vacuum-packed in the same laboratory. The Department of Food and Nutrition Sciences was responsible for labelling the bags of bread and packages of seeds with the subject's randomization number. Bread and packages of seeds were provided on a 3-month basis. The foods that both groups received was similar in appearance and packaging and was kept frozen until consumption to avoid essential FA"</p>
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants, investigators, staff, and statisticians were blinded to dietary assignments for the duration of the trial
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis. Loss to follow-up 10%, reasons given
Selective reporting (reporting bias)	Unclear risk	No protocol or clinical trial registry entry found
Attention	Low risk	All participants had same number of visits

Dodin 2005 (Continued)

Compliance	Low risk	1st morning urine collection was performed at randomisation and at month 12 to measure urinary lignin levels. In addition, trial participants recorded their daily intake of seeds on diary cards and were asked to return unused bread and packages of seeds at each visit. Good compliance reported
Other bias	Low risk	None noted

Doi 2014

Methods	RCT, parallel, (n-3 EPA vs nil), 12 months Summary risk of bias: moderate or high
Participants	People having percutaneous coronary intervention after acute MI N: 119 intervention, 119 control analysed Level of risk for CVD: high Men: 77% intervention, 76% control Mean age in years (SD): 70 (11) intervention, 71 (12) control Age range: unclear Smokers: 28% intervention, 32% control Hypertension: 71% intervention, 69% control Medications taken by at least 50% of those in the control group: aspirin, ticlopidine, beta-blockers, statins (as part of treatment) Medications taken by 20%-49% of those in the control group: ARB/ACE inhibitors Medications taken by some, but < 20% of the control group: none Location: Japan Ethnicity: not reported
Interventions	Type: supplement (EPA) Comparison: EPA vs nil Intervention: purified EPA ethyl esters (> 98%) 1800 mg EPA/day within 24 h after percutaneous coronary intervention plus statins. Dose: 1.8 g/d EPA Control: statins with no EPA Compliance: not reported Length of intervention: 12 months
Outcomes	Main trial outcome: CV events Dropouts: 1 intervention, 2 control Available outcomes: mortality, stroke, MI, sudden death, CV death, revascularisation Response to contact: no

Doi 2014 (Continued)

Notes Trial funding: trial registry state "self-funded". The trial authors received honoraria from Mochida Pharmaceutical Co.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated, randomisation plan, which included stratification by age and sex
Allocation concealment (selection bias)	Unclear risk	Carried out by research technician but unclear
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label but blind endpoint
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Data on outcomes were collected from clinical charts. Unclear if blinded. Diagnoses were confirmed by investigator blind to treatment allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 3 dropouts, similar rates between the groups and reasons given
Selective reporting (reporting bias)	High risk	Data collection completed before trial registry entry. Only 1% dropouts
Attention	Low risk	Timing of follow-up similar
Compliance	Unclear risk	Not reported
Other bias	Low risk	None observed

DREAM Asbell 2018

Methods	<p>Dry Eye Assessment and Management (DREAM) Study</p> <p>RCT, parallel, (LCn-3 vs MUFA), 12 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Adults with dry eye</p> <p>N: 349 intervention randomised, 186 control randomised</p> <p>Level of risk for CVD: low</p> <p>Men: 19% intervention, 19% control</p> <p>Mean age in years (SD): 58.3 (13.5) intervention, 57.5 (12.6) control</p> <p>Age range: unclear</p> <p>Smokers: unclear</p> <p>Hypertension: unclear</p>

DREAM Asbell 2018 (Continued)

Medications taken by at least 50% of those in the control group: artificial tears

Medications taken by 20%-49% of those in the control group: cyclosporine drops

Medications taken by some, but < 20% of the control group: warm lid soaks, lid scrubs or baby shampoo

Location: USA

Ethnicity: intervention, white 76%, black 11%, other 13%; control white 72%; black 13%; other 15%

Interventions	Type: supplement (LCn3) Comparison: LCn3 vs MUFA Intervention: omega-3 supplements (2000 mg EPA + 1000 mg DHA/d as 5 gel caps). Dose: 3.0 g/d LCn3 Control: olive oil supplements (5 gel caps) Compliance: change in red cell FAs: EPA intervention +2.2% (SD 1.2), control 0.0 (SD 0.2); DHA intervention +1.6% (SD 1.2), control -0.1 (SD 0.7). P values for difference between arms < 0.001 for both Length of intervention: 12 months
Outcomes	Main trial outcome: OSDI score Dropouts: 24 intervention, 22 control Available outcomes: secondary: other eye health measures, SF-36, healthcare utilisation costs, cost-effectiveness. Reported as adverse events: mortality, adverse events by organ class, including breast cancer and other cancers, colitis, AF, atrial flutter, psychotic disorder, pulmonary embolism, DVT, HT, GI disorders, angina, arrhythmia, constipation, diarrhoea, IBS, cognitive disorder, anxiety, depression, diabetes diagnosis, QoL (SF-36) Response to contact: no
Notes	NCT02128763 Trial funding: National Eye Institute and National Institutes of Health

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Assignment of active or placebo supplements was automatically sent electronically to the Investigational Drug Service. Randomization schedules were stratified by clinical centre. "Randomization was performed with the use of a Web-based module and was stratified according to clinical center with a permuted-block method with randomly chosen block sizes. Personnel at the Investigational Drug Service, University of Pennsylvania, mailed the supplements directly to the patients."
Allocation concealment (selection bias)	Low risk	Centralised randomisation, as above.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"All subjects, clinical staff, and laboratory personnel were unaware of the assignment to active or placebo supplements." "Personnel at the Investigational Drug Service, University of Pennsylvania, mailed the supplements directly to the patients."

DREAM Asbell 2018 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	Of 349 randomised to the intervention and 186 in control, 324 completed data collection in intervention (24 missed final visit and 1 died) and 164 in control (22 missed final visit), but all those randomised were assessed for adverse events.
Selective reporting (reporting bias)	Low risk	Trials register April 2014, recruitment began in November 2014. Outcomes reported mirror those in the trials register
Attention	Low risk	Treatment of both groups appeared identical.
Compliance	Low risk	Red cell EPA and DHA rose in intervention group compared to control
Other bias	Low risk	None noted

ENRGISE 2018

Methods	<p>ENabling Reduction of low-Grade Inflammation in SENiors (ENRGISE) pilot study</p> <p>RCT, 2x2, (LCn-3 vs PUFA plus or minus losartan), 12 months</p> <p>Summary risk of bias: moderate to high</p>
Participants	<p>People aged ≥ 70 years with self-reported walking or stair-climbing difficulty</p> <p>N: 148 intervention randomised (122 fish oil only, 26 fish oil plus losartan), 141 control randomised (102 placebo only, 39 placebo plus losartan)</p> <p>Level of risk for CVD: low</p> <p>Men: 53% intervention, 53% control</p> <p>Mean age in years (SD): 78 (5.6) intervention, 77 (5.3) control</p> <p>Age range: unclear (70+ years inclusion criteria, including participants in their 90s)</p> <p>Smokers: unclear</p> <p>Hypertension: int fish oil only 79%, intervention fish oil plus losartan 42%, control placebo only 70%, control placebo plus losartan 56%</p> <p>Medications taken by at least 50% of those in the control group: unclear</p> <p>Medications taken by 20%-49% of those in the control group: unclear</p> <p>Medications taken by some, but < 20% of the control group: unclear</p> <p>Location: USA</p> <p>Ethnicity: white intervention 78% and 85%, control 79% and 69%; African American intervention 17% and 12%, control 17% and 21%; Hispanic intervention 3% and 0%, control 2% and 5%; other intervention 5% and 4%, control 4% and 10%</p>
Interventions	<p>Type: supplement (LCn3)</p> <p>Comparison: LCn3 vs PUFA</p>

ENRGISE 2018 (Continued)

Intervention

- Arm 1: omega-3 fish oil (1.4 g/d for 6 months, discontinued if AF or intolerance at 6 months, increased to 2.8 g/d if IL-6 remained high at 6 months)
- Arm 4: omega-3 plus losartan

Dose: 1.2 g/d LCn3 (0.8 g/d EPA plus 0.4 g/d DHA), increasing to 2.4 g/d (1.6 g/d EPA plus 0.8 g/d DHA) in some from 6-12 months

Control:

- Arm 2: losartan 25 mg/d
- Arm 3: placebo corn oil (for omega-3) plus placebo cellulose (for losartan)
- Arm 5: placebo corn oil (for omega-3)
- Arm 6: placebo cellulose (for losartan)

Fish oil and corn oil placebo sourced from Epax, 0.7 g gel capsules, identical shape, colour, weight

Compliance: self-reported adherence at 12 months was excellent, very good or good in 85% intervention (fish oil), 77% control (placebo fish oil). 12% intervention and 19% control reported having discontinued. Pill counts also performed. Compliance unclear as self-reported

Duration of intervention: 12 months

Outcomes	<p>Main trial outcome: IL-6, 400-m walk test</p> <p>Dropouts: 24 intervention, 22 control</p> <p>Available outcomes: secondary: short physical performance battery, frailty, muscle strength using hand grip strength and knee dynamometry, SF-36, additional inflammatory markers (CRP and other novel markers). Reported as adverse events and serious adverse events: GI disorders, neoplasms, GI upset, "cardiac disorders" and "vascular disorders". Other measures at 12 months included anthropometry, vital signs, adverse events and medical history. (MMSE measured at baseline but not repeated)</p> <p>Response to contact: no</p>
Notes	<p>NCT02676466</p> <p>Funding: National Institutes of Health and National Institute on Aging. Additional funding from US Dept of Agriculture, Tufts University and Claude D Pepper Older Americans Independence Centers. Abbott Laboratories paid for purchase of the trial drug and matching placebo</p> <p>Note: at update trial results had been submitted to ClinicalTrials.gov, but not yet posted. Further details may be available in the near future.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomization used a permuted block algorithm (with random block lengths) and was concealed via the secure web-based data management system"
Allocation concealment (selection bias)	Low risk	Appears appropriate, as above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double-blind. Placebo appears well matched to fish oil capsules

ENRGISE 2018 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear, likely for biochemical measures, not clear for self-reported and interview measures
Incomplete outcome data (attrition bias) All outcomes	High risk	At 12 months 87% of those taking fish oil and 82% of those taking placebo had their IL-6 assessed, 76% and 68% had walk speed assessed. Appears to be a difference in retention rates
Selective reporting (reporting bias)	High risk	Primary outcomes and adverse events reported, but not secondary outcomes yet
Attention	Low risk	Likely that this was similar as placebo used
Compliance	Unclear risk	Only pill counts (not reported) and self-report assessed
Other bias	Low risk	None noted

EPE-A 2014

Methods	<p>EPE-A</p> <p>RCT, parallel, 3 arms (n-3 EPA, low dose vs high dose vs unclear placebo), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with NASH and NAFLD (mean BMI 33.6, mean TG 139 mg/dL, 30.7% diabetic)</p> <p>N: 86 intervention-high, 82 intervention low, 75 control (analysed 64, 55, 55 respectively, ITT analysis for primary outcomes)</p> <p>Level of risk for CVD: low (although 35% had type II diabetes)</p> <p>Men: 33.7% intervention-high, 41.5% intervention-low, 42.7% control</p> <p>Mean age in years (SD): 47.8 (11.1) intervention-high, 47.8 (12.5) intervention-low, 50.5 (12.5) control</p> <p>Age range: not reported</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: USA</p> <p>Ethnicity: white intervention-low: 94%, intervention-high: 87%, control: 90.7%</p> <p>African American intervention-low: 3.7%, intervention-high: 2.3%, control: 4.0%</p> <p>Others intervention-low: 2.4%, intervention-high: 10.5%, control: 5.3%</p>
Interventions	<p>Type: supplement (omega-3 capsule)</p> <p>Comparison 1: high EPA vs low EPA (unclear what replaced EPA)</p> <p>Comparison 2: EPA vs unclear (placebo contents not reported)</p>

EPE-A 2014 (Continued)

Intervention-high: EPA-E 2.7 g/d, 3 × EPA-E 300 mg capsules. Dose: 2.7 g/d EPA + DHA

Intervention-low: EPA-E 1.8 g/d, 2 × EPA-E 300 mg capsules + 1 placebo capsule

Dose: 1.8 g/d EPA + DHA

Control: 3 × placebo capsules. The pills were identical with respect to size, colour and smell

Compliance: estimated by pill count and measuring the ratio of serum EPA to arachidonic acid. compliance rates for the 3 groups (placebo vs EPA-E 1800 mg/d vs EPA-E 2700 mg/d) were 89.5% (6.8%), 90.3% (5.7%) and 89.5% (5.3%), respectively

Length of intervention: 12 months

Outcomes	<p>Main trial outcome: histological response in standardised scoring of liver biopsies and change in ALT level</p> <p>Dropouts: 22 intervention-high, 27 intervention-low, 20 control</p> <p>Available outcomes: cardiac events, deaths (none), angina, adverse events (weight, BMI, lipids, glucose, HbA1c, HOMA, hsCRP all reported as medians so not useable in meta-analyses)</p> <p>Response to contact: yes (provided methodological details)</p>
Notes	<p>Data combined for the 2 intervention groups for binary outcomes and higher dose data vs control used for continuous outcomes</p> <p>Trial funding: supported entirely by Mochida Pharmaceuticals</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomisation using an interactive voice-response system to assign subjects in a 1:1:1 ratio between the 2 arms for each site separately. Participants were stratified by the presence of type 2 diabetes. The total fraction of such individuals was capped at 40% of the trial cohort
Allocation concealment (selection bias)	Low risk	As above (remote computer-generated randomisation)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind stated, but no further details. Trial author confirmed researchers and outcome assessors were blinded to treatment allocation and pills were identical with respect to size, colour and smell
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	High risk	Number and characteristics of participants lost to follow-up similar across arms, however < 80% provided outcome data relevant to this systematic review
Selective reporting (reporting bias)	Low risk	Registered June 2010, trial started June 2010, completed October 2012. All outcomes in trials registry entry were also reported in the trials registry. Secondary outcomes reported were not planned (compared with 1st version of clinicaltrials.gov entry)
Attention	Low risk	All participants had same follow-up visits

EPE-A 2014 (Continued)

Compliance	Low risk	Compliance was estimated by pill count and measuring the ratio of serum EPA to arachidonic acid. Compliance rates for the 3 groups (placebo vs EPA-E 1800 mg/d vs EPA-E 2700 mg/d) were 89.5% (6.8%), 90.3% (5.7%) and 89.5% (5.3%) respectively
Other bias	Low risk	None noted

EPIC-1 2008

Methods	EPANOVA in Crohn's disease, study 1 (EPIC-1) RCT, parallel, 2-arm (omega-3 vs SFA as MCT), 52 weeks Summary risk of bias: moderate or high
Participants	Adults with quiescent Crohn's disease, CDAI score < 150 N: 188 intervention, 186 control Level of risk for CVD: low Men: 48.1% intervention, 41.1% control Mean age in years (SD): 40.5 (15.2) intervention, 38.2 (13.1) control Age range: 18-70 years Smokers: 30.6% intervention, 34.4% control Hypertension: unclear Medications taken by at least 50% of those in the control group: oral 5-ASA therapy, Systemic corticosteroids – prednisolone, budesonide Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: antibiotic therapy, topical rectal therapy, immune-modifying agents, immune modifiers/biologics Location: Canada, Europe, Israel, USA Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs SFA (MCTs of short SFAs) Intervention: 2 × 2 1 g gelatin capsules omega-3 free FAs (Epanova- 2.2 g EPA, 0.8 g DHA). Dose: 3 g/d EPA + DHA Control: 4 x1 g capsules MCT Compliance: pill counts, 79.2% adhered intervention, 75.6% adhered control Length of intervention: mean 52 weeks
Outcomes	Main trial outcome: Crohn's relapse-free time Dropouts: 80 intervention, 91 control Available outcomes: total deaths, non-fatal arrhythmias, cancer diagnoses, cancer deaths, adverse events Response to contact: yes (data provided)
Notes	Trial funding: Tillotts Pharma, trial authors had extensive financial disclosures

EPIC-1 2008 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by number generator. Used a centralised randomisation procedure via interactive voice recognition system
Allocation concealment (selection bias)	Low risk	Centralised randomisation (see above)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blinding stated, identical capsule (slow-release capsules). Neither investigator nor participant knew the allocation.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Trial states double-blind but does not state that outcome assessors were blinded or provide a mechanism for this
Incomplete outcome data (attrition bias) All outcomes	Low risk	Number of dropouts and reasons provided. 171 of 187 in intervention group and 174 of 184 in control group provided data for primary outcome, (7% dropout), though 80 in the intervention group and 91 in the control group terminated early.
Selective reporting (reporting bias)	High risk	Trials registration (NCT00613197) first received in 2008, but trial started in 2003 and was published in 2008
Attention	Low risk	As investigators were blinded attention bias was not possible.
Compliance	Unclear risk	Pill counts, 79.2% adhered intervention, 75.6% adhered control
Other bias	Low risk	No further bias noted

EPIC-2 2008

Methods	EPANOVA in Crohn's Disease, Study 2 (EPIC-2) RCT, parallel, 2 arms (omega-3 vs SFA - MCT), 58 weeks Summary risk of bias: moderate or high
Participants	Adults with a confirmed diagnosis of Crohn's Disease and a CDAI score < 150 who are responding to steroid induction therapy N: intervention, 189, control 190 (187 intervention, 188 control analysed) Level of risk for CVD: low (people with quiescent Crohn's disease) Men: 48.1% intervention, 41.1% control Mean age in years (SD): 38.5 (13.8) intervention, 40.0 (13.6) years control Age range: > 16 years Smokers: 25.1% intervention, 37.2% control Hypertension: unclear

EPIC-2 2008 (Continued)

Medications taken by at least 50% of those in the control group: systemic corticosteroids – prednisolone, budesonide (but tapered and discontinued during the trial)

Medications taken by 20%–49% of those in the control group: only reported for prior 12 months

Medications taken by some, but < 20% of the control group: only reported for prior 12 months

Location: Canada, Europe, Israel, USA

Ethnicity: not reported

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs SFA (MCTs of short SFAs)</p> <p>Intervention: 2 × 2 1 g gelatin capsules omega-3 free FAs (Epanova) providing total dose ~2.2 g/d EPA, 0.8 g/d DHA. Dose: ~3.0 g/d EPA + DHA</p> <p>Control: 2 × 2 1 g capsules MCT oil</p> <p>Compliance: measured by patient interviews and pill counts, 75.4% adhered intervention, 81.4% adhered control</p> <p>Length of intervention: mean 58 weeks</p>
Outcomes	<p>Main trial outcome: maintain Crohn's symptomatic remission</p> <p>Dropouts: 114 intervention, 112 control</p> <p>Available outcomes: mortality, CV events (nil), cancer diagnoses, adverse events</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>Trial funding: Tillotts Pharma, trial authors had extensive financial disclosures</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by number generator. Used a centralised randomisation procedure via interactive voice recognition system
Allocation concealment (selection bias)	Low risk	Centralised randomisation (see above)
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blinding stated, identical capsule (slow-release capsules). Neither investigator nor participant knew the allocation. However no information provided on capsules' taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Trial states double-blind but does not state that outcome assessors were blinded or provide a mechanism for this
Incomplete outcome data (attrition bias) All outcomes	High risk	Number of dropouts and reasons provided, however 114 of 189 in intervention group and 112 of 190 in control group terminated early.
Selective reporting (reporting bias)	High risk	NCT00074542. First received 2003, trial start 2002. Published 2008. Some outcomes, such as QoL, stated in trials registry but not in published papers
Attention	Low risk	As investigators were blinded, attention bias was not possible.
Compliance	Unclear risk	Measured by participant interviews and pill counts, 75.4% adhered intervention, 81.4% adhered control

EPIC-2 2008 (Continued)

Other bias	Low risk	No further bias noted
------------	----------	-----------------------

EPOCH 2014

Methods	<p>Older People, Omega-3 and Cognitive Health (EPOCH)</p> <p>RCT, parallel (n-3 EPA + DHA vs MUFA), 18 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Healthy older adults with no cognitive impairment</p> <p>N: 195 intervention, 196 control (reported by trial author)</p> <p>Level of risk for CVD: low</p> <p>Men: not reported</p> <p>Mean age in years (SD): not reported</p> <p>Age range: not reported, but 65-90 recruited</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: Australia</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (fish oil capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 4 capsules/d (1.72 g/d DHA and 0.60 g/d EPA). Dose: 2.32 g/d EPA + DHA</p> <p>Control: 4 capsules/d (3.960 g/d olive oil and 40 mg/d fish oil)</p> <p>Compliance: count of all unused supplements returned at 3-monthly intervals, plus self-report calendars, mailed back on a monthly basis. If compliance fell below 85% (re calendars), they were contacted by a researcher who noted the reasons. Compliance also assessed by erythrocyte membrane n-3 LC PUFA status</p> <p>Length of intervention: 18 months</p>
Outcomes	<p>Main trial outcome: change in cognitive performance</p> <p>Dropouts: not reported</p> <p>Available outcomes: mortality (nil), MI, stroke, revascularisation, arrhythmias, CV events</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>Trial authors reported some events, but don't appear to be published.</p>

EPOCH 2014 (Continued)

Trial funding: EPAX donated the Omega-3 concentrate and Blackmores Pty Ltd donated the placebo and packaging of the omega-3 concentrate. The trial was supported by the Brailsford Robertson Award 2007-2008 (University of Adelaide and CSIRO Food and Nutritional Sciences), and is funded by a National Health and Medical Research Project Grant (#578800).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Age-stratified, permuted-block randomisation, with mixed block-sizes (2-8, size unknown to trial investigators), 1:1 allocation. Computer-generated randomisation schedule
Allocation concealment (selection bias)	Low risk	An independent researcher prepared allocation to treatment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The researchers, project staff, and participants remained blinded to treatment allocation until the trial was completed and the database locked. However, no information provided on capsules appearance, taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No data for each group presented, and no attrition data presented
Selective reporting (reporting bias)	High risk	Only cognitive functions reported for whole population (not by arm). No secondary outcomes reported (MMSE; perceived health status, depressive symptoms, positive and negative affect, life satisfaction, self-reported cognitive functioning, and functional capacity; BP; biomarkers of glucose, glycated haemoglobin, triglycerides, total cholesterol, HDL, LDL, homocysteine, CRP, MDA, and telomere length)
Attention	Low risk	All had the same contact and attention
Compliance	Unclear risk	Count of all unused supplements returned at 3-monthly intervals, plus self-report calendars, mailed back on a monthly basis. If compliance fell below 85% (re calendars), they were contacted by a researcher who noted the reasons. Compliance also assessed by erythrocyte membrane n-3 LC PUFA status but results not reported
Other bias	Low risk	None noted

Erdogan 2007

Methods	RCT, parallel (n-3 EPA + DHA vs unclear), 12 months Summary risk of bias: moderate to high
Participants	People with successful external cardioversion N: unclear intervention, unclear control (54 analysed intervention, 54 control) Level of risk for CVD: high

Erdogan 2007 (Continued)

Men: 70% intervention, 74% control

Mean age in years (SD): 65.0 (mean for whole group, SD not reported)

Age range: not reported

Smokers: not reported

Hypertension: not reported

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Germany

Ethnicity: not reported

Interventions	<p>Type: supplement (probably, not described)</p> <p>Comparison: high EPA + DHA vs unclear placebo</p> <p>Intervention: described only as "PUFA" but included in systematic review (Mariani 2013) by Erdogan et al on effects of n-3 PUFA. Dose: unclear</p> <p>Control: described only as "placebo"</p> <p>Compliance: not reported</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: AF relapse</p> <p>Dropouts: not reported</p> <p>Available outcomes: recurrent AF (reported in Mariani 2013), mortality (none)</p> <p>Response to contact: no reply to date</p>
Notes	Funding source: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned"
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as triple-blind, but no further details provided (only an abstract with some details in a related trial publication and some in a systematic review by the same author)
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described, but analysis appears to have been carried out blind to intervention/control status

Erdogan 2007 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number randomised not described
Selective reporting (reporting bias)	Unclear risk	Unclear, no trial registry entry or protocol found
Attention	Unclear risk	Not described
Compliance	Unclear risk	Not described
Other bias	Low risk	None noted

FAAT 2005

Methods	<p>Fatty Acid Antiarrhythmia Trial – FAAT</p> <p>Randomisation: RCT, parallel, 2 arms, (n-3 EPA + DHA vs MUFA), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with implanted cardioverter defibrillators</p> <p>N: intervention 200, control 202</p> <p>Level of risk for CVD: high (patients with implanted cardioverter defibrillators)</p> <p>Men: intervention 84.5%, control 81.7%</p> <p>Mean age in years (SD): intervention 65.7 (11.6), control 65.3 (11.7)</p> <p>Age range: unclear</p> <p>Smokers: intervention 15%, control 11.4%</p> <p>Hypertension: unclear</p> <p>Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-blockers</p> <p>Medications taken by 20%-49%: diuretics</p> <p>Medications taken by some, but < 20%: calcium channel blockers, amiodarone, sotalol, type 1 antiarrhythmics</p> <p>Location: USA</p> <p>Ethnicity: intervention 95.5% white, control 96.5% white</p>
Interventions	<p>Type: supplement/capsule</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 4 ×1 g/d fish oil gelatin capsules, 2.6 g/d EPA + DHA (Pronova Biocare, quantities of EPA + DHA unclear). Dose: 2.6 g/d EPA + DHA</p> <p>Control: 4 ×1 g/d olive oil capsules, 4 g/d (in identical gelatin capsules, < 0.06 g/d EPA and < 0.06 g/d DHA)</p> <p>All were advised to use olive oil rather than the common plant seed oils for cooking, dressings, and sauces</p>

FAAT 2005 (Continued)

Compliance: pill counts and platelet phospholipid data suggested greater omega-3 intake in intervention participants. 35% were non-compliers (36.5% intervention, 34.2% control)

Duration of intervention: 12 months

Outcomes	<p>Main trial outcome: fatal ventricular arrhythmias</p> <p>Dropouts: intervention 13 deaths, unclear number of dropouts, control 12 deaths, dropouts unclear</p> <p>Available outcomes: deaths, CV deaths, CVD events, deaths from heart failure, fatal arrhythmias, MI, angina</p> <p>Response to contact: yes (data provided)</p>
Notes	Trial funding: the trial was supported in part by a grant from the NHLBI, NIH (HL62154)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation tables for each collaborating site, stratified by site
Allocation concealment (selection bias)	Low risk	Trial author confirmed allocation was concealed from investigators
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Trial referred to as "double blind" and gelatin capsules (verum and placebo) were stated as being of identical appearance but no discussion of taste or smell. Trial author confirmed that investigators and participants were blinded.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	VT and VF events were assessed blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	High risk	Large numbers dropped out so some deaths, etc. may have been missed, 35% discontinued early due to non-compliance but were assessed at trial end, data censored for some participants
Selective reporting (reporting bias)	High risk	Trials registry data received September 2005, paper published November 2005
Attention	Low risk	Time and attention appeared similar between the 2 arms
Compliance	High risk	Pill counts and platelet phospholipid data suggested greater omega-3 intake in intervention participants. 35% were non-compliers (36.5% intervention, 34.2% control)
Other bias	Low risk	None noted

FLAX-PAD 2013

Methods	<p>Effects of dietary flaxseed on symptoms of cardiovascular disease in patients with peripheral arterial disease (FLAX PAD)</p> <p>RCT, parallel, (n-3 ALA vs unclear), 12 months</p>
---------	--

FLAX-PAD 2013 (Continued)

Summary risk of bias: low

Participants	<p>Patients with peripheral artery disease, over 40 years old</p> <p>N: 58 intervention, 52 control</p> <p>Level of risk for CVD: high (all had peripheral artery disease, 80% had hyperlipidaemia)</p> <p>Men: 74.1% intervention, 73.1% control</p> <p>Mean age in years (SD): 67.4 (8.06) intervention, 65.3 (9.4) control</p> <p>Age range: unclear</p> <p>Smokers: 19.2% intervention, 34.6% control</p> <p>Hypertension: 81% intervention, 69.2% control</p> <p>Medications taken by at least 50% of those in the control group: lipid-lowering medication, antihypertensives, antithrombotics</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: insulin or blood sugar-lowering drugs</p> <p>Location: Canada</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: food supplement (milled flaxseed)</p> <p>Comparison: ALA vs unclear (mix of wheat, wheat germ and mixed dietary oils)</p> <p>Intervention: food products (i.e. bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily. Dose: ~6.8 g/d ALA (calculated based on 30 g milled flaxseed/d)</p> <p>Control: placebo food products (i.e. bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily</p> <p>Compliance: plasma levels of enterolignans and the n-3 FA ALA were used as markers of dietary compliance</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: all-cause mortality, CV mortality, stroke, and MI</p> <p>Dropouts: 15 intervention, 11 control</p> <p>Available outcomes: BP, lipids, adverse events, plasma ALA</p> <p>Response to contact: yes (but no data provided)</p>
Notes	<p>Different intervention dropout figures reported in 2 publications (13 or 15)</p> <p>Trial funding: funded by government organisations but foods created and provided by a company</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly selected by a computer programme

FLAX-PAD 2013 *(Continued)*

Allocation concealment (selection bias)	Low risk	Allocation was concealed. The person who determined if a participant was eligible for inclusion in the trial was unaware, when this decision was made, to which group the participant would be allocated
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Product colour and texture were similar to disguise the composition of the product. Participants, personnel administering the intervention and those assessing the outcomes were blinded to group assignment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All personnel that collected or analysed data were blinded to the intervention
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised accounted for in main outcomes
Selective reporting (reporting bias)	High risk	Prospectively registered October 2008, trial start October 2008, primary outcome data completed March 2011, end date December 2017. Cardiovascular mortality and measures of adiposity not reported in a useable way
Attention	Low risk	Both groups had the same care
Compliance	Unclear risk	12 in intervention group and 8 in placebo group unwilling to comply with diet
Other bias	Low risk	None noted

FORWARD 2013

Methods	Randomised trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent AF (FORWARD) RCT, parallel, (n-3 EPA + DHA vs MUFA), 12 months Summary risk of bias: low
Participants	People with paroxysmal AF N: 289 intervention, 297 control Level of risk for CVD: high Men: 57.8% intervention, 51.9% control Mean age in years (SD): 66.3 (12) intervention, 65.9 (10.5) control Age range: > 21 Smokers: 9% intervention, 6.2% control Hypertension: 92.2% intervention, 90.8% control Medications taken by at least 50% of those in the control group: aspirin, amiodarone, 'any antithrombotic treatment', beta-blockers Medications taken by 20%-49% of those in the control group: anticoagulants Medications taken by some, but < 20% of the control group: none reported

FORWARD 2013 (Continued)

	Location: Argentina
	Ethnicity: not reported
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 1 capsule/d containing 1 g of n-3 PUFA (Società Prodotti Antibiotici and SigmaTau, Italy) (provided 850 mg-882 mg EPA/DHA). Dose: 0.85 g/d EPA + DHA</p> <p>Control: identical placebo capsule containing olive oil</p> <p>Compliance: not reported</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: survival free of AF</p> <p>Dropouts: 20 intervention, 25 control</p> <p>Available outcomes: mortality, MI, AF, heart failure, stroke, hospitalisation, side effects. Trial authors supplied further info on CVD events and methodology</p> <p>Response to contact: yes</p>
Notes	Trial funding: through unrestricted grants provided by companies that supplied trial drugs, however "these companies did not have representatives on the Steering Committee" who terminated the trial after 1 year

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Participants were centrally assigned to receive either 1 g of n-3 PUFA or placebo in a ratio of 1:1" – computer generated in blocks of 4 and 6 stratified by trial location
Allocation concealment (selection bias)	Low risk	As above, centrally allocated. Communication from trial authors was ambiguous, stated that the person recruiting <i>was</i> aware of which arm the individual would be allocated to, but that the "study was double-blind, placebo-controlled."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Each study site will be supplied with study drug and placebo in identically appearing packaging". "Both placebo and active treatment have the same odour and produce a comparable degree of fishy aftertaste"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Patients, investigator staff, persons performing the assessments, and data analysts will remain blind to the identity of the treatment from the time of randomisation until database lock" "The adjudication committee members are unaware of participant allocation and assess all available data and documentation with reference to pre-established criteria".
Incomplete outcome data (attrition bias) All outcomes	High risk	Quote: "the study was cut short by the trial steering committee due to 'a slower-than-expected recruitment rate and lower event rates'. This 'resulted in an underpowered clinical trial unable to verify its hypothesis'. Therefore the outcome data were not as complete as they were initially meant to be".
Selective reporting (reporting bias)	Low risk	Prospectively registered January 2008, trial start January 2008, completion August 2011. All outcomes in trials registry appear to have been reported

FORWARD 2013 (Continued)

Attention	Low risk	Both intervention and control given the same exposure to research personnel. 2013 paper: "Clinical outcomes, adherence, and adverse events were assessed 2, 4, 8, and 12 months after randomization"
Compliance	Unclear risk	Not reported
Other bias	Low risk	None noted

FOSTAR 2016

Methods	<p>Fish Oil in knee OSTeoARthritis (FOSTAR)</p> <p>RCT, parallel, (n-3 EPA + DHA vs low n-3), 24 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Adults aged 40+ years with knee osteoarthritis</p> <p>N: 101 intervention, 101 control</p> <p>Level of risk for CVD: low</p> <p>Men: 41% intervention, 60% control</p> <p>Mean age in years (SD): 60.8 (10) intervention, 61.1 (10) control</p> <p>Age range: > 40</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: none reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported at baseline, but 'during' includes vitamin D ~ 32%</p> <p>Medications taken by some, but < 20% of the control group: not reported at baseline, but 'during' includes glucocorticoid, HRT/anti-resorptive, both ~ 10%</p> <p>Location: Australia</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplementary food (enriched orange juice)</p> <p>Comparison: high EPA + DHA vs low EPA + DHA plus ALA (replacement unclear, but low omega-3)</p> <p>Intervention: 1-3 × a day drink of fruit juice mixed with day total = 15 mL of fish oil supplement (18% EPA, 12% DHA, 4.5 g/day total omega-3). Dose: 4.5 g/d EPA + DHA</p> <p>Control: liquid oral oil 15 mL Sunola oil/day (which contains fish oil 2 mL plus 13 mL canola oil) (total omega-3 fat: ≥ 0.45 g EPA + DHA from 15 mL)</p> <p>Compliance: assessed by measuring the oil volume in returned bottles, compliance was > 80% in both groups. Both groups had increases from baseline in plasma EPA and DHA with the high-dose group having substantially larger increases, consistent with compliance with trial oil</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: change in pain scale of WOMAC index</p>

FOSTAR 2016 (Continued)

Dropouts: 18 intervention, 16 control

Available outcomes: mortality, CVD events, adverse events, analgesic use, bone marrow density, weight gain and serum FAs

Response to contact: yes

Notes

Data on QoL and pain score are presented in a figure and not in a usable format

Trial funding: government funding

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random allocation sequence
Allocation concealment (selection bias)	Low risk	A security-protected central automated allocation procedure was used to allocate participants to one of the 2 treatment arms. This was performed centrally at 1 pharmacy and then used to allocate and administer the oil at each site
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Citrus flavouring was added to both oils to achieve comparable taste and optimise masking. Both were provided in identical dark 500-mL bottles with <i>similar</i> labelling. At the end of the trial, 52% of participants were unsure which group to which they had been allocated (50% high dose, 50% low dose). Of the remaining who thought they knew which group they were allocated, only 57% answered correctly, suggesting that blinding had been well maintained
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and staff involved in patient care and assessment of BMD remained blinded throughout the trial.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Oil intolerance in 1st year differed, others appear similar, but numbers confused
Selective reporting (reporting bias)	High risk	Prospectively registered August 2007, recruitment started July 2007, outcomes published 2016. Variety of outcomes such as QoL stated in trials registry but not published
Attention	Low risk	Same contact and instruction schedule for all participants
Compliance	Low risk	Assessed by measuring the oil volume in returned bottles, compliance was > 80% in both groups. Both groups had increases from baseline in plasma EPA and DHA with the high-dose group having substantially larger increases, consistent with compliance with trial oil
Other bias	Low risk	None noted

Franzen 1993

Methods

RCT, parallel (n-3 EPA + DHA vs MUFA), 12 months

Summary risk of bias: moderate to high

Participants

Adults with documented CHD

Franzen 1993 (Continued)

N: 15 intervention, 15 control

Level of risk for CVD: high

Men: unclear

Mean age in years (SD): 52 (9) intervention, 54 (7) control

Age range: not reported

Smokers: 87% intervention, 100% control

Hypertension: not reported

Medications taken by at least 50% of those in the control group: aspirin, beta-blockers

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Lipid-lowering medications were not allowed

Location: Germany

Ethnicity: not reported

Interventions	<p>Type: fish oil capsules</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 9 × 1 g capsules/d of fish oils (20% EPA, 15% DHA, 3.15 g/d total omega-3). Dose: 3.15 g/d EPA + DHA</p> <p>Control: 9 × 1 g capsules/d olive oil (which contains 6.3 g/day MUFA, 1.35 g/day SFA, 1.35 g/d total omega-6 fat)</p> <p>Compliance: assessed by pill counts and FA in body tissue analysis</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: blood lipids and FA in body tissues</p> <p>Dropouts: 0 intervention, 0 control</p> <p>Available outcomes: mortality (nil death), CVD events (nil), lipids (only TC used as the others were different at baseline), adverse events, serum FAs</p> <p>Response to contact: yes</p>
Notes	<p>Trial funding: unclear</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated list
Allocation concealment (selection bias)	Unclear risk	No details. They received their initial allocation in a sealed box in person; subsequent doses arrived in the post
Blinding of participants and personnel (performance bias)	Unclear risk	No further details beyond stating "double blind"

Franzen 1993 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	No attrition
Selective reporting (reporting bias)	Unclear risk	No trial register or protocol found
Attention	Low risk	No difference between groups
Compliance	Unclear risk	Measured but no results
Other bias	Low risk	None noted

Gill 2012

Methods	RCT, parallel, (EPA + DHA vs unclear), 24 months Summary risk of bias: moderate or high
Participants	Adults with metabolic syndrome (mean baseline TG 157 mg/dL) N: unclear, total randomised 101 Level of risk for CVD: low Men: 47% total, no details by group Mean age in years (SD): 55 (10) total Age range: 18-75 years Smokers: 0% intervention, 0% control Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: USA Ethnicity: unclear
Interventions	Type: supplement (fish oil capsules) Comparison: EPA + DHA vs placebo (unclear what) Intervention: fO3FA capsules 1.8 g of EPA + DHA daily. Dose: 1.8 g/d EPA + DHA Control: matching placebo supplement Compliance: not reported

Gill 2012 (Continued)

Length of intervention: 12 months

Outcomes	Main trial outcome: change in carotid intima-media thickness Dropouts: unclear Available outcomes: lipids, insulin and glucose are stated as secondary outcomes but no usable data published Response to contact: no
Notes	Results cannot be used as numbers are not reported by trial arm. Trial funding: unclear, but mentions that Pfizer, NIH and "Northwest Lipids Clinic" are partners

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No data
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No data
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No data
Selective reporting (reporting bias)	High risk	Inadequate detail in reporting as no full-text publication found; Gill 2014 (see secondary ref under Gill 2012) does give detail on carotid IMT, but not on other primary or secondary outcomes. The trial was prospectively registered (registered July 2006, unclear when recruitment started, final data collection 2011, first data published 2012)
Attention	Unclear risk	No data
Compliance	Unclear risk	No data
Other bias	Unclear risk	No data

GISSI-HF 2008

Methods	Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto miocardico – Heart Failure (GISSI-HF) RCT, parallel, 2 arms (n-3 EPA + DHA vs MUFA), 3.9 years Summary risk of bias: moderate or high
---------	--

GISSI-HF 2008 (Continued)

Participants	<p>People with chronic heart failure</p> <p>N: 3494 intervention, 3481 control</p> <p>Level of risk for CVD: high</p> <p>Men: 77.8% intervention, 78.8% control</p> <p>Mean age: 67 (11) intervention, 67 (11) control</p> <p>Age range: ≥ 18 years</p> <p>Smokers: 14.4% intervention, 13.9% control</p> <p>Hypertension: 54.0% intervention, 55.2% control</p> <p>Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-blockers, diuretics</p> <p>Medications taken by 20%–49% of those in the control group: spironolactone, digitalis, oral anticoagulants, aspirin, nitrates, statins</p> <p>Medications taken by some, but < 20% of the control group: ARBs, other antiplatelets, calcium channel blockers, amiodarone</p> <p>Location: Italy</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 1 capsule/d of 1 g n-3 mainly EPA and DHA as ethyl esters in the average ratio of 1:1.2. Dose: ~0.866 g/d EPA + DHA</p> <p>Control: 1 g/d matching olive oil placebo capsule</p> <p>Compliance: unclear</p> <p>Length of intervention: median 3.9 years</p>
Outcomes	<p>Main trial outcome: time to death or admission to hospital for CV reasons</p> <p>Dropouts: 34 intervention, 46 control (1004 intervention and 1029 control stopped trial treatment)</p> <p>Available outcomes: mortality, CV mortality, MI, stroke, new heart failure, incident AF, resumed arrhythmia gatalitis</p> <p>Response to contact: yes (no data provided)</p>
Notes	<p>Trial funding: funders included Pfizer, AstraZeneca and others</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned (with stratification by site) to treatment groups
Allocation concealment (selection bias)	Low risk	Randomly assigned (with stratification by site) to treatment groups by a concealed computerised telephone randomisation system

GISSI-HF 2008 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blinding stated, but taste not reported as masked and blinding of participants not checked
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All events "adjudicated blindly by an ad-hoc committee on the basis of pre-agreed definitions and procedures"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for attrition and exclusion were stated and addressed. Numbers in each intervention compared to numbers were similar.
Selective reporting (reporting bias)	Unclear risk	Published rationale and design (Tavazzi 2004, see secondary ref under GISSI-HF 2008) suggested primary outcomes were deaths and death or CV hospitalisation (published). Secondary outcomes not stated and no trials registry entry found
Attention	Low risk	Scheduled clinic visits at 1, 3, 6 months then 6-monthly until the end of the trial (for both arms)
Compliance	Unclear risk	No details
Other bias	Low risk	No further bias noted

GISSI-P 1999

Methods	Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico – Prevention (GISSI-P) RCT, 2 × 2 (n-3 EPA + DHA vs nil), 42 months Summary risk of bias: moderate or high
Participants	People with recent (≤ 3 months) MI N: 5666 intervention, 5658 control (99.9% follow-up at trial end) Level of risk for CVD: high Men: 85.7% intervention, 84.9% control Mean age in years (SD): 59.3 (10.6) intervention, 59.5 (10.5) years control Age range: < 50 to > 80 Smokers: 42.6% intervention, 42.3% control Hypertension: 36.2% intervention, 34.9% control Medications taken by at least 50% of those in the control group: anti-platelet Medications taken by 20%-49% of those in the control group: ACE inhibitors, beta-blockers Medications taken by some, but < 20% of the control group: lipid-lowering Location: Italy Ethnicity: not reported

GISSI-P 1999 (Continued)

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention: gelatin capsules of omega-3-acid ethyl esters 90 (Omacor), 1/d (850-882 mg/d EPA + DHA daily, ratio 1:2)</p> <p>Dose: ~0.866 g/d EPA + DHA</p> <p>Control: nil (no placebo)</p> <p>Compliance: capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5% by the end of the trial</p> <p>Duration of intervention: median follow-up 40 months</p>
Outcomes	<p>Main trial outcome: all-cause mortality, CV mortality, stroke, MI</p> <p>Dropouts: unclear (however, all randomised were included in analyses)</p> <p>Available outcomes: total, sudden and CV deaths, MI, stroke, angioplasty or CABG, angina, CHD, cancer diagnosis, cancer death, combined CV events, side effects</p> <p>Response to contact: no</p>
Notes	<p>Numbers are slightly different in different publications (Lancet 1999 paper used as main source). Half of both groups were on vitamin E supplements (300 mg/d synthetic α-tocopherol) as this was the other 2 \times 2 intervention.</p> <p>Trial funding: Bristol Meyers Squibb, Pharmacia Upjohn, Societa Prodotti Antibiotici, Pfizer</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Telephone/computer network, stratified by hospital, based on a biased coin algorithm
Allocation concealment (selection bias)	Low risk	Randomisation by telephone with the co-ordinating centre
Blinding of participants and personnel (performance bias) All outcomes	High risk	No placebo intervention (capsule vs nil) so participants not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"validation of clinical events ... was assured by an ad-hoc committee of expert cardiologists and neurologists blinded to patients treatment assignment"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Clearly described, good follow-up (< 28% dropped out over 3.5 years)
Selective reporting (reporting bias)	Unclear risk	No trial protocol or trials registry entry was found
Attention	Low risk	Slight as no placebo, otherwise similar

GISSI-P 1999 (Continued)

Compliance	Unclear risk	Capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5% by the end of the trial
Other bias	Low risk	No further bias noted

HARP 1995

Methods	<p>Harvard Atherosclerosis Reversibility Project (HARP)</p> <p>RCT, (n-3 EPA + DHA vs MUFA), 24 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with CHD</p> <p>N: 41 intervention, 39 control (99.9% follow-up at trial end)</p> <p>Level of risk for CVD: high</p> <p>Men: 93.5% intervention, 92.9 % control</p> <p>Mean age in years (SD): 62 (7) intervention, 62 (7) years control</p> <p>Age range: 30-75</p> <p>Smokers: 0% (exclusion criteria)</p> <p>Hypertension: 48% intervention, 36% control</p> <p>Medications taken by at least 50% of those in the control group: beta blockers, antiplatelet agents</p> <p>Medications taken by 20%-49% of those in the control group: calcium channel blockers, nitrates</p> <p>Medications taken by some, but < 20% of the control group: ACE inhibitors, oral hypoglycaemic drugs</p> <p>Location: USA</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: LCn3 vs MUFA</p> <p>Intervention: 12 fish oil capsules/d (Promega, Parke-Davis) in divided doses, preferably after meals. Each fish oil capsule contained 500 mg of n-3 polyunsaturated FAs composed of EPA (240 mg), DHA (160 mg) and other (100 mg) (mainly DPA) providing total daily dose of 6 g of n-3 FAs. Dose: 6 g/d LCn3</p> <p>Control: olive oil capsules identical in appearance to the fish oil capsules</p> <p>Compliance: capsule counts and serum level measurements. Adherence averaged 80% intervention, and 90% control with significant levels of adipose n-3 FAs in the fish oil group.</p> <p>Duration of intervention: average 28 months</p>
Outcomes	<p>Main trial outcome: regression of coronary artery lesions</p> <p>Dropouts: 10 intervention, 11 control</p> <p>Available outcomes: all-cause and CV deaths, fatal and non-fatal MI, stroke, angioplasty or CABG, unstable angina, CHD, cancer diagnosis, combined CV events, side effects</p> <p>Response to contact: yes</p>
Notes	<p>Trial funding: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, Maryland, Warner Lambert-Parke Davis, East Hanover, New Jersey; and by an Established Investigator Award to Dr Sacks from the American Heart Association, Dallas, Texas</p>

HARP 1995 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomization" stratified by clinical management regime and total/HDL cholesterol ratio
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "patients and personnel responsible for lab measurements, cardiac catheterization, and analysis of angiography films were blinded to the treatment assignment". Although capsules were identical in appearance, no information on their taste and smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "patients and personnel responsible for lab measurements, cardiac catheterization, and analysis of angiography films were blinded to the treatment assignment"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low attrition rate over 28 months and all reasons are well documented
Selective reporting (reporting bias)	High risk	Trial registered retrospectively after publication
Attention	Low risk	Nothing in description implies the arms were treated differently
Compliance	Low risk	Very clear ($P < 0.001$) differences between arms for the 3 main n-3 components in the fish oil
Other bias	Low risk	None noted

HEARTS 2017

Methods	<p>Slowing HEART diSease with lifestyle and omega-3 fatty acids (HEARTS)</p> <p>RCT, (LCn3 vs nil), 30 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with stable coronary artery disease on statins</p> <p>N: 143 intervention randomised, 126 in ITT analysis, 142 control randomised, 114 in ITT analysis</p> <p>Level of risk for CVD: high</p> <p>Men: 84.9% intervention, 85.1% control</p> <p>Mean age in years (SD): 62.5 (7.8) intervention, 63.5 (7.6) years control</p> <p>Age range: unclear (21-80 years were eligible)</p> <p>Smokers: unclear</p> <p>Hypertension: 79% intervention, 89% control</p> <p>Medications taken by at least 50% of those in the control group: statins, aspirin, ACE-I, beta-blockers</p>

HEARTS 2017 (Continued)

Medications taken by 20%-49% of those in the control group: ARB, hydrochlorothiazide, calcium-channel blocker

Medications taken by some, but < 20% of the control group: furosemide

Location: USA

Ethnicity: not reported

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: LCn3 vs nil</p> <p>Intervention: LCn3 ethyl esters from fish oil (Lovaza, GlaxoSmithKline), 4 x 1000 mg capsules/d. 3.36 g/d LCn3 (1.86 g/d EPA, 1.5 g/d DHA)</p> <p>Control: nil (no placebo)</p> <p>Compliance: unclear</p> <p>Duration of intervention: 30 months</p>
Outcomes	<p>Main trial outcome: coronary noncalcified plaque volume</p> <p>Dropouts: 10 intervention, 11 control</p> <p>Available outcomes: coronary artery plaque (% atheroma volume, maximum % diameter stenosis, minimal luminal diameter, number of participants with categorical variables of maximal stenosis > 50%, number with 3-vessel disease > 20%, number of participants with stenosis of 0%-29%, 30%-49%, 50%-69% and > 70% stenosis, remodeling index), physical function, pain, stiffness, exercise, inflammatory markers (CRP, PAI-1, serum amyloid A, matrix metalloproteinase -9 (MMP-9), IL-6, TNF-α, IL-1β, VCAM-1, ICAM-1, adiponectin serum nitrotyrosine), pericardial fat, insulin resistance, NASH, cognitive function, exercise capacity, urinary microalbumin. Serious adverse events reported include cardiac and GI, non-serious adverse events cardiac, atypical chest pain, dental, pulmonary, GI, musculoskeletal and more. Mortality, BP, measures of adiposity, glucose metabolism, lipids and blood count data also reported in publications.</p> <p>Response to contact: not attempted</p>
Notes	<p>NCT01624727</p> <p>Trial funding: National Heart, Lung and Blood Institute, Harvard internal funding. GlaxoSmithKline donated the Lavaza</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomization was computer allocated in blocks of 4 and stratified by presence or absence of diabetes mellitus".
Allocation concealment (selection bias)	Unclear risk	Unclear (no further information provided)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label trial, no placebo used
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Plaque analysis was performed independently by 2 readers blinded to treatment allocation. Unclear whether outcome assessors were blinded for other outcomes
Incomplete outcome data (attrition bias)	High risk	143 intervention randomised, 126 in ITT analysis (17 missing), 142 control randomised, 114 in ITT analysis (28 missing)

HEARTS 2017 (Continued)

All outcomes

Selective reporting (reporting bias)	High risk	Several outcomes do not appear to be published yet (for example, inflammatory markers, pain, physical function)
Attention	Unclear risk	Unclear, possible as open label
Compliance	Unclear risk	Unclear, not reported
Other bias	Low risk	None noted

HERO 2009

Methods	<p>Healthy Eating to Reduce Overweight in people with type 2 diabetes (HERO)</p> <p>RCT, parallel, (n-3 ALA vs low n-3 (nil)), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Overweight adults with non-insulin treated diabetes (mean baseline TG 2.4 mmol/L)</p> <p>N: 26 intervention, 24 control (analysed, intervention: 18 control: 17)</p> <p>Level of risk for CVD: moderate</p> <p>Male %: not reported</p> <p>Mean age in years (SD): 54 (8.7), not reported by arm</p> <p>Age range: 33-70 years</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: lipid-lowering drugs, oral hypoglycemics</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: Australia</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: food supplement (walnuts)</p> <p>Comparison: ALA vs nil</p> <p>Intervention: 30 g/d snack portions of walnuts (provided 10% MUFA, 10% E PUFA, and a P/S ratio of 1.0) and advised not to take fish oil supplements. ALA dose not reported. Dose: ~3 g/d ALA based on 30 g/d intake of walnuts</p> <p>Control: no supplements</p> <p>Both groups were given low-fat isocaloric dietary advice (30% E fat (10% E SFA, 15% E MUFA; 5% E PUFA, P/S ratio of 0.5), 20% E protein and 50% E CHO) plus advice to brisk walk 30 min × 3 times/week</p> <p>Compliance: measured by erythrocyte membrane FA levels, which were similar in both groups</p>

HERO 2009 (Continued)

Duration of intervention: 12 months

Outcomes	<p>Main trial outcome: change in body weight and % body fat</p> <p>Dropouts: 8 intervention, 5 control</p> <p>Available outcomes: all-cause mortality (nil deaths), weight, visceral adipose tissue, lipids, glucose, insulin, HbA1c (body fat % and subcutaneous adipose tissue measured but too different at baseline to use)</p> <p>Response to contact: not yet attempted</p>
Notes	<p>Body fat % was too different between groups at baseline hence data not used</p> <p>Trial funding: California Walnuts Commission</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was conducted using a computerised random-number generator by a researcher independent of the subject interface.
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Subjects, but not dietitians, were blinded to the type of overall diet (a prepackaged 30 g snack portion of walnuts was given to the walnut group unbeknown to the controls)". However, there was no placebo supplement, so blinding easily broken
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Paper states "code was concealed from the researchers collecting data, as well as from subjects." However as participants could not be blinded outcome assessors may not have been (problem for measures of adiposity, not for biochemical measures)
Incomplete outcome data (attrition bias) All outcomes	High risk	High dropout rate 35 of 50 analysed (30% attrition rate)
Selective reporting (reporting bias)	Unclear risk	Trial was registered postanalysis
Attention	Low risk	Both groups appear to have had same level of attention
Compliance	High risk	ALA levels almost exactly the same in intervention and control
Other bias	Low risk	None noted

JELIS 2007

Methods	<p>Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS)</p> <p>RCT, parallel, 2-arm (EPA capsule vs nil), 5 years</p> <p>Summary risk of bias: moderate or high</p>
Participants	People with hypercholesterolaemia (mean baseline TG 1.7mmol/L)

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)

JELIS 2007 (Continued)

N: intervention, 9326, control 9319 (analysed intervention 9326, control 9319)

Level of risk for CVD: moderate (people with hypercholesterolaemia)

Men: 32% intervention, 31% control

Mean age in years (SD): 61 (8) intervention 61 (9) control

Age range: 40-75 years

Smokers: 20% intervention, 18% control

Hypertension: 36% intervention, 35% control

Medications taken by at least 50% of those in the control group: statins

Medications taken by 20%-49% of those in the control group: calcium channel blockers, other antihypertensives

Medications taken by some, but < 20% of the control group: beta-blockers, antiplatelet, hypoglycemics, nitrates

Location: Japan

Ethnicity: Japanese

Interventions	<p>Type: supplement (EPA capsule)</p> <p>Comparison 1: EPA vs nil</p> <p>Intervention: 3 × 2 × 300 mg capsules/d EPA ethyl ester (total dose of 1.8 g/d EPA), after meals. Dose: 1.8 g/d EPA</p> <p>Control: nothing (though all in both groups received "appropriate" dietary advice). All participants in both groups were on statins</p> <p>Compliance: monitored by local physicians and measuring plasma FA concentrations trial drug regimens, 71% adhered EPA intervention, 73% adhered EPA control, 74% adhered statin</p> <p>Duration of intervention: maximum 5 years, mean 4.7 (1.1) years</p>
Outcomes	<p>Main trial outcome: major coronary events</p> <p>Dropouts: 1766 intervention, 1582 control (but all had endpoint evaluation)</p> <p>Available outcomes: major coronary events: sudden cardiac death, fatal or non-fatal MI, unstable angina, angioplasty or CABG. Also all-cause mortality, stroke, peripheral artery disease, cancer, lipids, rise in blood sugar, fasting glucose, HbA1c</p> <p>Response to contact: no</p>
Notes	<p>Trial funding: Mochida Pharmaceutical Company</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Statistical co-ordination centre: "permitted block randomisation with a block size of 4"
Allocation concealment (selection bias)	Low risk	Centralised. Statistical co-ordinating centre (see above)

JELIS 2007 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded as there was no placebo. Quote: "[o]pen label blinded end point"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Clinical endpoints ... reported by local physicians were checked by members of a regional organizing committee in a blinded fashion. Then an endpoints adjudication committee ... confirmed them once a year without knowledge of the treatment allocation"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Well documented, dropout numbers low
Selective reporting (reporting bias)	Unclear risk	NCT00231738 registered October 2005, recruitment November 1996-November 1999, main results published 2007. Rationale and design paper published in 2003 (reported baseline characteristics, so before completed follow-up, but after data collection began). All reported outcomes appear to have been published.
Attention	Low risk	Slight, as no placebo provided to control group, but only capsules to intervention group. Otherwise 2 groups appeared to be treated equally
Compliance	Unclear risk	Monitored by local physicians and measuring plasma FA concentrations. Trial drug regimens, 71% adhered EPA intervention, 73% adhered EPA control, 74% adhered statin
Other bias	Low risk	No further bias noted

Kumar 2012

Methods	RCT, parallel, (fish oil vs nil), 12 months Summary risk of bias: moderate or high
Participants	People with persistent AF on warfarin N: 92 intervention, 90 control (91 and 87 analysed ITT) Level of risk for CVD: high Male %: 82.4 intervention, 72.4 control Mean age in years (SD): 63 (10) intervention, 61(13) control Age range: 18-85 years (inclusion criteria) Smokers: 22.2% intervention, 11.5% control Hypertension: 45.6% intervention, 58.6% control Medications taken by at least 50% of those in the control group: anti-arrhythmic drugs, renin-angiotensin system inhibitors Medications taken by 20%-49% of those in the control group: statins Medications taken by some, but < 20% of the control group: not reported Location: Australia

Kumar 2012 (Continued)

Ethnicity: not reported

Interventions	<p>Type: fish oil capsule</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention: 6 capsules/d of a fish oil preparation containing a total dose of 1.02 g of EPA and 0.72 g DHA. Participants in the omega-3 group were asked to continue fish oils till a maximum of 1 year or till return of persistent AF. Dose: 1.7 g/d EPA + DHA</p> <p>Control: no supplements. Participants were advised not to take any fish oil supplements.</p> <p>All participants underwent cardioversion following randomisation.</p> <p>Compliance: was monitored on a weekly basis via telephone and during follow-up by using a pill count plus serum EPA and DHA levels, which were significantly increased</p> <p>Duration of intervention: 1 year (or AF recurrence)</p>
Outcomes	<p>Main trial outcome: AF recurrence</p> <p>Dropouts: 4 intervention, 0 control</p> <p>Available outcomes: all-cause mortality (nil death), AF recurrence, time to AF recurrence, adverse events</p> <p>Response to contact: contact not yet established</p>
Notes	<p>Trial funding: the trial was funded in part by the National Heart Foundation of Australia and the Pfizer Cardiovascular Lipid Research Grant.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were randomised to a control or an omega-3 group in a 1:1 fashion (no details of method)
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label with no placebo control
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open-label
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis was conducted
Selective reporting (reporting bias)	Unclear risk	Trial registered 2005 but data collection started 2003
Attention	Unclear risk	Intervention group had capsules, while control group did not. Potential for greater contact and checking with intervention group on this basis, although otherwise both groups seem to have had the same care.

Kumar 2012 *(Continued)*

Compliance	Low risk	EPA and DHA levels were significantly higher in intervention group
Other bias	Low risk	None noted

Kumar 2013

Methods	<p>RCT, parallel, (fish oil vs nil), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People > 60 years with sinoatrial node disease and dual chamber pacemakers</p> <p>N: 39 intervention, 39 control randomised (18 intervention vs 39 control at 12 months)</p> <p>Level of risk for CVD: moderate/high</p> <p>Male %: 46% intervention, 56% control</p> <p>Mean age in years (SD): 78 (7) intervention, 77(8) control</p> <p>Age range: not reported</p> <p>Smokers: not reported</p> <p>Hypertension: 72%</p> <p>Medications taken by at least 50% of those in the control group: statins, renin-angiotensin system inhibitors</p> <p>Medications taken by 20%-49% of those in the control group: anti-arrhythmic drugs</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: Australia</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: omega-3 capsule</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention: a TG preparation containing a total of 6 g/d of omega-3 polyunsaturated FAs of which 1.8 g/d were n-3 (1.02 g EPA and 0.72 g DHA). Dose: 1.8 g/d EPA + DHA</p> <p>Control: no supplements</p> <p>Compliance: measured by weekly dietary history and pill count. FA status measured at randomisation and between 1-3 months post randomisation (blood samples).</p> <p>Duration of intervention: median 378 days</p>
Outcomes	<p>Main trial outcome: AF burden</p> <p>Dropouts: 1 intervention, 0 control</p> <p>Available outcomes: all-cause mortality, CV mortality, AF (frequency and duration but not recurrence so not used), adverse events</p> <p>Response to contact: written but no contact yet</p>
Notes	<p>Trial funding: unclear</p>

Kumar 2013 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was performed using sequentially numbered, opaque, sealed envelopes.
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label design
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "At each visit, stored AT/AF diagnostic data were retrieved in an unblinded fashion"
Incomplete outcome data (attrition bias) All outcomes	High risk	Only 1 lost, and reason explained. 21 of the 39 randomised to the intervention were crossed over to control at 6 months so 12-month outcomes are reported for 17/18 intervention while baseline characteristics are reported for the 39 participants.
Selective reporting (reporting bias)	Low risk	Trial prospectively registered and outcomes stated were reported
Attention	Unclear risk	As only the intervention group had supplements there was potential for attention differences. Other contact appears the same.
Compliance	Low risk	EPA was 3-fold higher and DHA 1.8 fold higher compared with controls. EPA and DHA did not change significantly in controls upon repeat testing
Other bias	High risk	Odd design – 21 of the 39 randomised to the intervention were crossed over to control at 6 months

Lorenz-Meyer 1996

Methods	RCT- parallel, 2 arms (omega-3 vs corn oil), 12 months Summary risk of bias: low
Participants	People with Crohn's disease in remission (but with a recent relapse) N: 70 intervention, 63 control Level of risk for CVD: low Men: 35.7% intervention, 27.0% control Mean age in years (SD): 29.5 (9.6) intervention, 31.8 (10.9) control Age range: 17-62 years intervention, 17-65 years control Smokers: not reported Hypertension: not reported

Lorenz-Meyer 1996 (Continued)

Medications taken by at least 50% of those in the control group: methylprednisolone (all for 1st 8 weeks)

Medications taken by 20%-49%: not reported

Medications taken by some, but < 20%: not reported

Location: Germany

Ethnicity: not reported

Interventions	<p>Type: supplement (fish oil)</p> <p>Comparison: EPA + DHA vs omega-6</p> <p>Intervention: 2 × 3 1 g gelatin capsules/d of ethylester fish oil concentrate (3.3 g/d EPA + 1.8 g/d DHA). Dose: 5.1 g/d EPA + DHA</p> <p>Control: 2 × 3 1 g gelatin capsules/d of corn oil</p> <p>Compliance: pill count, 5 non-compliant participants, among compliant participants, 18 were censored (for not using the medication for 3 continuous weeks)</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: Crohn's disease duration of remission</p> <p>Dropouts: unclear</p> <p>Available outcomes: mortality (nil), Crohn's disease activity and relapses, TG</p> <p>Response to contact: yes (methodological details provided)</p>
Notes	<p>There was a 3rd arm of dietary advice (for low CHO diet)</p> <p>Trial funding: not reported</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised within the centres in blocks of 6 (block size blinded to the centres)
Allocation concealment (selection bias)	Low risk	Trial author reported allocation was concealed
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Double blind conditions were intended for the verum-placebo comparisons". Trial author stated that capsules were identical in appearance (taste not mentioned).
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome was relapses "classified in a blind fashion by a primary endpoint committee"
Incomplete outcome data (attrition bias) All outcomes	High risk	Participants were accounted for based on the main outcome of the trial (relapses), however 20% omitted from analyses and numbers confusing

Lorenz-Meyer 1996 (Continued)

Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found
Attention	Low risk	All participants were seen by their physician in the respective centre after regular time intervals (1, 2, 3, 6, 9 and 12 months).
Compliance	Unclear risk	Pill count, 5 non-compliant participants, among compliant participants, 18 were censored (for not using the medication for 3 continuous weeks). 23 of 133 non-compliant
Other bias	Low risk	None noted

MAPT 2017

Methods	<p>Multidomain Alzheimer Preventive Trial (MAPT)</p> <p>4 arms RCT, parallel, (n-3 ± multidomain intervention vs placebo (paraffin) ± multidomain intervention), 36 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Population: people aged ≥ 70 years without dementia but with memory complaint, IADL limitation or slow gait speed</p> <p>N: 840 intervention (arms 1 and 3), 840 control (arms 2 and 4) randomised. Numbers analysed differ by outcome</p> <p>Level of risk for CVD: low</p> <p>Men: 37.2% intervention, 34.5% control (combined groups)</p> <p>Mean age in years (SD): 75.6 (4.7) and 74.4 (4.4) intervention, 75.1 (4.3) and 75 (4.1) control</p> <p>Age range: not reported</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: France and Monaco</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs paraffin oil (non-fat)</p> <p>Intervention</p> <p>Arm 1: omega-3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soft capsules). Dose for arms 1 and 3: 1.025 g/d EPA + DHA</p> <p>Arm 3: omega-3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soft capsules) plus multi-domain intervention (nutrition, physical exercise, cognitive stimulation, social activities)</p>

MAPT 2017 (Continued)

Control:

Arm 2: placebo capsules containing flavoured paraffin oil. All capsules were supplied by Pierre Fabre Médicament (Castres, France)

Arm 4: placebo capsules plus multi-domain intervention (nutrition, physical exercise, cognitive stimulation, social activities)

Compliance: adherence to trial interventions was assessed every 6 months. For supplementation, adherence was assessed by counting the number of capsules returned by participants (or based on treatment dates if the number of capsules was missing). Furthermore, biological samples were obtained at baseline and after 12 months to assess concentrations of DHA and EPA in red blood cell membranes.

Duration of intervention: 36 months

Outcomes	<p>Main trial outcome: change in cognitive function)</p> <p>Dropouts: 200 intervention, 194 control</p> <p>Available outcomes: mortality, CVD events, haemorrhagic stroke, adverse events, functional capacity, other cognitive functions, safety and tolerability</p> <p>Response to contact: no</p>
Notes	<p>Trial funding: Gérontopôle of Toulouse, the French Ministry of Health (PHRC 2008, 2009), the Pierre Fabre Research Institute (manufacturer of the PUFA supplement), Exhonit Therapeutics, and Avid Radiopharmaceuticals</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned (1:1:1:1) to the combined intervention (i.e. the multidomain intervention plus PUFAs), the multidomain intervention plus placebo, PUFAs only, or placebo only. A computer-generated randomisation procedure (done by ClinInfo, a subcontractor) was used with block sizes of 8 and stratification by centre.
Allocation concealment (selection bias)	Low risk	A clinical research assistant, who was not involved in the assessment of participants, used a centralised interactive voice response system to identify which group to allocate the participant to, and which lot number to administer.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All participants and trial staff were blinded to PUFA or placebo assignment – both sets of capsules looked and tasted identical. In view of the nature of the multidomain intervention, the trial was unblinded for this component, but the independent neuropsychologists who were trained to assess cognitive outcomes were blinded to group assignment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All participants and trial staff were blinded to PUFA or placebo assignment—both sets of capsules looked and tasted identical. In view of the nature of the multidomain intervention, the trial was unblinded for this component, but the independent neuropsychologists who were trained to assess cognitive outcomes were blinded to group assignment. Data analysts were not blinded to group assignment, but 2 data managers, 1 statistician (CC) and 2 physicians (SA and BV) did a blinded data review.
Incomplete outcome data (attrition bias) All outcomes	Low risk	1680 participants were enrolled and randomly allocated, the modified ITT population (N = 1525), i.e. 155 excluded (9% over 3 years)

MAPT 2017 (Continued)

Selective reporting (reporting bias)	Low risk	Protocol registered ClinicalTrials.gov (NCT00672685) – outcomes match report. "Because of advances in the field since our trial was designed in 2007, we decided to modify the primary outcome from one cognitive test to a composite cognitive score, which is now thought to be a better endpoint." This protocol amendment was submitted to the local ethical committee on 2 February 2015 and was subsequently approved
Attention	Low risk	Both groups assessed at baseline, 6, 12, 24, 36 months. Groups 1 and 2 only differed by content of capsules.
Compliance	Unclear risk	Adherence to trial interventions was assessed every 6 months, by counting the number of capsules returned (or based on treatment dates if the number of capsules was missing). Biological samples were obtained at baseline and after 12 months to assess concentrations of DHA and EPA in red blood cell membranes, but outcomes not reported
Other bias	Low risk	None noted

MARGARIN 2002

Methods	Mediterranean alpha-linolenic enriched Groningen dietary intervention trial (MARGARIN) RCT, factorial 2 × 2 (ALA-rich margarine vs LA-rich margarine, also nutrition education vs no education but this is not included), 2 years Summary risk of bias: low
Participants	Hypercholesterolemic adults with ≥ 2 CVD risk factors (mean baseline TG 1.9 mmol/L) N: total 282 randomised; 114 intervention (51 with nutrition education, 58 without nutrition education) 157 control (52 with nutrition education, 105 without nutrition education) Level of risk for CVD: moderate (multiple CV risk factors, 10-year IHD risk ~20%) Men: 41.9% intervention, 45.7% control Mean age in years (SD): 54.4 (9.5) intervention, 53.9 (9.8) control Age range: 30-70 Smokers: 49.1% intervention, 49.3% control Hypertension: 52.9% intervention, 45.3% control (on anti-hypertensives) Medications taken by at least 50% of those in the control group: antihypertensives Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: not reported Location: the Netherlands Ethnicity: not reported
Interventions	Type: supplementary food (ALA-enriched margarine) Intervention: provided with ALA-rich margarine (80% fat of which 15% was ALA and 46% LA) to be eaten as desired. Dose: average intake 6.3 g/d ALA (was also 1 g/d ALA in the control group).

MARGARIN 2002 (Continued)

Control: provided with linoleic-rich margarine (80% fat of which 0.3% was ALA and 58% LA), identical in taste and packaging. Both margarines contained 0.66 mg vitamin E/g, 9 micro-g vitamin A/g and 0.023 micro-g vitamin D/g

Comparison: ALA vs omega-6

Compliance: serum FAs used to assess, ALA rose by 0.47 mol % (SD 0.04) and 0.36 mol % (SD 0.04) intervention arms (with and without nutrition education) and fell by 0.06 mol % (SD 0.04) and 0.11 mol % (SD 0.03) control arms (with and without nutrition education), significantly different

Duration of intervention: 24 months

Outcomes	Main trial outcome: CV risk factors and IHD risk Dropouts: unclear Available outcomes: total and CV deaths, non-fatal MI, stroke, CABG and angioplasty, BMI, lipids, BP Response to contact: yes
Notes	Trial funding: Prevent fund and Unilever Research Other intervention (2 × 2) was educational, teaching a multifactorial dietary intervention. It was excluded as multifactorial

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random allocation, allocated by an independent trial co-ordination centre that organised masked distribution of margarines
Allocation concealment (selection bias)	Low risk	Allocated by an independent trial co-ordination centre that organised masked distribution of margarines
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind; the 2 margarines are described as identical as to taste and packaging (though not reported as checked)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	2 independent physicians, a cardiologist and a general practitioner validated and classified results in a blinded fashion
Incomplete outcome data (attrition bias) All outcomes	Low risk	The number randomised to each arm was unclear, but 1 publication clarifies (55 randomised to each arm, 51 intervention and 52 control analysed)
Selective reporting (reporting bias)	Unclear risk	No trial protocol or trials registry entry was found.
Attention	High risk	There was no difference in attention between margarine types, but the dietary-advice group spent more time with trial staff than the control group, and some (not quite randomly allocated) were sent individual motivational letters (Siero 2000, see secondary ref under MARGARIN 2002).
Compliance	Low risk	Serum FAs used to assess, ALA rose by 0.47 mol % (SD 0.04) and 0.36 mol % (SD 0.04) intervention arms (with and without nutrition education) and fell by 0.06 mol % (SD 0.04) and 0.11 mol % (SD 0.03) control arms (with and without nutrition education), Significantly different
Other bias	Low risk	No further bias noted

MARINA 2011

Methods	<p>Modulation of Atherosclerosis Risk by INcreasing dose of n-3 fatty Acids (MARINA)</p> <p>RCT, parallel, 4 arms (n-3 PUFA 3 different doses or olive oil placebo), 12 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Non-smoking men and women aged 45-70 years</p> <p>N: intervention. 279 in 3 groups (G1 0.45 g/d n = 94, G2 0.9 g/d n = 93, G3 1.8 g/d n = 92); control: 88 (analysed G1 0.45 g/d n = 81, G2 0.9 g/d n = 80, G3 1.8 g/d n = 80, control 71)</p> <p>Level of risk for CVD: low</p> <p>Men: 38.7% intervention, 38.6% control</p> <p>Mean age in years (CI): G1: 55 (53, 56), G2: 55 (54, 56), G3: 55 (54, 57) intervention 55 (54,57) control</p> <p>Age range: 45-70</p> <p>Smokers: 0% intervention, 0% control</p> <p>Hypertension: 5.4% intervention, 5% control</p> <p>Medications taken by at least 50% of those in the control group: none</p> <p>Medications taken by 20%-49% of those in the control group: none</p> <p>Medications taken by some, but < 20% of the control group: statins, antihypertensives, HRT, thyroxine</p> <p>Location: UK</p> <p>Ethnicity: G1: white 80.9%, black 4.3%, Asian 6.4%, East Asian 4.3%, other 4.3%</p> <p>G2: white 78.5%, black 6.5%, Asian 10.8%, East Asian 0%, other 4.3%</p> <p>G3: white 85.9%, black 1.1%, Asian 2.2%, East Asian 4.3%, other 6.5%</p> <p>Control: white 77.3%, black 10.2%, Asian 6.8%, East Asian 2.3%, other 3.4%</p>
Interventions	<p>Type: supplement (fish oil capsules)</p> <p>Comparison 1: EPA + DHA vs MUFA</p> <p>Comparison 2: high EPA + DHA vs low EPA + DHA</p> <p>Intervention: 3 × 1 g oil gelatin capsule/d consisting of blend of EPA concentrate, DHA concentrate, re-fined olive oil and 0.1% peppermint oil. Providing a daily dose of: 0.45 g, 0.9 g, or 1.8 g/d (all with EPA/DHA ratio of 1.51). Dose: 1.8 g/d EPA + DHA (G3 used for outcomes)</p> <p>Control: 3 gelatin capsules/ day containing refined olive oil + 0.1% peppermint oil</p> <p>Compliance: measured by capsule counting and erythrocyte lipids for proportion of EPA/DHA @ base-line, 6 months, 12 months. 88.5% of participants consumed > 90% of capsules provided. EPA and DHA in erythrocyte lipids increased in dose-dependent manner compared with placebo, indicating long-term compliance with intervention.</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: endothelial function, arterial stiffness</p> <p>Dropouts: 38 intervention (13,13,12), 17 control</p> <p>Available outcomes: lipids, dietary intake, CRP, BP (supine and ambulatory – numeric data not provided, but trial states that there were no significant differences between arms). Weight data not used as</p>

MARINA 2011 (Continued)

baseline is different between groups (FMD, arterials stiffness, carotid intima media thickness, heart rate variability, heart rate, endothelial progenitor cells reported but not used)

Contact with trial authors: yes (many outcomes above provided in end of trial report from trial authors)

Notes

Outcome data used G3 (highest dose) vs placebo for continuous outcomes and combined the 3 intervention groups vs placebo for dichotomous outcomes

Trial funding: Food Standards Agency

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "the random allocation sequence was generated with a computer program by using the process of minimisation to balance age, sex and ethnicity between treatment groups."
Allocation concealment (selection bias)	Low risk	Quote: "We enrolled eligible participants and the study database program allocated a series of capsules to the participant. The treatments associated with the capsule codes were concealed from all investigators and associated clinical staff until the data analysis was complete. The code breaker was an employee of MedSciNet who constructed the trial database."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "We enrolled eligible participants and the study database program allocated a series of capsules to the participant. The treatments associated with the capsule codes were concealed from all investigators and associated clinical staff until the data analysis was complete. The code breaker was an employee of MedSciNet who constructed the trial database." "blends of the test fat with 0.1% peppermint oil to disguise the fish taste of the EPA and DHA" (peppermint oil in both intervention and control capsules)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "We enrolled eligible participants and the study database program allocated a series of capsules to the participant. The treatments associated with the capsule codes were concealed from all investigators and associated clinical staff until the data analysis was complete. The code breaker was an employee of MedSciNet who constructed the trial database."
Incomplete outcome data (attrition bias) All outcomes	Low risk	15% withdrawal, reasons for attrition reported
Selective reporting (reporting bias)	Low risk	Outcomes published match trials register. Registered September 2008, trial started June 2008, ended December 2010, main publication 2011
Attention	Low risk	No difference between groups
Compliance	Low risk	Statistically significant difference in erythrocyte omega-3 fats at 12 months between different arms
Other bias	Low risk	None noted

MENU 2016
Methods

Metabolism, Exercise and Nutrition at UCSD (MENU)

RCT, parallel, (ALA as walnut-rich moderate-fat diet vs MUFA as moderate-fat diet), 12 months

MENU 2016 (Continued)

Summary risk of bias: moderate or high

Participants	<p>Overweight and obese women, of whom half were insulin-resistant (mean baseline TG 124 mg/dL)</p> <p>N: 82 intervention, 81 control (analysed, intervention: 65 control: 61)</p> <p>Level of risk for CVD: low</p> <p>Men: 0% intervention, 0% control</p> <p>Mean age (SD) years: 51 (not reported) intervention, 50 (not reported) control</p> <p>Age range: 22-67 years intervention, 25-72 years control</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: 10% were on cholesterol medications</p> <p>Location: USA</p> <p>Ethnicity: Hispanic 18% intervention, 14% control; black 9% intervention, 3% control; Asian American 1% intervention, 4% control; white non-Hispanic 71% intervention, 78% control</p>
Interventions	<p>Type: food and advice</p> <p>Comparison: walnut-rich, moderate-fat diet (ALA) vs moderate-fat diet (MUFA)</p> <p>Intervention: advice to follow walnut-rich higher-fat diet (35%E fat with limited SFA, MUFA encouraged, including 42 g/d walnuts (provided by trial), 45%E CHO, 20%E protein). Participants given print materials on diet and exercise, attended group sessions weekly for 1st 4 months, biweekly for next 2 months, then monthly to 1 year), provided web-based tracking for dietary constituents, scale, pedometer, measuring cups and exercise videos. Regular dietetic and group leader support. Clinic visits were at 0, 6 and 12 months. Dose: ~4.2 g/d ALA (calculated based on 42 g/d intake of walnuts)</p> <p>Control: exactly as intervention for goals, materials and support except higher-fat diet did not include walnuts (35% E fat with limited SFA, MUFA encouraged, 45%E CHO, 20%E protein)</p> <p>Compliance: walnut consumption reported on form and nuts provided. Red blood cell ALA significantly higher in intervention at 12 months than control</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: body weight</p> <p>Dropouts: 13 of 82 intervention, 12 of 81 control</p> <p>Available outcomes: weight, waist circumference, HDL and LDL cholesterol, TG, insulin, glucose, HOMA-IR, HOMA-beta, CRP and IL-6 (estradiol, SHBG, nutrient gene interactions, physical activity and heart rate also presented)</p> <p>Response to contact: no reply received to date</p>
Notes	<p>Trial funding: National Cancer Institute and California Walnut Commission</p>
Risk of bias	
Bias	<p>Authors' judgement Support for judgement</p>

MENU 2016 (Continued)

Random sequence generation (selection bias)	Low risk	Randomisation stratified by age and insulin resistance
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial, participants were advised on their diets extensively
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding not mentioned, so unclear for their primary outcome, weight
Incomplete outcome data (attrition bias) All outcomes	Low risk	Paper states ITT analysis but 25 dropouts (15%) not included in 1-year data, but dropout reasons clear
Selective reporting (reporting bias)	Low risk	Pre-registered, all mentioned outcomes reported at 12 months
Attention	Low risk	Appear very equal
Compliance	Low risk	Statistically significant difference between intervention and control arms for ALA in blood cell membranes at 12 months
Other bias	Low risk	None noted

Mita 2007

Methods	RCT, parallel, (EPA capsules vs nil), 2 years Summary risk of bias: moderate to high
Participants	Japanese people with type 2 diabetes (mean baseline TG 1.5mmol/L) N: intervention. 40, control: 41 (analysed 30, 30) Level of risk for CVD: moderate Men: 53% intervention, 67% control Mean age in years (SD): 59 (11.2) intervention 61.2 (8.4) control Age range: not reported Smokers: 40% intervention, 43% control Hypertension: not reported Medications taken by at least 50% of those in the control group: oral hypoglycemics Medications taken by 20%-49% of those in the control group: insulin, lipid-lowering drugs, antihypertensives Medications taken by some, but < 20% of the control group: antithrombotics Location: Japan

Mita 2007 (Continued)

Ethnicity: 100% Japanese

Interventions	<p>Type: supplement (EPA oil capsules)</p> <p>Comparison: EPA vs nil</p> <p>Intervention: 1800 mg/d EPA EPADEL capsules (Mochida Pharmaceutical Co Ltd Japan): 98% pure ethyl-ester EPA (unclear how many caps). Dose: ~1.8 g/d EPA</p> <p>Control: no intervention</p> <p>Compliance: checked during 3-month reviews throughout trial and 5 participants were excluded for poor compliance but no details on method or results</p> <p>Length of intervention: mean 2.1 (0.2) years</p>
Outcomes	<p>Main trial outcome: progression of diabetic macroangiopathy measured by carotid intima-media thickness and brachial-ankle pulse wave velocity</p> <p>Dropouts: 10 intervention, 11 control</p> <p>Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis</p> <p>Response to contact: not yet attempted</p>
Notes	<p>BP data not used as groups are different at baseline</p> <p>Trial funding: not stated</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants randomly divided into 2 groups matched for age and gender
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessors of main trial outcomes were blinded to the treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropout rate (26%) over 2 years. All dropouts explained, however, 5 were excluded for poor compliance but no clear predefined protocol for exclusion
Selective reporting (reporting bias)	Unclear risk	No protocol
Attention	Low risk	All participants had the same contact
Compliance	Unclear risk	Compliance measured but no clear methods or reported results
Other bias	Low risk	None noted

NAT2 2013

Methods	<p>Nutritional AMD Treatment-2 (NAT2)</p> <p>RCT, parallel, (EPA + DHA vs MUFA), 36 months</p> <p>Summary risk of bias: low</p>
Participants	<p>People with early AMD</p> <p>N: 150 intervention, 150 control</p> <p>Level of risk for CVD: high (92.5% intervention and 79.8 controls had past CVD)</p> <p>Men: 31.3% intervention, 39.5% control</p> <p>Mean age in years (SD): 73.9 (6.6) intervention, 73.2 (6.8) control</p> <p>Age range: 55-85</p> <p>Smokers: 6.7% intervention, 8.5% control</p> <p>Hypertension: 58% total (not reported by trial arm)</p> <p>Medications taken by at least 50% of those in the control group: lipid-lowering medication</p> <p>Medications taken by 20%-49% of those in the control group: agents acting on renin-angiotensin system, anti-inflammatory and anti-rheumatic products</p> <p>Medications taken by some, but < 20% of the control group: insulin or blood sugar-lowering drugs</p> <p>Location: France</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: supplement (fish oil capsule)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 3 daily fish oil capsules containing 1110 total n-3 FAs (EPA: 270 mg/d DHA: 840 mg/d) and vit E: 6 mg/d. Dose: 1.1 g/d EPA + DHA</p> <p>Control: 3 × 602 mg/d olive oil capsules containing 0.2 g total PUFA and vitamin E: 0.09 g/d</p> <p>Compliance: assessed during visits from unused capsules and serum PUFA levels Overall compliance over the 3 years; 69.4% intervention, 70.5% control</p> <p>Length of intervention: 36 months</p>
Outcomes	<p>Main trial outcome: time to occurrence of choroidal new vessels in the trial eye from prospective assessment of fluorescein angiography</p> <p>Dropouts: 29 intervention, 34 control</p> <p>Available outcomes: all-cause mortality, plasma lipids, adverse events, serum FAs</p> <p>Response to contact: yes (no added data)</p>
Notes	<p>TG data not used as presented as median (5th-95th percentile)</p> <p>Trial funding: Laboratoire Chauvin, Bausch & Lomb Inc</p>

Risk of bias

NAT2 2013 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	QL Rancin software was used to generate the randomisation list before enrolment. Both participants and trial personnel were blinded to the treatment assignment
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The capsules had the same appearance, the same size, and the same weight (602 mg) in both DHA and placebo groups. No masking flavour was added to the capsules, which were otherwise odourless
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Trial author confirmed blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Any temporary discontinuation of the treatment was considered to be a deviation from the trial protocol. Discontinuation for more than 5 months was considered to be a major deviation from the trial protocol. Participants who dropped out were taken into account in the survival analysis and occurrence of choroidal new vessels and were counted at last angiography performed.
Selective reporting (reporting bias)	Unclear risk	ISRCTN98246501. Retrospectively registered May 2007, recruitment started December 2003, completed November 2008, key publication 2013
Attention	Low risk	Same amount of time spent with both trial arms
Compliance	Low risk	Assessed during visits from unused capsules and serum PUFA levels. Overall compliance over the 3 years; 69.4% intervention, 70.5% control
Other bias	Low risk	None noted

Nodari 2011 AF

Methods	RCT, parallel, (DHA + EPA vs MUFA), 12 months Summary risk of bias: moderate or high
Participants	People with persistent AF with at least 1 relapse after cardioversion N: 102 intervention, 103 control (analysed, intervention: 94 control: 94) Level of risk for CVD: high Men: 70% intervention, 63% control Mean age in years (SD): 70 (6) intervention, 69 (9) control Age range: not reported (18-80 inclusion criteria) Smokers: 10% intervention, 9.1% control Hypertension: 47% intervention, 40% control Medications taken by at least 50% of those in the control group: beta-blockers, ACE inhibitors, anticoagulant therapy, amiodarone

Nodari 2011 AF (Continued)

Medications taken by 20%-49% of those in the control group: diuretics, antiplatelet, statins

Medications taken by some, but < 20% of the control group: calcium channel blockers

Location: Italy

Ethnicity: not reported

Interventions	Type: supplement (omega-3-acid ethyl esters 90: Omacor) Comparison: EPA + DHA vs MUFA Intervention: 2 × 1 g/d Omacor (total 1.7 g/d EPA + DHA at a ratio of 0.9:1.5). Dose: 1.7 g/d EPA + DHA Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor) Compliance: no details Duration of intervention: 12 months
Outcomes	Main trial outcome: probability of maintenance of sinus rhythm Dropouts: 6 intervention, 5 control Available outcomes: adverse events, AF recurrence (nil death) Response to contact: no
Notes	Trial funding: 'Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco' of the University of Brescia, Brescia, Italy. The work of Dr Campia was supported by National Institutes of Health grant K12 HL083790-01a1

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random assignment followed a computer-generated randomisation list obtained using blocks of size 4
Allocation concealment (selection bias)	Low risk	The randomisation schedule was kept in the research pharmacy area and was available only to unblinded pharmacy personnel until after the database was locked. At that time, the unblinded participant treatment information was made available to the investigators.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Placebo gelatin capsules identical in appearance to Omacor. However no information provided as to their smell and taste.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised participants were accounted for. ITT analysis for main outcomes
Selective reporting (reporting bias)	Unclear risk	NCT01198275. Registered retrospectively in September 2010, trial started January 2006, completed May 2008, main publication 2011
Attention	Low risk	No difference between groups

Nodari 2011 AF (Continued)

Compliance	Unclear risk	No details
Other bias	Low risk	None noted

Nodari 2011 HF

Methods	<p>RCT, parallel, (DHA + EPA vs MUFA), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with heart failure (non-ischaemic dilated cardiomyopathy)</p> <p>N: 67 intervention, 66 control (analysed, intervention: 67 control: 66)</p> <p>Level of risk for CVD: high</p> <p>Men: 95.5% intervention, 84.9% control</p> <p>Mean age in years (SD): 61 (11) intervention, 64 (9) control</p> <p>Age range: not reported (18-75 inclusion criteria)</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: beta-blockers, ACE inhibitors, furosemide, amiodarone, aldosterone blockers</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: statins, ARB</p> <p>Location: Italy</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (Omacor)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 2 × 1 g/d Omacor (1.7 g/d EPA + DHA at a ratio of 0.9:1.5)</p> <p>Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor)</p> <p>Compliance: pill counts – participants were withdrawn if < 80% capsules taken (none were withdrawn). FA EPA + DHA 0.83% in intervention group, 0.41% in control group.</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: left ventricular function and functional capacity</p> <p>Dropouts: 0 intervention, 0 control</p> <p>Available outcomes: mortality (nil death), combined CVD events, AF, BMI, hospitalisation for CV reasons, hospitalisation for worsening heart failure, lipids, blood glucose (but too different at baseline to use), serum cytokine</p> <p>Response to contact: yes</p>

Nodari 2011 HF (Continued)

Notes Trial funding: Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco, one author was a consultant for 8 pharmaceutical companies

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomised"
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Paper states that placebo and verum were identical and that the trial was double-blind, but blinding of participants not checked. Trial author confirmed investigators not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Trial author confirmed assessors not blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether all participants were assessed for all outcomes (e.g. hospitalisation), but some outcomes report no attrition
Selective reporting (reporting bias)	Unclear risk	NCT01223703 – trial registration October 2010, recruitment November 2007–June 2009. Retrospective
Attention	Low risk	No suggestion of this, and investigators appeared blinded (so could not differ in attention provided by allocation)
Compliance	Low risk	See characteristics table
Other bias	Low risk	None noted

Norouzi 2014

Methods	RCT, parallel, (MorDHA capsules vs unclear placebo), 14 months Summary risk of bias: moderate or high
Participants	People with chronic traumatic spinal cord injury N: 55 intervention, 55 control (analysed, intervention: 54 control: 50) Level of risk for CVD: low Men: 81.5% intervention, 82% control Mean age in years (SD): 51.15 (13.43) intervention, 54.12 (11.76) control Age range: 15–74 years intervention, 30–74 years control Smokers: 0% (exclusion criteria) Hypertension: not reported

Norouzi 2014 (Continued)

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Iran

Ethnicity: not reported

Interventions	<p>Type: supplement (n-3 capsules)</p> <p>Comparison: EPA + DHA vs placebo (unclear what)</p> <p>Intervention: 2 MorDHA capsules (providing 870 mg DHA and 130 mg EPA)/d. Dose: 1 g/d DHA + EPA</p> <p>Control: 2 placebo capsules/d. Both capsules were similar in colour, shape, and taste. Both groups received 1 calcium capsule/d consisting of 1000 mg calcium and 400 IU vitamin D.</p> <p>Compliance: pill counts – compliance averaged 80% in both groups</p> <p>Duration of intervention: 14 months</p>
Outcomes	<p>Main trial outcome: professionals' evaluation of neurological function</p> <p>Dropouts: 1 intervention, 5 control</p> <p>Available outcomes: functional measures (total and subscales), BMI, leptin and adiponectin concentration</p> <p>Response to contact: no</p>
Notes	<p>Trial funding: PhD university funding. Omega-3 capsules were provided by Minami Nutrition Co (Aartse-laar, Belgium) and placebo capsules were supplied by Zahravi Pharmaceutical Co. (Tabriz, Iran). Calcium capsules were provided by Darou Pakhsh Pharm Co. (Tehran, Iran)</p> <p>Data were collected at the beginning of the trial and after 14 months</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using permuted balanced block randomisation method
Allocation concealment (selection bias)	Unclear risk	No further detail on allocation
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Stated as double-blind but content of placebo not stated and no report of attempt to mask n-3 FA taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unclear, few details
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was 1 in intervention group, 5 in control group, so minor; "the two most common reasons for dropouts were experiencing GI side effects or difficulty to maintain scheduled clinic visits"

Norouzi 2014 (Continued)

Selective reporting (reporting bias)	High risk	Some of the outcomes stated in the trial register were not reported. Registered March 2011, trial start November 2010, completion April 2012
Attention	Low risk	No difference between groups
Compliance	Unclear risk	Pill counts – compliance averaged 80% in both groups
Other bias	Low risk	None noted

Norwegian 1968

Methods	<p>Norwegian vegetable oil experiment of 1965-6</p> <p>RCT, parallel, 2 arms (ALA linseed oil vs omega-6 sunflower oil), 1 year</p> <p>Risk of bias: moderate or high</p>
Participants	<p>Men working in Norwegian companies aged 50-59 years</p> <p>N: 6716 intervention, 6690 control</p> <p>Level of risk for CVD: low (working men, though a few had had a previous MI or angina)</p> <p>Men: 100%</p> <p>Mean age in years (SD): unclear</p> <p>Age range: 50-59 years</p> <p>Smokers: unclear (~48% non-smokers)</p> <p>Hypertension: unclear</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: Norway</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: supplementary food (oil)</p> <p>Comparison: ALA vs omega-6</p> <p>Intervention: linseed oil, 10 mL/d (55% ALA), 5.5 g/d ALA, 1.5 g/d linoleic. Dose: 5.5 g/d ALA</p> <p>Control: sunflower oil, 10 mL/d (1.4% ALA), 0.1 g/d ALA, 6.3 g/d linoleic. Vitamin E was added to both oils</p> <p>Compliance: 73% were still taking the linseed oil at 1 year, 72% were still taking their sunflower oil at 1 year (unclear how this was ascertained)</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: morbidity and mortality</p> <p>Dropouts: survival status was traced for all but 4 included men, health status was missing for about 80 men in total or 0.6%</p>

Norwegian 1968 (Continued)

Available outcomes: total and CV deaths, MI, angina, stroke, PVD, combined CV events, total cholesterol (subgroup)

Response to contact: no

Notes

Trial funding: not stated

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Paper states "simple randomisation" without clarification
Allocation concealment (selection bias)	Unclear risk	Few details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Paper states that the workplace doctors who administered the trial locally were sent bottles for each participant marked only with their trial number, and that "appearance and taste of the products were so similar that most participants were unable to identify the type"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Company physicians recorded health status, and were also blinded to intervention (as above)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Detailed description, and those who left employment during the trial were followed up for survival and morbidity via the main health system
Selective reporting (reporting bias)	Unclear risk	No protocol or trials registration found
Attention	Low risk	As company physicians administered oils and assessed outcomes but were blind to treatment arm there could not be attention bias
Compliance	Unclear risk	73% were still taking the linseed oil at 1 year, 72% were still taking their sunflower oil at 1 year (unclear how this was ascertained)
Other bias	Low risk	No further bias noted

Nutristroke 2009

Methods	<p>Nutristroke</p> <p>RCT, parallel, (diet rich in vitamins and omega-3 plus omega-3 supplement vs diet rich in vitamins and omega-3), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People in a rehabilitation unit who had survived a stroke</p> <p>N: 38 intervention, 34 control (analysed, intervention: 32 control: 20)</p> <p>Level of risk for CVD: high</p> <p>Men: 74% intervention, 56% control</p>

Nutristroke 2009 (Continued)

Mean age in years (SD): 61.3 (13.6) n-3, 66.3 (11.4) n-3 + antioxidant intervention, 68.4 (12.6) placebo, 65.1 (12.8) antioxidant – control

Age range: not reported

Smokers: not reported

Hypertension: not reported

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%–49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Italy

Ethnicity: not reported

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: fish oil vs unclear placebo</p> <p>Intervention: fish oil gelatin capsules including 250 mg DHA + 250 mg EPA. Dose: 0.5 g/d EPA + DHA</p> <p>Control: "identical to supplement but contained no antioxidants or polyunsaturated fatty acids"</p> <p>Compliance: appears to have been assessed at meetings or on the phone monthly, but results unclear</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: functional status in stroke survivors</p> <p>Dropouts: 6 intervention, 14 control</p> <p>Available outcomes: mortality and CV mortality, lipids (6 months), albumin and lymphocyte counts (6 months), Barthel Index (functional status), neurological impairment (not reported by intervention group), mobility, adiposity (no numerical data presented; quote: "there were no statistically significant differences in body weight, BMI, arm circumference and triceps skin fold at the different time points")</p> <p>Response to contact: not yet attempted</p>
Notes	<p>2 × 2 trial that also had an antioxidant supplementary focus (supplementary vitamins C and E, beta carotene and polyphenols)</p> <p>Trial funding: Italian Ministry of Health, Sigma-Tau Health Science provided omega-3 capsules</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized by means of a specific list"
Allocation concealment (selection bias)	Unclear risk	Randomisation methodology not mentioned
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "the placebo was identical to the supplement but contained no antioxidants or polyunsaturated fatty acids; no patient, research assistant, investigator or any other medical or nursing staff could distinguish the placebo from the supplements during the study". However, only one placebo discussed and unclear whether it was a placebo capsule (for omega-3) or pill (for antioxidants)

Nutristroke 2009 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "assays were quality control checked by internal standard and calibration curve in a random and double blind way"
Incomplete outcome data (attrition bias) All outcomes	High risk	High rates of dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol or trials registry entry found
Attention	Low risk	All assessments and treatments appear equal across the intervention groups
Compliance	Unclear risk	Appears to have been assessed at meetings or on the phone monthly, but results unclear
Other bias	Low risk	None noted

Nye 1990

Methods	Randomisation: parallel, 3 groups (omega-3 vs olive oil vs aspirin and dipyridamole), 1 year Risk of bias: moderate or high
Participants	People undergoing PTCA N: 36 intervention, 37 control (also 35 allocated to arm 3, aspirin and dipyridamole) Level of risk for CVD: high (people undergoing angioplasty) Men: 78% intervention, 76% control Mean age in years (SD): 54 (8) intervention, 55 (8) control years Age range: unclear Smokers: unclear Hypertension: unclear Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: New Zealand Ethnicity: unclear
Interventions	Type: supplement (capsules) Comparison: EPA vs MUFA Intervention: MaxEPA capsules 12/d (2.2 g EPA). Dose: 2.2 g/d EPA Control: olive oil capsules, 12/d, identical to MaxEPA. Both capsules included vitamin E Compliance: no data

Nye 1990 (Continued)

Length of intervention: 12 months

Outcomes	Main trial outcome: angina, restenosis Dropouts: none Available outcomes: angina, interventions, lipids (Nil death) Response to contact: no
Notes	Trial funding: Medical Research Council of New Zealand and Scherer Ltd (who supplied MaxEPA and the olive oil capsules)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly divided without exclusions into 3 groups"
Allocation concealment (selection bias)	Unclear risk	Unclear, no further info
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	States that placebo capsules were identical to the MaxEPA, and "neither the patient nor the attending cardiologist knew which capsules were being used" (but no masking of taste was reported, and participant guesses as to allocation were not reported)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "neither the patient, nor the attending cardiologist knew which capsules were being used" ... "Angioplasty was repeated electively at one year or before where symptoms recurred, and assessed without knowledge of the patient's treatment group."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Some participants were lost to follow-up and reasons for this were unclear
Selective reporting (reporting bias)	Unclear risk	No protocol or trials registration found
Attention	Low risk	No suggestion of attention bias, symptomatic participants were reviewed between scheduled visits, otherwise all on the same schedule
Compliance	Unclear risk	No data
Other bias	Low risk	No further bias noted

OFAMI 2001

Methods	Omacor Following Acute Myocardial Infarction (OFAMI) RCT, parallel, 2 arms (omega-3 vs corn oil), 2 years Summary risk of bias: moderate or high
Participants	Participants recruited 4-8 days after confirmed MI N: 150 intervention, 150 control

OFAMI 2001 (Continued)

Level of risk for CVD: high

Men: 77% intervention, 82% control

Mean age in years (SD): 64.4 intervention, 63.6 control (no SD)

Age range: 28-86 years intervention, 29-87 years control

Smokers: 39% intervention, 38% control

Hypertension: 29% intervention, 23% control

Medications taken by at least 50% of those in the control group: beta-blockers, aspirin

Medications taken by 20%-49% of those in the control group: statins, ACE inhibitors

Medications taken by some, but < 20% of the control group: diuretics, warfarin

Location: Norway

Ethnicity: unclear

Interventions	<p>Type: supplement (capsules)</p> <p>Comparison: EPA + DHA vs omega-6</p> <p>Intervention: 4 gelatin capsules of omega-3-acid ethyl esters 90 (Omacor, Pronova A/S, Oslo, Norway), each is 1 g containing 850-882 mg EPA and DHA as concentrated ethylesters Dose ~3.4- 3.5 g/d EPA + DHA</p> <p>Control: corn oil capsules, 4/d, each contains 1 g of corn oil</p> <p>Compliance: assessed by questionnaire and capsule count, 82% intervention group had complete compliance after 6 weeks, 86% of controls</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: CV events</p> <p>Dropouts: unclear</p> <p>Available outcomes: total and CV deaths, MI, unstable angina, interventions, combined CV events, BMI, lipids, BP (trial authors provided additional data on glucose, AF, stroke)</p> <p>Response to contact: yes</p>
Notes	<p>Trial funding: Pharmacia-Upjohn and Pronova</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned" – Pharmacia was responsible for randomisation. Trial author response: participants were randomised in blocks of 4
Allocation concealment (selection bias)	Low risk	Trial author confirmed allocation was concealed
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical capsules containing either Omacor or corn oil. Double-blinding stated, but taste not reported as masked and blinding of participants not checked

OFAMI 2001 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Trial author stated: all later analyses performed without the knowledge of outcome
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number of dropouts was unclear
Selective reporting (reporting bias)	Unclear risk	Trials registry NCT01422317. Outcomes reported in trials registry appear to have been published, but registration was retrospective.
Attention	Low risk	All participants appear to have been reviewed at the same intervals
Compliance	Unclear risk	Assessed by questionnaire and capsule count, 82% intervention group had complete compliance after 6 weeks, 86% of controls
Other bias	Low risk	No further bias noted

OMEGA 2009

Methods	<p>Effect of omega-3 FAs on reduction of sudden cardiac death after MI (OMEGA)</p> <p>2 arm, parallel RCT (omega-3 vs olive oil), 12 months</p> <p>Summary risk of bias: low</p>
Participants	<p>People who had had an acute MI</p> <p>N: 1940 intervention, 1911 control (analysed for primary endpoints 1919 intervention, 1885 control)</p> <p>Level of risk for CVD: high</p> <p>Men: 75.1% intervention, 73.7% control</p> <p>Age (median): 64.0 years, intervention, 64.0 years control</p> <p>Age range: unclear (upper and lower quartiles 54-72)</p> <p>Smokers: 35.9% intervention, 37.5% control</p> <p>Hypertension: 66.9% intervention, 66.1% control</p> <p>Medications taken by at least 50% of those in the control group: statins, ACE inhibitors, beta-blockers, clopidogrel, aspirin</p> <p>Medications taken by 20%-49%: diuretics</p> <p>Medications taken by some, but < 20%: AT1 receptor blockers, vitamin K antagonist, calcium channel blockers, digitalis, amiodarone, oral antidiabetics, insulin</p> <p>Location: Germany</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 1 × 1 g/d Pronova BiCare soft gelatin capsule 'zodin' omega-3 acid ethyl esters (460 mg/d EPA and 386 mg/d DHA). Dose: 0.85 g/d EPA + DHA</p>

OMEGA 2009 (Continued)

Control: 1 × 1 g/d olive oil capsule identical to intervention

Compliance: 93.1% of intervention group and 93.2% of control participants took > 70% of capsules

Duration of intervention: 12 months

Outcomes	<p>Main trial outcome: sudden cardiac death, cardiac arrest</p> <p>Dropouts: control: 26 (8 lost to follow-up, 2 withdrew before allocation, 16 excluded) intervention: 21</p> <p>Available outcomes: deaths, CV mortality, MACCE, MI, arrhythmias, heart failure, stroke, revascularisation, lipids; trial authors supplied information on angina, depression, cancers, AF</p> <p>Response to contact: yes</p>
----------	---

Notes	Trial funding: Tromsdorff Arzneimittel commissioned the research
-------	--

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation code generated by alpha med PHARBIL, done in blocks of 8. Randomisation was stratified by centre.
Allocation concealment (selection bias)	Low risk	Appearance of the drugs or the drug containers did not allow participants and physicians to deduce the trial arm. 4-digit number on a concealed container
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Capsules for placebo and intervention looked the same, randomisation code unknown to investigator (taste and smell not mentioned)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Classification of adverse events blinded to allocation, and there was a blinded endpoint committee for all prespecified outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	All events were documented by the investigators and reported to the assigned clinical research organisation and the sponsor. The data safety monitoring board judged any imbalances between the trial arms.
Selective reporting (reporting bias)	Low risk	NCT00251134 registered in 2005. Trial start date: 2003, Completed: 2008, trial design: 2006, Published paper: 2010. All trials registry primary and secondary outcomes reported
Attention	Low risk	Capsules for both arms
Compliance	Low risk	93.1% of intervention group and 93.2% of control participants took > 70% of capsules. EAIC 0.65 intervention, and control
Other bias	Low risk	None noted

OPAL 2010

Methods	<p>Older People And n-3 Long-chain PUFA (OPAL)</p> <p>2-arm, parallel, RCT, (omega-3 vs MUFA), 12 months</p> <p>Summary risk of bias: low</p>
---------	---

OPAL 2010 (Continued)

Participants	<p>Healthy cognitively normal adults aged 70-79 years</p> <p>N: 434 intervention, 433 control (analysed 376 intervention, 372 control)</p> <p>Level of risk for CVD: low</p> <p>Men: 53.4% intervention, 56.6% control</p> <p>Mean age in years (SD): 74.7 (2.5) intervention, 74.6 (2.7) control</p> <p>Age range: 70-79 years</p> <p>Smokers: not reported</p> <p>Hypertension: 54.9% intervention, 56.9% control</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49%: not reported</p> <p>Medications taken by some, but < 20%: not reported</p> <p>Location: England and Wales</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 2 × 650 mg capsule/d Ocean Nutrition vanilla flavoured soft gelatin capsule (total daily dose of 200 mg EPA and 500 mg DHA). Dose: 0.7 g/d EPA + DHA</p> <p>Control: 2 × 650 mg olive oil capsule identical to intervention</p> <p>Compliance: count returned capsules</p> <p>Capsules not returned:</p> <ul style="list-style-type: none"> intervention - median: 0.95; IQR: 0.82, 1.00 control - median: 0.95; IQR: 0.81, 1.00 <p>Fasting serum FAs, mg/L, mean (SD)</p> <ul style="list-style-type: none"> EPA: intervention 49.9, (2.7); control 39.1 (3.1) DHA: intervention 95.6 (3.1); control, 70.7 (2.9) ALA intervention 21.5 (0.8); control 22.0 (0.9) <p>Length of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: delayed onset of cognitive decline</p> <p>Dropouts: control: 78 (8 died, 53 withdrew, 17 discontinued intervention but provided data); intervention: 67 (9 died, 49 withdrew, 9 discontinued intervention but provided data)</p> <p>Available outcomes: deaths, MI, arrhythmias, stroke, diabetes, lipids</p> <p>Response to contact: yes</p>
Notes	<p>Trial funding: UK Food Standards Agency, National Health Service Research & Development provided support costs</p>

Risk of bias

OPAL 2010 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were "selected in random blocks". "Research nurses telephoned a central computerized randomization service to obtain treatment allocation codes".
Allocation concealment (selection bias)	Low risk	Central allocation via telephone
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical capsules (vanilla-flavoured, dark-brown coloured). Supplements packaged into identical pots, each containing 180 capsules, labelled by staff not involved in the trial. All project staff were unaware of group assignments until after data analysis.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All project staff were unaware of group assignments until after data analysis.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Participants who discontinued the supplements invited to an interview at 24 months. Dropouts explained and similar in both arms (intervention 49 withdrew, control 53 withdrew)
Selective reporting (reporting bias)	High risk	ISRCTN72331636. Trial registered 2004, before trial began. Protocol published 2006. Publication of first results 2010. Many outcomes, such as depression and BP were stated in trials registry entry but not reported.
Attention	Low risk	All participants had the same review schedule, and staff were unaware of assignments
Compliance	Low risk	Count returned capsules. Capsules not returned (intervention - median: 0.95; IQR: 0.82, 1.00; control - median: 0.95; IQR: 0.81, 1.00). Fasting serum FAs, mg/L, mean (SD): EPA, intervention 49.9 (2.7); control 39.1 (3.1). DHA, intervention 95.6 (3.1); control 70.7 (2.9). ALA: intervention 21.5 (0.8); control 22.0 (0.9)
Other bias	Low risk	No further bias noted

ORIGIN 2012

Methods	Outcome Reduction with Initial Glargine INtervention (ORIGIN) RCT, 2 × 2 factorial, (n-3 vs MUFA), 72 months Summary risk of bias: low
Participants	People at high risk of CV events with IFG, IGT or diabetes (mean baseline TG 140 mg/dL, 88.4% had diabetes) N: 6319 intervention, 6292 control (analysed, intervention: 6281 control: 6255) Level of risk for CVD: moderate Men: 65.4% intervention, 64.7% control Mean age in years (SD): 63.5 (7.8) intervention, 63.6 (7.9) control Age range: unclear, eligible if aged ≥ 50 years Smokers: current smokers 12.1% intervention, 12.6% control

ORIGIN 2012 (Continued)

Hypertension: 78.7% intervention, 80.3% control

Medications taken by at least 50% of those in the control group: ACE inhibitor or ARB, aspirin or other antiplatelet, beta-blocker, statin, glucose-lowering drug

Medications taken by 20%-49%: calcium-channel blocker

Medications taken by some, but < 20%: thiazide diuretics, anticoagulant

Location: 40 trial locations in Europe and the Americas

Ethnicity: unclear

Interventions	<p>Type: supplement capsule (Omacor)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 1 gelatin capsule/d Omacor containing at least 900 mg ethyl esters of n-3 fats (465 mg EPA + 375 mg DHA). Dose: 0.84 g/d EPA + DHA</p> <p>Control: 1 × 1 g gelatin capsule/d olive oil</p> <p>Compliance: methods of assessment unclear, but reported that "rates of adherence to the study-drug regimen were similar in the two groups with 96% of patients continuing to receive the study drug at 1 year ... and 88% at the end of the study".</p> <p>Length of intervention: 74 months mean follow-up (median 6.2 years)</p>
Outcomes	<p>Main trial outcome: composite of the 1st occurrence of CV death, nonfatal MI or nonfatal stroke</p> <p>Dropouts: 38 intervention, 37 control (some of the remainder did not have final outcome status, were lost or withdrew consent, but were included in analysis)</p> <p>Available outcomes: mortality, CV mortality, fatal arrhythmia, MI, stroke, heart failure, angina, revascularisation, breast cancer, cancer diagnoses and cancer deaths, BP, lipids (HbA1c given as medians only)</p> <p>Response to contact: yes but no data provided</p>
Notes	<p>The other 2 × 2 assignment was to insulin glargine vs standard care, and is not discussed here. Results are reported here for the trial duration and not the follow-up post trial (the ORIGIN and Legacy Effects, ORIGINALE).</p> <p>Trial funding: Sanofi Aventis, Omacor provided by Pronova Biocare</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomized by an automated telephone randomization system (using randomly varying block sizes)"
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Trial described as "double blind" and placebo described as identical. Blinding of participants, investigators, local and central trials personnel described. However, no information provided as to the capsules' smell and taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "all primary and secondary outcomes were adjudicated with the use of prespecified definitions by a committee whose members were unaware of study-group assignments"

ORIGIN 2012 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Almost all participants were included in outcomes
Selective reporting (reporting bias)	Low risk	NCT00069784 – registered October 2003, trial started August 2003, final data collection December 2011. Most outcomes appear to have been reported in various publications (CV events only reported by glargine randomisation).
Attention	Low risk	No suggestion of differences between groups
Compliance	Unclear risk	Methods of assessment unclear, but reported that "rates of adherence to the study-drug regimen were similar in the two groups with 96% of patients continuing to receive the study drug at 1 year ... and 88% at the end of the study"
Other bias	Low risk	None noted

ORL 2013

Methods	<p>Omega-3 FAs randomised long-term (ORL)</p> <p>RCT- parallel, 3 arms (TAK-085 2 g, TAK-085 4 g, and EPA-E 1.8 g, n-3 vs unclear), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Population: Japanese adults with hypertriglyceridaemia (mean baseline TG 263 mg/dL)</p> <p>N: 171 intervention (4 g TAK), 165 control (2 g TAK)</p> <p>Level of risk for CVD: moderate</p> <p>Men: 70.8% intervention, 71.5% control</p> <p>Mean age in years (SD): 55.9 (10.12) intervention, 56 (10.95) control</p> <p>Age range: 20-74</p> <p>Smokers (current): 27.5% intervention, 31.5% control</p> <p>Hypertension: 66.7% intervention, 67.3% control</p> <p>Medications taken by at least 50% of those in the control group: HMG-CoA reductase inhibitor</p> <p>Medications taken by 20%-49%: statin</p> <p>Medications taken by some, but < 20%: not reported</p> <p>Location: Japan</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: supplement (TAK-085 capsules)</p> <p>Comparison: EPA + DHA higher vs lower dose</p> <p>Intervention: 1 × 2/d capsule each containing 2 g of TAK-085 (1 g of FA in TAK-085 capsules contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 1.86 g/d EPA + 1.5 g/d DHA. Dose: ~3.4 g/d EPA + DHA (difference of +1.7 g/d from control arm)</p> <p>Control: 1 capsule/d containing 2 g of TAK-085 (1 g of FA in TAK-085 capsules contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 0.93 g/d EPA + 0.75 g/d DHA. Dose: 1.7 g/d EPA + DHA</p>

ORL 2013 (Continued)

Compliance: monitored every 4 weeks, mean rate of compliance reported as > 96% in each group

Length of intervention: 12 months

Outcomes	<p>Main trial outcome: safety outcomes and adverse events</p> <p>Dropouts: group 1: 8, group 2: 14, group 3 (not analysed): 21</p> <p>Available outcomes: adverse events (including CVD events, cancers), CRP, waist circumference, weight, BP (nil death), lipids provided as % change from baseline, but no baseline data available, so not used in meta-analyses</p> <p>Response to contact: no</p>
Notes	<p>A 3rd arm of EPA-E 1.8 g supplementation is not used here. Outcome data used TAK-4 vs TAK-2</p> <p>Trial funding: Takeda Pharmaceutical Company</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was stratified according to statin use and performed by an independent registration centre
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open-label
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were accounted for and analysed for main outcomes
Selective reporting (reporting bias)	Low risk	Trials registry entry May 2011, trial start date November 2009, completion November 2011, so partially retrospective. However, entry appears to reflect reported outcomes
Attention	Low risk	Capsules, appear similar
Compliance	Low risk	Monitored every 4 weeks, mean rate of compliance reported as > 96% in each group
Other bias	Low risk	None noted

Proudman 2015

Methods	<p>RCT, parallel, (EPA + DHA fish oil vs omega-6 Sunola oil), 12 months</p> <p>Summary risk of bias: low</p>
---------	--

Proudman 2015 (Continued)

Participants	<p>People with RA < 12 months' duration, DMARD-naïve</p> <p>N: 87 intervention, 53 control (analysed, intervention: 75 control: 47)</p> <p>Level of risk for CVD: low</p> <p>Men: 29% intervention, 25% control</p> <p>Mean age in years (SD): 56.1 (15.9) intervention, 55.5 (14.1) control</p> <p>Age range: unclear</p> <p>Smokers: 65.1% intervention, 54.7% control (includes current and previous smokers)</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: triple DMARD therapy (SSZ 0.5 g/d, HCQ 200 mg twice/day and MTX 10 mg once/week)</p> <p>Medications taken by 20%-49% of those in the control group: NSAIDS</p> <p>Medications taken by some, but < 20% of the control group: oral or parenteral steroids</p> <p>Location: Australia</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (fish oil)</p> <p>Comparison: high EPA + DHA vs omega-6 (low EPA + DHA with Sunola oil)</p> <p>Intervention: 10 mL/d fish oil concentrate (BLT Incromega TG3525) providing 5.5 g/day (3.2 EPA + 2.3 DHA). Dose: 5.5 g/d EPA + DHA</p> <p>Control: 10 mL/d Sunola oil:capelin oil (2:1) providing 0.21 g EPA + 0.19 g DHA/d as TAG (0.40 g/day EPA + DHA)</p> <p>Compliance: consumption checked at each visit. 100% compliance would be consumption of 3650 mL oil at 12 months. The fish oil group was less compliant than the control group with median intakes of 2482 mL and 3248 mL, respectively (P = 0.015, Mann-Whitney U test). This provided an average daily intake of EPA + DHA of 3.7 g and 0.36 g in the fish oil and control groups, respectively.</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: DMARD failure and remission</p> <p>Dropouts: 11 intervention, 6 control</p> <p>Available outcomes: mortality (nil death), adverse events including CVD, DAS score, diabetes, authors supplied methodology data plus BMI change</p> <p>Response to contact: yes</p>
Notes	<p>DAS scores are reported as median and IQR in Proudman 2012 abstract (see secondary ref under Proudman 2015)</p> <p>Trial funding: National Health Medical Research Council of Australia and Royal Adelaide Hospital Research Committee. Melrose Health provided support for ongoing trials. The oil was made by the Royal Adelaide Hospital Pharmacy</p>
Risk of bias	
Bias	Authors' judgement Support for judgement

Proudman 2015 (Continued)

Random sequence generation (selection bias)	Low risk	Quote: "The randomisation schedule was prepared using an online random number generator and involved randomly permuted blocks of size six."
Allocation concealment (selection bias)	Low risk	Quote: "Randomisation was performed by the RAH pharmacy, which also prepared and provided the study oils in 500 mL identical dark brown bottles labelled with consecutive study numbers"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Both participants and investigators/assessors were blinded to the group allocation. Although the control oil was paler in colour than the fish oil, this was not evident in the brown bottles. The 'fishy' odour of each oil was similar."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Both participants and investigators/assessors were blinded to the group allocation. Quote: "Investigators and subjects remained blinded for all withdrawals."
Incomplete outcome data (attrition bias) All outcomes	Low risk	The flow of all trial participants shown in FIGURE 2
Selective reporting (reporting bias)	Unclear risk	Outcomes reported in trial register matched with the outcomes reported in publications. However, the trial was retrospectively registered – registered in 2013, recruitment began in 2001
Attention	Low risk	No difference between groups
Compliance	High risk	Consumption checked at each visit. 100% compliance would be consumption of 3650 mL oil at 12 months. The fish oil group was less compliant than the control group with median intakes of 2482 mL (68%) and 3248 mL (89%), respectively ($P = 0.015$, Mann-Whitney U test). This provided an average daily intake of EPA + DHA of 3.7 g and 0.36 g in the fish oil and control groups, respectively
Other bias	Low risk	None noted

Puri 2005

Methods	RCT, parallel (ethyl-EPA vs paraffin), 2 arm, 12 months Summary risk of bias: low
Participants	People with Huntington's disease N: 67 intervention, 68 control (analysed, intervention: 39 control: 44) Level of risk for CVD: low Men: 57% intervention, 44% control Mean age in years (SD): 50 (9.3) intervention, 49 (9.0) control Age range: not reported Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported

Puri 2005 (Continued)

Medications taken by 20%-49% of those in the control group: antidepressants

Medications taken by some, but < 20%: neuroleptics

Location: Australia, Canada, UK, USA

Ethnicity: intervention: 94% white, 4% black, 1% Asian; control: 97%, 3%, 0%, respectively

Interventions	<p>Type: supplement (ethyl-EPA)</p> <p>Comparison: EPA vs paraffin (non-fat)</p> <p>Intervention: 2 × 2 × 500 mg capsules/d, total dose of 2 g/d ethyl-EPA (code name LAX-101, purity 95%). Dose: 1.9 g/d EPA</p> <p>Control: 2 × 2 × 500 mg capsules/d liquid paraffin</p> <p>Compliance: 38 were excluded for protocol violations, 4 intervention and 16 control were non-compliant with capsules</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: functional status in Huntington's disease</p> <p>Dropouts: 7 intervention, 7 control</p> <p>Available outcomes: measures of functional capacity, CV events, cancers (nil deaths)</p> <p>Response to contact: yes (no additional data provided)</p>
Notes	<p>Trial funding: Amarin Neuroscience Ltd. (formerly known as Laxdale Ltd.), provided organisation, funding and salaries</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "After screening and acceptance... patients were assigned to treatment by receiving a numbered pack supplied by a clinical trials packaging organization ... independent of all other aspects of the trial. Randomization was stratified in a block size of four, with the appropriate number of blocks allocated to each center. PCI Clinical Services held the randomization code until the database had been closed and all patients had been assigned"
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "[p]lacebo and ethyl-EPA capsules were of identical appearance" (though taste and smell not reported)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation described as "double-blind", "neither the patients nor the participating medical staff had access to this code during the course of the study"
Incomplete outcome data (attrition bias) All outcomes	High risk	Clearly reported and complete, however > 20% attrition

Puri 2005 (Continued)

Selective reporting (reporting bias)	Unclear risk	No protocol or trials registry entry identified
Attention	Low risk	Unlikely
Compliance	Unclear risk	38 were excluded for protocol violations, 4 intervention and 16 control were non-compliant with capsules
Other bias	Low risk	None noted

Raitt 2005

Methods	<p>RCT, parallel, (fish oil or olive oil), 24 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with implantable cardioverter defibrillators and recent sustained VT/VF</p> <p>N: 100 intervention, 100 control</p> <p>Level of risk for CVD: high</p> <p>Men: 86% intervention, 86% control</p> <p>Mean age in years (SD): 63 (13) intervention, 62 (13) control</p> <p>Age range: not reported but 18-75 inclusion criteria</p> <p>Smokers: not reported</p> <p>Hypertension: 46% intervention, 55% control</p> <p>Medications taken by at least 50% of those in the control group: diuretic, beta blockers, ACE inhibitors</p> <p>Medications taken by 20%-49% of those in the control group: digoxin, statins</p> <p>Medications taken by some, but < 20% of the control group: calcium channel blocker</p> <p>Location: USA</p> <p>Ethnicity: 94% white in intervention group, 97% in control group</p>
Interventions	<p>Type: supplement (fish oil capsules vs olive oil capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 1.8 g/d fish oil capsules (Hoffman LaRoche, including ethyl esters of EPA and DHA, 0.76 g/d EPA, 0.54 g/d DHA). Dose: 1.3 g/d EPA + DHA</p> <p>Control: 1.8 g/d olive oil capsules (Hoffman LaRoche, 73% oleic acid)</p> <p>Compliance: while control group plasma and platelet DHA and EPA did not change, there were increases of 2%-8.3% in the intervention group</p> <p>Duration of intervention: 24 months (median 718 days)</p>
Outcomes	<p>Main trial outcome: time to 1st episode of VT/VF</p> <p>Dropouts: 17 intervention, 26 control</p>

Raatt 2005 (Continued)

Available outcomes: deaths, CV death, MI, angina, revascularisation, arrhythmias, sudden cardiac death, cancer

Response to contact: yes but no data provided

Notes

Trial funding: NIH and Hoffman LaRoche

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "computer generated block randomisation scheme"
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participant blinding unclear
Blinding of outcome assessment (detection bias) All outcomes	Low risk	implanted cardioverter defibrillator traces were viewed by researchers blinded to allocation, "double blind placebo-controlled"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Almost all participants were included in outcome assessment, well described
Selective reporting (reporting bias)	High risk	NCT registered in February 2000, trial carried out from February 1999-January 2004. Most outcomes stated in registry entry reported, but QoL missing
Attention	Low risk	Capsules were the only different interventions between arms, little opportunity for attention bias
Compliance	Low risk	While control group plasma and platelet DHA and EPA did not change, there were increases of 2%-8.3% in the intervention group
Other bias	Low risk	None noted

Ramirez-Ramirez 2013

Methods	RCT, parallel, (fish oil vs sunflower oil), 12 months Summary risk of bias: moderate or high
Participants	People with relapsing remitting MS N: 25 intervention, 25 control (analysed, intervention: 20 control: 19) Level of risk for CVD: low Men: 83% intervention, 82% control (but these appear unlikely) Mean age (SD) years: 35.1 (7.6) intervention, 34.9 (7.8) control Age range: not reported but 18-55 years were inclusion criteria

Ramirez-Ramirez 2013 (Continued)

Smokers: not reported

Hypertension: not reported

Medications taken by at least 50% of those in the control group: 100% treated with interferon beta1b for at least 1 year before the trial began

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Mexico

Ethnicity: not reported

Interventions	<p>Type: supplement</p> <p>Comparison: DHA + EPA vs n6</p> <p>Intervention: 4 g/d omega Rx capsules (Dr Sears zone diet, with excipient of glycerin, water, tocopherol, sunflower oil, titanium dioxide, includes 0.8 g/d EPA plus 1.6 g/d DHA). Dose: 2.4 g/d EPA + DHA</p> <p>Control: excipient only (Perfect Source Natural Products, glycerin, water, tocopherol, sunflower oil, titanium dioxide)</p> <p>Compliance: consumption diary plus pills returned at each visit, adherence calculated (correct formula?? pills consumed × 100/pills returned), optimal adherence was considered to be > 80%, 1 intervention and 3 control were excluded due to compliance < 80%. Blood DHA and EPA were significantly different at 12 months.</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: TNF-alpha</p> <p>Dropouts: 5 of 25 intervention, 6 of 25 control</p> <p>Available outcomes: TNF-alpha, IL-6, IL-1 beta, nitric oxide catabolites, MS relapse, disability EDSS, liver and renal function tests, haemoglobin, leucocytes, platelets, oxidative outcomes (glucose and lipids data collected but not reported, for BMI and BP paper reports "no difference through study")</p> <p>Response to contact: not yet attempted</p>
Notes	<p>Trial funding: not reported</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation sequence (blocks of 4)
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "capsules were identical in appearance, packaging and labelling", "physicians and patients were blind to the intervention", and there was a rosemary flavour to mask.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "an independent physician evaluated the EDSS score and collected samples at each clinic visit"

Ramirez-Ramirez 2013 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	Loss of 11/50 over 1 year, 22% loss
Selective reporting (reporting bias)	High risk	Paper reports analysis of glucose and lipids but these are not reported
Attention	Low risk	Appeared similar, reviewed every 3 months
Compliance	Low risk	Blood DHA and EPA were significantly different at 12 months
Other bias	Low risk	None noted

REDUCE-IT 2019

Methods	Reduction of cardiovascular events with EPA - intervention trial (REDUCE-IT) RCT, parallel, (LCn3 vs paraffin oil), median 4.9 years Summary risk of bias: moderate or high
Participants	People (45 years+) with hypertriglyceridaemia, and with CVD or with DM and another risk factor, and on statin (58% had DM at baseline, mean baseline TG > 200 mg/dL) N: intervention 4089 randomised, control 4090 randomised (analysed, intervention: 4083 control: 4077) Level of risk for CVD: moderate (with DM in 29.3% of both intervention and control groups) and high (with CVD, 70.7% of both groups) Men: 71.6% intervention, 70.8% control Age median (IQ range) years: median 64 (57-69) intervention, 64 (57-69) control Age range: not reported those with CVD included if at least 45 years, those with DM if at least 50 years old, 45.4% intervention and 46.6% control groups aged 65+ years. Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: 100% treated with statins to be randomised, 54% of both groups on anti-diabetic medication, 95% on antihypertensives, 80% on antiplatelets, 52% on ACE, 71% on beta blockers. Medications taken by 20%-49% of those in the control group: 27% on ARB Medications taken by some, but < 20% of the control group: 6% on ezetimibe, 9% on anticoagulant Location: 11 countries including USA, Netherlands, Ukraine, Russia, South Africa, Poland, India, Romania, Australia, New Zealand (westernised 71%, Eastern Europe 26%, Asia Pacific 3%) Ethnicity: white 90.3% intervention, 90.2% control
Interventions	Type: supplement Comparison: EPA vs paraffin Intervention: EPA ethyl ester derived from fish oil (AMR101 4 g/d, Amarin), 3.99 g/d EPA plus 8 mg/d vitamin E (2 capsules twice/d) Control: 3.73 g/d light liquid paraffin oil in 4 capsules (2 capsules twice a day)

REDUCE-IT 2019 (Continued)

Compliance: serum EPA assessed, expressed as medians, ~26 µg/mL at baseline, at 1 year rose to 144 in intervention group, 23.3 in control

Duration of intervention: median 4.9 years (max 6.2 years)

Outcomes	<p>Main trial outcome: composite of CV death, MI, stroke, coronary revascularisation and hospitalisation for unstable angina</p> <p>Dropouts: 6 intervention, 13 control</p> <p>Available outcomes: deaths, CVD deaths, CVD events, MACCEs, stroke, MI, sudden cardiac death, new angina, heart failure, amputations due to PVD, AF, revascularisation, DM, TIA, HT (lipid levels and CRP provided as medians). CVD event data provided by diabetes and TG status</p> <p>Response to contact: not yet attempted</p>
Notes	<p>NCT01492361</p> <p>Trial funding: trial designed, run and funded by Amarin (who produce the intervention capsules)</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified randomisation
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and personnel stated to be blinded, not clearly stated that containers were identical but capsular content was identical
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Adjudication was by independent clinical endpoint committee unaware of assignment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low levels of participant loss
Selective reporting (reporting bias)	Low risk	Only 2 outcomes mentioned in trials register, both reported plus many more. Registered November 2011, recruitment November 2011 to August 2016
Attention	Low risk	Appeared similar
Compliance	Low risk	Median serum EPA rose in intervention but not in control
Other bias	High risk	CHD and MI data suggest fewer participants in the intervention arm experienced these outcomes, BUT this is contradicted in Bhatt JACC 2019 (online figure 3), which suggests the data are the wrong way around (suggesting worse outcomes with higher omega-3). Analyses have assumed main data set correct. Some changes in inclusion criteria (levels of TG included) during trial.

Reed 2014

Methods	<p>RCT, parallel, 3 arms (fish oil or borage oil), 18 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Adults with RA</p> <p>N: 53 intervention, 52 control (28 intervention, 24 control analysed)</p> <p>Level of risk for CVD: low</p> <p>Men: 13.2% intervention, 23.1% control</p> <p>Mean age in years (SD): 57.3 (12.3) intervention, 60.3 (9.2) control</p> <p>Age range: not reported but 18-85 inclusion criteria</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: MTX, DMARDs, and TNF blockers</p> <p>Medications taken by 20%-49% of those in the control group: corticosteroids and TNF blockers</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: USA</p> <p>Ethnicity: black/African-American: intervention (fish oil): 7.8% control (borage oil): 7.8%</p>
Interventions	<p>Type: supplement (fish oil vs borage oil)</p> <p>Comparison: EPA + DHA vs omega-6</p> <p>Intervention: 7 fish oil (2.1 g EPA:1.4 g DHA) capsules and 6 sunflower seed oil capsules daily = 13 capsules divided doses. Dose: 3.5 g/d EPA + DHA</p> <p>Control: 6 borage seed oil (1.8 g GLA) capsules plus 7 sunflower seed oil capsules daily</p> <p>Compliance: assessed by capsule counts and participant report. Participant report, indicates that 45% of participants reported ever missing a dose (borage: 42%, fish 48%). Median total capsules missed (excluding those with 0) were 182 (borage: 164, fish 169)</p> <p>Duration of intervention: 18 months</p>
Outcomes	<p>Main trial outcome: RA modified DAS</p> <p>Dropouts: 25 intervention, 28 control</p> <p>Available outcomes: mortality (nil death), CVD events (nil), DAS score, CDAI score. Trial authors suggested that LDL and total cholesterol were reduced in the intervention group at 18 months, and HDL was increased in both intervention and control at 18 months, while DBP was reduced in the intervention group at 18 months, but no numbers provided. CRP and ESR data were provided combined for the intervention and control arms in the trial author response, so not useable</p> <p>Response to contact: yes, trial authors supplied details of methodology but no usable outcome data</p>
Notes	<p>A 3rd arm (45 participants) were given a combination of both oils but not discussed here</p> <p>Trial funding: National Institutes of Health Grant RO1-AT000309 from the National Center for Complementary and Alternative Medicine</p>

Risk of bias

Reed 2014 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Trial author stated "stratified random block, stratified by site using random blocks of 3 & 6"
Allocation concealment (selection bias)	Low risk	No methodology provided in the paper, but the trial author suggested concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, all capsules were identical in appearance and colour, they were shipped in opaque plastic bottles to the University of Massachusetts University Hospital pharmacy, from where they were distributed to participating centres. However no information provided as to their smell and taste.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Trial author confirmed outcome assessors were blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	Trial authors mention ITT analysis but shows completers analysis. Numbers of participants are not provided for all outcomes measured. Provided results for the overall group (69 participants table 3a) while the flow diagram states there are 74 completers. 51% dropped out.
Selective reporting (reporting bias)	Low risk	Trial prospectively registered in 2003, estimated trial completion November 2008, published in 2014. Both outcomes reported in registry are reported in the publication.
Attention	Low risk	All participants were evaluated at 3-month intervals, by the same examiner.
Compliance	Unclear risk	Assessed by capsule counts and participant report. Participant report, indicates that 45% of participants reported ever missing a dose (borage: 42%, fish 48%). Median total capsules missed (excluding those with 0) were 182 (borage: 164, fish 169)
Other bias	Low risk	None noted

Risk & Prevention 2013

Methods	RCT, parallel, (n-3 vs olive oil), 60 months Summary risk of bias: moderate or high
Participants	Patients with multiple CV risk factors (59.9% had diabetes) N: 6244 intervention, 6269 control (analysed, intervention: 6239 control: 6266) Level of risk for CVD: high Men: 62.3% intervention, 60.6% control Mean age in years (SD): 63.9 (9.3) intervention, 64.0 (9.6) control Age range: not reported Smokers: 22.1% intervention, 21.4% control Hypertension: 84.6% intervention, 84.5% control Medications taken by at least 50% of those in the control group: not reported

Risk & Prevention 2013 (Continued)

Medications taken by 20%-49% of those in the control group: ACE inhibitor; ARB; diuretic agent; calcium-channel blocker; beta-blocker; oral hypoglycaemic drug; statin; antiplatelet agent

Medications taken by some, but < 20% of the control group: insulin

Location: Italy

Ethnicity: not reported

Interventions	<p>Type: supplement (n-3 capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 1 g/d n-3 capsules polyunsaturated FA ethyl esters (EPA and DHA content 850-882 mg with an average ratio of 1.0:1.2). Dose: ~0.87 g/d EPA + DHA</p> <p>Control: 1 g/d olive oil capsules</p> <p>Compliance: measured by self-report during follow-up visits but no results reported</p> <p>Duration of intervention: 60 months</p>
Outcomes	<p>Main trial outcome: composite of time to death from CV causes or hospital admission for CV causes</p> <p>Dropouts: intervention: 5 withdrew consent before baseline, 43 lost to follow-up, 1115 stopped treatment. 6239 analysed</p> <p>Control: 3 (withdrew consent before baseline), 39 lost to follow-up, 1218 stopped treatment. 6266 analysed</p> <p>Available outcomes: mortality, CV mortality, CV events, coronary-related events and mortality, MI, AF, heart failure, side effects, stroke, cancer diagnosis, cancer death Trial authors provided data on diabetes diagnosis, glucose and HbA1c.</p> <p>Response to contact: yes</p>
Notes	<p>All continuous outcomes change data are reported as least squares mean hence not used.</p> <p>Trial funding, quote: "The steering committee had the full and sole responsibility for planning and coordinating the study, analyzing and interpreting the data, and preparing the manuscript and submitting it for publication. Società Prodotti Antibiotici, Pfizer, and Sigma Tau funded the trial but had no role in the study design, planning, conduct, or analysis or in the interpretation or reporting of the results"</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Treatment was centrally assigned by means of telephone on the basis of a concealed, computer-generated randomization list, stratified according to general practitioner."
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "Patients, general practitioners, coordination and statistical staff, and outcome assessors were unaware of the study assignments until the final analyses were completed." However, there was no mention of placebo appearance or other methods of blinding, so unclear.

Risk & Prevention 2013 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Patients, general practitioners, coordination and statistical staff, and outcome assessors were unaware of the study assignments until the final analyses were completed." Quote: "All events included in the primary efficacy end point were documented with the use of a narrative summary and supporting documentation and were adjudicated on the basis of prespecified criteria by an ad hoc committee consisting of a cardiologist, an internist, and a neurologist who were unaware of the study assignments"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Analyses were performed in the intention-to-treat population, except for a prespecified per protocol analysis of the primary end point in patients with no major protocol violations who did not permanently stop treatment." Figures differ in Visentin 2008: (p. i73) "At the end of March 2006, 12 521 patients have been Randomized"; "After 1-year of follow-up, 2.5% of the patients withdrawn from the trial and 5% of the patients discontinued treatment. The reasons for drug discontinuation were 1.7% for side effects (mainly GI) and 3.3% others (clinical or patient's refusal)... After 1-year of follow-up, 1.0% had CV death and 3.4% hospitalisation for CV events (primary end point)"
Selective reporting (reporting bias)	High risk	Primary endpoint was amended part way through trial. Differences in groupings of CV events in tables 2; S4 and S5. For hospital admissions notes each participant could have > 1 CV cause
Attention	Unclear risk	Does not state attention differs or is the same between groups- regularly see GP for follow-up and blinding not clear
Compliance	Unclear risk	No results
Other bias	Low risk	None noted

Rossing 1996

Methods	RCT, parallel, (fish oil vs olive oil), 12 months Summary risk of bias: moderate or high
Participants	Adults with insulin-dependent DM, diabetic nephropathy and normal BP (mean baseline TG 1.0 mmol/L) N: 18 intervention, 18 control (analysed, 17 intervention, 15 control) Level of risk for CVD: moderate Men: 64% intervention, 67% control Mean age (SD) years: 32 (7) intervention, 34 (10) control Age range: 18-55 years Smokers: 50% intervention, 47% control Hypertension: not reported Medications taken by at least 50% of those in the control group: insulin Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported

Rossing 1996 (Continued)

	Location: Denmark
	Ethnicity: not reported
Interventions	<p>Type: supplement</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: cod-liver oil emulsion (Pharma-Vinci A/S Denmark). EPA 2 g, DHA 2.6 g, total PUFA 4.6 g/d. Dose: 4.6 g/d EPA + DHA</p> <p>Control: olive oil emulsion (Pharma-Vinci A/S Denmark)</p> <p>Compliance: assessed through omega-3 incorporation in platelets, and the paper reports significantly higher omega-3 levels in platelets at 12 months</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: diabetic nephropathy</p> <p>Dropouts: 1 intervention, 3 control (though 3 further intervention participants are not included in all data)</p> <p>Available outcomes: mortality (nil), breast cancer, total and LDL cholesterol, SBP (TGs reported as medians so not used, albuminuria, fractional albumin clearance, transcapillary escape rate of albumin, prothrombin fragment reported as geometric means or medians, HbA1c, HDL and DBP too different at baseline to include, GFR, PAI1, TPA, fibrinogen, etc. not relevant)</p> <p>Response to contact: yes</p>
Notes	Trial funding: the Danish Heart Association. Eskisol Fish oil and placebo oil emulsions were provided by Pharma-Vinci A/S, Frederiksvaerk, Denmark

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Patients were randomised using concealed randomisation to receive either fish oil or olive oil in blocks of 4 according to their glomerular filtration rate."
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Active and placebo (olive oil) were given as emulsions with orange flavour. At the end patients were allowed to guess about treatment and ~50% were right"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropouts similar between groups although relatively high for small sample size. 3 dropouts from fish oil and 1 from control due to side effects. ITT analysis appears to have been given for albuminuria only
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found

Rossing 1996 (Continued)

Attention	Low risk	Time and attention appear to be the same. All participants were given dietary advice
Compliance	Low risk	Reports significantly higher omega-3 levels in platelets at 12 months for the intervention group
Other bias	Low risk	None noted

Sandhu 2016

Methods	<p>RCT, parallel, 5 arms (combined groups 4 and 5 omega-3-acid ethyl esters (Lovaza) n-3 ± raloxifene vs control groups 1 and 3 ± raloxifene), 24 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese) with high breast density detected on their routine screening mammograms</p> <p>N: 54 + 53 intervention, 53 + 53 control</p> <p>Level of risk for CVD: low</p> <p>Men: 0% intervention, 0% control</p> <p>Mean age in years (SD): 56.56 (6.9) + 57.85 (5.1) intervention, 57.11 (5.9) + 57.68 (5.1) control</p> <p>Age range: not reported</p> <p>Smokers: 0% intervention, 0% control</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: USA</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (n-3 capsules)</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention: group 4, Lovaza 4 g/d. Lovaza is the FDA-approved n-3 FA formulation containing 465 mg of EPA + 375 mg of DHA per gram, total dose; 1860 mg/d EPA, 1500 mg/d DHA. Group 5 as group 4 plus 30 mg raloxifene/d. Dose: 3.36 g/d EPA + DHA</p> <p>Control: group 1, no treatment; group 3, 30 mg raloxifene/d</p> <p>Compliance: measured by pill count, recorded at follow-up visits and further verified by serum FA monitoring. Compliance was 94% (SE 2%) at 6 months and 97% (SE 2%) at 12 months. Only 2 participants had a compliance < 85% (84% and 81%).</p> <p>Duration of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: change in breast density</p> <p>Dropouts: 5 intervention, 6 control</p>

Sandhu 2016 (Continued)

Available outcomes: CV events, breast cancer, lipids, dietary intake, plasma FAs, adverse events (including 1 incidence of hyperglycaemia)

Response to contact: yes

Notes

The trial had 5 arms: group 1, no treatment, control; group 2, raloxifene 60 mg orally daily; group 3, raloxifene 30 mg orally daily; group 4, Lovaza 4 g orally daily; and group 5, Lovaza 4 g/d plus raloxifene 30 mg orally daily. Data here are combined for groups 4 and 5 vs 1 and 3 for binary outcomes and group 1 vs 4 used for continuous outcomes

Trial funding: GlaxoSmith Kline and Eli Lilly provided Lovaza and raloxifene, respectively. Funded by Susan G Komen for the Cure, KG081632 (A Manni) and pilot funds from the Penn State Hershey Cancer Institute (K El-Bayoumy)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Sandhu 2016 pg 276: "each study participant was randomly assigned with equal probability to one of the following five groups. A block randomization scheme was used to ensure balance treatment allocation during the course of enrolment."
Allocation concealment (selection bias)	Unclear risk	No description of concealment of allocation
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open-label
Incomplete outcome data (attrition bias) All outcomes	Low risk	< 20% lost over 2 years, detailed reasons provided, no suggestion these are unbalanced
Selective reporting (reporting bias)	High risk	Biomarkers of oxidative stress (urinary 8-(isoprostane) F-2α and 8OHdG, Lymphocyte 8-OHdG, DNA etheno adducts), urinary 2-OHE1, 4-OHE1, and 16α-OHE1, serum level of CRP and IL-6, Serum level of IGF-I and IGFBP-3, complete blood count mentioned in trial registry but not reported in Sandhu 2016 . (More outcomes reported than in registry – diet, physical activity levels, adverse events)
Attention	Low risk	Participants assessed at baseline, 1-year and 2-year follow-up
Compliance	Unclear risk	Measured by pill count, recorded at follow-up visits and further verified by serum FA monitoring. Compliance was 94% (SE 2%) at 6 months and 97% (SE 2%) at 12 months. Only 2 participants had a compliance < 85% (84% and 81%)
Other bias	Low risk	None noted

SCIMO 1999
Methods

Study on prevention of coronary atherosclerosis with marine omega-3 FAs (SCIMO)

SCIMO 1999 (Continued)

	<p>RCT, parallel (omega-3 vs average European fats), 2 years</p> <p>Summary risk of bias: low</p>
Participants	<p>People with angiographically proven coronary artery disease</p> <p>N: 112 intervention, 111 control (analysed 82 intervention, 80 control)</p> <p>Level of risk for CVD: high</p> <p>Men: 82% intervention, 78.6% control</p> <p>Mean age in years (SD): 57.8 (9.7) intervention, 58.9 (8.1) control</p> <p>Age range: unclear (18-75 inclusion criteria)</p> <p>Smokers: 16.2% intervention, 22.3% control</p> <p>Hypertension: 53.1% intervention, 45.5% control (history of high BP)</p> <p>Medications taken by at least 50% of those in the control group: platelet inhibitors, beta-blockers</p> <p>Medications taken by 20%-49% of those in the control group: long-term nitrate therapy, lipid-lowering agents, ACE inhibitors, diuretics, calcium antagonists, other antihypertensive agents and digitalis</p> <p>Medications taken by some, but < 20% of the control group: nitrates only on demand</p> <p>Location: Germany</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs SFA + MUFA (average European fat composition)</p> <p>Intervention: concentrated fish oil capsules, 6 x 1 g capsules/d for first 3 months, 3 x 1 g/d for rest of trial (4 g/d EPA +DHA + DPA + ALA for first 3 months, then 2 g/d). Dose: ~2 g/d LCn3</p> <p>Control: capsules containing fat that replicated the fat composition of the average European diet, 6/d for first 3 months, 3/d for rest of trial, opaque soft gelatin capsules identical to fish capsules in identical screw-top containers</p> <p>Compliance: capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed for each person, erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months in intervention, and didn't alter from baseline in controls</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main trial outcome: changes in stenosis on angiography</p> <p>Dropouts: unclear</p> <p>Available outcomes: mortality, MI, CV events, revascularisation, angina, stroke, cancer diagnosis, weight, lipids, BP, side effects</p> <p>Response to contact: yes</p>
Notes	<p>Asked participants to guess treatment allocation, of those in intervention 63/90 were unsure, 5/90 guessed placebo and 22/90 guessed fish oil; of those in control 66/85 were unsure, 9/85 guessed placebo and 10/85 guessed fish oil</p> <p>Trial funding: Pronova provided capsules and funds for trial monitoring but it was stated that the funders played no part in analysis or publication</p>

Risk of bias

SCIMO 1999 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified, and for the resulting 9 strata "a random sequence of study group assignments was computer generated by the trial monitor"
Allocation concealment (selection bias)	Low risk	Sealed, sequential numbered envelopes used (opaque not stated, but provided only a random number which linked to a specific container of capsules).
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo and fish oil capsules "looked identical and were made of soft opaque gelatin and each contained 1 g of a fatty acid mixture". These were provided in identical containers with identical labels with a randomisation number. Participants were told that capsules differed in composition but not in taste.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding is described and is very strong for angiographic outcomes, but there is no description of how CV events were assessed or recorded. However outcomes assessors were probably the same assessors and so blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear for how many participants clinical events were assessed (though described in detail for angiographic outcomes), so trial flow unclear
Selective reporting (reporting bias)	Unclear risk	No trial trials register entry or protocol was found
Attention	Low risk	As trial personnel were unaware of assignments bias in attention was not possible
Compliance	Low risk	Capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed for each person, erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months in intervention and didn't alter from baseline in controls
Other bias	Low risk	No further bias noted

seAFood Hull 2018

Methods	<p>Systematic Evaluation of Aspirin and Fish Oil (seAFood) polyp prevention trial</p> <p>RCT, parallel, 2x2 (n3 EPA vs SFA MCT), 12 months (also randomised to aspirin arm)</p> <p>Summary risk of bias: low</p>
Participants	<p>NHS Bowel Cancer Screening Programme patients (55-73 years) identified as "high risk" (≥ 5 small adenomas; or ≥ 3 adenomas with at least 1 being ≥ 10 mm in diameter) after their 1st screening colonoscopy</p> <p>N: 356 intervention, 353 control (analysed 314 intervention, 326 control)</p> <p>Level of risk for CVD: low</p> <p>Male: 80% intervention, 80% control</p> <p>Mean age (SD): 65 or 66 years intervention, 65 years control (IQR 62-69)</p> <p>Age range: unclear (55-73 inclusion criteria)</p> <p>Smokers: 12% intervention, 17% control</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: nil</p> <p>Medications taken by 20-49% of those in the control group: statins (28%)</p>

seAFood Hull 2018 (Continued)

Medications taken by some, but < 20% of the control group: metformin (8%), PPI (11%), others 1% or less

Location: England, UK

Ethnicity: not reported

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA vs capric and caprylic acid MCTs</p> <p>Intervention:</p> <p>Arm 1: EPA (ALFA capsules: 2 x 500 mg twice/d = 2 g/d EPA) and aspirin placebo (1/d)</p> <p>Arm 2: EPA placebo (capric and caprylic acid triglycerides: 2/d) and enteric-coated aspirin (1/d = 300 mg/d)</p> <p>Control:</p> <p>Arm 3: EPA (ALFA capsules: 2 x 500 mg twice/d = 2 g/d) and enteric-coated aspirin (1/d = 300 mg/d)</p> <p>Arm 4: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin placebo (1/d)</p> <p>Identical looking capsules and pills</p> <p>Compliance: capsule count, 95% capsules taken by all arms, red blood cell EPA at 12 months was ~1.5% FAs in intervention, ~0.5% in control (as at baseline)</p> <p>Oily fish intake: 42% of intervention and 40% control ate ≥ 1 portions of oily fish/week at 12 months</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: number of participants with ≥ 1 adenomas at 12 months</p> <p>Dropouts: 40 intervention, 27 control</p> <p>Available outcomes: mortality, colorectal adenoma counts (and various types of severity e.g. number of "advanced" adenomas per participant, number of "high risk" participants re-classified as "intermediate risk", number participants with ≥ 1 advanced adenomas, adenoma region in the colorectum, total number of adenomas per participant, number of participants with colorectal cancer, levels of bioactive lipid mediators e.g. omega-3), adverse events (red blood cell lipids, oily fish intake)</p> <p>Response to contact: not yet attempted</p>
Notes	<p>ISRCTN05926847</p> <p>EudraCT 2010-020943-10</p> <p>www.seafood-trial.co.uk</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation used a secure web-based system with treatment assignment established by pseudorandom code, using random permuted blocks of randomly varying size
Allocation concealment (selection bias)	Low risk	As above, allocation of participants not revealed to anyone until data lock
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical looking placebos were used for both interventions

seAFOod Hull 2018 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and outcome assessors blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Few drop-outs, ITT analysis
Selective reporting (reporting bias)	Low risk	Outcomes in registry entry appear in paper
Attention	Low risk	All capsules, no scope for attention bias
Compliance	Low risk	Good compliance by all counts
Other bias	Low risk	None noted

Shinto 2014

Methods	RCT, parallel (fish oil capsule vs soybean oil capsule), 12 months Summary risk of bias: moderate to high
Participants	People aged ≥ 55 with probable Alzheimer dementia diagnosis N: 13 intervention, 13 control Level of risk for CVD: low Men: 61% intervention 46% control Mean age in years (SD): 75.9 (8.1) intervention, 75.2 (10.8) control Age range: 55+ (inclusion criteria) Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: anti-cholinesterases or memantine Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Lipid-lowering medications and many other drugs were not allowed Location: USA Ethnicity: 100% white
Interventions	Type: fish oil capsules Comparison: EPA + DHA vs n-6 Intervention: 3×1 g capsules/d of fish oils (975 mg EPA, 675 mg DHA/d). Dose: 1.65 g/d EPA + DHA Control: 3×1 g capsules/d soybean oil (which contains 5% fish oil) Both groups had a placebo lipoic acid tablet and lemon-flavoured capsules

Shinto 2014 (Continued)

Compliance: assessed by pill counts and FA in red blood cell membranes. Results showed increased EPA + DHA levels in the intervention group.

Length of intervention: 12 months

Outcomes	<p>Main trial outcome: F2-isoprostane levels (oxidative stress measure)</p> <p>Dropouts: 2 intervention, 2 control</p> <p>Available outcomes: mortality, CVD events, adverse events, serum FAs, measures of cognition (ADAS Cog and MMSE), ADL, IADL (also F2 isoprostane)</p> <p>Response to contact: not attempted</p>
Notes	Trial funding: National Institutes of Health/National Institute of Aging (NIH/NIA) and NIH General Clinical Research

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised by a computer-generated scheme that was stratified by smoking status
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Capsules matched for taste and flavour. Blinding assessed at the end and majority of staff and participants were unaware of treatment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	15% dropouts explained and included
Selective reporting (reporting bias)	Low risk	NCT00090402 first received: 25 August 2004, trial start date April 2004. More secondary outcomes reported than included in the trial register entry
Attention	Low risk	Both arms seem to have had the same contact
Compliance	Low risk	Compliance measured and FAs levels reported. Results showed increased EPA + DHA levels in the intervention group
Other bias	Low risk	None noted

SHOT 1996

Methods	<p>SHunt Occlusion Trial (SHOT)</p> <p>RCT, parallel (omega-3 vs nil), 4 arms, 1 year</p> <p>Summary risk of bias: moderate or high</p>
---------	---

SHOT 1996 (Continued)

Participants	<p>People admitted for CABG</p> <p>N: 317 intervention, 293 control</p> <p>Level of risk for CVD: high</p> <p>Men: 86% intervention, 88% control</p> <p>Mean age in years (SD): 59.9 (8.7) intervention, 59.4 (8.8) control</p> <p>Age range: unclear</p> <p>Smokers: 19% intervention, 20% control</p> <p>Hypertension: 20% intervention, 25% control</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: antihypertensives</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: Norway</p> <p>Ethnicity: not reported</p>	
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs nil</p> <p>Intervention: 4 fish-oil concentrate soft gelatin capsules/d (Omacor; Pronova AS, Oslo, Norway) containing 51% EPA and 32% DHA ethyl esters and 3.7 mg vitamin E as an antioxidant. Dose: 3.3 g/d EPA + DHA</p> <p>Control: no treatment</p> <p>Compliance: capsule count, 88% taken, serum EPA + DHA rose in the intervention group (176-257 mg/L at 9 months) and fell in the control group (170 to 169 mg/L at 9 months)</p> <p>Length of intervention: 12 months</p>	
Outcomes	<p>Main trial outcome: CABG graft patency</p> <p>Dropouts: 15 intervention, 14 control</p> <p>Available outcomes: deaths, CV deaths, MI, stroke, repeat CABG, combined CV events, lipids, side effects</p> <p>Response to contact: yes</p>	
Notes	<p>The trial had 4 arms; aspirin; warfarin; fish oil + aspirin; and warfarin + fish oil. We combined the first 2 groups as the control and the last 2 as intervention.</p> <p>Dietary assessment suggested total diet plus supplement intakes as follows: 2.7 g/d EPA + DHA at baseline, 5.5 g/d at 9 months intervention, 2.5 g/d at baseline, 2.2 g/d at 9 months control group</p> <p>Trial funding: in part by Pronova and Nycomed Pharma</p>	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random numbers were provided in consecutively sealed envelopes generated centrally

SHOT 1996 (Continued)

Allocation concealment (selection bias)	Unclear risk	Envelopes not reported as opaque
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial, no blinding apart from outcome assessors so participants and trial personnel were aware of assignments. However, trial author suggested in personal communication that participants were not aware of their assignments.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors (radiologists) reported as blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for attrition and exclusions stated, numbers clear, dropouts < 20% per year
Selective reporting (reporting bias)	Unclear risk	No trial protocol or trials register entry was found
Attention	Low risk	Appeared equivalent between arms
Compliance	Low risk	Capsule count, 88% taken, serum EPA + DHA rose in the intervention group (176-257 mg/L at 9 months) and fell in the control group (170-169 mg/L at 9 months)
Other bias	Low risk	No further bias noted

Sianni 2013

Methods	RCT, parallel, (fish oil vs unclear placebo), 12 months Summary risk of bias: moderate or high
Participants	People with hypertension and paroxysmal or persistent AF N: 268 intervention, 60 control Level of risk for CVD: moderate Men: not reported Mean age (SD) years: 62 (6), not reported by arm Age range: not reported Smokers: not reported Hypertension: 100% Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: Greece Ethnicity: not reported

Sianni 2013 (Continued)

Interventions	Type: supplement Comparison: fish oil vs unclear placebo Intervention: omega-3 FAs with no further details. Dose: 4 g/d omega-3 Control: placebo, no further details Compliance: no details Duration of intervention: 12 months
Outcomes	Main trial outcome: AF recurrence and BP Dropouts: no details Available outcomes: new AF episodes, BP (not in a usable format) Response to contact: no
Notes	Trial funding: unclear The trial's only publication was a conference abstract.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details, probably randomised but unclear
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details
Selective reporting (reporting bias)	Unclear risk	No protocol or trial register record found
Attention	Unclear risk	No details
Compliance	Unclear risk	No details
Other bias	Unclear risk	No details

SMART 2013

Methods	<p>SMART trial (from the Smart Foods Centre)</p> <p>RCT, 3-arm parallel, (fish + S: hypocaloric diet plus fish plus fish oil capsules vs fish: hypocaloric diet plus fish plus olive oil capsules vs control: hypocaloric diet plus olive oil capsules), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Overweight adults (mean baseline TG 1.3 mmol/L)</p> <p>N: fish + S intervention 41, fish 43, control 42. (analysed, fish + S intervention 21, fish 25, control 18)</p> <p>Level of risk for CVD: low</p> <p>Men: 27% fish + S intervention, 23% fish intervention, 28% control</p> <p>Mean age (SD) years: unclear by arm, overall 45.1 (8.4)</p> <p>Age range: not reported but 18-60 years eligible</p> <p>Smokers: not reported but 5.9% overall</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but < 20% of the control group: not reported</p> <p>Location: Australia</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement and food</p> <p>Comparison: EPA + DHA vs MUFA (fish plus fish oil supplements vs fish plus olive oil supplements vs olive oil supplements)</p> <p>Intervention, fish + S: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus 180 g fish/week plus capsules including 420 mg/d EPA + 210 mg/d DHA (Blackmores Promega Heart). Dose: 0.63 g/d EPA + DHA</p> <p>Intervention, fish: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus 180 g fish/week plus capsules including 1 g olive oil/d</p> <p>Control: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus capsules including 1 g olive oil/d</p> <p>Compliance: assessed through diet histories (fish) and erythrocyte FA supplements (capsules), but results not reported</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: total % body fat</p> <p>Dropouts: fish + supplement intervention 20, fish intervention 18, control 24</p> <p>Available outcomes: weight, BMI, lipids, BP, fasting glucose, fasting insulin, % body fat (leptin also reported), no deaths or CV events occurred (trial authors' report)</p> <p>Response to contact: trial authors provided data on CVD events (none) and mean/SD data for TGs and fasting insulin</p>

SMART 2013 (Continued)

Notes

To assess effects of omega-3 fats the best comparison in this trial is fish + S vs fish, so numerical data reflect this comparison.

Trial funding: Australian National Health and Medical Research Council, fish and olive oil capsules were provided free by Blackmores Australia

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A researcher independent of the subject interface undertook the randomisation of participants into diet groups (stratified by sex and block randomised...)"
Allocation concealment (selection bias)	Low risk	Quote: "Randomisation was performed centrally, off-site and the holder of the allocation schedule provided the codes to a single researcher who was independent to the subject interface. The placebo and active ingredient capsules were coded off-site. The codes were kept from the researchers collecting dietary data and delivering treatment. Allocation concealment was maintained as the persons responsible for screening eligible participants for inclusion in the trial was unaware to which supplement group the subject would be allocated. Different dietitians collected the dietary data and provided dietary advice"
Blinding of participants and personnel (performance bias) All outcomes	High risk	As above, but impossible to blind participants to the fish advice
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	Very high levels of attrition, though ITT analyses carried out
Selective reporting (reporting bias)	High risk	We were unable to find data on 24-h energy expenditure, oxidation or heart rate, which were stated as primary and secondary outcomes in the trials registry.
Attention	Unclear risk	While dietary education was for 1 h then 6 further half-h follow-ups plus written materials and monthly newsletters plus dietary interviews it is not clear whether this was in all arms or only some of them.
Compliance	High risk	Quote: "Of the 12 months completers, 57% were judged to be compliant, 39% (n = 7) for the control group who reported < 180 g fish/week, 48% (n = 12) for the Fish group who reported ≥180 g fish/week, and 85% (n = 17) for the Fish + S group who reported ≥180 g fish/week or ≥90% supplements". However, erythrocyte (EPA + DHA)/total FAs × 100 was significantly different for the fish-oil-supplemented group compared to the 2 others – but it was only measured in around half of the participants as the others dropped out, so presumably were non-compliant.
Other bias	Low risk	None noted

SOFA 2006

Methods	<p>Study on Omega-3 Fatty Acids and ventricular arrhythmia (SOFA)</p> <p>2-arm, parallel RCT (n-3 EPA + DHA vs MUFA and n6), 12 months</p> <p>Summary risk of bias: low</p>
Participants	<p>People with previous ventricular arrhythmias and implanted cardioverter defibrillator</p> <p>N: 273 intervention, 273 control (273 intervention, 273 control analysed)</p> <p>Level of risk for CVD: high</p> <p>Men: 84% intervention, 85 % control</p> <p>Mean age in years (SD): 60.5 (12.8) intervention, 62.4 (11.4) control</p> <p>Age range: unclear (≥ 18 years)</p> <p>Smokers: 16% intervention, 8% control</p> <p>Hypertension: 53% intervention, 49% control</p> <p>Medications taken by at least 50% of those in the control group: beta-blockers</p> <p>Medications taken by 20%-49% of those in the control group: lipid-lowering, antiarrhythmic medications (combined)</p> <p>Medications taken by some, but < 20% of the control group: amiodarone, sotalol</p> <p>Location: 8 countries in Europe</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs MUFA + omega-6</p> <p>Intervention: 2 g/d (4 capsules) purified fish oil. 961 mg n-3 PUFAS (464 mg EPA + 335 mg DHA and 162 mg other n-3 PUFAs) daily. 3000 ppm vitamin E (Loders Croklann, Wormerveer). Dose: 0.8 g/d EPA + DHA</p> <p>Control: 2 g/d high-oleic acid sunflower oil. 3000 ppm vitamin E (Loders Croklann, Wormerveer)</p> <p>Compliance: daily diary, checked by research nurses every 4 months. Judging by capsule count, 207 participants in the fish-oil group and 218 in the placebo took > 80% of their capsules. N-3 FA composition in serum cholesterol levels was measured at baseline and the end of the trial. The EPA concentration in serum cholesterol esters increased in the expected range. No data provided</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: spontaneous VTs and all-cause mortality</p> <p>Dropouts: 33 intervention (23 partial follow-up), 33 control (14 partial follow-up)</p> <p>Available outcomes: deaths, MI, new angina, new heart failure, no fatal arrhythmias, cancer, CV events, side effects</p> <p>Response to contact: yes but no data provided</p>
Notes	<p>Trial funding: Wageningen Centre for Food Sciences (alliance of major Dutch food industries and others)</p>
Risk of bias	
Bias	Authors' judgement Support for judgement

SOFA 2006 (Continued)

Random sequence generation (selection bias)	Low risk	Participants using beta-blockers were separately randomised in blocks of 2. A computer randomisation programme randomly took the first treatment of a block. The second participant in a block of 2 always received the opposite treatment.
Allocation concealment (selection bias)	Low risk	Treatments (blinded medication numbers) were centrally assigned by a telephone allocation service.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blinding. Bottles contained capsules labelled with medication numbers that were unidentifiable for participants as well as investigators. Fish oil and placebo capsules had identical appearance. Difference could not be tasted if swallowed with water (as suggested)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "blinded endpoint adjudication committee"
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis. Did a partial follow-up on some participants who dropped out due to non-compliance
Selective reporting (reporting bias)	Low risk	NCT00110838, trial registered in May 2005, end of trial January 2005, trial results published in 2006. However, rationale and design paper (stating outcomes) published in 2003. Outcomes in the 2006 paper appear to be the same as in Rationale paper
Attention	Low risk	Unlikely as intervention blinded to investigators and only intervention was capsules
Compliance	Unclear risk	Daily diary, checked by research nurses every 4 months. Judging by capsule count, 207 participants in the fish-oil group and 218 in the placebo took > 80% of their capsules. N-3 FA composition in serum cholesterol levels was measured at baseline and the end of the trial. The EPA concentration in serum cholesterol esters increased in the expected range. No data provided
Other bias	Low risk	No further bias noted

Sofi 2010

Methods	2-arm, parallel RCT (enriched olive oil vs olive oil), 12 months Summary risk of bias: moderate or high
Participants	People with NAFLD patients (mean TG 143 mg/dL, mean BMI 29.3) N: 6 intervention, 5 control Level of risk for CVD: low Men: 66.7% intervention, 100% control Median age: 55 intervention, 54 control Age range: 30-41 intervention, 42-70 control Smokers: not reported Hypertension: not reported

Sofi 2010 (Continued)

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Italy

Ethnicity: not reported

Interventions	Type: supplement (oil) Comparison: EPA + DHA vs MUFA Intervention: 6.5 mL/d olive oil enriched with n-3 (t-omega-3, tFarma Srl, Italy) containing 0.47 g EPA, 0.24 g DHA plus dietary recommendations. Dose: 0.83 g/d EPA + DHA Control: 6.5 mL/d olive oil plus dietary recommendations Compliance: was verified by counting the empty boxes on return but no data reported Length of intervention: 12 months
Outcomes	Main trial outcome: fatty liver status Dropouts: unclear Available outcomes: lipids, glucose, insulin, HOMA, (BMI not in usable format, also liver function tests, oxidative markers, adiponectin, fatty liver and steatosis outcomes) Response to contact: not yet attempted
Notes	Trial funding: oil supplied by tFarma and funding not stated

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "The patients were randomized into two groups"
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Numbers analysed for liver health are for those randomised. Numbers analysed for other outcomes not stated. No mention of dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration
Attention	Low risk	Both groups received same contact
Compliance	Unclear risk	Measured but no results reported

Sofi 2010 (Continued)

Other bias	Low risk	None noted
------------	----------	------------

SU.FOL.OM3 2010

Methods	Supplementation en Folates et omega-3 (SU.FOL.OM3) RCT, 2 × 2 factorial (LCn3 omega-3 vs paraffin (non-fat), also B vitamin comparison), 4 years Summary risk of bias: low
Participants	People with a history of MI, unstable angina or ischaemic stroke N: control: 1248, intervention: 1253 Level of risk for CVD: high Men: 80.85% intervention, 78.25% control Mean age in years (SD): 61.1 (8.8) intervention, 60.8 (8.7) control Age range: 53-68 years intervention, 54-68 years control Smokers: 11.1% intervention, 10.4% control Hypertension: not reported Medications taken by at least 50% of those in the control group: beta-blockers, aspirin or antiplatelets, lipid-lowering, ACE inhibitors Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: calcium channel blocker, angiotensin II receptor blockers Location: France Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs non fat placebo Intervention: 2 gelatin capsules Pierre Fabre omega-3 (400 mg/d EPA and 200 mg/d DHA) Control: 2 gelatin capsules/d placebo (liquid paraffin with fish flavour) Compliance: tested by questionnaire, response rate was on average 96%. Out of this, 86% complied Duration of intervention: 4 years
Outcomes	Main trial outcome: composite of MI, cerebral vascular ischaemic accident or CV deaths Dropouts: control: 145 (66 withdrew, 11 lost to follow-up, 68 deaths), intervention: 134 (61 withdrew, 7 lost to follow-up, 66 deaths) Available outcomes: deaths, CV death, non fatal MI, stroke, CV events, coronary events, cancer events, Geriatric Depression Scale score, trial authors provided additional information on outcomes and methodology Response to contact: yes (data provided)
Notes	The other factorial intervention was B-vitamins (560 µg methyl-tetrahydrofolate, 3 mg B-6, 20 µg B12) vs placebo

SU.FOL.OM3 2010 (Continued)

Trial funding: French Ministry of Research, Ministry of Health, Sodexo, Candia, Unilever, Danone, Roche, Merck

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Used computerized block randomisation with stratification by sex, age, prior CVD, and city of residence". "Permuted block randomisation (with a block size randomly selected as 8) was used".
Allocation concealment (selection bias)	Low risk	Allocation of participants was programmed by the statistical co-ordinating centre, who sent participants sufficient treatment capsules for 1 year in an appropriately labelled package
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "All subjects and investigators were blinded to treatment allocation", and placebo capsules looked and tasted "identical to the active supplementation". Fish oil flavour was used in placebos.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome investigators were blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attritions and exclusions were well described. Only 10% loss over 4 years, well balanced
Selective reporting (reporting bias)	Low risk	ISRCTN41926726 registered 2005, 2003 publication on background and rationale, recruitment started April 2003, 2008 protocol, recruitment ended June 2009, 2010 results published. Outcomes in registry entry appear to have been published.
Attention	Low risk	Not likely as capsules used
Compliance	Low risk	Quote: "Allocation to omega 3 fatty acids increased plasma concentrations of omega 3 fatty acids by 37% compared with placebo" (appears statistically significantly different, though not explicitly stated) ... "The overall response rate for return of completed questionnaires was 99%, 96%, 94%, and 95% at 6, 12, and 24 months and at the end of the trial, respectively. About 86% of those who returned a questionnaire reported that they were compliant with the study treatment and compliance was similar in all four groups"
Other bias	Low risk	No further bias noted

Tande 2016

Methods	2-arm, parallel RCT (Calanus (marine) oil vs olive oil), 12 months Summary risk of bias: moderate to high
Participants	Healthy male and female volunteers with BMI 25-35 kg/m ² (mean baseline TG 1.4 mmol/L) N: 64 intervention, 63 control (50 intervention, 50 control analysed) Level of risk for CVD: low Men: 42% intervention, 43 % control Mean age in years (SD): 50.7 (7.7) intervention, 49 (9.4) control

Tande 2016 (Continued)

Age range: unclear (≥ 18 years)
Smokers: not reported
Hypertension: not reported

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but $< 20\%$ of the control group: not reported

Location: Norway

Ethnicity: not reported

Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 2×500 mg Calanus oil capsules twice daily to provide a daily dose of 2 g. Supplements were provided by Ayanda AS (Norway) as blister packs of 60 capsules each. The Calanus oil contained approximately 85% wax ester with a sum of neutral lipids $> 90\%$. Dose: 2 g/d EPA + DHA</p> <p>Control: identical capsules of olive oil. Compositional analysis indicated that the FA content of the olive oil was primarily oleic acid (76.9%), palmitic acid (10.2%), and linoleic acid (7.7%).</p> <p>Compliance: assessed through the return of unused capsules. Compliance rate reported for both intervention and placebo groups was good (86%-88%)</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: safety of Calanus oil consumption</p> <p>Dropouts: 14 intervention, 13 control</p> <p>Available outcomes: BMI, waist-hip ratio, BP, pulse, HbA1c, ESR, CRP, lipids, glucose tolerance, insulin, clinical chemistry parameters, adverse events (no CVD events, deaths or other major health outcomes occurred according to trial author reply)</p> <p>Response to contact: trial author replied with methodological and event information</p>
Notes	Trial funding: Calanus AS

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization of the study subjects into the intervention group or the placebo group was performed by the University Hospital of North Norway clinical research unit and was stratified by gender." Author reply stated that "[r]andomization was performed by competent people at the drugstore affiliated to the University Hospital, with no interconnection, formally or materially with the research department from where the study was managed. Randomization was performed prior to recruiting subjects."
Allocation concealment (selection bias)	Unclear risk	As above, unclear
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants in the placebo group received identical capsules at similar daily doses to the intervention group. However, no information provided as to their smell and taste. Also unclear if investigators were blinded. Trial author reply stated "Each trial subject was given a randomization number, which carried the name of the person, date of birth and treatment information (intervention or control). The randomization number was the only information made available to the trial personnel, and the code was managed by personnel outside the research department. This code was broken after the completion of all

Tande 2016 (Continued)

		analysis with all primary data processed." Blinding of participants only possible for fish plus supplementation vs fish plus placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	All dropouts (~20%) are explained
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found
Attention	Low risk	Appear to be similar in both groups
Compliance	Unclear risk	Quote: "levels of DHA and EPA in the blood were generally higher in the Calanus oil group over baseline values relative to the placebo controls" but no data provided
Other bias	Low risk	None noted

THIS DIET 2008

Methods	<p>The Heart Institute of Spokane diet study (THIS-DIET)</p> <p>RCT- parallel, EPA + DHA vs MUFA, 24 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>Recent survivors of 1st MI (within < 6 weeks)</p> <p>N: 51 intervention, 50 control</p> <p>Level of CVD risk: high</p> <p>Men: 80% intervention, 68% control</p> <p>Mean age in years (SD): 58 (10) intervention, 58 (9) control</p> <p>Age range: unclear</p> <p>Smokers: 25% intervention, 30% control</p> <p>Hypertension: 43% intervention, 50% control (uncontrolled or secondary hypertension excluded)</p> <p>Medications taken by at least 50% of those in the control group: aspirin, statins, beta-blockers, and ACE inhibitors or ARBs</p> <p>Medications taken by 20%-49%: not reported</p> <p>Medications taken by some, but < 20%: not reported</p> <p>Location: USA</p> <p>Ethnicity: intervention 98% white; control 94% white</p>
Interventions	<p>Type: dietary advice (to follow a Mediterranean style diet high in n-3)</p> <p>Comparison: EPA + DHA vs MUFA (biggest dietary change)</p>

THIS DIET 2008 (Continued)

Intervention: Mediterranean-style diet high in n-3. Dietary counselling group sessions; 2 in 1st month then at months 3, 6, 12 and 24. Sessions focused on behaviour modification and practical aspects of assigned diet including recipes, shopping and dining out. Aim to increase omega-3 fat intake to > 0.75% kcal. Dose: ~1.5 g/d omega-3 fat, or 0.31% E by intake assessment

Control: dietary advice (to follow the American Heart Association Step II diet). Same number of group sessions as intervention

The 2 diets were low in saturated fat (< 7% kcal) and cholesterol (< 200 mg/d); the Mediterranean-style diet was distinguished by greater omega-3 fat intake (> 0.75% kcal).

Compliance: participants were required to attend 6 sessions and only invited but not required to attend extra sessions. 3-day food diaries were reviewed with dietitians. Compliance results not stated

Dietary achievements:

Total fat intake, % E (at 24 months): control 29.7 (SD 9.3), intervention 29.1 (SD 8.6)

Saturated fat intake, % E (at 24 months): control 8.0 (SD 2.9), intervention 7.9 (SD 3.2)

PUFA intake, % E (at 24 months): control 5.7 (SD 3.1), intervention 5.7 (SD 2.4)

PUFA n-3 intake, % E: control 0.46 (SD 0.38), intervention 0.67 (SD 0.35) g/week

PUFA n-6 intake: not reported

MUFA intake, % E (at 24 months): control 10.3 (SD 5.1), intervention 9.7 (SD 3.6)

CHO intake, % E (at 24 months): control 54 (SD 11), intervention 54 (SD 10)

Protein intake, % E (at 24 months): control 17 (SD 2), intervention 18 (SD 3)

Trans fat intake: not reported

Length of intervention: 24 months

Outcomes	<p>Main trial outcome: a composite of endpoints including all-cause and cardiac death, MI, hospital admissions for heart failure, unstable angina, or stroke</p> <p>Dropouts: none for primary outcomes</p> <p>Available outcomes: total and CVD deaths (nil deaths), CV events, stroke, MI, diagnosis of DM, BMI and weight (different at baseline hence not used), waist circumference, lipids, BP, albuminuria, CRP, creatinine and dietary intake (trial authors supplied further data on newly diagnosed DM, glucose and insulin data, cancers, depression, AF)</p> <p>Response to contact: yes further data supplied as above</p>
Notes	<p>The trial compared the 2 intervention groups to a non-randomised usual-care control group (not reported here)</p> <p>Trial funding: no funding details is provided but some reported conflict of interests for one trial author.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Sealed envelopes concealing the allocation sequence were prepared by a research co-ordinator. Assignment was stratified by DM status using 10-envelope blocks. Envelopes were selected in the prepared order from a locked drawer by a trial dietitian to assign interventions

THIS DIET 2008 (Continued)

Allocation concealment (selection bias)	Unclear risk	As above but opacity of envelopes is not stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	Neither the intervention team nor participants could be blinded to dietary assignment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The PI was blinded for the purpose of adjudicating clinical end points and adverse events by the removal of identifiers from records used for review.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcomes data provided for all randomised
Selective reporting (reporting bias)	High risk	NCT00269425. Trial was registered in 2005, data collection started in October 2000, January 2008 (final data collection date for primary outcome measure), publication 2008. A number of the outcomes from the registration were not reported e.g. CV revascularisation, peripheral revascularisation or amputation, doubling of serum creatinine, dialysis, or kidney transplant, new hypertension. Also numerous secondary measures were reported that were not in the original registration.
Attention	Low risk	Both arms had the same contact and attention
Compliance	Unclear risk	No details
Other bias	Low risk	None noted

VITAL 2019

Methods	Vitamin D and omega-3 trial (VITAL) RCT- parallel 2x2 (LCn3 vs MUFA), median 5.3 years Summary risk of bias: low
Participants	Multi-ethnic population of > 25,000 apparently healthy adults (men ≥ 50 years, women ≥ 55 years) without cancer or CVD at baseline N: 12,933 intervention, 12,938 control (analysed int 12,933, control 12,938) Level of CVD risk: low Men: 49.4% intervention, 49.5% control Mean age in years (SD): 67.2 (7.1) intervention, 67.1 (7.1) control Age range: unclear Smokers: 7.2% intervention, 7.2% control Hypertension: 49.3% intervention, 50.22% control Medications taken by at least 50% of those in the control group: antihypertensives Medications taken by 20%-49%: cholesterol-lowering medication, aspirin, multivitamins

VITAL 2019 (Continued)

	<p>Medications taken by some, but < 20%: post-menopausal hormones</p> <p>Location: USA</p> <p>Ethnicity: intervention 71.5% white, 20.1% black, 3.9% Hispanic, 1.6% Asian; control 71.2% white, 20.2% black, 4.1% Hispanic, 1.5% Asian</p>
Interventions	<p>Type: supplement</p> <p>Comparison: LCn3 vs MUFA</p> <p>Intervention:</p> <p>Arm 1: omega-3, 1 capsule/d, Omacor fish oil, ProNova. EPA + DHA 840 mg/d: 465 mg EPA; 375 mg DHA provided in calendar packs and placebo D3</p> <p>Arm 3: omega-3 as in Arm 1 and vitamin D3 (1/d, 2000 IU)</p> <p>Control:</p> <p>Arm 2: placebo omega-3 and vitamin D3 (1/d, 2,000IU)</p> <p>Arm 4: placebo omega-3 and placebo D3</p> <p>Dose: 840 mg/d LCn3, or 0.38% E</p> <p>Compliance: % of participants who reported taking at least 2/3 of capsules - intervention 75.8%, control 75.7% at 5 years. N3 index was measured in ~10% who volunteered - unclear if representative</p> <p>Dietary achievements: not mentioned</p> <p>Duration of intervention: median 5.3 years, range 3.8-6.1 years</p>
Outcomes	<p>Main trial outcome: reduction in risk for total cancer and CVD events (a composite of MI, stroke, and CV mortality)</p> <p>Dropouts: none for primary outcomes (ITT)</p> <p>Available outcomes: death, CVD death, total stroke (also ischaemic and haemorrhagic stroke, stroke death), total MI, fatal MI, revascularisation (percutaneous coronary intervention and CABG), any cancer diagnosis, breast cancer diagnosis, prostate and colorectal cancer diagnoses, cancer deaths, CVD events (CV death, MI and stroke), side effects (various trial registry entries also suggest diabetes, hypertension, cognitive decline, autoimmune conditions, infections, chronic respiratory disease, depression, bone health, fractures, chronic knee pain, body composition, physical disability, falls, plasma biomarker measures)</p> <p>Response to contact: not yet attempted</p>
Notes	<p>NCT01169259</p> <p>www.vitalstudy.org</p> <p>Trial funding: NIH with some additional funding e.g. Quest Diagnostics analysed vitamin D, Omacor donated by Pronova BioPharma and matching placebos</p> <p>VITAL substudies (most of which are ongoing) include:</p> <ul style="list-style-type: none"> • VITAL adiposity-NCT01785004 (assessing effects on adiposity) • VITAL AMD-NCT01782352 (assessing effects on age-related macular degeneration) • VITAL bone-NCT01747447 (assessing effects on bone) • VITAL breast-NCT02239874 (assessing effects on breast tissue and mammographic density) • VITAL Cog-NCT01669915 (assessing effects on cognition) • VITAL Dep-NCT01696435 (assessing effects on depression)

VITAL 2019 (Continued)

- VITAL DKD-NCT01684722 (assessing effects on diabetic kidney disease)
- Vital DM-NCT01633177 (assessing prevention of diabetes)
- VITAL Echo-NCT01630213 (assessing effects on cardiac structure & function)
- VITAL eye-NCT01880463 (assessing effects on dry eye disease)
- VITAL HF-NCT02271230 (assessing effects on heart failure)
- VITAL HT- NCT01653678 (assessing effects on hypertension)
- VITAL infection-NCT01758081 (assessing effects on infectious diseases)
- VITAL Lung-NCT01728571 (assessing effects on respiratory function)
- VITAL fractures-NCT01704859 (assessing effects on fractures)
- VITAL anemia- NCT01632761 (assessing effects on anaemia)
- VITAL Rythm-NCT02178410 (assessing effects on AF)
- VITAL inflam-NCT01351805 (assessing effects on autoimmune disease and inflammation)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was computer-generated within sex, race and 5-year age groups in blocks of 8
Allocation concealment (selection bias)	Low risk	Computer randomisation and lack of direct contact with trial staff probably ensured adequate allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo described as "matching", no contact with trial personnel except via mailed questionnaire
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Endpoints committee were unaware of trial-group assignments
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis
Selective reporting (reporting bias)	Low risk	All outcomes of the main trial are reported. Other subtrials have not yet reported.
Attention	Low risk	No contact with trial personnel, little opportunity for attention bias
Compliance	Low risk	Compliance appears acceptable though lipid data were in a small self-selected sample
Other bias	Low risk	None noted

WAHA 2016

Methods	The WALnut and Healthy Aging study (WAHA) 2-arm, parallel RCT (ALA vs unclear), 2 years Summary risk of bias: moderate to high
Participants	Middle-aged healthy adults

WAHA 2016 (Continued)

N: 362 intervention, 346 control (only preliminary data on 312 participants from 1 of the 2 centres is available)

Level of risk for CVD: low

Men: 32.6% intervention, 31.5% control

Mean age in years (SD): 69.4 (3.8) intervention, 68.9 (3.5) control

Age range: 63-79 (inclusion criteria)

Smokers: 4.4% intervention, 1.2% control

Hypertension: 52.8% intervention, 52.9% control

Medications taken by at least 50% of those in the control group: not reported

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: Spain and USA

Ethnicity: not reported

Interventions

Type: supplement (food)

Comparison: ALA vs unclear (usual diet plus walnuts vs usual diet)

Intervention: 15% of daily energy intake as walnuts. The estimated amount of walnuts ranged from about 30–60 g/day (1-2 ounces). Sachets for daily consumption containing 30 g, 45 g, or 60 g of raw, pieced walnuts were provided as 8-week allotments to be eaten daily, preferably as the raw product, either as a snack or by incorporating them into shakes, yogurts, cereals, or salads. To improve participants' compliance, 1-kg extra walnut allowances were provided every 2 months to take into account family needs. Dose: ~ 5 g/d ALA

Control: usual diet without walnut

Compliance: assessed by dietitians through FFQs, recount of empty packages, and changes in FA concentrations. 95% consumed at least 30 g/d. The proportion of ALA in red blood cells increased in the walnut group by 0.16% (95% CI 0.14 to 0.18) and in the control group by 0.02% (95% CI -0.01 to 0.04; $P < 0.001$). No data on dietary intake provided.

Length of intervention: 2 years (only 1-year results have partly been published)

Outcomes

Main trial outcome: change in cognitive decline (results not yet published)

Dropouts: 36 intervention, 21 control (after 1 year)

Available outcomes: lipids (for TG and HDL only data states "no between diet differences were observed"), weight (waist circumference was provided but without variance, abstract stated that "there were no significant changes in body fat and waist-to-hip ratio over time and between the two groups"). Trial authors provided data on mortality, CVD events, cancer deaths and diagnoses, IBD diagnosis (no CVD deaths). Cognitive, ophthalmological, inflammatory markers, glycaemic status and other outcomes are not yet available.

Response to contact: trial authors provided additional outcome and methodology data.

Notes

Trial funding: California Walnut Commission

The 2-year results as well the full 1-year results are yet to be published. Outcome data reported are for only for participants from 1 centre (USA)

Risk of bias

WAHA 2016 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomized to either the control or walnut group using a computerized random number table with stratification by center, sex, and age range. Couples entering the trial were treated as one number and were randomized into the same group".
Allocation concealment (selection bias)	Low risk	Trial author reply states, "Baseline subject data was collected before randomization. Randomization was done by the clinician, pressing the key on the computer. Since this was a dual center (Barcelona and Loma Linda) trial, a single computer software randomized participants for both the centers."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blind. "An unavoidable limitation of the study is not being able to blind participants to the intervention since it consists of a whole food" Rajaram 2017.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Trial author reply states "Study personnel not in contact with the subjects were blind to the treatment assignment. So (lab technicians, ophthalmology technician, neuro cognitive testers) were not aware of the treatment assignment. Of course clinicians who were visited by subjects every two months, knew the treatment assignment". This suggests that allocation was known by physicians, so high risk for event data
Incomplete outcome data (attrition bias) All outcomes	Low risk	38/362 dropouts in intervention group = 10.5%. 34/346 dropouts in control group = 9.8%. Similar dropout in groups over 2 years
Selective reporting (reporting bias)	Unclear risk	Although prospectively registered, no full results paper published – results from conference abstracts only report some secondary outcomes
Attention	Unclear risk	Not enough details
Compliance	Low risk	ALA levels were significantly higher in the intervention group
Other bias	Low risk	None noted

Weinstock-Guttman 2005

Methods	RCT, parallel, (low-fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat ≤ 30%) with olive oil supplements), 12 months Summary risk of bias: moderate or high
Participants	Population: adults with MS N: 15 intervention, 16 control (analysed, intervention: 13, control: 14) Level of risk for CVD: low Men: 15.4% intervention, 14.3% control Mean age in years (SD): 39.9 (10.0) intervention, 45.1 (7.7) control Age range: not reported Smokers: not reported

Weinstock-Guttman 2005 (Continued)

Hypertension: not reported

Medications taken by at least 50% of those in the control group: all participants received 400 units of vitamin E, 1 multivitamin tablet (not containing any PUFA) and at least 500 mg calcium/d

Medications taken by 20%-49% of those in the control group: not reported

Medications taken by some, but < 20% of the control group: not reported

Location: USA

Ethnicity: not reported

Interventions	<p>Type: dietary advice plus supplement</p> <p>Comparison: EPA + DHA vs MUFA (low-fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat ≤ 30%) with olive oil supplements)</p> <p>Intervention: 1.98 g/d EPA, 1.32 g/d DHA supplements (EPAX 5500 EE, Tishcon Corp) + low fat diet (< 15% total calories). Dose: 3.3 g/d EPA + DHA</p> <p>Control: one 1 g olive oil placebo capsules 6 times/d, moderate-fat diet (< 30% total calories) (AHA Step 1 diet)</p> <p>Compliance: assessed by individual food records; intervention 69.2% control 66.7% compliance; also at 12 months there was a significant difference between the FA status of the intervention and control groups in terms of EPA (P = 0.027), as described in table 3 of the main paper</p> <p>Duration of intervention: 12 months</p>
Outcomes	<p>Main trial outcome: physical component scale (PCS)</p> <p>Dropouts: 3 intervention, 7 control</p> <p>Available outcomes: Mental Health Inventory, Modified Fatigue Impact Scale, weight change, HDL and LDL cholesterol, adverse events (MS relapse, TNF-alpha, ICAM-1, VCAM-1 and other inflammatory markers, SF-36 not used)</p> <p>Response to contact: no</p>
Notes	<p>Trial funding: National Multiple Sclerosis Society (PP0620T), Mellen Center Foundation and "The Jog for the Jake" grant</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	States "randomly assigned", no further details
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Patients knew the percentage of dietary fat but did not know the assignment of capsules oil supplementation."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported

Weinstock-Guttman 2005 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	Discrepancy in numbers of participants discontinued and numbers analysed. Per-protocol analysis
Selective reporting (reporting bias)	Unclear risk	No protocol or trials register entry found
Attention	Low risk	Treated equally
Compliance	Low risk	Assessed by individual food records; intervention 69.2% control 66.7% compliance. At 12 months there was a significant difference between the EPA status of the intervention and control groups ($P = 0.027$)
Other bias	Low risk	None noted

WELCOME 2015

Methods	<p>Wessex Evaluation of fatty Liver and Cardiovascular Markers in NAFLD with Omacor Therapy (WELCOME)</p> <p>RCT, parallel, (DHA + EPA vs MUFA), 15-18 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Patients with NAFLD (mean TG 1.4mmol/L, mean BMI 32.0, 9% diabetic)</p> <p>N: 51 intervention, 52 control (analysed, 47 intervention, 48 control)</p> <p>Level of risk for CVD: moderate</p> <p>Men: 49% intervention, 67% control</p> <p>Mean age in years (SD): 48.6 (11.1) intervention, 54 (9.6) control</p> <p>Age range: not reported (18-75 years inclusion criteria)</p> <p>Smokers: 14.3% intervention, 11.8% control</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: lipid-lowering drugs</p> <p>Medications taken by 20%-49% of those in the control group: antihypertensives, metformin (data not provided by group)</p> <p>Medications taken by some, but < 20% of the control group: none reported</p> <p>Location: UK</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (Omacor capsules)</p> <p>Comparison: DHA + EPA vs MUFA</p> <p>Intervention: 4 g OMACOR/d (providing 1.84 g EPA, 1.52 g DHA as ethyl esters). Dose: 3.36 g/d EPA + DHA</p> <p>Control: 4 g olive oil capsules/d (providing; ALA 1%, oleic acid 67%, palmitic acid 15%, stearic acid 2%, n-6 fat: 15%)</p>

WELCOME 2015 (Continued)

Compliance: was assessed by recording the returned unused capsules and quantification of erythrocyte EPA + DHA enrichment (a prespecified threshold of 2% for DHA and threshold of 0.7% for EPA enrichment)

Duration of intervention: 15-18 months

Outcomes	<p>Main trial outcome: changes in mean liver fat %, changes in 2 liver fibrosis scores, change in serum biomarkers</p> <p>Dropouts: 4 intervention, 4 control</p> <p>Available outcomes: weight, BMI, lipids, BP, glucose, insulin sensitivity, body fat measures, liver enzymes, HbA1c, serum n-3 FAs, trial authors provided details of diabetes diagnoses, % body fat, BP and carotid intima media thickness</p> <p>Response to contact: yes</p>
Notes	<p>Trial funding: National Institute for Health Research (NIHR) Southampton Biomedical Research Unit grant and by a Diabetes UK allied health research training fellowship awarded to KGM (Diabetes UK. BDA 09/ 0003937). CDB, PCC and ES are supported in part by the NIHR Southampton Biomedical Research Centre. Omacor and placebo were provided by Pronova Biopharma through Abbott Laboratories, Southampton, UK</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	<p>Participants were block randomised by an independent clinical trials pharmacist to treatment with identical capsules by mouth of either n-3 FA ethyl esters (4 g/d Omacor; Pronova, Sandefjord, Norway) or placebo (4 g/d olive oil) for a minimum of 15 months and a maximum of 18 months (McCormick-2015, p2).</p> <p>Patients were randomised according to standardised procedures (computerised block randomisation) by a research pharmacist at University Hospital Southampton NHS Foundation Trust. Simple randomisation in blocks of 4, either to trial medication or placebo was used. (Scorletti-2014, p 2). (See secondary refs for WELCOME 2015)</p>
Allocation concealment (selection bias)	Low risk	<p>Participants were block randomised by an independent clinical trials pharmacist to treatment with identical capsules by mouth of either n-3 FA ethyl esters (4 g/d Omacor; Pronova, Sandefjord, Norway) or placebo (4 g/d olive oil) for a minimum of 15 months and a maximum of 18 months (McCormick-2015, p2). Only the clinical trials pharmacist was unblinded, and randomisation group allocation was concealed from all trial members throughout the trial. (McCormick-2015, p 2). (See secondary refs for WELCOME 2015)</p>
Blinding of participants and personnel (performance bias) All outcomes	Low risk	<p>Paper states that only the clinical trials pharmacist was unblinded, and randomisation group allocation was concealed from all trial members throughout the trial. However, the trial register record states "single blind (investigator)". Although the capsules were identical, no information provided as to their smell and taste</p>
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	<p>The ITT analysis included all participants randomised who had complete data (baseline and end-of-trial measurements), regardless of whether they were later found to be ineligible, a protocol violator, given the wrong treatment al-</p>

WELCOME 2015 (Continued)

		location, or never treated) (Scorletti 2014, p 4; see secondary ref for WELCOME 2015)
Selective reporting (reporting bias)	Unclear risk	Prospectively registered September 2008, trial start September 2009, end February 2017. Outcome data for cardiac function not yet published, though other CV measures reported – take as ongoing as recent end date
Attention	Low risk	Both groups had the same attention
Compliance	Low risk	Assessed by recording the returned unused capsules and quantification of erythrocyte EPA + DHA enrichment (a prespecified threshold of 2% for DHA and threshold of 0.7% for EPA enrichment). Quote: "Enrichment was highly variable in the DHA+EPA group and 5 and 6 participants in the DHA+EPA group did not reach the prespecified threshold for EPA and DHA enrichment, respectively. In the placebo group, we expected no enrichment between baseline and end of trial in all participants in this group, but 3 and 4 participants reached the thresholds set for the DHA+EPA group, for EPA and DHA, respectively. One participant in the placebo group admitted to taking cod liver oil during the trial and another markedly increased consumption of fish." 10 of 95 non-compliant
Other bias	Low risk	None noted

Zhang 2017

Methods	RCT, parallel, (n-3 DHA vs n-6 LA), 12 months Summary risk of bias: moderate to high
Participants	Otherwise healthy elderly people with mild cognitive impairment N: 120 intervention, 120 control (analysed, intervention: 110 control: 109) Level of risk for CVD: low Men: 35.8% intervention, 34.2% control Mean age in years (SD): 74.5 (2.65) intervention, 74.6 (3.31) control Age range: eligibility criteria were age 65-85 years at trial start Smokers: 59.17% intervention, 61.67% control Hypertension: 9.17% intervention, 7.50% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but < 20% of the control group: not reported Location: China Ethnicity: assumed Chinese
Interventions	Type: supplement (capsule) Comparison: DHA vs corn oil (n-6) Intervention: 1 capsule twice a day, with meals, including 2 g algal DHA (45%-55% DHA by weight). Martek Biosciences, Columbia, MD. Dose: ~1 g/d DHA

Zhang 2017 (Continued)

Control: corn oil, orange-flavoured and orange colour to protect the trial blind

Compliance: participants were asked to return any remaining tablets. Compliance was defined as a ratio (actually taken/should have taken). Achieved 97% for intervention, 95% for control. Serum levels of DHA also measured, DHA at 6 months barely higher in intervention than in controls

Duration of intervention: 12 months

Outcomes	<p>Main trial outcome: cognitive function and hippocampal volume</p> <p>Dropouts: 10 intervention, 11 control</p> <p>Available outcomes: mortality, cognitive outcomes and cerebral volume measurements</p> <p>Response to contact: no reply to date</p>
Notes	Trial funding: Chinese Nutrition Society (CNS) Nutrition Research Foundation- DSM Research Fund

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated, also statistics analyst ignorant to this trial used random number table
Allocation concealment (selection bias)	Unclear risk	Insufficient information
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo capsules ... identical in appearance. All capsules were orange-flavoured and orange colour to protect the trial blind. Packaged into identical pots, each containing 180 capsules, and labelled by staff who were not involved in the trial. A blinding key linked each participant to his or her assigned treatment. This key was kept by an investigator not involved in any data collection or analyses, in a secure electronic file. The code was revealed at the completion of the trial following analyses of the main trial aims.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All project staff were unaware of group assignments until the completion of the trial and after data analysis
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	They did not describe how they imputed missing data (lost contact with participants, but called this an ITT analysis). Overall well matched and not high attrition
Selective reporting (reporting bias)	Low risk	Registered trial prospectively. Outcomes match protocol
Attention	Low risk	"Adherence was encouraged and monitored throughout the trial by telephone assessment at 15 time points, and by blood assay at baseline" 6 months and 12 months. This and assessments were described as same for both arms
Compliance	Unclear risk	<p>Quote: "participants were requested to return any remaining tablets in order to measure compliance, together with the replenishment of capsules for the following month." Compliance ... defined "as a ratio = actually taken/should have taken". "Adherence was encouraged and monitored throughout the trial by telephone assessment at 15 time points, and by blood assay at baseline" 6 months and 12 months</p> <p>On compliance tree, leads to "No, because no P values were supplied" therefore risk of compliance bias unclear</p>

Zhang 2017 (Continued)

Other bias	Unclear risk	Although the register says single-blind, the publication very clearly describes a double-blind RCT
------------	--------------	--

Özaydin 2011

Methods	<p>RCT, parallel, (n-3 fish oil + amiodarone vs amiodarone), 12 months</p> <p>Summary risk of bias: moderate or high</p>
Participants	<p>People with persistent AF referred to cardioversion</p> <p>N: 23 intervention, 24 control</p> <p>Level of risk for CVD: high</p> <p>Men: 47.8% intervention, 37.5% control</p> <p>Mean age in years (SD): 62 (12) intervention, 61 (11) control</p> <p>Age range: 37-81</p> <p>Smokers: not reported</p> <p>Hypertension: 56.5% intervention, 50% control</p> <p>Medications taken by at least 50% of those in the control group: all participants received amiodarone (an antiarrhythmic medication)</p> <p>Medications taken by 20%-49% of those in the control group: beta-blockers, statins, ACE inhibitors and ARBs</p> <p>Medications taken by some, but < 20% of the control group: calcium antagonists</p> <p>Location: Turkey</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: LCn3 vs nil</p> <p>Intervention: 2 g/d n-3 PUFA (Marincap, Kocak, Turkey). 4 × 500 mg capsules providing EPA 18% (360 mg/d); DHA 12% (240 mg/d). Dose: 0.6 g/d EPA + DHA</p> <p>Control: no placebo. Amiodarone was given to both groups.</p> <p>Compliance: no details</p> <p>Duration of intervention: 12 months or AF recurrence</p>
Outcomes	<p>Main trial outcome: AF recurrence (endpoint)</p> <p>Dropouts: no details</p> <p>Available outcomes: all-cause mortality (nil death), stroke, TIA, AF recurrence (hyperthyroidism diagnosis, hospitalisation)</p> <p>Response to contact: not yet attempted</p>
Notes	<p>Trial funding: unclear</p>

Özaydin 2011 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details
Allocation concealment (selection bias)	Unclear risk	Quote: "randomised"; no further details
Blinding of participants and personnel (performance bias) All outcomes	High risk	No placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	All were accounted for
Selective reporting (reporting bias)	Unclear risk	No trial registry entry or protocol found
Attention	Low risk	Both groups seem to have the same care
Compliance	Unclear risk	No information
Other bias	Low risk	None noted

ACE: angiotensin-converting enzyme; **ADAS:** Alzheimer's Disease Assessment Scale; **ADL:** activities of daily living; **AF:** atrial fibrillation; **AHA:** American Heart Association; **ALA:** alpha-linolenic acid; **AMD:** age-related macular degeneration; **BMI:** body mass index; **ALT:** alanine transaminase; **ARB:** angiotensin-receptor blocker; **BMD:** bone mineral density; **BMI:** body mass index; **BP:** blood pressure; **CABG:** coronary artery bypass grafting; **CAD:** coronary artery disease; **CDAI:** Clinical Disease Activity Index; **CHD:** coronary heart disease; **CHO:** carbohydrate; **CI:** confidence interval; **CV:** cardiovascular; **CRP:** C-reactive protein; **CVD:** cardiovascular disease; **DAS:** Disease Activity Score; **DBP:** diastolic blood pressure; **DHA:** docosahexaenoic acid; **DM:** diabetes mellitus; **DMARD:** disease-modifying antirheumatic drugs; **DPA:** docosapentaenoic acid; **E:** dietary energy; **EC:** enteric coated; **ECG:** electrocardiogram; **EDSS:** Expanded Disability Status Scale; **EPA:** eicosapentaenoic acid; **ESR:** erythrocyte sedimentation rate; **FA:** fatty acid; **FFQ:** food frequency questionnaire; **FH:** family history; **FMD:** flow-mediated dilation; **GFR:** glomerular filtration rate; **GI:** gastrointestinal; **GLA:** gamma linolenic acid; **HbA1c:** glycated haemoglobin; **HCQ:** hydroxychloroquine; **HDL:** high-density lipoprotein; **H/O:** personal history of; **HOMA-IR:** homeostatic model assessment of insulin resistance; **HRT:** hormone replacement therapy; **HT:** hypertension; **IADL:** instrumental activities of daily living; **IBD:** inflammatory bowel disease; **ICAM-1:** intercellular adhesion molecule 1; **ICD:** implanted cardioverter defibrillator; **IFG:** impaired fasting glucose; **IGT:** impaired glucose tolerance; **IHD:** ischaemic heart disease; **IL:** interleukin; **IMT:** immune-mediated thrombocytopenia; **IQR:** interquartile range; **ITT:** intention-to-treat; **LA:** linolenic acid (an omega-6 fatty acid); **LCn3:** long-chain omega-3 fatty acids; **LDL:** low-density lipoprotein; **MACCE:** major adverse cerebrovascular or cardiovascular events; **MCT:** medium-chain triglycerides; **MD:** mean difference; **MDA:** malondialdehyde; **MI:** myocardial infarction; **MMP-9:** Matrix metalloproteinase 9; **MMSE:** Mini-Mental State Examination; **MS:** multiple sclerosis; **MUFA:** mono-unsaturated fatty acids; **MTX:** methotrexate; **n-3:** omega-3; **NAFLD:** non-alcoholic fatty liver disease; **NASH:** non-alcoholic steatohepatitis; **n-3:** omega-3 fats; **NSAID:** non-steroidal anti-inflammatory drug; **OSDI:** ocular surface disease index; **PAI1:** plasminogen activator inhibitor-1; **PCI:** percutaneous coronary intervention; **PI:** principal investigator; **PPI:** proton pump inhibitors; **PTCA:** percutaneous transluminal coronary angioplasty; **P/S:** polyunsaturated/saturated fat ratio; **PUFA:** polyunsaturated fatty acids; **PVD:** peripheral vascular disease; **QoL:** quality of life; **QUICKI:** quantitative insulin sensitivity check index; **RA:** rheumatoid arthritis; **RCT:** randomised controlled trial; **SBP:** systolic blood pressure; **SD:** standard deviation; **SE:** standard error; **SFA:** saturated fatty acids; **SHBG:** sex hormone-binding globulin; **SSZ:** sulfasalazine; **TAG:** triacylglycerol; **TC:** total cholesterol; **TG:** serum triglycerides; **TIA:** transient ischaemic attack; **TNF:** tumour necrosis factor; **VCAM-1:** vascular cell adhesion molecule 1; **VF:** ventricular fibrillation; **VO2 max:** maximal oxygen uptake; **VT:** ventricular tachycardia; **WHO:** World Health Organization; **WOMAC:** Western Ontario and McMaster Universities Arthritis Index

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Aleksseeva 2000	Trial not randomised
Baleztena 2015	No relevant outcomes measured
Belch 1988	No relevant outcomes measured
Belluzzi 1996	Trial authors confirmed no relevant outcomes measured
Berthouex 1992	Participants not adult humans, or participants unwell at baseline
Borchgrevink 1966	Mean duration of intervention 10 months (range 3-16 months)
Busnach 1998	Participants not adult humans, or participants unwell at baseline
CANN 2015	Intervention is multifactorial (FA/flavanoid blend)
Cappelli 1997	Participants not adult humans, or participants unwell at baseline
CARES 2015	Multisupplement intervention
Cheng 1990a	No appropriate control group
Cheng 1990b	No appropriate control group
Clark 1993	No relevant outcomes measured
Clark 1994	Participants not adult humans, or participants unwell at baseline
Clark 2001	Participants not adult humans, or participants unwell at baseline
Clausen 1989	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Diskin 1990	No omega-3 supplementation or dietary advice
Donadio 1994	Participants not adult humans, or participants unwell at baseline
Doyle 2001	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Dry 1991	No relevant outcomes measured
Ezaki 1999	Trial not randomised
Feher 2005	Intervention is multifactorial (omega-3 given with coenzyme Q and other compounds vs placebo)
FISH 2012	No clinical outcomes collected (confirmed by corresponding author, 30 November 2016)
Fonolla 2009	Intervention was milk enriched with EPA and DHA but also other vitamins and minerals - multifactorial dietary intervention
Fonolla-Joya 2016	Intervention was milk enriched with EPA and DHA but also other vitamins and minerals - multifactorial dietary intervention

Study	Reason for exclusion
Franzen 1989	Trial not randomised
Galarraaga 2008	9-month intervention period
Gapparova 2000	Trial not randomised
Gazso 1992	No omega-3 supplementation or dietary advice
Geusens 1994	No relevant outcomes measured
Gogos 1998	Participants not adult humans, or participants unwell at baseline
Greatrex 2000	Trial not randomised
Griffin 1999	Trial not randomised
Hamazaki 1984	Participants not adult humans, or participants unwell at baseline
Hansen 1996	Multi-factorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Harris 1991	No appropriate control group
Hashimoto 2012	No relevant outcomes measured
Hashimoto 2016	No relevant outcomes measured
Hawthorne 1992	Trial authors confirmed no relevant outcomes measured
Hogg 1995	Participants not adult humans, or participants unwell at baseline
HOPE epilepsy 2012	Trial recruitment was suspended due to lack of funding
Huang 1996	No relevant outcomes measured
Huang 2008	Intervention was 9 months and no relevant outcomes
InTrePad 2013	Trial never run, withdrawn due to lack of funding (see trials register)
ISRCTN38354847	The proposed 1-year trial was never conducted
Junker 1990	Follow-up not at least a year
Kachorovskii 1977	No omega-3 supplementation or dietary advice
Kanorskii 2007	LCn3 compared to sotalol (group 1), sotalol and perindopril (group 2), sotalol, perindopril and ro-suvastatin (group 3), so no useful control group
Karlsson 1998	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Kaul 1992	Intervention duration 6 months
Khan 2003	Intervention was 8 months

Study	Reason for exclusion
Konya 2000	Trial not randomised
Kremer 1995	< 1 year duration
Kruger 1998	No relevant outcomes measured
Kurabayashi 2000	< 1 year duration
Lau 1993	Trial authors confirmed no relevant outcomes
Leaf 1995	Trial not randomised
Lee 2010	Trial authors confirmed no relevant outcomes measured
Leng 1998	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
LipiDiDiet 2016	Multifactorial dietary intervention that included omega-3 fats but many other nutrition components
Loeschke 1996	No relevant outcomes measured
LUTEGA 2013	Multisupplement intervention
Lyon Diet Heart 1994	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary interventions)
Maachi 1995	Participants not adult humans, or participants unwell at baseline
Macsai 2008	No relevant outcomes measured
Mansel 1990	Not an omega-3 intervention
Mantzaris 1996	No relevant outcomes measured
Mate-Jimenez 1991	Trial authors confirmed no relevant outcomes
Matsuyama 2005	Publication retracted (fraudulent)
Middleton 2002	Unbalanced intervention as the intervention arm contains additional GLA
MoodFOOD 2016	Multisupplement intervention
NAYAB 2017	No planned relevant outcomes. Follow-up < 12 months
NCT01235533	48 weeks' intervention planned in trials register entry
NCT01784042	Not randomised. Trial appears not to have been funded
NU-AGE 2014	Multifactorial dietary intervention
NutriMEMO 2014	Mutlisupplement intervention
OFAMS 2012	No relevant outcomes measured

Study	Reason for exclusion
Okuda 1996	No appropriate control group
OLIVE 1998	Trial was not funded and did not achieve full recruitment (info provided by co-author)
Oslo DIET HEART 1970	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Pogozheva 1997	Trial not randomised
Pogozheva 2000	Trial not randomised
Puri 2008	Trial authors confirmed no relevant outcomes
Quazi 1994	Trial not randomised, < 1 year intervention
Sacks 1994	< 1 year intervention
Saynor 1988	Trial not randomised
Saynor 1992	No appropriate control group
Selvais 1995	Intervention was < 1 year
Shimizu 1995	Trial authors confirmed no relevant outcomes
Singh 1992	Expressions of concern issued by <i>BMJ</i> and <i>Lancet</i> regarding research by this first author (BMJ 2005 ; Horton 2005)
Singh 1997	Expressions of concern issued by <i>BMJ</i> and <i>Lancet</i> regarding research by this first author (BMJ 2005 ; Horton 2005)
Singh 2002	Expressions of concern issued by <i>BMJ</i> and <i>Lancet</i> regarding research by this first author (BMJ 2005 ; Horton 2005)
Tariq 1989	Participants not adult humans, or participants unwell at baseline and intervention is < 1 year
Terano 1999	Trial authors confirmed no relevant outcomes during trial
Tomer 2001	No relevant outcomes. Measured lipids but unclear baseline and endpoint is probably 4 weeks
Torjesen 1997	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
VSDR 2015	The supplement (Nutrof Omega) contained DHA, Vitamins C, E, B1, B2, B3, B6, B9, B12, Zn, Mn, Se, Cu, lutein and zeaxanthin (multifactorial dietary intervention)
Wheaton 2010	Participants were not a minimum of 18 years old
Yasui 2001	No appropriate control group
Zinger 1987	Trial not randomised

DHA: docosahexaenoic acid; **EPA:** eicosapentaenoic acid; **FA:** fatty acid; **GLA:** gamma linolenic acid

Characteristics of studies awaiting assessment *[ordered by study ID]*

IRCT20100123003140N21

Methods	RCT
Participants	People aged 50-70 years with Parkinson's disease
Interventions	Each for unclear duration Intervention: daily 2 capsules of omega-3 capsules with an EPA of 180 mg and DHA of 120 mg from the Zahrawi Pharmaceuticals Company Control: 2 capsules each day, in combination with soy oil, from Zahrawi Pharmaceuticals Company
Outcomes	Primary: inflammatory factors (IL-1 β , IL-6, TNF- α , IL-10) and lipids Secondary: anthropometry, physical activity
Notes	Status unclear as duration is unclear, also unclear whether complete or ongoing but no trial results found

DHA: docosahexaenoic acid; **EPA:** eicosapentaenoic acid; **IL:** interleukin; **RCT:** randomised controlled trial; **TNF:** tumour necrosis factor

Characteristics of ongoing studies *[ordered by study ID]*

AC Omega3 2014

Trial name or title	Aboriginal cardiovascular omega-3 randomised controlled trial (AC Omega3)
Methods	RCT
Participants	Indigenous Australian adults with stable coronary artery disease
Interventions	Each for 12 months: Arm 1: omega-3 (1800 mg/d AlaskOmega: 3 capsules/d: 400 mg EPA and 200 mg DHA) Arm 2: placebo mixed oil capsules (1000 mg/d: 3 capsules/d containing palm oil, gelatin, glycerol, sunflower oil, rapeseed oil, mixed tocopherols, and a "small amount" of fish oil (for taste to aid blinding)
Outcomes	Primary: serum non-HDL-C Secondary: TG, total cholesterol, LDL cholesterol, HDL cholesterol, lipid functionality by cholesterol efflux and CETP, heart rate variability, platelet function and thrombosis markers, inflammation markers, cumulative combined rate of major adverse cardiac events (including death, non-fatal MI, unstable angina, non-fatal stroke, revascularisation and cardiac-related hospital admissions)
Starting date	Registered on trials registry: 10 July 2014 Trial start date: 1 October 2014 Estimated trial completion date: data collection completed November 2017
Contact information	Alex Brown (PI), Wardliparingga Aboriginal Unit, Adelaide, Australia, alex.brown@sahmri.com
Notes	ACTRN12614000732684 Alex Brown contacted in 2016: confirmed trial is actively recruiting

AC Omega3 2014 (Continued)

Checked for updates and publications, none found, 2 August 2019

ACTRN12618000761268 2018

Trial name or title	A 56 week, double-blind, randomised trial to evaluate the efficacy of testosterone, with and without DHA supplementation on cerebral amyloid load in known brain amyloid-PET positive men with subjective memory complaints
Methods	RCT
Participants	Older men (6-80 years) concerned about their memory
Interventions	Each for 56 weeks Intervention: testosterone 1000 mg/4 mL plus 1720 mg of DHA (4 capsules/d) Control: testosterone 1000 mg/4 mL plus placebo-DHA (Also arm 3: placebo-testosterone plus placebo-DHA)
Outcomes	Primary: brain amyloid levels Secondary: composite score of cognitive functioning derived from scores on California Verbal Learning Test – Second Edition (CVLT-II), Brief Visuospatial Memory Test – Revised (BVM-T-R), Logical Memory subtest of the Wechsler Memory Scale-R, Executive Abilities: Methods and Instruments for Neurobehavioral Evaluation and Research Battery (NIH EXAMINER), Boston Naming Test (BNT), Controlled Oral Word Association Test (COWAT), and the WAIS-III Digit Span and Digit Symbol Coding Tasks; as well as a change in global cognition measured by the Montreal Cognitive Assessment (MoCA)
Starting date	Registered on trials registry: 21 March 2018 Trial start date: 16 April 2018 Estimated trial completion date: unclear - likely 2020
Contact information	Kevin Taddei, k.taddei@ecu.edu.au
Notes	ACTRN12618000761268 Added 2 August 2019

AFORRD 2010

Trial name or title	Atorvastatin in factorial with omega-3 fatty acid risk reduction in diabetes (AFORRD)
Methods	RCT
Participants	People with type 2 diabetes with no known CVD and not taking lipid-lowering therapy, adults (> 18 years) N: intervention 397, control 403 (analysed intervention 371, control 361)
Interventions	Each for 12 months: Arm 1: atorvastatin (Lipitor 20 mg/d) and olive oil placebo (2 g/d)

AFORRD 2010 (Continued)

	Arm 2: omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA) and placebo tablets for atorvastatin
	Arm 3: atorvastatin (Lipitor 20 mg/d) and Omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA)
	Arm 4: placebo tablets for atorvastatin and olive oil placebo (2 g/d)
Outcomes	Primary: lipid profiles Secondary: phytosterol changes, HbA1c, estimated CVD risk using the UK Prospective Diabetes Study risk engine
Starting date	Registered on trials registry: 4 April 2004 Trial start date: 1 November 2004 Estimated trial completion date: 31 July 2006
Contact information	Rury Holman, Oxford Centre for Diabetes
Notes	ISRCTN76737502 Rury Holman contacted in 2016: confirmed results are not yet published, but planned Checked for updates and publications, none found, 2 August 2019

Bartold 2010

Trial name or title	Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis
Methods	RCT
Participants	People (25-80 years, non-smokers) with newly diagnosed severe but non-aggressive periodontitis
Interventions	Each for 13 months: Arm 1: fish oil rich in EPA (6 × 500 mg capsules/d: 277 mg EPA; 27 mg DHA) and standard periodontal treatment (scaling and debridement) Arm 2: fish oil rich in DHA (6 × 500 mg capsules/d: 66 mg EPA; 258 mg DHA) and standard periodontal treatment Arm 3: soya oil placebo (6 × 500 mg capsules/d) and standard periodontal treatment
Outcomes	Primary: probing pocket depth, clinical attachment level (CAL) Secondary: inflammatory biomarkers in gingival crevicular fluid, erythrocyte omega-3, CRP
Starting date	Registered on trials registry: 23 July 2010 Trial start date: July 2010 Estimated trial completion date: unclear
Contact information	Mark Bartold, University of Adelaide, mark.bartold@adelaide.edu.au
Notes	ACTRN12610000594022 PhD, Boram Park, available giving 4 month outcome data for pilot trial N = 33 participants Mark Bartold written to in 2016. Confirmed preparing full publications for submission

Bartold 2010 (Continued)

Checked for updates and publications, none found, 2 August 2019

Beyond Aging Project 2015

Trial name or title	Beyond ageing project phase 2: a selective prevention trial using novel pharmacotherapies in an older age cohort at risk for depression
Methods	RCT
Participants	Older adults (60+ years) at risk of depression (K-10 score ranging from 16-29) who initially participated in the first Beyond Ageing Project
Interventions	Each for 12 months: Arm 1: omega-3 (4 capsules, total 2 g/d: 1200 mg EPA and 800 mg DHA) and placebo microcrystalline cellulose (1 capsule) Arm 2: paraffin oil placebo (4 capsules) and sertraline hydrochloride (1 capsule, 50 mg) Arm 3: paraffin oil placebo (4 capsules) and placebo microcrystalline cellulose (1 capsule)
Outcomes	Primary: depressive symptoms (PHQ-9, patient health questionnaire 9) Secondary: cognitive decline, MMSE, brain metabolism, hippocampal volume, anxiety (assessed using GAD-7), disability (WHODAS-II), sleeping problems (PSQI, Pittsburgh Sleep Quality Index), exercise (Active Australian Survey)
Starting date	Registered on trials registry: 12 January 2010 Trial start date: June 2011 Estimated trial completion date: main results expected in 2017
Contact information	Ian Hickie (PI), Brain and Mind Centre, University of Sydney, ian.hickie@sydney.edu.au
Notes	ACTRN12610000032055 Checked for updates and publications, 2 August 2019. Trials registry updated in January 2019, suggests last participant recruited January 2019, recruitment 205 (aim was 450), states that results are not currently available in journal or other format.

Chandrakala 2010

Trial name or title	Long-term effects of a reduced fat diet intervention in pre-diabetes
Methods	RCT
Participants	Participants with pre-diabetes, IFG or IGT, 201 participants discussed in 1 abstract, 134 in a later abstract
Interventions	Each for 3 years: Arm 1: reduced-fat diet (fat content \leq 20% total energy, ratio of PUFA/SFA 0.8;1.0) Arm 2: normal/control diet

Chandrakala 2010 (Continued)

Outcomes	Incidence of diabetes, BMI, lipids, insulin, plasma glucose, HbA1c, BP, nutritional intake
Starting date	Registered on trials registry: no registration found Trial start date: not stated Estimated trial completion date: not stated
Contact information	Chandrakala Galla, chandrakala.galla@gmail.com; Arpana Gaddam, dr.arpanag@gmail.com
Notes	We wrote to trial authors in 2016: Dr Gaddam confirmed work submitted as a PhD but not published in full. Requested copy of PhD thesis, but no reply to date. Funding: DiabetOmics India Checked for updates and publications, none found, 2 August 2019

ChiCTR-TRC-12002014

Trial name or title	Influence of different sources of n-3 fatty acid on plasma lipid in moderately hypercholesterolaemic subjects
Methods	RCT
Participants	Adults (40-65 years) with mild to moderate hypercholesterolaemia
Interventions	Arm 1: EPA/DHA 1.8 g/d Arm 2: EPA/DHA 3.6 g/d Arm 3: ALA 4 g/d Arm 4: placebo
Outcomes	FAs, lipids, cytokines (IL-6, IL-1a)
Starting date	Registered on trials registry: 13 March 2012 Trial start date: unclear Estimated trial completion date: unclear
Contact information	Su Yixiang, Sun-Yat Sen University, China, suyx@mail.sysu.edu.cn; Zhou Quan, Guangzhou Medical University, joan_zq@126.com
Notes	ChiCTR-TRC-12002014 Su Yixiang and Zhou Quan contacted in 2016: no response Checked for updates and publications, none found, 2 August 2019

DO HEALTH

Trial name or title	Vitamin D3- omega3- home exercise- healthy ageing and longevity trial (DO-HEALTH)
---------------------	---

DO HEALTH (Continued)

Methods	RCT
Participants	Community-dwelling adults ≥ 70 years, 50% of seniors enrolled based on a fall in the year before enrolment
Interventions	<p>Each for 3 years:</p> <p>Arm 1: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and strength home exercise (3 \times 30 min/week)</p> <p>Arm 2: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and flexibility home exercise (3 \times 30 min/week)</p> <p>Arm 3: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and strength home exercise (3 \times 30 min/week)</p> <p>Arm 4: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and flexibility home exercise (3 \times 30 min/week)</p> <p>Arm 5: placebo and vitamin D3 (2000 IU/d) capsules and strength home exercise (3 \times 30 min/week)</p> <p>Arm 6: placebo and vitamin D3 (2000 IU/d) capsules and flexibility home exercise (3 \times 30 min/week)</p> <p>Arm 7: placebo and placebo capsules and strength home exercise (3 \times 30 min/week)</p> <p>Arm 8: placebo and placebo capsules and flexibility home exercise (3 \times 30 min/week)</p>
Outcomes	<p>Primary: non-vertebral fractures, functional decline, BP, cognitive decline, rate of any infection</p> <p>Secondary: other fractures, falls, pain in knee osteoarthritis, musculoskeletal changes, GI symptoms, mental and oral health, QoL, life-expectancy, CVD events, cancer, glucose measures, cost-benefit. All endpoints supported by a DO-HEALTH biomarker trial</p>
Starting date	<p>Registered on trials registry: 6 December 2012</p> <p>Trial start date: December 2012</p> <p>Estimated trial completion date: November 2017</p> <p>Actual trial completion date: January 2018</p>
Contact information	Heike Bischoff-Ferrari (PI), Centre on Aging and Mobility, University of Zurich
Notes	<p>NCT01745263</p> <p>EudraCT: 2012-001249-41</p> <p>www.do-health.eu</p> <p>Checked for updates and publications, 2 August 2019. <i>Lancet</i> letter by Bischoff in February 2019 gave no results but referred to the "soon to be published DO-HEALTH trial". Website provides no results after December 2017 newsletter, no publications noted</p>

EVAPORATE 2016

Trial name or title	Effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy (EVAPORATE)
Methods	RCT

EVAPORATE 2016 (Continued)

Participants	Adults (30-85 years) with raised TG (200-499 mg/dL)
Interventions	Each for 18 months: Intervention: EPA (Vascepa) 4 gm/d Control: placebo (not specified)
Outcomes	Primary: progression rates of low attenuation plaque Secondary: morphology of non-calcified coronary atherosclerotic plaque (NCP), markers of inflammation (Lp-PLA2), changes in LDL and HDL cholesterol, composition of non-calcified coronary atherosclerotic plaque (NCP)
Starting date	Registered on trials registry 6 October 2016 Trial start date: 14 September 2016 Estimated trial completion date: September 2019
Contact information	Matthew J. Budoff, Principal Investigator, Los Angeles Biomedical Research Institute
Notes	NCT02926027 Added 2 August 2019

LO-MAPT 2018

Trial name or title	Prevention of cognitive decline in older adults with low DHA/EPA index in red blood cells (LO-MAPT)
Methods	RCT (18 months) followed by 18 months open-label
Participants	Older adults (≥ 70 years) with low DHA/EPA status (red blood cell DHA/EPA index $\leq 4.83\%$) and subjective memory complaints or family history of Alzheimer's disease
Interventions	Each for 18 months: Intervention: 3/d 1 g softgel vegetarian capsules of DHA-O; each 1 g capsule of DHA-O providing 324 mg DHA and 185 mg EPA (total daily DHA + EPA dose = 1.53 g/d) Control: 3/d 1 g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil)
Outcomes	Primary: composite z-score of cognitive performance Secondary: FCSRT Test, MMSE score, Category Naming Test (CNT)
Starting date	Registered on Trials Registry 1 October 2018 Trial start date: 17 April 2018 Estimated trial completion date: April 2022
Contact information	Bruno Vellas, vellas.b@chu-toulouse.fr
Notes	NCT03691519 Added 2 August 2019

MAPT PLUS

Trial name or title	Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT PLUS)
Methods	RCT – extension of MAPT trial
Participants	Participants of MAPT trial
Interventions	Follow-up 2 year extension of participants in MAPT, after completion of MAPT interventions
Outcomes	Primary: cognitive and functional status (Grober and Buschke test) Secondary: markers of cerebral atrophy, cost-effectiveness
Starting date	Registered on trials registry: 30 December 2011 Trial start date: December 2011 Estimated trial completion date: December 2018
Contact information	Bruno Vellas (PI), University Hospital, Toulouse, vellas.b@chu-toulouse.fr
Notes	NCT01513252 Bruno Vellas written to in 2016- no response Checked for updates and publications, none found, 2 August 2019

MTG 2018

Trial name or title	Improving metabolic health in patients with diastolic dysfunction (MTG)
Methods	RCT 2 x 2
Participants	People aged 40-60 years, who were previously sedentary obese and middle aged, at high risk for development of HF
Interventions	Each for 12 months: Intervention: 2 g/d omega-3 fish oil Control: 1 g/d olive oil Both with yoga or high-intensity exercise (2 x 2)
Outcomes	Primary: myocardial TG Secondary: cardiorespiratory fitness, arterial stiffness, diastolic function and left ventricular mass and volume
Starting date	Registered on trials registry: 27 February 2018 Trial start date: 1 June 2015 Estimated trial completion date: 1 June 2019
Contact information	Benjamin D Levine, University of Texas Southwestern Medical Center

MTG 2018 (Continued)

Notes NCT03448185
Added 2 August 2019

NCT00010868

Trial name or title	Omega 3 fatty acids in bipolar disorder prophylaxis
Methods	RCT
Participants	People aged 18-65 with bipolar disorder
Interventions	Each for 12 months: Arm 1: omega-3 Arm 2: placebo
Outcomes	Prophylactic efficacy
Starting date	Trial Registration entry: 2 February 2001 Trial start date: July 2000 Estimated trial completion: July 2004
Contact information	Andrew Stoll, Mclean Hospital
Notes	NCT00010868 The PI, Andrew Stoll, appears to have been struck off the medical register in Massachusetts in 2011 (Commonwealth of Massachusetts Board of Registration in Medicine, Adjudicatory Case number 2011-026) so it has not been possible to contact him and no publication of results has been found. Checked for updates and publications, none found, 2 August 2019

NCT00309439

Trial name or title	Studies of serum PSA (prostate specific antigen) to help resolve the current implication of alpha-linolenic acid and prostate cancer
Methods	RCT
Participants	Adults 18-77 years
Interventions	Arm 1: ALA-rich diet Arm 2: control (not detailed)
Outcomes	Prostate specific antigen, AF
Starting date	Registered on trials registry: 29 March 2006 Trial start date: unclear

NCT00309439 (Continued)

Estimated trial completion date: unclear

Contact information	David Jenkins, University of Toronto, nutritionproject@smh.toronto.on.ca
Notes	NCT00309439 David Jenkins contacted in 2016: confirmed not published in full and data incomplete Checked for updates and publications, none found, 2 August 2019

NCT02211560

Trial name or title	Investigating a phosphatidylserine based dietary approach for the management of mild cognitive impairment
Methods	RCT
Participants	People with mild cognitive impairment (MCI) aged 65-85 years
Interventions	Each for 24 months: Arm 1: phosphatidylserine omega-3 (DHA-enriched) Arm 2: placebo cellulose capsules
Outcomes	Primary: selective reminding test (SRT) Secondary: MMSE, neurological battery test (NBT), dementia (DSM-4 criteria), mini sleep questionnaire (MSQ), Hamilton Anxiety rating scale (HAM-A), safety and adverse events
Starting date	Registered on trials registry: 6 August 2014 Trial start date: September 2014 Estimated trial completion date: September 2019
Contact information	Nadia Niemerzyanski, nadiaN@enzymotec.com; Yael Richter, yaelr@enzymotec.com
Notes	NCT02211560 Checked for updates and publications, 2 August 2019. Trial terminated early due to poor recruitment, 97 recruited, no results posted or published.

NCT02295059

Trial name or title	Omega 3 fatty acids and ERPR(-)HER2(±) breast cancer prevention
Methods	RCT
Participants	Women at risk for recurrent breast cancer- with prior diagnosis of stage 0-III breast cancer and completion of surgery, chemotherapy or trastuzumab or radiation therapy
Interventions	Each for 12 months: Arm 1: omega-3 high-dose capsules (5 g/d EPA + DHA)

NCT02295059 (Continued)

	Arm 2: omega-3 low-dose capsules (0.9 g/d EPA + DHA)
Outcomes	Primary: breast adipose tissue metabolites Secondary: cytomorphology or cell proliferation of mammary epithelial cells, DNA promoter methylation and pro-inflammatory gene expression in mammary epithelial and adipose tissue
Starting date	Registered on trials registry: 14 October 2014 Trial start date: August 2014 Estimated trial completion date: January 2020
Contact information	Anitra Sumbry, anitra.sumbry@osumc.edu; Lisa Yee (PI), Ohio State University
Notes	NCT02295059 Checked for updates and publications, none found, 2 August 2019

NCT02719327

Trial name or title	Impact of icosapent ethyl on Alzheimer's disease (AD) biomarkers in preclinical adults
Methods	RCT
Participants	Cognitively healthy adults aged 50-70 years whose parents had AD
Interventions	Each for 18 months: Arm 1: icosapent ethyl EPA (Vascepa) 4 g/d gel capsule Arm 2: matching gel capsule placebo
Outcomes	Primary: cerebral blood flow by MRI Secondary: cerebrospinal fluid biomarkers of AD, cognitive performance (Preclinical Alzheimer's Cognitive Composite, PACC)
Starting date	Registered on trials registry: 21 March 2016 Trial start date: December 2016 Estimated trial completion date: November 2021
Contact information	Cynthia Carlsson, cynthia.carlsson@va.gov; Elena Beckman, elena.beckman@va.gov
Notes	NCT02719327 Checked for updates and publications, none found, 2 August 2019

NCT03784963

Trial name or title	Efficacy of omega-3 fatty acid therapy in preventing gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices (CF-LVAD)
Methods	RCT

NCT03784963 (Continued)

Participants	Adults (aged ≥ 18 years) with CF-LVAD or scheduled to receive a CF-LVAD implant
Interventions	Each for 1 year: Intervention: 4 g/d Nature Made Ultra Omega-3 fish oil Control: no fish oil
Outcomes	Primary: markers of angiogenesis including angiopoietin-1, angiopoietin-2, VEGF, TNF alpha and CRP Secondary: GI bleeding, changes in the microbiome
Starting date	Registered on trials registry: 24 December 2018 Trial start date: 23 January 2019 Estimated trial completion date: 1 January 2021
Contact information	Nir Uriel, nuriel@medicine.bsd.uchicago.edu
Notes	NCT03784963 Added 2 August 2019

NCT03806426

Trial name or title	Effect of EPA-FFA on polypectomy in familial adenomatous polyposis
Methods	RCT
Participants	Adults (18-65 years) with familial adenomatous polyposis
Interventions	Each for 2 years: Intervention: Eicosapentaenoic acid free fatty acid (EPA-FFA), 500 mg capsule, 2 x 500 mg capsules to be taken twice daily for 24 months Control: placebo, 500 mg capsule, 2 x 500 mg capsules to be taken twice daily for 24 months
Outcomes	Primary: total number of polypectomies and numbers of proctectomies at 24 months Secondary: change in polyp number and change in InSIGHT Polyposis Staging System (IPSS) score
Starting date	Registered on trials registry: 16 January 2019 Trial start date: 5 December 2018 Estimated trial completion date: 1 March 2021
Contact information	Justin Slagel, CEO, info@slapharma.com

NCT03806426 (Continued)

Notes	NCT03806426
	First added 2 August 2019

OMEMI 2014

Trial name or title	Omega-3 fatty acids in elderly patients with myocardial infarction study (OMEMI)
Methods	RCT
Participants	Elderly people (70-82 years) with acute MI
Interventions	Each for 24 months: Arm 1: omega-3 capsules, 3/d (Pikazol, total of 1.8 g/d EPA + DHA) and standard therapy Arm 2: corn oil placebo, 3/d and standard therapy
Outcomes	Primary: composite of total mortality, first non-fatal recurring acute MI, stroke and revascularisation Secondary: new onset AF, adipose tissue, serum FAs, markers of endothelial function, inflammation, coagulation and fibrinolytic activity, genes associated with atherothrombosis
Starting date	Registered on trials registry: 16 April 2013 Trial start date: November 2012 Estimated trial completion date: November 2019
Contact information	Svein Solheim, Center for Clinical Heart Research, Oslo University Hospital, arnljot.tveit@vestreviken.no
Notes	NCT01841944 Checked for updates and publications, none found, 2 August 2019

POSEIDON 2018

Trial name or title	Pilot study of omega-3 and vitamin D in high-dose in type I diabetic patients (POSEIDON)
Methods	RCT
Participants	Adults with new or established type 1 diabetes
Interventions	For 1 year Intervention: omega-3 fats and vitamin D Control: vitamin D
Outcomes	Primary: Mixed Meal Tolerance Test (MMTT) Secondary: haemoglobin A1c, insulin requirements, adverse events
Starting date	Registered on trials registry: 23 January 2018

POSEIDON 2018 (Continued)

Trial start date: 23 July 2018

Estimated trial completion date: December 2023

Contact information	David Baidal, dbaidal@med.miami.edu
Notes	NCT03406897 Added 2 August 2019

Shinto 2015

Trial name or title	N-3 PUFA for vascular cognitive aging
Methods	RCT
Participants	Older adults (≥ 80 years) at high risk for cognitive decline and dementia of Alzheimer's type
Interventions	Each for 3 years: Arm 1: omega-3 fish oil (1.65 g/d EPA + DHA) Arm 2: soybean oil placebo (1.65 g/d)
Outcomes	Primary: total cerebral white matter volume Secondary: biomarkers of endothelial health, total brain atrophy, medial temporal lobe atrophy, ventricular expansion, trail making test part B, digit symbol WAIS-R, cerebral blood flow, fractional anisotropy within frontal gyri
Starting date	Registered on trials registry: 24 September 2013 Trial start date: May 2014 Estimated trial completion date: August 2019
Contact information	Alena Borgatti, borgatti@ohsu.edu ; James Dursch, dursch@ohsu.edu ; Gene Bowman and Lynne Shinto (PIs), Oregon Health and Science University
Notes	NCT01953705 Checked for updates and publications, none found, 2 August 2019

STRENGTH 2015

Trial name or title	A long-term outcomes study to assess statin residual risk reduction with Epanova in high CVD risk patients with hypertriglyceridemia (STRENGTH)
Methods	RCT
Participants	Adults with hypertriglyceridaemia and low HDL and high risk for CVD
Interventions	Each for 3-5 years Arm 1: omega-3 carboxylic acid capsule (Epanova, not < 800 mg/g) and statin (once daily)

STRENGTH 2015 (Continued)

	Arm 2: corn oil placebo capsule and statin (once daily)
Outcomes	<p>Primary: time to 1st occurrence of any component of the composite MACE (CVD death, nonfatal MI, nonfatal stroke, emergent/elective coronary revascularisation, hospitalisation for unstable angina)</p> <p>Secondary: composite measure of CVD events that include the first occurrence of CVD death, non-fatal MI and non-fatal stroke; composite measure of coronary events that include the first occurrence of cardiac death; first occurrence of individual components of MACE; time to CVD death. Other measures include: all-cause mortality, new AF, thrombotic events, heart failure events</p>
Starting date	<p>Trial Registration entry: 2 April 2014</p> <p>Trial start date: October 2014</p> <p>Estimated trial completion: September 2020</p>
Contact information	AstraZeneca Clinical Study Information Centre, information.center@astrazeneca.com. Pls Steven Nissen (Cleveland Clinic), Michael Lincoff (Cleveland Clinic) Stephen Nicholls (Adelaide Clinical Research)
Notes	<p>NCT02104817</p> <p>EudraCT: 2014-001069-28</p> <p>Checked for updates and publications, none found, 2 August 2019</p>

SUPERIOR SVG 2010

Trial name or title	Surgical and pharmacological novel interventions to improve overall results of saphenous vein graft patency in coronary artery bypass grafting surgery (SUPERIOR SVG)
Methods	RCT
Participants	Adults having CABG using SVG
Interventions	<p>Each for 12 months:</p> <p>Arm 1: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and SVG conventionally harvested</p> <p>Arm 2: placebo and SVG conventionally harvested</p> <p>Arm 3: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and SVG no-touch harvest</p> <p>Arm 4: placebo and SVG no-touch harvest</p>
Outcomes	<p>Primary: proportion of grafts occluded</p> <p>Secondary: significant stenosis, adverse SVG harvesting events, composite outcome of all-cause mortality, non-fatal MI and repeat revascularisation</p>
Starting date	<p>Registered on trials registry: 12 January 2010</p> <p>Trial start date: July 2011</p> <p>Estimated trial completion date: December 2016</p>
Contact information	Stephen Fries, Sunnybrook Health Sciences Centre (PI)

SUPERIOR SVG 2010 (Continued)

Notes

NCT01047449

Checked for updates and publications, 2 August 2019. Results of the surgical intervention found (Feb 2019), but no results yet for the omega-3 intervention.

UMIN000012825

Trial name or title	Effect of PUFA on vascular healing process in hypercholesterolemic patients with ACS
Methods	RCT
Participants	Hypercholesterolemic patients (20-80 years) with acute coronary syndrome who have received successful OCT-guided PCI
Interventions	Each for 12 months: Arm 1: intensive lipid-lowering therapy with both statin and EPA + DHA Arm 2: intensive lipid-lowering therapy with both statin and EPA Arm 3: standard lipid-lowering therapy with statins
Outcomes	Primary: changes in OCT parameter Secondary: lipids, serum plasma profile, inflammatory parameters, adverse CVD events
Starting date	Registered on trials registry: 1 February 2014 Trial start date: 1 February 2014 Estimated trial completion date: not stated Date of final participant recruitment: 30 June 2019
Contact information	Shiro Uemura (PI), Nara Medical University, Japan, suemura@naramed-u.ac.jp
Notes	UMIN000012825 Checked for updates and publications, none found, 2 August 2019

ACS: acute coronary syndrome; **AD:** Alzheimer's disease; **AF:** atrial fibrillation; **BMI:** body mass index; **BP:** blood pressure; **CABG:** coronary artery bypass graft; **CETP:** cholesteryl ester transfer protein; **CHD:** coronary heart disease; **CRP:** C-reactive protein; **CVD:** cardiovascular disease; **DHA:** docosahexaenoic acid; **EPA:** eicosapentaenoic acid; **FA:** fatty acid(s); **FCSRT:** Free and Cued Selective Reminding Test; **GAD-7:** generalised anxiety disorder 7; **GI:** gastrointestinal; **HbA1c:** glycated haemoglobin; **HDL:** high-density lipoprotein; **IFG:** impaired fasting glucose; **IGT:** impaired glucose tolerance; **IL:** interleukin; **LDL:** low-density lipoprotein; **MACE:** major adverse coronary event; **MI:** myocardial infarction; **MMSE:** Mini-Mental State Examination; **MRI:** magnetic resonance imaging; **OCT:** optical coherence tomography; **OSDI:** ocular surface disease index; **PCI:** percutaneous coronary intervention; **PHQ-9:** patient health questionnaire 9; **PI:** principal investigator; **PSA:** prostate specific antigen; **PSQI:** Pittsburgh Sleep Quality Index; **PUFA:** polyunsaturated fatty acids; **QoL:** quality of life; **RCT:** randomised controlled trial; **SFA:** saturated fatty acids; **SVG:** saphenous vein graft; **TG:** serum triglycerides; **TNF:** tumour necrosis factor; **VEGF:** vascular endothelial growth factor; **WAIS-R:** Wechsler Adult Intelligence Scale - revised

DATA AND ANALYSES

Comparison 1. High vs low LCn3 omega-3 fats (primary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All-cause mortality (overall) - LCn3	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
2 All-cause mortality -LCn3 - sensitivity analysis (SA) fixed-effect	45	143693	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.93, 1.00]
3 All-cause mortality - LCn3 - SA by summary risk of bias	45		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Low summary risk of bias	19	75741	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.95, 1.04]
3.2 Moderate or high summary risk of bias	26	67952	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.87, 1.01]
4 All-cause mortality - LCn3 - SA by compliance and study size	44		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 SA - low risk of compliance bias	22	50929	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
4.2 SA - 100+ randomised	41	143437	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
5 All-cause mortality - LCn3 - subgroup by dose	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
5.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 LCn3 > 150 ≤ 250 mg/d	1	407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.27, 2.18]
5.3 LCn3 > 250 ≤ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.56, 0.92]
5.4 LCn3 > 400 ≤ 2400 mg/d	31	129505	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.03]
5.5 LCn3 > 2.4 ≤ 4.4 g/d	10	11466	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.77, 1.04]
5.6 LCn3 > 4.4 g/d	2	282	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.03, 3.08]
6 All-cause mortality - LCn3 - subgroup by replacement	45		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 LCn3 replacing SFA	6	3988	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.56, 0.91]
6.2 LCn3 replacing MUFA	18	88062	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
6.3 LCn3 replacing N-6	8	2601	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.51, 1.10]
6.4 LCn3 replacing CHO	1	281	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.05, 5.65]
6.5 LCn3 replacing nil/low n-3 placebo	11	47844	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.86, 1.08]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.6 LCn3 replacement unclear	5	4000	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.77, 1.43]
7 All-cause mortality - LCn3 - subgroup by intervention type	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
7.1 Dietary advice	3	5554	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.60, 1.35]
7.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.84, 1.24]
7.3 Supplements (capsule)	39	132895	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.93, 1.00]
7.4 Any combination	1	205	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.11, 3.79]
8 All-cause mortality - LCn3 - subgroup by duration	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
8.1 Medium duration 1 to < 2 years in study	20	10981	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.82, 1.29]
8.2 Medium-long duration: 2 to < 4 years in study	15	29519	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.86, 0.96]
8.3 Long duration: ≥ 4 years in study	10	103193	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.96, 1.05]
9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
9.1 Primary CVD prevention	21	83797	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.95, 1.05]
9.2 Secondary CVD prevention	23	51736	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
9.3 Mixed primary & secondary CVD prevention	1	8160	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.75, 1.03]
10 All-cause mortality - LCn3 - subgroup by statin use	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
10.1 LCn3 ≥ 50% of control group on statins	11	66834	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.92, 1.04]
10.2 LCn3 < 50% of control group on statins	29	73719	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.91, 1.03]
10.3 LCn3 - use of statins unclear	5	3140	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.58, 1.63]
11 All-cause mortality - LCn3 - subgroup by baseline TG	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
11.1 Baseline TG not restricted	43	135413	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.94, 1.01]
11.2 Baseline TG raised	2	8280	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.54, 1.36]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12 All-cause mortality - LCn3 - subgroup by baseline DM	45	143693	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
12.1 Normal diabetes risk	40	94761	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.92, 1.04]
12.2 Diabetes risk factors at baseline	2	12787	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.90, 1.06]
12.3 Diabetes at baseline	3	36145	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.89, 1.03]
13 Cardiovascular mortality (overall) - LCn3	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
14 CVD mortality - LCn3 - SA fixed-effect	29	117837	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.88, 0.97]
15 CVD mortality - LCn3 - SA by summary risk of bias	29		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
15.1 Low risk of bias	12	71019	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
15.2 Moderate/high risk of bias	17	46818	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.80, 1.02]
16 CVD mortality - LCn3 - SA by compliance and study size	28		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
16.1 SA - low risk of compliance bias	15	47829	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.82, 1.04]
16.2 SA - 100+ randomised	24	91710	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.85, 1.00]
17 CVD mortality - LCn3 - subgroup by dose	30	117938	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
17.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 LCn3 > 150 ≤ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 LCn3 > 250 ≤ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.53, 0.91]
17.4 LCn3 > 400 ≤ 2400 mg/d	21	105477	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
17.5 LCn3 > 2.4 ≤ 4.4 g/d	6	10146	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.70, 1.01]
17.6 LCn3 > 4.4 g/d	2	282	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.03, 3.08]
18 CVD mortality - LCn3 - subgroup by replacement	30		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
18.1 N-3 replacing SFA	3	2537	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.53, 0.90]
18.2 N-3 replacing MUFA	15	86128	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.00]
18.3 N-3 replacing N-6	4	1435	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.41, 1.19]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
18.4 N-3 replacing carbohydrates/sugars	1	281	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.12, 4.07]
18.5 N-3 replacing nil/low n-3 placebo	8	27252	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.74, 0.93]
18.6 Replacement unclear	3	3388	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.13, 2.88]
19 CVD mortality - LCn3 - subgroup by intervention type	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
19.1 Dietary advice	2	5147	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.52, 1.71]
19.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.72, 1.32]
19.3 Supplements (capsule)	25	107651	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.87, 0.97]
19.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
20 CVD mortality - LCn3 - subgroup by duration	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
20.1 Medium duration 1 to < 2 years in study	11	6712	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.64, 1.37]
20.2 Medium-long duration: 2 to < 4 years in study	10	26736	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.82, 0.95]
20.3 Long duration: ≥ 4 years in study	8	84389	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.86, 1.07]
21 CVD mortality - LCn3 - subgroup by primary or secondary prevention	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
21.1 Primary prevention	10	59817	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.02]
21.2 Secondary prevention	18	49841	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.83, 1.06]
21.3 Mixed primary & secondary prevention	1	8179	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.67, 0.99]
22 CVD mortality - LCn3 - subgroup by statin uses	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
22.1 LCn3 - ≥ 50% of control group on statins	8	47653	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.82, 1.04]
22.2 LCn3 - < 50% of control group on statins	18	69296	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.03]
22.3 LCn3- Use of statins unclear	3	888	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.13, 2.05]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
23 CVD mortality - LCn3 - subgroup by baseline TG	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
23.1 Baseline TG not restricted	27	109538	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.87, 1.01]
23.2 Baseline TG raised	2	8299	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.67, 0.99]
24 CVD mortality - LCn3 - subgroup by baseline DM	29	117837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.99]
24.1 Normal diabetes risk	24	68856	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.03]
24.2 Diabetes risk factors at baseline	2	12817	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.88, 1.10]
24.3 Diabetes at baseline	3	36164	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.75, 1.01]
25 Cardiovascular events (overall) - LCn3	43	140482	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.92, 1.01]
26 CVD events - LCn3 - SA fixed effect	43	140482	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.94, 0.99]
27 CVD events - LCn3 - SA by summary risk of bias	43		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
27.1 Low summary risk of bias	16	73000	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.95, 1.02]
27.2 Moderate or high summary risk of bias	27	67482	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.02]
28 CVD events - LCn3 - SA by compliance and study size	42		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
28.1 SA - low risk of compliance bias	18	47699	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.81, 1.06]
28.2 SA - 100+ randomised	38	140162	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.92, 1.02]
29 CVD events - LCn3 - subgroup by dose	43		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
29.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29.2 LCn3 > 150 ≤ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29.3 LCn3 > 250 ≤ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.88, 1.05]
29.4 LCn3 > 400 ≤ 2400 mg/d	31	127458	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
29.5 LCn3 > 2.4 ≤ 4.4 g/d	9	10644	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.73, 1.14]
29.6 LCn3 > 4.4 g/d	3	422	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.65, 1.81]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
30 CVD events - LCn3 - subgroup by replacement	43		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
30.1 N-3 replacing SFA	4	2888	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.04]
30.2 N-3 replacing MUFA	18	86416	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.94, 1.00]
30.3 N-3 replacing n-6	7	2180	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.86, 1.32]
30.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.12, 3.98]
30.5 N-3 replacing nil/low n-3 placebo	13	48169	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.84, 1.06]
30.6 Replacement unclear	4	3631	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.50, 1.64]
31 CVD events - LCn3 - subgroup by intervention type	43	140482	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.92, 1.01]
31.1 Dietary advice	3	5248	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.86, 1.49]
31.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.89, 1.17]
31.3 Supplements (capsule)	38	130195	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.90, 1.00]
31.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
32 CVD events - LCn3 - subgroup by duration	43	140482	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.92, 1.01]
32.1 Medium duration 1 to < 2 years in study	19	8396	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.69, 1.07]
32.2 Medium-long duration: 2 to < 4 years in study	15	29052	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.95, 1.03]
32.3 Long duration: ≥ 4 years in study	9	103034	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
33 CVD events - LCn3 - subgroup by primary or secondary prevention	43	140482	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.92, 1.01]
33.1 Primary prevention of CVD	19	81391	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.91, 1.02]
33.2 Secondary prevention	23	50912	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.93, 1.05]
33.3 Mixed primary & secondary prevention	1	8179	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.68, 0.85]
34 CVD events - LCn3 - subgroup by statin use	43	140482	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.92, 1.01]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
34.1 LCn3 - ≥ 50% of control group on statins	11	66333	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.01]
34.2 LCn3 - < 50% of control group on statins	25	71031	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.04]
34.3 LCn3 - use of statins unclear	7	3118	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.51, 1.43]
35 CVD events - LCn3 - subgroup by baseline TG	43	140478	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.91, 1.00]
35.1 Baseline TG not restricted	41	135344	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.92, 1.01]
35.2 Baseline TG raised	3	5134	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.67, 0.90]
36 CVD events - LCn3 - subgroup by baseline diabetes	43	140479	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.91, 1.00]
36.1 Normal diabetes risk	37	91281	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.04]
36.2 Diabetes risk factors at baseline	4	16426	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.72, 1.07]
36.3 Diabetes at baseline	3	32772	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.76, 1.05]
37 Coronary heart disease mortality (overall) - LCn3	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
38 CHD mortality - LCn3 - SA fixed effect	24	127378	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.86, 0.98]
39 CHD mortality - LCn3 - SA by summary risk of bias	24		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
39.1 Low summary risk of bias	10	70259	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.76, 1.04]
39.2 Moderate or high summary risk of bias	14	57119	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.06]
40 CHD mortality - LCn3 - SA by compliance and study size	23		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
40.1 SA - low risk of compliance bias	10	38809	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.67, 1.03]
40.2 SA - 100+ randomised	22	114762	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.77, 0.98]
41 CHD mortality - LCn3 - SA omitting cardiac death	18	106676	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.73, 0.90]
41.1 Low risk of bias	7	53373	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.68, 0.97]
41.2 Moderate/high risk of bias	11	53303	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.71, 0.94]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
42 CHD mortality - LCn3 - subgroup by dose	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
42.1 LCn3 ≤ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
42.2 LCn3 > 250 ≤ 400 mg/d	2	5147	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.50, 1.74]
42.3 LCn3 > 400 ≤ 2400 mg/d	18	121329	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.83, 0.99]
42.4 LCn3 > 2.4 ≤ 4.4g/d	3	822	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.49, 1.78]
42.5 LCn3 > 4.4g/d	1	80	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.01, 7.57]
43 CHD mortality - LCn3 - subgroup by replacement	23		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
43.1 N-3 replacing SFA	3	2514	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.51, 0.88]
43.2 N-3 replacing MUFA	13	85492	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
43.3 N-3 replacing n-6	3	1409	Risk Ratio (M-H, Random, 95% CI)	0.60 [0.33, 1.09]
43.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.23]
43.5 N-3 replacing nil/low n-3 placebo	7	37651	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.70, 0.94]
44 CHD mortality - LCn3 - subgroup by intervention type	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
44.1 Dietary advice	2	5147	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.50, 1.74]
44.2 Supplemental foods	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.69, 1.33]
44.3 Supplements (capsule)	21	117394	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.83, 0.98]
44.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
45 CHD mortality - LCn3 - subgroup by duration	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
45.1 Medium duration 1 to < 2 years in study	7	5978	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.58, 1.23]
45.2 Medium-long duration: 2 to < 4 years in study	9	26545	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.77, 0.94]
45.3 Long duration: ≥ 4 years in study	8	94855	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.83, 1.16]
46 CHD mortality - LCn3 - subgroup by primary or secondary prevention	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
46.1 Primary prevention	8	77676	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.75, 1.07]
46.2 secondary prevention	16	49702	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.79, 1.04]
47 CHD mortality - LCn3 - subgroup by statin use	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
47.1 LCn3 - ≥ 50% of control group on statins	7	58041	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.78, 1.09]
47.2 LCn3 - < 50% of control group on statins	16	69079	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.77, 1.03]
47.3 LCn3 - use of statins unclear	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.23]
48 CHD mortality - LCn3 - subgroup by CAD history	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
48.1 Previous CAD	11	29074	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.71, 1.10]
48.2 No previous CAD	13	98304	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.03]
49 CHD mortality - LCn3 - subgroup by baseline TG	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
49.1 Baseline TG not restricted	23	127258	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
49.2 Baseline TG raised	1	120	Risk Ratio (M-H, Random, 95% CI)	0.17 [0.01, 4.05]
50 CHD mortality - LCn3 - subgroup by baseline DM	24	127378	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.81, 1.00]
50.1 Normal diabetes risk	20	86599	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.77, 0.99]
50.2 Diabetes risk factors at baseline	2	12794	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.92, 1.25]
50.3 Diabetes at baseline	2	27985	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.67, 1.25]
51 Coronary heart disease events (overall) - LCn3	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]
52 CHD events - LCn3 - SA fixed effect	32	134116	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.89, 0.96]
53 CHD events - LCn3 - SA by summary risk of bias	32		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
53.1 Low summary risk of bias	14	71578	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.82, 1.05]
53.2 Moderate or high summary risk of bias	18	62538	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.83, 0.97]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
54 CHD events - LCn3 - SA by compliance and study size	31		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
54.1 SA - low risk of compliance bias	14	47497	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.74, 0.95]
54.2 SA - 100+ randomised	29	133899	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.84, 0.95]
55 CHD events - LCn3 - subgroup by dose	32		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
55.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
55.2 LCn3 > 150 ≤ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
55.3 LCn3 > 250 ≤ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.82, 1.04]
55.4 LCn3 > 400 ≤ 2400 mg/d	23	122081	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.87, 0.99]
55.5 LCn3 > 2.4 ≤ 4.4 g/d	6	9655	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.63, 1.22]
55.6 LCn3 > 4.4 g/d	3	422	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.54, 1.85]
56 CHD events - LCn3 - subgroup by replacement	32		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
56.1 N-3 replacing SFA	3	2514	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.16, 1.75]
56.2 N-3 replacing MUFA	17	86305	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.89, 1.02]
56.3 N-3 replacing n-6	4	1549	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.78, 1.53]
56.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.11 [0.01, 2.07]
56.5 N-3 replacing nil/low n-3 placebo	9	46105	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.72, 0.92]
56.6 Replacement unclear	2	445	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.45, 2.17]
57 CHD events - LCn3 - subgroup by intervention type	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]
57.1 Dietary advice	2	2134	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.67, 1.52]
57.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.75, 1.20]
57.3 Supplements (capsule)	28	126943	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.83, 0.98]
57.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58 CHD events - LCn3 - subgroup by duration	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
58.1 Medium duration 1 to < 2 years in study	11	7009	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.64, 1.25]
58.2 Medium-long duration: 2 to < 4 years in study	13	27187	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.90, 0.99]
58.3 Long duration: ≥ 4 years in study	8	99920	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.74, 0.98]
59 CHD events - LCn3 - subgroup by primary or secondary prevention	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]
59.1 Primary prevention of CVD	13	78716	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.75, 1.02]
59.2 Secondary prevention of CVD	18	47221	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.91, 0.99]
59.3 Mixed primary & secondary prevention	1	8179	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.60, 0.82]
60 CHD events - LCn3 - subgroup by statin use	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]
60.1 LCn3 - ≥ 50% of control group on statins	11	66679	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.80, 1.07]
60.2 LCn3 - < 50% of control group on statins	18	66545	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.89, 0.97]
60.3 LCn3 - use of statins unclear	3	892	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.11, 3.83]
61 CHD events - LCn3 subgroup by CAD history	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]
61.1 Previous CAD	13	26409	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.87, 1.02]
61.2 No previous CAD	18	99528	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.00]
61.3 Mixed - some previous CAD	1	8179	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.60, 0.82]
62 CHD events - LCn3 - subgroup by baseline TG	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]
62.1 Baseline TG not restricted	29	125753	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.89, 0.99]
62.2 Baseline TG raised	3	8363	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.60, 0.82]
63 CHD events - LCn3 - subgroup by baseline DM	32	134116	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.85, 0.97]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
63.1 Normal diabetes risk	26	84915	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.88, 0.97]
63.2 Diabetes risk factors at baseline	3	13037	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.45, 1.95]
63.3 Diabetes at baseline	3	36164	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.70, 1.01]
64 Stroke (overall) - LCn3	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
65 Stroke - LCn3 - SA fixed effect	31	138888	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.94, 1.09]
66 Stroke - LCn3 - SA by summary risk of bias	31		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
66.1 Low risk of bias	14	73390	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.90, 1.09]
66.2 Moderate/high risk of bias	17	65498	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.87, 1.26]
67 Stroke - LCn3 - SA by compliance and study size	30		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
67.1 SA - low risk of compliance bias	14	48501	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.19]
67.2 SA - 100+ randomised	29	138761	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.93, 1.12]
68 Stroke - LCn3 - subgroup by stroke type	15		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
68.1 Ischaemic stroke - LCn3	10	69090	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.79, 1.20]
68.2 Haemorrhagic stroke - LCn3	10	70695	Risk Ratio (M-H, Random, 95% CI)	1.23 [0.93, 1.64]
68.3 Transient ischaemic attack (TIA)	6	13211	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.76, 1.60]
69 Stroke - LCn3 - subgroup by dose	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
69.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
69.2 LCn3 > 150 ≤ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
69.3 LCn3 > 250 ≤ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.45 [0.14, 1.44]
69.4 LCn3 > 400 ≤ 2400 mg/d	26	127686	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.96, 1.12]
69.5 LCn3 > 2.4 ≤ 4.4 g/d	2	8789	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.57, 0.94]
69.6 LCn3 > 4.4 g/d	2	380	Risk Ratio (M-H, Random, 95% CI)	6.58 [0.78, 55.16]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
70 Stroke - LCn3 - subgroup by replacement	31		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
70.1 N-3 replacing SFA	3	2514	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.19, 1.50]
70.2 N-3 replacing MUFA	16	86603	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.94, 1.14]
70.3 N-3 replacing n-6	3	1179	Risk Ratio (M-H, Random, 95% CI)	2.08 [0.18, 24.31]
70.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.23]
70.5 N-3 replacing nil/low n-3 placebo	9	47398	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.17]
70.6 Replacement unclear	2	3450	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.61, 2.43]
71 Stroke - LCn3 - subgroup by intervention type	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
71.1 Dietary advice	3	5248	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.42, 2.05]
71.2 Supplemental foods	1	4837	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.47, 2.62]
71.3 Supplements (capsule)	27	128803	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.93, 1.13]
71.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
72 Stroke - LCn3 - subgroup by duration	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
72.1 Medium duration 1 to < 2 years in study	11	7467	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.86, 2.12]
72.2 Medium-long duration: 2 to < 4 years in study	11	28387	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.93, 1.41]
72.3 Long duration: ≥ 4 years in study	9	103034	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.89, 1.08]
73 Stroke - LCn3 - subgroup by primary or secondary prevention	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
73.1 Primary prevention of CVD	11	80683	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.90, 1.07]
73.2 Secondary prevention of CVD	19	50026	Risk Ratio (M-H, Random, 95% CI)	1.21 [1.05, 1.40]
73.3 Mixed primary & secondary prevention	1	8179	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.57, 0.95]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
74 Stroke - LCn3 - subgroup by statin use	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
74.1 LCn3 - ≥ 50% of control group on statins	10	66621	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.84, 1.10]
74.2 LCn3 - < 50% of control group on statins	18	70870	Risk Ratio (M-H, Random, 95% CI)	1.14 [1.01, 1.29]
74.3 LCn3 - use of statins unclear	3	1397	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.38, 2.34]
75 Stroke - LCn3 - subgroup by baseline TG	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
75.1 Baseline TG not restricted	29	130373	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.96, 1.12]
75.2 Baseline TG raised	2	8515	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.25, 4.00]
76 Stroke - LCn3 - subgroup by baseline DM	31	138888	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.94, 1.12]
76.1 Normal diabetes risk	25	89594	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.98, 1.22]
76.2 Diabetes risk factors at baseline	3	13130	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.80, 1.08]
76.3 Diabetes at baseline	3	36164	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.73, 1.30]
77 Arrhythmia (overall) - LCn3	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
78 Arrhythmia - LCn3 - SA fixed effects	30	77990	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.98, 1.09]
79 Arrhythmia- LCn3 - SA by summary risk of bias	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
79.1 Low summary risk of bias	12	41816	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.99, 1.20]
79.2 Moderate to high risk of bias	18	36174	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.04]
80 Arrhythmia- LCn3 - SA by compliance and study size	29		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
80.1 SA - low risk of compliance bias	12	21628	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.88, 1.12]
80.2 SA - 100+ randomised	29	77943	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.91, 1.06]
81 Arrhythmia - LCn3 - subgroup by new or recurrent	30		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
81.1 New arrhythmia	19	74111	Risk Ratio (M-H, Random, 95% CI)	1.09 [1.01, 1.17]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
81.2 Recurrent arrhythmia	12	4425	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.03]
82 Arrhythmia - LCn3 - subgroup by fatality	9		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
82.1 Fatal arrhythmias - LCn3	2	12938	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.95, 1.31]
82.2 Non-fatal arrhythmias - LCn3	8	2079	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.57, 0.96]
83 Arrhythmia - LCn3 - subgroup by dose	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
83.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
83.2 LCn3 > 150 ≤ 250 mg/d	1	407	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.90, 1.12]
83.3 LCn3 > 250 ≤ 400 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
83.4 LCn3 > 400 ≤ 2400 mg/d	20	67015	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.90, 1.08]
83.5 LCn3 > 2.4 ≤ 4.4 g/d	5	9790	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.58, 1.32]
83.6 LCn3 > 4.4 g/d	2	342	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.32, 3.83]
83.7 Unclear LCn3 dose	2	436	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.76, 1.28]
84 Arrhythmia - LCn3 - subgroup by replacement	30		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
84.1 N-3 replacing SFA	2	632	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.10, 5.67]
84.2 N-3 replacing MUFA	15	58652	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.91, 1.11]
84.3 N-3 replacing n-6	4	1302	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.86, 1.16]
84.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.04, 3.21]
84.5 N-3 replacing nil/low n-3 placebo	5	16569	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.70, 1.30]
84.6 Replacement unclear	5	1381	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.91, 1.08]
85 Arrhythmia - LCn3 - subgroup by intervention type	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
85.1 Dietary advice	2	508	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.44, 1.72]
85.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.67, 1.26]
85.3 Supplements (capsule)	26	72443	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.91, 1.08]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
85.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
86 Arrhythmia - LCn3 - subgroup by duration	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
86.1 Medium duration 1 to < 2 years in study	18	9088	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.84, 1.04]
86.2 Medium-long duration: 2 to < 4 years in study	7	17701	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.84, 1.10]
86.3 Long duration: ≥ 4 years in study	5	51201	Risk Ratio (M-H, Random, 95% CI)	1.13 [1.03, 1.25]
87 Arrhythmia - LCn3 - subgroup by primary or secondary prevention³	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
87.1 Primary prevention	10	30580	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.98, 1.22]
87.2 Secondary prevention	19	39231	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
87.3 Mixed primary & secondary prevention	1	8179	Risk Ratio (M-H, Random, 95% CI)	1.22 [0.99, 1.50]
88 Arrhythmia - LCn3 - subgroup by statin use	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
88.1 LCn3 - ≥ 50% of control group on statins	7	47438	Risk Ratio (M-H, Random, 95% CI)	1.10 [1.00, 1.21]
88.2 LCn3 - < 50% of control group on statins	19	29467	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.85, 1.04]
88.3 LCn3 - use of statins unclear	4	1085	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.18]
89 Arrhythmia - LCn3 - subgroup by baseline TG	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
89.1 Baseline TG not restricted	28	69475	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
89.2 Baseline TG raised	2	8515	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.99, 1.50]
90 Arrhythmia - LCn3 - subgroup by baseline DM	30	77990	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
90.1 Normal diabetes risk	24	28696	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
90.2 Diabetes risk factors at baseline	3	13130	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.93, 1.29]
90.3 Diabetes at baseline	3	36164	Risk Ratio (M-H, Random, 95% CI)	1.16 [1.02, 1.31]


**Analysis 1.1. Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 1 All-cause mortality (overall) - LCn3.**







Analysis 1.2. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 2 All-cause mortality -LCn3 - sensitivity analysis (SA) fixed-effect.







Analysis 1.3. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 3 All-cause mortality - LCn3 - SA by summary risk of bias.







Analysis 1.4. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 4 All-cause mortality - LCn3 - SA by compliance and study size.










Analysis 1.5. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 5 All-cause mortality - LCn3 - subgroup by dose.










Analysis 1.6. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 6 All-cause mortality - LCn3 - subgroup by replacement.







Analysis 1.7. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 7 All-cause mortality - LCn3 - subgroup by intervention type.







Analysis 1.8. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 8 All-cause mortality - LCn3 - subgroup by duration.







Analysis 1.9. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention.







Analysis 1.10. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 10 All-cause mortality - LCn3 - subgroup by statin use.







Analysis 1.11. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 11 All-cause mortality - LCn3 - subgroup by baseline TG.






Analysis 1.12. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 12 All-cause mortality - LCn3 - subgroup by baseline DM.







Analysis 1.13. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 13 Cardiovascular mortality (overall) - LCn3.





Analysis 1.14. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 14 CVD mortality - LCn3 - SA fixed-effect.







Analysis 1.15. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 15 CVD mortality - LCn3 - SA by summary risk of bias.







Analysis 1.16. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 16 CVD mortality - LCn3 - SA by compliance and study size.







Analysis 1.17. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 17 CVD mortality - LCn3 - subgroup by dose.










Analysis 1.18. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 18 CVD mortality - LCn3 - subgroup by replacement.







Analysis 1.19. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 19 CVD mortality - LCn3 - subgroup by intervention type.










Analysis 1.20. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 20 CVD mortality - LCn3 - subgroup by duration.







Analysis 1.21. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 21 CVD mortality - LCn3 - subgroup by primary or secondary prevention.







Analysis 1.22. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 22 CVD mortality - LCn3 - subgroup by statin uses.







Analysis 1.23. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 23 CVD mortality - LCn3 - subgroup by baseline TG.






Analysis 1.24. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 24 CVD mortality - LCn3 - subgroup by baseline DM.







Analysis 1.25. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 25 Cardiovascular events (overall) - LCn3.





Analysis 1.26. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 26 CVD events - LCn3 - SA fixed effect.







Analysis 1.27. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 27 CVD events - LCn3 - SA by summary risk of bias.







Analysis 1.28. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 28 CVD events - LCn3 - SA by compliance and study size.







Analysis 1.29. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 29 CVD events - LCn3 - subgroup by dose.







Analysis 1.30. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 30 CVD events - LCn3 - subgroup by replacement.










Analysis 1.31. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 31 CVD events - LCn3 - subgroup by intervention type.







Analysis 1.32. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 32 CVD events - LCn3 - subgroup by duration.







Analysis 1.33. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 33 CVD events - LCn3 - subgroup by primary or secondary prevention.







Analysis 1.34. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 34 CVD events - LCn3 - subgroup by statin use.







Analysis 1.35. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 35 CVD events - LCn3 - subgroup by baseline TG.







Analysis 1.36. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 36 CVD events - LCn3 - subgroup by baseline diabetes.









Analysis 1.37. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 37 Coronary heart disease mortality (overall) - LCn3.




Analysis 1.38. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 38 CHD mortality - LCn3 - SA fixed effect.





Analysis 1.39. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 39 CHD mortality - LCn3 - SA by summary risk of bias.







Analysis 1.40. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 40 CHD mortality - LCn3 - SA by compliance and study size.







Analysis 1.41. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 41 CHD mortality - LCn3 - SA omitting cardiac death.







Analysis 1.42. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 42 CHD mortality - LCn3 - subgroup by dose.







Analysis 1.43. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 43 CHD mortality - LCn3 - subgroup by replacement.







Analysis 1.44. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 44 CHD mortality - LCn3 - subgroup by intervention type.







Analysis 1.45. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 45 CHD mortality - LCn3 - subgroup by duration







Analysis 1.46. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 46 CHD mortality - LCn3 - subgroup by primary or secondary prevention.







Analysis 1.47. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 47 CHD mortality - LCn3 - subgroup by statin use.







Analysis 1.48. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 48 CHD mortality - LCn3 - subgroup by CAD history.







Analysis 1.49. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 49 CHD mortality - LCn3 - subgroup by baseline TG.







Analysis 1.50. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 50 CHD mortality - LCn3 - subgroup by baseline DM.







Analysis 1.51. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 51 Coronary heart disease events (overall) - LCn3.







Analysis 1.52. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 52 CHD events - LCn3 - SA fixed effect.







Analysis 1.53. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 53 CHD events - LCn3 - SA by summary risk of bias.







Analysis 1.54. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 54 CHD events - LCn3 - SA by compliance and study size.







Analysis 1.55. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 55 CHD events - LCn3 - subgroup by dose.







Analysis 1.56. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 56 CHD events - LCn3 - subgroup by replacement.







Analysis 1.57. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 57 CHD events - LCn3 - subgroup by intervention type.







Analysis 1.58. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 58 CHD events - LCn3 - subgroup by duration.







Analysis 1.59. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 59 CHD events - LCn3 - subgroup by primary or secondary prevention.






Analysis 1.60. Comparison 1 High vs low LCN3 omega-3 fats (primary outcomes), Outcome 60 CHD events - LCN3 - subgroup by statin use.







Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for subgroup differences: $\chi^2=0.16$, $df=1$ ($P=0.93$), $I^2=0\%$					
Favours higher omega 3 0.1 0.2 0.5 1 2 5 10 Favours lower omega 3					


Analysis 1.61. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 61 CHD events - LCn3 subgroup by CAD history.







Analysis 1.62. Comparison 1 High vs low LCN3 omega-3 fats (primary outcomes), Outcome 62 CHD events - LCN3 - subgroup by baseline TG.







Analysis 1.63. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 63 CHD events - LCn3 - subgroup by baseline DM.







Analysis 1.64. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 64 Stroke (overall) - LCn3.







Analysis 1.65. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 65 Stroke - LCn3 - SA fixed effect.







Analysis 1.66. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 66 Stroke - LCn3 - SA by summary risk of bias.







Analysis 1.67. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 67 Stroke - LCn3 - SA by compliance and study size.







Analysis 1.68. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 68 Stroke - LCn3 - subgroup by stroke type.







Analysis 1.69. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 69 Stroke - LCn3 - subgroup by dose.










Analysis 1.70. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 70 Stroke - LCn3 - subgroup by replacement.







Analysis 1.71. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 71 Stroke - LCn3 - subgroup by intervention type.







Analysis 1.72. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 72 Stroke - LCn3 - subgroup by duration.







Analysis 1.73. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 73 Stroke - LCn3 - subgroup by primary or secondary prevention.






Analysis 1.74. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 74 Stroke - LCn3 - subgroup by statin use.







Analysis 1.75. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 75 Stroke - LCn3 - subgroup by baseline TG.




Analysis 1.76. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 76 Stroke - LCn3 - subgroup by baseline DM.





































Analysis 1.77. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 77 Arrhythmia (overall) - LCn3.




Study or subgroup	Favours high- er omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Heterogeneity: $\tau^2=0.01$; $\chi^2=53.93$, $df=30$ ($P=0$); $I^2=44.37\%$					
Test for overall effect: $Z=0.38$ ($P=0.7$)					
Favours higher omega 3 0.5 0.7 1 1.5 2 Favours lower omega 3					


Analysis 1.78. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 78 Arrhythmia - LCn3 - SA fixed effects.


Study or subgroup	Favours high- er omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
AFFORD 2013	98/153	103/163		4.49%	1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010	67/2404	74/2433		3.31%	0.92[0.66,1.27]
ASCEND 2018	236/7740	219/7740		9.85%	1.08[0.9,1.29]
Derosa 2016	1/128	3/130		0.13%	0.34[0.04,3.21]
DISAF 2003	154/201	157/206		6.98%	1.01[0.9,1.12]
DREAM Asbell 2018	0/349	1/186		0.09%	0.18[0.01,4.35]
EPIC-1 2008	1/188	0/186		0.02%	2.97[0.12,72.4]
EPOCH 2014	2/195	1/196		0.04%	2.01[0.18,21.99]
Erdoğan 2007	41/54	46/54		2.07%	0.89[0.74,1.07]
FAAT 2005	60/200	79/202		3.54%	0.77[0.58,1.01]
FORWARD 2013	68/289	56/297		2.49%	1.25[0.91,1.71]
FOSTAR 2016	4/101	4/101		0.18%	1[0.26,3.89]
GISSI-HF 2008	76/278	98/284		4.36%	0.79[0.62,1.02]
GISSI-HF 2008	444/2921	408/2914		18.38%	1.09[0.96,1.23]
GISSI-P 1999	40/2836	46/2828		2.07%	0.87[0.57,1.32]
Kumar 2012	61/91	78/87		3.59%	0.75[0.64,0.88]
Nodari 2011 AF	37/100	56/99		2.53%	0.65[0.48,0.89]
Nodari 2011 HF	1/67	4/66		0.18%	0.25[0.03,2.15]
OFAMI 2001	8/150	15/150		0.67%	0.53[0.23,1.22]
OMEGA 2009	99/1919	84/1885		3.81%	1.16[0.87,1.54]
ORIGIN 2012	288/6281	259/6255		11.68%	1.11[0.94,1.3]
ORL 2013	0/171	1/165		0.07%	0.32[0.01,7.84]
Proudman 2015	1/87	0/53		0.03%	1.84[0.08,44.38]
Raitt 2005	65/100	59/100		2.65%	1.1[0.89,1.37]
REDUCE-IT 2019	188/4089	154/4090		6.93%	1.22[0.99,1.5]
Risk & Prevention 2013	113/6239	92/6266		4.13%	1.23[0.94,1.62]
Sianni 2013	147/268	29/60		2.13%	1.13[0.85,1.51]
SOFA 2006	36/273	34/273		1.53%	1.06[0.68,1.64]
SU.FOL.OM3 2010	33/1253	32/1248		1.44%	1.03[0.64,1.66]
THIS DIET 2008	2/51	5/50		0.23%	0.39[0.08,1.93]
Özaydin 2011	9/23	9/24		0.4%	1.04[0.51,2.16]
Total (95% CI)	39199	38791		100%	1.03[0.98,1.09]
Total events: 2380 (Favours higher omega 3), 2206 (Lower omega 3)					
Heterogeneity: $\tau^2=0$; $\chi^2=53.93$, $df=30$ ($P=0$); $I^2=44.37\%$					
Test for overall effect: $Z=1.18$ ($P=0.24$)					
Favours higher omega 3 0.5 0.7 1 1.5 2 Favours lower omega 3					

Analysis 1.79. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 79 Arrhythmia- LCn3 - SA by summary risk of bias.





Analysis 1.80. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 80 Arrhythmia- LCn3 - SA by compliance and study size.






Analysis 1.81. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 81 Arrhythmia - LCn3 - subgroup by new or recurrent.








Analysis 1.82. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 82 Arrhythmia - LCn3 - subgroup by fatality.




Analysis 1.83. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 83 Arrhythmia - LCn3 - subgroup by dose.










Analysis 1.84. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 84 Arrhythmia - LCn3 - subgroup by replacement.







Analysis 1.85. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 85 Arrhythmia - LCn3 - subgroup by intervention type.







Analysis 1.86. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 86 Arrhythmia - LCn3 - subgroup by duration.







Analysis 1.87. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 87 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3.






Analysis 1.88. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 88 Arrhythmia - LCn3 - subgroup by statin use.







Analysis 1.89. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 89 Arrhythmia - LCn3 - subgroup by baseline TG.



Analysis 1.90. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 90 Arrhythmia - LCn3 - subgroup by baseline DM.





Comparison 2. High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 MACCEs - LCn3	5	34730	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.97, 1.09]
2 Myocardial infarction (overall) - LCn3	27	133012	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.81, 0.96]
3 Total MI - LCn3 - SA fixed effects	27	133012	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.83, 0.94]
4 Total MI - LCn3 - SA by summary risk of bias	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 Low summary risk of bias	13	71376	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.83, 1.05]
4.2 Moderate or high summary risk of bias	14	61636	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.76, 0.94]
5 Total MI - LCn3 - SA by compliance and study size	26		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 SA - low risk of compliance bias	12	47052	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.70, 0.94]
5.2 SA - 100+ randomised	24	121545	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.80, 0.96]
6 Total MI - LCn3 - subgroup by fatality	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 Fatal MI	16	86342	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.52, 1.03]
6.2 Non-fatal MI	25	132443	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.84, 1.02]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7 Sudden cardiac death (overall) - LCn3	15	73183	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.77, 1.11]
8 Angina - LCn3	13	48621	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.92, 1.06]
8.1 Low summary risk of bias	6	21355	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.90, 1.08]
8.2 Moderate or high risk of bias	7	27266	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.88, 1.10]
9 Heart failure - LCn3	17	73303	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.87, 1.02]
9.1 Low summary risk of bias	7	39656	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.05]
9.2 Moderate to high risk of bias	10	33647	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.69, 1.04]
10 Revascularisation - LCn3	24	129382	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.86, 1.00]
10.1 Low summary risk of bias	8	64545	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.91, 1.01]
10.2 Moderate to high risk of bias	16	64837	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.78, 1.00]
11 Peripheral arterial disease - LCn3	7	57214	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.76, 1.18]
12 PAD - LCn3 - SA fixed effects	7	57214	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.76, 1.18]
13 PAD - LCn3 - SA by summary risk of bias	7		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
13.1 Low summary risk of bias	2	12738	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.75, 1.62]
13.2 Moderate or high risk of bias	5	44476	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.68, 1.15]
14 PAD - LCn3 - SA compliance and study size	7		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
14.1 SA compliance	2	8381	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.58, 1.87]
14.2 SA study size 100+	7	57214	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.76, 1.18]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
15 Acute coronary syndrome - LCn3	2	2703	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.71, 2.00]
15.1 LCn3	2	2703	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.71, 2.00]
16 Body weight, kg - LCn3	14	17000	Mean Difference (IV, Random, 95% CI)	0.00 [-0.69, 0.70]
17 Weight, kg - LCn3 - SA fixed effects	14	17000	Mean Difference (IV, Fixed, 95% CI)	0.19 [-0.19, 0.57]
18 Weight, kg - LCn3 - SA by summary risk of bias	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
18.1 Low summary risk of bias	8	16406	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.94, 0.75]
18.2 Moderate or high risk of bias	6	594	Mean Difference (IV, Random, 95% CI)	0.27 [-1.08, 1.63]
19 Weight, kg - LCn3 - SA by compliance and study size	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
19.1 SA - low risk of compliance bias	7	828	Mean Difference (IV, Random, 95% CI)	0.58 [-0.52, 1.69]
19.2 SA - 100+ randomised	9	16733	Mean Difference (IV, Random, 95% CI)	0.06 [-0.67, 0.79]
20 Weight, kg - LCn3 - subgroup by dose	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
20.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
20.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
20.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
20.4 LCn3 > 400 ≤ 2400 mg/d	9	16368	Mean Difference (IV, Random, 95% CI)	-0.34 [-1.14, 0.46]
20.5 LCn3 > 2.4 ≤ 4.4 g/d	4	481	Mean Difference (IV, Random, 95% CI)	0.11 [-2.58, 2.80]
20.6 LCn3 > 4.4 g/d	2	261	Mean Difference (IV, Random, 95% CI)	1.51 [0.28, 2.75]
21 Weight, kg - LCn3 - subgroup by replacement	14		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
21.1 N-3 replacing SFA	2	433	Mean Difference (IV, Random, 95% CI)	-2.51 [-4.30, -0.72]
21.2 N-3 replacing MUFA	8	16036	Mean Difference (IV, Random, 95% CI)	0.17 [-0.34, 0.68]
21.3 N-3 replacing n-6	1	41	Mean Difference (IV, Random, 95% CI)	-1.3 [-3.83, 1.23]
21.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-2.70 [-4.75, -0.65]
21.5 N-3 replacing nil/low n-3 placebo	1	240	Mean Difference (IV, Random, 95% CI)	0.44 [-1.11, 1.99]
21.6 Replacement unclear	3	425	Mean Difference (IV, Random, 95% CI)	1.46 [0.23, 2.68]
22 Weight, kg - LCn3 - subgroup by intervention type	14	17000	Mean Difference (IV, Random, 95% CI)	0.00 [-0.69, 0.70]
22.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
22.2 Supplemental foods	1	202	Mean Difference (IV, Random, 95% CI)	1.5 [0.25, 2.75]
22.3 Supplement (capsule)	11	16726	Mean Difference (IV, Random, 95% CI)	-0.14 [-0.82, 0.53]
22.4 Any combination	2	72	Mean Difference (IV, Random, 95% CI)	-0.43 [-6.47, 5.61]
23 Weight, kg - LCn3 - subgroup by duration	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
23.1 Medium duration 1 to < 2 years in study	8	840	Mean Difference (IV, Random, 95% CI)	-0.54 [-2.21, 1.12]
23.2 Medium-long duration: 2 to < 4 years in study	4	676	Mean Difference (IV, Random, 95% CI)	0.81 [-0.30, 1.92]
23.3 Long duration ≥ 4 years in study	2	15484	Mean Difference (IV, Random, 95% CI)	0.03 [-0.53, 0.59]
24 Weight, kg - LCn3 - subgroup by primary or secondary prevention	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
24.1 Primary CVD prevention	11	16526	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.87, 0.78]
24.2 Secondary CVD prevention	3	474	Mean Difference (IV, Random, 95% CI)	0.16 [-1.24, 1.56]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
25 Weight, kg - LCn3 - subgroup by statin use	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
25.1 LCn3 - ≥ 50% of control group on statins	4	15819	Mean Difference (IV, Random, 95% CI)	0.11 [-0.42, 0.63]
25.2 LCn3 - < 50% of control group on statins	5	614	Mean Difference (IV, Random, 95% CI)	0.47 [-0.66, 1.60]
25.3 LCn3 - use of statins unclear	5	567	Mean Difference (IV, Random, 95% CI)	-1.51 [-3.30, 0.27]
26 Body mass index, kg/m ² - LCn3	15	15474	Mean Difference (IV, Random, 95% CI)	0.06 [-0.14, 0.25]
27 BMI, kg/m ² - LCn3 - SA fixed effects	15	15474	Mean Difference (IV, Random, 95% CI)	0.06 [-0.14, 0.25]
28 BMI, kg/m ² - LCn3 - SA by summary risk of bias	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
28.1 Low risk of bias	5	14190	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.36, 0.33]
28.2 Moderate/high risk of bias	10	1284	Mean Difference (IV, Random, 95% CI)	0.05 [-0.12, 0.21]
29 BMI, kg/m ² - LCn3 - SA by compliance and study size	11		Mean Difference (IV, Random, 95% CI)	Subtotals only
29.1 SA - low risk of compliance bias	5	1848	Mean Difference (IV, Random, 95% CI)	0.09 [-0.21, 0.38]
29.2 SA - 100+ randomised	10	15222	Mean Difference (IV, Random, 95% CI)	0.01 [-0.12, 0.15]
30 BMI, kg/m ² - LCn3 - subgroup by dose	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
30.1 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
30.2 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
30.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
30.4 LCn3 > 400 ≤ 2400 mg/d	11	14789	Mean Difference (IV, Random, 95% CI)	0.01 [-0.11, 0.13]
30.5 LCn3 > 2.4 ≤ 4.4 g/d	4	685	Mean Difference (IV, Random, 95% CI)	1.08 [0.07, 2.10]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
30.6 LCn3 > 4.4 g/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
31 BMI, kg/m² - LCn3 - subgroup by replacement	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
31.1 N-3 replacing SFA	1	258	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.14, -0.06]
31.2 N-3 replacing MUFA	7	14180	Mean Difference (IV, Random, 95% CI)	0.08 [-0.12, 0.28]
31.3 N-3 replacing n-6	3	513	Mean Difference (IV, Random, 95% CI)	0.18 [-0.46, 0.81]
31.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.14, -0.06]
31.5 N-3 replacing nil/low n-3 placebo	2	300	Mean Difference (IV, Random, 95% CI)	0.86 [-0.30, 2.01]
31.6 Replacement unclear	2	223	Mean Difference (IV, Random, 95% CI)	0.58 [-1.17, 2.33]
32 BMI, kg/m² - LCn3 - subgroup by intervention type	15	15474	Mean Difference (IV, Random, 95% CI)	0.06 [-0.14, 0.25]
32.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
32.2 Supplemental foods	1	1260	Mean Difference (IV, Random, 95% CI)	0.1 [-0.10, 0.30]
32.3 Supplement (capsule)	13	14169	Mean Difference (IV, Random, 95% CI)	0.04 [-0.22, 0.29]
32.4 Any combination	1	45	Mean Difference (IV, Random, 95% CI)	1.60 [-0.43, 3.63]
33 BMI, kg/m² - LCn3 - subgroup by duration	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
33.1 Medium duration 1 to < 2 years in study	9	906	Mean Difference (IV, Random, 95% CI)	0.24 [-0.40, 0.88]
33.2 Medium-long duration: 2 to < 4 years in study	5	2032	Mean Difference (IV, Random, 95% CI)	0.13 [-0.06, 0.32]
33.3 Long duration ≥ 4 years in study	1	12536	Mean Difference (IV, Random, 95% CI)	0.0 [-0.20, 0.20]
34 BMI, kg/m² - LCn3 - subgroup by primary or secondary prevention	15		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
34.1 Primary CVD prevention	11	13610	Mean Difference (IV, Random, 95% CI)	0.15 [-0.36, 0.66]
34.2 Secondary CVD prevention	4	1864	Mean Difference (IV, Random, 95% CI)	0.06 [-0.07, 0.20]
35 BMI, kg/m ² - LCn3 - subgroup by statin use	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
35.1 LCn3 - ≥ 50% of control group on statins	4	14131	Mean Difference (IV, Random, 95% CI)	0.17 [-0.17, 0.50]
35.2 LCn3 - < 50% of control group on statins	4	665	Mean Difference (IV, Random, 95% CI)	0.02 [-0.15, 0.19]
35.3 LCn3 - use of statins unclear	7	678	Mean Difference (IV, Random, 95% CI)	0.06 [-0.86, 0.97]
36 Other measures of adiposity - LCn3	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
36.1 Percentage body fat	2	127	Mean Difference (IV, Random, 95% CI)	0.85 [-6.87, 8.57]
36.2 Percentage visceral fat	1	95	Mean Difference (IV, Random, 95% CI)	-1.80 [-15.03, 11.43]
36.3 Waist circumference, cm	4	916	Mean Difference (IV, Random, 95% CI)	0.72 [-0.17, 1.62]
36.4 Waist-hip ratio	1	100	Mean Difference (IV, Random, 95% CI)	0.0 [-0.01, 0.01]
36.5 Abdominal circumference, cm	1	256	Mean Difference (IV, Random, 95% CI)	-0.70 [-8.78, 7.38]
36.6 Hip circumference, cm	1	258	Mean Difference (IV, Random, 95% CI)	-2.40 [-9.80, 5.00]
37 Total cholesterol, serum, mmol/L - LCn3	30	38469	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
38 TC, mmol/L - LCn3 - SA fixed effects	30	38469	Mean Difference (IV, Fixed, 95% CI)	-0.04 [-0.06, -0.02]
39 TC, mmol/L - LCn3 - SA by summary risk of bias	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
39.1 Low summary risk of bias	10	15878	Mean Difference (IV, Random, 95% CI)	0.01 [-0.04, 0.06]
39.2 Moderate or high risk of bias	20	22591	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.08, 0.02]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
40 TC, mmol/L - LCn3 - SA by compliance and study size	22		Mean Difference (IV, Random, 95% CI)	Subtotals only
40.1 SA - low risk of compliance bias	14	3341	Mean Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.09]
40.2 SA - 100+ randomised	17	37810	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.05, 0.05]
41 TC, mmol/L - LCn3 - subgroup by dose	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
41.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
41.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
41.3 LCn3 > 250 ≤ 400 mg/d	1	1715	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.21]
41.4 LCn3 > 400 ≤ 2400 mg/d	19	35210	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.06, -0.01]
41.5 LCn3 > 2.4 ≤ 4.4 g/d	8	1456	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.22, 0.01]
41.6 LCn3 > 4.4 g/d	2	88	Mean Difference (IV, Random, 95% CI)	0.08 [-0.28, 0.45]
42 TC, mmol/L - LCn3 - subgroup by replacement	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
42.1 N-3 replacing SFA	3	2148	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.20]
42.2 N-3 replacing MUFA	16	17452	Mean Difference (IV, Random, 95% CI)	0.01 [-0.04, 0.05]
42.3 N-3 replacing n-6	4	729	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.34, 0.31]
42.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-0.20 [-1.03, 0.63]
42.5 N-3 replacing nil/low n-3 placebo	7	19745	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.07, -0.03]
42.6 Replacement unclear	2	285	Mean Difference (IV, Random, 95% CI)	0.12 [-0.14, 0.38]
43 TC, mmol/L - LCn3 - subgroup by intervention type	30		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
43.1 Dietary advice	1	1715	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.21]
43.2 Supplemental foods	1	1210	Mean Difference (IV, Random, 95% CI)	0.02 [-0.09, 0.13]
43.3 Supplement (capsule)	26	35333	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.07, -0.02]
43.4 Any combination	2	211	Mean Difference (IV, Random, 95% CI)	0.13 [-0.10, 0.37]
44 TC, mmol/L - LCn3 - subgroup by duration	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
44.1 Medium duration 1 to < 2 years in study	15	1661	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.16, 0.04]
44.2 Medium-long duration: 2 to < 4 years in study	11	4471	Mean Difference (IV, Random, 95% CI)	0.03 [-0.04, 0.09]
44.3 Long duration ≥ 4 years in study	4	32337	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.08, 0.07]
45 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
45.1 Primary prevention	18	33744	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.06, -0.02]
45.2 Secondary prevention	12	4725	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.08, 0.07]
46 TC, mmol/L - LCn3 - subgroup by statin use	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
46.1 LCn3 - ≥ 50% of control group on statins	8	34011	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.06, -0.02]
46.2 LCn3 - < 50% of control group on statins	15	3871	Mean Difference (IV, Random, 95% CI)	0.01 [-0.08, 0.10]
46.3 LCn3 - use of statins unclear	7	587	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.27, 0.22]
47 Triglycerides, fasting, serum, mmol/L - LCn3	27	43998	Mean Difference (IV, Random, 95% CI)	-0.24 [-0.31, -0.16]
48 TG, fasting, mmol/L - LCn3 - SA fixed effects	27	43998	Mean Difference (IV, Fixed, 95% CI)	-0.21 [-0.26, -0.17]
49 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias	27		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
49.1 Low summary risk of bias	8	14654	Mean Difference (IV, Random, 95% CI)	-0.19 [-0.28, -0.10]
49.2 Moderate or high risk of bias	19	29344	Mean Difference (IV, Random, 95% CI)	-0.25 [-0.35, -0.15]
50 TG, fasting, mmol/L - LCn3 - SA by compliance and study size	20		Mean Difference (IV, Random, 95% CI)	Subtotals only
50.1 SA - low risk of compliance bias	13	11485	Mean Difference (IV, Random, 95% CI)	-0.26 [-0.36, -0.16]
50.2 SA - 100+ randomised	17	43484	Mean Difference (IV, Random, 95% CI)	-0.24 [-0.32, -0.15]
51 TG, fasting, mmol/L - LCn3 - subgroup by dose	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
51.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
51.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
51.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
51.4 LCn3 > 400 ≤ 2400 mg/d	18	34388	Mean Difference (IV, Random, 95% CI)	-0.18 [-0.25, -0.11]
51.5 LCn3 > 2.4 ≤ 4.4 g/d	7	9526	Mean Difference (IV, Random, 95% CI)	-0.36 [-0.53, -0.20]
51.6 LCn3 > 4.4 g/d	2	84	Mean Difference (IV, Random, 95% CI)	-0.41 [-0.68, -0.14]
52 TG, fasting, mmol/L - LCn3 - subgroup by replacement	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
52.1 N-3 replacing SFA	2	429	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.59, 0.04]
52.2 N-3 replacing MUFA	13	14634	Mean Difference (IV, Random, 95% CI)	-0.18 [-0.25, -0.10]
52.3 N-3 replacing n-6	4	715	Mean Difference (IV, Random, 95% CI)	-0.33 [-0.50, -0.16]
52.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-0.5 [-1.49, 0.49]
52.5 N-3 replacing nil/low n-3 placebo	6	27776	Mean Difference (IV, Random, 95% CI)	-0.18 [-0.51, 0.14]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
52.6 Replacement unclear	3	615	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.58, 0.18]
53 TG, fasting, mmol/L - LCn3 - subgroup by intervention type	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
53.1 Dietary advice	1	71	Mean Difference (IV, Random, 95% CI)	0.02 [-0.36, 0.40]
53.2 Supplemental foods	1	1210	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.15, 0.09]
53.3 Supplement (capsule)	24	42556	Mean Difference (IV, Random, 95% CI)	-0.19 [-0.38, -0.00]
53.4 Any combination	1	161	Mean Difference (IV, Random, 95% CI)	0.01 [-0.28, 0.30]
54 TG, fasting, mmol/L - LCn3 - subgroup by duration	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
54.1 Medium duration 1 to < 2 years in study	13	1880	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.36, -0.19]
54.2 Medium-long duration: 2 to < 4 years in study	10	2550	Mean Difference (IV, Random, 95% CI)	-0.16 [-0.31, -0.02]
54.3 Long duration ≥ 4 years in study	4	39568	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.32, -0.07]
55 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
55.1 Primary prevention	17	33114	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.26, -0.14]
55.2 Secondary prevention	9	2705	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.44, -0.10]
55.3 Mixed primary & secondary prevention	1	8179	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
56 TG, fasting, mmol/L - LCn3 - subgroup by statin use	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
56.1 LCn3 - ≥ 50% of control group on statins	7	40976	Mean Difference (IV, Random, 95% CI)	-0.11 [-0.21, -0.01]
56.2 LCn3 - < 50% of control group on statins	14	2414	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.36, -0.18]
56.3 LCn3 - use of statins unclear	6	608	Mean Difference (IV, Random, 95% CI)	-0.23 [-0.38, -0.08]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
57 High-density lipoprotein, serum, mmol/L - LCn3	30	46604	Mean Difference (IV, Random, 95% CI)	0.03 [0.01, 0.05]
58 HDL, mmol/L - LCn3 - SA fixed effects	30	46604	Mean Difference (IV, Fixed, 95% CI)	0.01 [0.00, 0.02]
59 HDL, mmol/L - LCn3 - SA by summary risk of bias	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
59.1 Low summary risk of bias	9	15840	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
59.2 Moderate or high risk of bias	21	30764	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
60 HDL, mmol/L - LCn3 - SA by compliance and study size	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
60.1 SA - low risk of compliance bias	14	11381	Mean Difference (IV, Random, 95% CI)	0.05 [0.01, 0.10]
60.2 SA - 100+ randomised	18	45940	Mean Difference (IV, Random, 95% CI)	0.03 [0.01, 0.05]
61 HDL, mmol/L - LCn3 - subgroup by dose	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
61.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
61.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
61.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
61.4 LCn3 > 400 ≤ 2400 mg/d	20	36920	Mean Difference (IV, Random, 95% CI)	0.02 [0.00, 0.04]
61.5 LCn3 > 2.4 ≤ 4.4 g/d	9	9625	Mean Difference (IV, Random, 95% CI)	0.06 [0.02, 0.10]
61.6 LCn3 > 4.4 g/d	1	59	Mean Difference (IV, Random, 95% CI)	0.0 [-0.16, 0.16]
62 HDL, mmol/L - LCn3 - subgroup by replacement	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
62.1 N-3 replacing SFA	3	2143	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.07]
62.2 N-3 replacing MUFA	16	17453	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.06]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
62.3 N-3 replacing n-6	3	688	Mean Difference (IV, Random, 95% CI)	0.06 [0.00, 0.11]
62.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	0.10 [-0.17, 0.37]
62.5 N-3 replacing nil/low n-3 placebo	8	27924	Mean Difference (IV, Random, 95% CI)	0.04 [-0.01, 0.09]
62.6 Replacement unclear	2	281	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.14, 0.08]
63 HDL, mmol/L - LCn3 - subgroup by intervention type	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
63.1 Dietary advice	2	1785	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
63.2 Supplemental foods	1	1210	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
63.3 Supplement (capsule)	24	43375	Mean Difference (IV, Random, 95% CI)	0.04 [0.01, 0.06]
63.4 Any combination	3	234	Mean Difference (IV, Random, 95% CI)	0.10 [-0.10, 0.31]
64 HDL, mmol/L - LCn3 - subgroup by duration	30		Mean Difference (IV, Random, 95% CI)	Subtotals only
64.1 Medium duration 1 to < 2 years in study	13	1562	Mean Difference (IV, Random, 95% CI)	0.08 [0.01, 0.14]
64.2 Medium-long duration: 2 to < 4 years in study	12	4526	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.04]
64.3 Long duration ≥ 4 years in study	5	40516	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.04]
65 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention	29		Mean Difference (IV, Random, 95% CI)	Subtotals only
65.1 Primary prevention	18	33804	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
65.2 Secondary prevention	10	4547	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.06]
65.3 Mixed primary & secondary prevention	1	8179	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
66 HDL, mmol/L - LCn3 - subgroup by statin use	30		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
66.1 LCn3 - \geq 50% of control group on statins	10	42261	Mean Difference (IV, Random, 95% CI)	0.02 [0.00, 0.04]
66.2 LCn3 - $<$ 50% of control group on statins	13	3690	Mean Difference (IV, Random, 95% CI)	0.04 [-0.00, 0.08]
66.3 LCn3 - use of statins unclear	7	653	Mean Difference (IV, Random, 95% CI)	0.07 [-0.07, 0.21]
67 Low-density lipoprotein, serum, mmol/L - LCn3	25	43454	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
68 LDL, mmol/L - LCn3 - SA fixed effects	25	43454	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.01, 0.03]
69 LDL, mmol/L - LCn3 - SA by summary risk of bias	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
69.1 Low summary risk of bias	9	14840	Mean Difference (IV, Random, 95% CI)	0.02 [-0.03, 0.07]
69.2 Moderate or high risk of bias	16	28614	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.03]
70 LDL, mmol/L - LCn3 - SA by compliance and study size	19		Mean Difference (IV, Random, 95% CI)	Subtotals only
70.1 SA - low risk of compliance bias	14	11344	Mean Difference (IV, Random, 95% CI)	0.05 [-0.02, 0.11]
70.2 SA - 100+ randomised	14	42885	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
71 LDL, mmol/L - LCn3 - subgroup by dose	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
71.1 LCn3 \leq 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
71.2 LCn3 $>$ 150 \leq 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
71.3 LCn3 $>$ 250 \leq 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
71.4 LCn3 $>$ 400 \leq 2400 mg/d	16	34054	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.02]
71.5 LCn3 $>$ 2.4 \leq 4.4 g/d	7	9312	Mean Difference (IV, Random, 95% CI)	0.03 [-0.08, 0.15]
71.6 LCn3 $>$ 4.4 g/d	2	88	Mean Difference (IV, Random, 95% CI)	0.22 [-0.09, 0.54]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
72 LDL, mmol/L - LCn3 - subgroup by replacement	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
72.1 N-3 replacing SFA	2	429	Mean Difference (IV, Random, 95% CI)	0.17 [-0.14, 0.47]
72.2 N-3 replacing MUFA	14	14710	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.05]
72.3 N-3 replacing n-6	2	242	Mean Difference (IV, Random, 95% CI)	0.14 [-0.26, 0.55]
72.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	0.20 [-0.51, 0.91]
72.5 N-3 replacing nil/low n-3 placebo	6	27790	Mean Difference (IV, Random, 95% CI)	0.00 [-0.02, 0.02]
72.6 Replacement unclear	2	454	Mean Difference (IV, Random, 95% CI)	0.09 [-0.04, 0.23]
73 LDL, mmol/L - LCn3 - subgroup by intervention type	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
73.1 Dietary advice	1	71	Mean Difference (IV, Random, 95% CI)	0.08 [-0.22, 0.38]
73.2 Supplemental foods	1	1124	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.06]
73.3 Supplement (capsule)	21	42187	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
73.4 Any combination	2	72	Mean Difference (IV, Random, 95% CI)	0.08 [-0.44, 0.61]
74 LDL, mmol/L - LCn3 - subgroup by duration	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
74.1 Medium duration 1 to < 2 years in study	14	1862	Mean Difference (IV, Random, 95% CI)	0.06 [-0.03, 0.14]
74.2 Medium-long duration: 2 to < 4 years in study	7	2024	Mean Difference (IV, Random, 95% CI)	0.01 [-0.06, 0.07]
74.3 Long duration ≥ 4 years in study	4	39568	Mean Difference (IV, Random, 95% CI)	0.03 [-0.04, 0.10]
75 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
75.1 Primary prevention	16	32717	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
75.2 Secondary prevention	8	2558	Mean Difference (IV, Random, 95% CI)	0.02 [-0.04, 0.09]
75.3 Mixed primary & secondary prevention	1	8179	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
76 LDL, mmol/L - LCn3 - subgroup by statin use	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
76.1 LCn3 - \geq 50% of control group on statins	9	41227	Mean Difference (IV, Random, 95% CI)	0.00 [-0.02, 0.02]
76.2 LCn3 - < 50% of control group on statins	9	1564	Mean Difference (IV, Random, 95% CI)	0.12 [0.03, 0.21]
76.3 LCn3 - use of statins unclear	7	663	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.17, 0.14]

Analysis 2.1. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 1 MACCEs - LCn3.





Analysis 2.2. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 2 Myocardial infarction (overall) - LCn3.







Analysis 2.3. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 3 Total MI - LCn3 - SA fixed effects.







Analysis 2.4. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 4 Total MI - LCn3 - SA by summary risk of bias.







Analysis 2.5. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 5 Total MI - LCn3 - SA by compliance and study size.







Analysis 2.6. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 6 Total MI - LCn3 - subgroup by fatality.






Analysis 2.7. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 7 Sudden cardiac death (overall) - LCn3.







Analysis 2.8. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 8 Angina - LCn3.




Analysis 2.9. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 9 Heart failure - LCn3.





Analysis 2.10. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 10 Revascularisation - LCn3.






Analysis 2.11. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 11 Peripheral arterial disease - LCn3.






Analysis 2.12. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 12 PAD - LCn3 - SA fixed effects.













Analysis 2.13. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 13 PAD - LCn3 - SA by summary risk of bias.







Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for overall effect: $Z=0.9(P=0.37)$					
Test for subgroup differences: $\text{Chi}^2=0.81$, $\text{df}=1$ ($P=0.37$), $I^2=0\%$					
Favours higher omega 3 0.1 0.2 0.5 1 2 5 10 Favours lower omega 3					

Analysis 2.14. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 14 PAD - LCn3 - SA compliance and study size.















Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
2.14.1 SA compliance					
FOSTAR 2016	1/101	1/101		4.47%	1[0.06,15.77]
REDUCE-IT 2019	22/4089	21/4090		95.53%	1.05[0.58,1.9]
Subtotal (95% CI)	4190	4191		100%	1.05[0.58,1.87]
Total events: 23 (Higher omega 3), 22 (Lower omega 3)					
Heterogeneity: $\text{Tau}^2=0$; $\text{Chi}^2=0$, $\text{df}=1$ ($P=0.97$); $I^2=0\%$					
Test for overall effect: $Z=0.15(P=0.88)$					
2.14.2 SA study size 100+					
JELIS 2007	21/9326	29/9319		14.98%	0.72[0.41,1.27]
ORIGIN 2012	52/6281	47/6255		30.51%	1.1[0.74,1.63]
Risk & Prevention 2013	62/6239	68/6266		40.19%	0.92[0.65,1.29]
FOSTAR 2016	1/101	1/101		0.62%	1[0.06,15.77]
DART 1989	0/1015	1/1018		0.46%	0.33[0.01,8.2]
DART2 2003	0/1571	0/1543			Not estimable
REDUCE-IT 2019	22/4089	21/4090		13.25%	1.05[0.58,1.9]
Subtotal (95% CI)	28622	28592		100%	0.95[0.76,1.18]
Total events: 158 (Higher omega 3), 167 (Lower omega 3)					
Heterogeneity: $\text{Tau}^2=0$; $\text{Chi}^2=2.01$, $\text{df}=5$ ($P=0.85$); $I^2=0\%$					
Test for overall effect: $Z=0.48(P=0.63)$					
Favours higher omega 3 0.1 0.2 0.5 1 2 5 10 Favours lower omega 3					

Analysis 2.15. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 15 Acute coronary syndrome - LCn3.














Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
2.15.1 LCn3					
FOSTAR 2016	10/101	10/101		38.97%	1[0.44,2.3]
SU.FOL.OM3 2010	20/1253	15/1248		61.03%	1.33[0.68,2.58]
Subtotal (95% CI)	1354	1349		100%	1.19[0.71,2]
Total events: 30 (Higher omega 3), 25 (Lower omega 3)					
Heterogeneity: $\text{Tau}^2=0$; $\text{Chi}^2=0.27$, $\text{df}=1$ ($P=0.6$); $I^2=0\%$					
Test for overall effect: $Z=0.65(P=0.51)$					
Total (95% CI)	1354	1349		100%	1.19[0.71,2]
Total events: 30 (Higher omega 3), 25 (Lower omega 3)					
Heterogeneity: $\text{Tau}^2=0$; $\text{Chi}^2=0.27$, $\text{df}=1$ ($P=0.6$); $I^2=0\%$					
Favours high LCn3 0.01 0.1 1 10 100 Favours low LCn3					


Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI					Weight	Risk Ratio M-H, Random, 95% CI	
Test for overall effect: Z=0.65(P=0.51)										
			Favours high LCn3	0.01	0.1	1	10	100	Favours low LCn3	

Analysis 2.16. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 16 Body weight, kg - LCn3.


Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
ASCEND 2018	471	88 (17.4)	477	89 (17.5)		7.15%	-1[-3.22,1.22]
Caldwell 2011	20	-1.5 (4.5)	21	-0.2 (3.7)		5.86%	-1.3[-3.83,1.23]
Derosa 2016	128	78.7 (7.9)	130	81.4 (8.9)		7.99%	-2.7[-4.75,-0.65]
EPE-A 2014	64	0 (0)	55	-1 (0)			Not estimable
FOSTAR 2016	101	1.8 (5)	101	0.3 (4)		14.23%	1.5[0.25,2.75]
HARP 1995	31	82 (14)	28	80 (15)		0.84%	2[-5.43,9.43]
HEARTS 2017	126	-0.8 (6.8)	114	-1.3 (5.4)		11.46%	0.44[-1.11,1.99]
MARINA 2011	80	0.2 (1.8)	71	-0.3 (2.5)		20.83%	0.5[-0.21,1.21]
Norouzi 2014	54	71.4 (14.4)	50	70.8 (14.4)		1.48%	0.6[-4.93,6.13]
ORIGIN 2012	8281	83.9 (17.8)	6255	83.8 (17.6)		22.43%	0.1[-0.48,0.68]
SCIMO 1999	89	79.1 (12.5)	86	81 (12.3)		3.14%	-1.9[-5.57,1.77]
SMART 2013	20	84.3 (11.7)	25	80.9 (12.7)		0.91%	3.4[-3.75,10.55]
Weinstock-Guttman 2005	13	-2.7 (6.2)	14	0.2 (5.1)		2.37%	-2.91[-7.21,1.39]
WELCOME 2015	47	94.1 (13)	48	90.4 (16.3)		1.3%	3.7[-2.22,9.62]
Total ***	9525		7475			100%	0[-0.69,0.7]
Heterogeneity: Tau ² =0.47; Chi ² =20.79, df=12(P=0.05); I ² =42.27%							
Test for overall effect: Z=0.01(P=0.99)							
					Favours higher omega 3	-5 -2.5 0 2.5 5	Favours lower omega 3

Analysis 2.17. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 17 Weight, kg - LCn3 - SA fixed effects.


Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
	N	Mean(SD)	N	Mean(SD)			
ASCEND 2018	471	88 (17.4)	477	89 (17.5)		2.98%	-1[-3.22,1.22]
Caldwell 2011	20	-1.5 (4.5)	21	-0.2 (3.7)		2.29%	-1.3[-3.83,1.23]
Derosa 2016	128	78.7 (7.9)	130	81.4 (8.9)		3.47%	-2.7[-4.75,-0.65]
EPE-A 2014	64	0 (0)	55	-1 (0)			Not estimable
FOSTAR 2016	101	1.8 (5)	101	0.3 (4)		9.3%	1.5[0.25,2.75]
HARP 1995	31	82 (14)	28	80 (15)		0.27%	2[-5.43,9.43]
HEARTS 2017	126	-0.8 (6.8)	114	-1.3 (5.4)		6.12%	0.44[-1.11,1.99]
MARINA 2011	80	0.2 (1.8)	71	-0.3 (2.5)		29.15%	0.5[-0.21,1.21]
Norouzi 2014	54	71.4 (14.4)	50	70.8 (14.4)		0.48%	0.6[-4.93,6.13]
ORIGIN 2012	8281	83.9 (17.8)	6255	83.8 (17.6)		43.38%	0.1[-0.48,0.68]
SCIMO 1999	89	79.1 (12.5)	86	81 (12.3)		1.08%	-1.9[-5.57,1.77]
SMART 2013	20	84.3 (11.7)	25	80.9 (12.7)		0.29%	3.4[-3.75,10.55]
Weinstock-Guttman 2005	13	-2.7 (6.2)	14	0.2 (5.1)		0.79%	-2.91[-7.21,1.39]
WELCOME 2015	47	94.1 (13)	48	90.4 (16.3)		0.42%	3.7[-2.22,9.62]
					Favours higher omega 3	-5 -2.5 0 2.5 5	Favours lower omega 3




Analysis 2.18. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 18 Weight, kg - LCn3 - SA by summary risk of bias.





Analysis 2.19. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 19 Weight, kg - LCn3 - SA by compliance and study size.







Analysis 2.20. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 20 Weight, kg - LCn3 - subgroup by dose.







Analysis 2.21. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 21 Weight, kg - LCn3 - subgroup by replacement.







Analysis 2.22. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 22 Weight, kg - LCn3 - subgroup by intervention type.






Analysis 2.23. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 23 Weight, kg - LCn3 - subgroup by duration.







Analysis 2.24. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 24 Weight, kg - LCn3 - subgroup by primary or secondary prevention.




Analysis 2.25. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 25 Weight, kg - LCn3 - subgroup by statin use.




Analysis 2.26. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 26 Body mass index, kg/m² - LCn3.







Analysis 2.27. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 27 BMI, kg/m^2 - LCn3 - SA fixed effects.




Analysis 2.28. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 28 BMI, kg/m^2 - LCn3 - SA by summary risk of bias.





















Analysis 2.29. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 29 BMI, kg/m²- LCn3 - SA by compliance and study size.



Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI			
	N	Mean(SD)	N	Mean(SD)						
Test for overall effect: Z=0.21(P=0.83)										
Test for subgroup differences: Chi²=0.2, df=1 (P=0.66), I²=0%										
					-4	-2	0	2	4	
					Favours higher omega 3			Favours lower omega 3		


Analysis 2.30. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 30 BMI, kg/m^2 - LCn3 - subgroup by dose.

Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
2.30.1 LCn3 > 150 ≤ 250 mg/d							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
2.30.2 LCn3 ≤ 150 mg/d							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
2.30.3 LCn3 > 250 ≤ 400 mg/d							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
2.30.4 LCn3 > 400 ≤ 2400 mg/d							
AlphaOmega - EPA+DHA 2010	630	0 (1.8)	630	-0.1 (1.8)		28.38%	0.1[-0.1,0.3]
Caldwell 2011	20	-0.5 (4.5)	21	-0.2 (3.7)		0.23%	-0.3[-2.83,2.23]
Derosa 2016	128	28.6 (2.1)	130	29.2 (2.3)		4.87%	-0.6[-1.14,-0.06]
DO IT 2010	124	26.8 (3.5)	117	27 (3.9)		1.65%	-0.2[-1.14,0.74]
Mita 2007	30	25.1 (5.3)	30	24.1 (3)		0.31%	1[-1.18,3.18]
Nodari 2011 HF	67	26 (0.4)	66	26 (0.6)		34.68%	0[-0.17,0.17]
Norouzi 2014	54	24.8 (4.9)	50	24.2 (4.2)		0.48%	0.58[-1.17,2.33]
ORIGIN 2012	6281	30.3 (5.6)	6255	30.3 (5.6)		28.98%	0[-0.2,0.2]
SMART 2013	20	29.8 (3.5)	25	28.2 (3.4)		0.35%	1.6[-0.43,3.63]
Sofi 2010	6	-0.6 (0)	5	-0.1 (0)			Not estimable
Tande 2016	50	0.6 (9.7)	50	-0.4 (12.1)		0.08%	1[-3.3,5.3]
Subtotal ***	7410		7379			100%	0.01[-0.11,0.13]
Heterogeneity: Tau²=0; Chi²=9.77, df=9(P=0.37); I²=7.85%							
Test for overall effect: Z=0.12(P=0.9)							
2.30.5 LCn3 > 2.4 ≤ 4.4 g/d							
EPE-A 2014	64	0 (0)	55	-0.3 (0)			Not estimable
HEARTS 2017	126	0.6 (7.5)	114	-0.2 (1.8)		32.23%	0.8[-0.56,2.16]
OFAMI 2001	115	26.6 (3.9)	116	26 (3.2)		46.86%	0.6[-0.32,1.52]
WELCOME 2015	47	33.4 (4.9)	48	30.8 (4.5)		20.91%	2.6[0.71,4.49]
Subtotal ***	352		333			100%	1.08[0.07,2.1]
Heterogeneity: Tau²=0.35; Chi²=3.52, df=2(P=0.17); I²=43.16%							
Test for overall effect: Z=2.09(P=0.04)							
					-20 -10 0 10 20		
					Favours higher omega 3	Favours lower omega 3	


Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
2.30.6 LCn3 > 4.4 g/d							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Test for subgroup differences: Chi ² =4.24, df=1 (P=0.04), I ² =76.41%							
					-20 -10 0 10 20		
					Favours higher omega 3	Favours lower omega 3	


Analysis 2.31. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 31 BMI, kg/m² - LCn3 - subgroup by replacement.

Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
2.31.1 N-3 replacing SFA							
Derosa 2016	128	28.6 (2.1)	130	29.2 (2.3)		100%	-0.6[-1.14,-0.06]
Subtotal ***	128		130			100%	-0.6[-1.14,-0.06]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.19(P=0.03)							
2.31.2 N-3 replacing MUFA							
AlphaOmega - EPA+DHA 2010	630	0 (1.8)	630	-0.1 (1.8)		31.65%	0.1[-0.1,0.3]
Nodari 2011 HF	67	26 (0.4)	66	26 (0.6)		34.09%	0[-0.17,0.17]
ORIGIN 2012	6281	30.3 (5.6)	6255	30.3 (5.6)		31.92%	0[-0.2,0.2]
SMART 2013	20	29.8 (3.5)	25	28.2 (3.4)		0.98%	1.6[-0.43,3.63]
Sofi 2010	6	-0.6 (0)	5	-0.1 (0)			Not estimable
Tande 2016	50	0.6 (9.7)	50	-0.4 (12.1)		0.22%	1[-3.3,5.3]
WELCOME 2015	47	33.4 (4.9)	48	30.8 (4.5)		1.13%	2.6[0.71,4.49]
Subtotal ***	7101		7079			100%	0.08[-0.12,0.28]
Heterogeneity: Tau ² =0.02; Chi ² =10.19, df=5(P=0.07); I ² =50.94%							
Test for overall effect: Z=0.76(P=0.45)							
2.31.3 N-3 replacing n-6							
Caldwell 2011	20	-0.5 (4.5)	21	-0.2 (3.7)		6.32%	-0.3[-2.83,2.23]
DO IT 2010	124	26.8 (3.5)	117	27 (3.9)		45.98%	-0.2[-1.14,0.74]
OFAMI 2001	115	26.6 (3.9)	116	26 (3.2)		47.7%	0.6[-0.32,1.52]
Subtotal ***	259		254			100%	0.18[-0.46,0.81]
Heterogeneity: Tau ² =0; Chi ² =1.57, df=2(P=0.46); I ² =0%							
Test for overall effect: Z=0.54(P=0.59)							
2.31.4 N-3 replacing carbs/sugars							
Derosa 2016	128	28.6 (2.1)	130	29.2 (2.3)		100%	-0.6[-1.14,-0.06]
Subtotal ***	128		130			100%	-0.6[-1.14,-0.06]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.19(P=0.03)							
2.31.5 N-3 replacing nil/low n-3 placebo							
HEARTS 2017	126	0.6 (7.5)	114	-0.2 (1.8)		71.99%	0.8[-0.56,2.16]
Mita 2007	30	25.1 (5.3)	30	24.1 (3)		28.01%	1[-1.18,3.18]
Subtotal ***	156		144			100%	0.86[-0.3,2.01]
Heterogeneity: Tau ² =0; Chi ² =0.02, df=1(P=0.88); I ² =0%							
					-0.5 -0.25 0 0.25 0.5		
					Favours higher omega 3	Favours lower omega 3	




Analysis 2.32. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 32 BMI, kg/m^2 - LCn3 - subgroup by intervention type.







Analysis 2.33. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 33 BMI, kg/m² - LCn3 - subgroup by duration.




Analysis 2.34. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 34 BMI, kg/m² - LCn3 - subgroup by primary or secondary prevention.





Analysis 2.35. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 35 BMI, kg/m² - LCn3 - subgroup by statin use.







Analysis 2.36. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 36 Other measures of adiposity - LCn3.






Analysis 2.37. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 37 Total cholesterol, serum, mmol/L - LCn3.







Analysis 2.38. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 38 TC, mmol/L - LCn3 - SA fixed effects.




Analysis 2.39. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 39 TC, mmol/L - LCn3 - SA by summary risk of bias.




Analysis 2.40. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 40 TC, mmol/L - LCn3 - SA by compliance and study size.





Analysis 2.41. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 41 TC, mmol/L - LCn3 - subgroup by dose.







Analysis 2.42. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 42 TC, mmol/L - LCn3 - subgroup by replacement.







Analysis 2.43. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 43 TC, mmol/L - LCn3 - subgroup by intervention type.






Analysis 2.44. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 44 TC, mmol/L - LCn3 - subgroup by duration.







Analysis 2.45. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 45 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention.




Analysis 2.46. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 46 TC, mmol/L - LCn3 - subgroup by statin use.




Analysis 2.47. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 47 Triglycerides, fasting, serum, mmol/L - LCn3.





Analysis 2.48. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 48 TG, fasting, mmol/L - LCn3 - SA fixed effects.







Analysis 2.49. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 49 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias.







Analysis 2.50. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 50 TG, fasting, mmol/L - LCn3 - SA by compliance and study size.







Analysis 2.51. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 51 TG, fasting, mmol/L - LCn3 - subgroup by dose.







Analysis 2.52. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 52 TG, fasting, mmol/L - LCn3 - subgroup by replacement.










Analysis 2.53. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 53 TG, fasting, mmol/L - LCn3 - subgroup by intervention type.







Analysis 2.54. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 54 TG, fasting, mmol/L - LCn3 - subgroup by duration.







Analysis 2.55. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 55 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention.







Analysis 2.56. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 56 TG, fasting, mmol/L - LCn3 - subgroup by statin use.






Analysis 2.57. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 57 High-density lipoprotein, serum, mmol/L - LCn3.







Analysis 2.58. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 58 HDL, mmol/L - LCn3 - SA fixed effects.




Analysis 2.59. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 59 HDL, mmol/L - LCn3 - SA by summary risk of bias.




Analysis 2.60. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 60 HDL, mmol/L - LCn3 - SA by compliance and study size.





Analysis 2.61. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 61 HDL, mmol/L - LCn3 - subgroup by dose.







Analysis 2.62. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 62 HDL, mmol/L - LCn3 - subgroup by replacement.







Analysis 2.63. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 63 HDL, mmol/L - LCn3 - subgroup by intervention type.






Analysis 2.64. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 64 HDL, mmol/L - LCn3 - subgroup by duration.







Analysis 2.65. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 65 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention.




Analysis 2.66. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 66 HDL, mmol/L - LCn3 - subgroup by statin use.




Analysis 2.67. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 67 Low-density lipoprotein, serum, mmol/L - LCn3.





Analysis 2.68. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 68 LDL, mmol/L - LCn3 - SA fixed effects.







Analysis 2.69. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 69 LDL, mmol/L - LCn3 - SA by summary risk of bias.







Analysis 2.70. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 70 LDL, mmol/L - LCn3 - SA by compliance and study size.







Analysis 2.71. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 71 LDL, mmol/L - LCn3 - subgroup by dose.







Analysis 2.72. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 72 LDL, mmol/L - LCn3 - subgroup by replacement.






Analysis 2.73. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 73 LDL, mmol/L - LCn3 - subgroup by intervention type.







Analysis 2.74. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 74 LDL, mmol/L - LCn3 - subgroup by duration.



Analysis 2.75. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 75 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention.



Analysis 2.76. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 76 LDL, mmol/L - LCn3 - subgroup by statin use.





Comparison 3. High vs low LCn3 omega-3 fats (tertiary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Blood pressure, mmHg - LCn3	17		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Systolic BP - LCn3	17	35601	Mean Difference (IV, Random, 95% CI)	0.01 [-0.31, 0.34]
1.2 Diastolic BP - LCn3	15	35626	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.22, 0.17]
2 Serious adverse events - LCn3	19		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Any serious adverse events	3	9116	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.94, 1.06]
2.2 Bleeding	11	80147	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.91, 1.37]
2.3 Serious GI events	3	774	Risk Ratio (M-H, Random, 95% CI)	1.34 [0.64, 2.80]
2.4 Pulmonary embolus or DVT - LCn3	5	3546	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.44, 2.98]
2.5 Progression to advanced AMD (age-related macular degeneration)	1	4203	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.90, 1.02]
3 Side effects - LCn3	38		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Dropouts due to side effects	23	16755	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.99, 1.36]
3.2 Abdominal pain or discomfort	9	41056	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.91, 1.20]
3.3 Diarrhoea	13	37013	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.87, 1.19]
3.4 Nausea	8	35819	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.96, 1.49]
3.5 Any gastrointestinal side effect - LCn3 fats	33	89668	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.97, 1.26]
3.6 Skin problems (itching, rashes)	9	36721	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.52, 2.37]
3.7 Headache or worsening migraine	4	1526	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.51, 1.40]
3.8 Reflux	3	8916	Risk Ratio (M-H, Random, 95% CI)	1.23 [0.79, 1.91]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.9 Pain (joint, lumbar, muscle pain)	3	27359	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.74, 1.23]
3.10 All side effects combined	14	39439	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.95, 1.08]
4 Dropouts - LCn3	35	56089	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.04]


Analysis 3.1. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - LCn3.







Analysis 3.2. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - LCn3.







Analysis 3.3. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 3 Side effects - LCn3.










Analysis 3.4. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - LCn3.



Comparison 4. High vs low ALA omega-3 fat (primary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All-cause mortality (overall) - ALA	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect	5	19327	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.85, 1.21]
3 All-cause mortality - ALA - SA by summary risk of bias	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.72, 1.45]
3.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.71, 1.67]
4 All-cause mortality - ALA - SA by compliance and study size	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 SA - low risk of compliance bias	3	5811	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.68, 1.63]
4.2 SA - 100+ randomised	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
5 All-cause mortality - ALA - subgroup by dose	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
5.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.80, 1.19]
5.2 ALA high ≥ 5 g/d	4	14490	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.77, 1.75]
6 All-cause mortality - ALA - subgroup by replacement	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 ALA replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 ALA replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.80, 1.19]
6.3 ALA replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.37 [0.48, 3.86]
6.4 ALA replacing CHO	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.5 ALA replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.6 ALA replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	2.78 [0.29, 26.49]
7 All cause mortality - ALA - subgroup by intervention type	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
7.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.2 Supplemental foods	4	5921	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.82, 1.21]
7.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.70, 1.64]
7.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8 All-cause mortality - ALA - subgroup by duration	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
8.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.71, 1.67]
8.2 Medium-long duration: 2 to < 4 years in study	3	5811	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.68, 1.63]
8.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
9 All-cause mortality - ALA - subgroup by primary or secondary prevention	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
9.1 Primary CVD prevention	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.75, 1.74]
9.2 Secondary CVD prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.81, 1.19]
10 All-cause mortality - ALA - subgroup by statin use	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
10.1 ALA - ≥ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.81, 1.19]
10.2 ALA - < 50% of control group on statins	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.75, 1.74]
11 Cardiovascular mortality (overall) - ALA	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
12 CVD mortality - ALA - SA fixed-effect	4	18619	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.74, 1.25]
13 CVD mortality - ALA - SA by summary risk of bias	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
13.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.70, 1.28]
13.2 Moderate/high risk of bias	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
14 CVD mortality - ALA - SA by compliance and study size	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
14.1 SA - low risk of compliance bias	2	5103	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.27]
14.2 SA - 100+ randomised	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
15 CVD mortality - ALA - subgroup by dose	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
15.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.69, 1.27]
15.2 ALA high ≥ 5 g/d	3	13782	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.62, 1.73]
16 CVD mortality - ALA - subgroup by replacement	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
16.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.69, 1.27]
16.3 N-3 replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.60, 1.70]
16.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.6 Replacement unclear	1	110	Risk Ratio (M-H, Random, 95% CI)	2.69 [0.11, 64.74]
17 CVD mortality - ALA - subgroup by intervention type	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
17.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 Supplemental foods	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.70, 1.28]
17.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
17.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
18 CVD mortality - ALA - subgroup by duration	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
18.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
18.2 Medium-long duration: 2 to < 4 years in study	2	5103	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.27]
18.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
19 CVD mortality - ALA - subgroup by primary or secondary prevention	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
19.1 Primary prevention	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
19.2 Secondary prevention	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.70, 1.28]
20 CVD mortality - ALA - subgroup by statin uses	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
20.1 ALA - \geq 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.28]
20.2 ALA - $<$ 50% of control group on statins	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.60, 1.70]
21 Cardiovascular events (overall) - ALA	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
22 CVD events - ALA - SA fixed-effect	5	19327	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.84, 1.07]
23 CVD events - ALA - SA by summary risk of bias	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
23.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.04]
23.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.84, 1.48]
24 CVD events - ALA - SA by compliance and study size	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
24.1 SA - low risk of compliance bias	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.79, 1.04]
24.2 SA - 100+ randomised	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
25 CVD events - ALA - subgroup by dose	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
25.1 ALA low $<$ 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.05]
25.2 ALA high \geq 5 g/d	4	14490	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.82, 1.40]
26 CVD events - ALA - subgroup by replacement	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
26.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.05]
26.3 N-3 replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.24, 2.41]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
26.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.6 Replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.36, 2.43]
27 CVD events - ALA - subgroup by intervention type	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
27.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
27.2 Supplemental foods	4	5921	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.04]
27.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.85, 1.51]
27.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28 CVD events - ALA - subgroup by duration	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
28.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.86, 1.50]
28.2 Medium-long duration: 2 to < 4 years in study	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.79, 1.04]
28.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29 CVD events - ALA - subgroup by primary or secondary prevention	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
29.1 Primary prevention	3	14380	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.46, 1.67]
29.2 Secondary prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.05]
30 CVD events - ALA - subgroup by statin use	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
30.1 ALA - ≥ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.05]
30.2 ALA - < 50% of control group on statins	3	14380	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.46, 1.67]
31 Coronary heart disease mortality (overall) - ALA	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
32 CHD mortality - ALA - SA fixed-effect	3	18353	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.72, 1.26]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
33 CHD mortality - ALA - SA by summary risk of bias	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
33.1 Low risk of bias	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
33.2 Moderate/high risk of bias	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
34 CHD mortality - ALA - SA by compliance and study size	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
34.1 SA - low risk of compliance bias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
34.2 SA - 100+ randomised	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
35 CHD mortality - ALA - subgroup by dose	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
35.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
35.2 ALA high ≥ 5 g/d	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
36 CHD mortality - ALA - subgroup by replacement	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
36.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.2 Coronary heart mortality- ALA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.3 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
36.4 N-3 replacing n-6	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
36.5 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.6 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.7 Replacement unclear	1	110	Risk Ratio (M-H, Random, 95% CI)	2.69 [0.11, 64.74]
37 CHD mortality - ALA - subgroup by intervention type	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
37.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
37.2 Supplemental foods	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
37.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
37.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
38 CHD mortality - ALA - subgroup by duration	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
38.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
38.2 Medium-long duration: 2 to < 4 years in study	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
38.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
39 CHD mortality - ALA - subgroup by primary or secondary prevention	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
39.1 Primary prevention of CVD	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
39.2 Secondary prevention of CVD	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
40 CHD mortality - ALA - subgroup by statin use	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
40.1 ALA - ≥ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
40.2 ALA - < 50% of control group on statins	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
41 CHD mortality - ALA - subgroup by CAD history	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
41.1 Previous CAD	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
41.2 No previous CAD	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
42 Coronary heart disease events (overall) - ALA	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
43 CHD events - ALA - SA fixed-effect	4	19061	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.82, 1.21]
44 CHD events - ALA - SA by summary risk of bias	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
44.1 Low risk of bias	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.71, 1.15]
44.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.86, 1.67]
45 CHD events - ALA - SA by compliance and study size	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
45.1 SA - low risk of compliance bias	2	5545	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.73, 1.17]
45.2 SA - 100+ randomised	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
46 CHD events - ALA - subgroup by dose	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
46.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.72, 1.17]
46.2 ALA high ≥ 5 g/d	3	14224	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.84, 1.61]
47 CHD events - ALA - subgroup by replacement	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
47.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.72, 1.17]
47.3 N-3 replacing n-6	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.85, 1.65]
47.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.6 Replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.08, 5.81]
48 CHD events - ALA - subgroup by intervention type	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
48.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
48.2 Supplemental foods	3	5655	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.72, 1.16]
48.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.85, 1.65]
48.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
49 CHD events - ALA - subgroup by duration	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
49.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.34, 2.58]
49.2 Medium-long duration: 2 to < 4 years in study	2	5545	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.73, 1.17]
49.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
50 CHD events - ALA - subgroup by primary or secondary prevention	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
50.1 Primary prevention	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.86, 1.67]
50.2 Secondary prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.71, 1.15]
51 CHD events - ALA - subgroup by statin use	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
51.1 ALA - \geq 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.71, 1.15]
51.2 ALA - $<$ 50% of control group on statins	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.86, 1.67]
52 CHD events - ALA - subgroup by CAD history	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
52.1 Previous CAD	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.72, 1.17]
52.2 No previous CAD	3	14224	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.84, 1.61]
53 Stroke (overall) - ALA	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
54 Stroke - ALA - SA fixed-effect	5	19327	Risk Ratio (M-H, Fixed, 95% CI)	1.23 [0.71, 2.13]
55 Stroke - ALA - SA by summary risk of bias	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
55.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.45, 2.09]
55.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.62, 3.13]
56 Stroke - ALA - SA by compliance and study size	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
56.1 SA - low risk of compliance bias	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.39, 1.87]
56.2 SA - 100+ randomised	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
57 Stroke - ALA - subgroup by dose	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
57.1 ALA low $<$ 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.39, 2.15]
57.2 ALA high \geq 5 g/d	4	14490	Risk Ratio (M-H, Random, 95% CI)	1.36 [0.65, 2.85]
58 Stroke - ALA - subgroup by replacement	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
58.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.39, 2.15]
58.3 N-3 replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.53, 3.01]
58.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58.6 Replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	1.79 [0.31, 10.17]
59 Stroke - ALA - subgroup by intervention type	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
59.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
59.2 Supplemental foods	4	5921	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.46, 2.03]
59.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.44 [0.62, 3.36]
59.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
60 Stroke - ALA - subgroup by duration	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
60.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.70, 3.44]
60.2 Medium-long duration: 2 to < 4 years in study	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.39, 1.87]
60.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
61 Stroke - ALA - subgroup by primary or secondary prevention	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
61.1 Primary prevention	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.57, 2.74]
61.2 Secondary prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.47, 2.34]
62 Stroke - ALA - subgroup by statin use	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.71, 2.18]
62.1 ALA - ≥ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.56, 2.77]
62.2 ALA - < 50% of control group on statins	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.57, 2.74]







Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
63 Stroke - ALA - subgroup by stroke type	3	13782	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.65, 3.01]
63.1 Ischaemic stroke - ALA	3	13782	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.65, 3.01]
63.2 Haemorrhagic stroke - ALA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
64 Arrhythmia (overall) - ALA	2	4912	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.55, 0.97]
64.1 ALA - new arrhythmias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
64.2 ALA - recurrent arrhythmias	1	75	Risk Ratio (M-H, Random, 95% CI)	0.60 [0.35, 1.03]
65 Arrhythmia - ALA - SA fixed-effect	2	4912	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.57, 1.00]
66 Arrhythmia - ALA - SA by summary risk of bias	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
66.1 Low risk of bias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
66.2 Moderate/high risk of bias	1	75	Risk Ratio (M-H, Random, 95% CI)	0.60 [0.35, 1.03]
67 Arrhythmia - ALA - SA by compliance and study size	1	9674	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.63, 1.00]
67.1 SA - low risk of compliance bias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
67.2 SA - 100+ randomised	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]

Analysis 4.1. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 1 All-cause mortality (overall) - ALA.










Study or subgroup	Favours high- er omega 3 n/N	Lower omega 3 fats n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for overall effect: $Z=0.08(P=0.94)$					
Favours higher omega 3 0.05 0.2 1 5 20 Favours lower omega 3					


Analysis 4.2. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect.

Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
AlphaOmega - ALA 2010	182/2409	188/2428		81.7%	0.98[0.8,1.19]
FLAX-PAD 2013	1/58	0/52		0.23%	2.69[0.11,64.74]
MARGARIN 2002	3/109	1/157		0.36%	4.32[0.46,41]
Norwegian 1968	43/6716	40/6690		17.49%	1.07[0.7,1.64]
WAHA 2016	1/362	0/346		0.22%	2.87[0.12,70.16]
Total (95% CI)	9654	9673		100%	1.01[0.85,1.21]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)					
Heterogeneity: $\tau^2=0$; $\chi^2=2.57$, $df=4(P=0.63)$; $I^2=0\%$					
Test for overall effect: $Z=0.14(P=0.89)$					
Favours higher omega 3 0.1 0.2 0.5 1 2 5 10 Favours lower omega 3					


Analysis 4.3. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 3 All-cause mortality - ALA - SA by summary risk of bias.

Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
4.3.1 Low risk of bias					
AlphaOmega - ALA 2010	182/2409	188/2428		96.41%	0.98[0.8,1.19]
FLAX-PAD 2013	1/58	0/52		1.2%	2.69[0.11,64.74]
MARGARIN 2002	3/109	1/157		2.38%	4.32[0.46,41]
Subtotal (95% CI)	2576	2637		100%	1.02[0.72,1.45]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)					
Heterogeneity: $\tau^2=0.02$; $\chi^2=2.05$, $df=2(P=0.36)$; $I^2=2.55\%$					
Test for overall effect: $Z=0.13(P=0.9)$					
4.3.2 Moderate/high risk of bias					
Norwegian 1968	43/6716	40/6690		98.23%	1.07[0.7,1.64]
WAHA 2016	1/362	0/346		1.77%	2.87[0.12,70.16]
Subtotal (95% CI)	7078	7036		100%	1.09[0.71,1.67]
Total events: 44 (Higher omega 3), 40 (Lower omega 3)					
Heterogeneity: $\tau^2=0$; $\chi^2=0.36$, $df=1(P=0.55)$; $I^2=0\%$					
Test for overall effect: $Z=0.4(P=0.69)$					
Test for subgroup differences: $\chi^2=0.05$, $df=1(P=0.82)$, $I^2=0\%$					
Favours high ALA 0.01 0.1 1 10 100 Favours low ALA					

Analysis 4.4. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 4 All-cause mortality - ALA - SA by compliance and study size.











Analysis 4.5. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 5 All-cause mortality - ALA - subgroup by dose.









Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for overall effect: $Z=0.08(P=0.94)$					
Test for subgroup differences: $\text{Chi}^2=0.54, \text{df}=1 (P=0.46), I^2=0\%$					
Favours higher omega 3 0.1 0.2 0.5 1 2 5 10 Favours lower omega 3					

Analysis 4.6. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 6 All-cause mortality - ALA - subgroup by replacement.


Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
4.6.1 ALA replacing SFA					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
4.6.2 ALA replacing MUFA					
AlphaOmega - ALA 2010	182/2409	188/2428		100%	0.98[0.8,1.19]
Subtotal (95% CI)	2409	2428		100%	0.98[0.8,1.19]
Total events: 182 (Higher omega 3), 188 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: $Z=0.25(P=0.81)$					
4.6.3 ALA replacing n-6					
MARGARIN 2002	3/109	1/157		17.43%	4.32[0.46,41]
Norwegian 1968	43/6716	40/6690		82.57%	1.07[0.7,1.64]
Subtotal (95% CI)	6825	6847		100%	1.37[0.48,3.86]
Total events: 46 (Higher omega 3), 41 (Lower omega 3)					
Heterogeneity: $\text{Tau}^2=0.29; \text{Chi}^2=1.43, \text{df}=1(P=0.23); I^2=29.93\%$					
Test for overall effect: $Z=0.59(P=0.56)$					
4.6.4 ALA replacing CHO					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
4.6.5 ALA replacing nil/low n-3 placebo					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
4.6.6 ALA replacement unclear					
FLAX-PAD 2013	1/58	0/52		50.29%	2.69[0.11,64.74]
WAHA 2016	1/362	0/346		49.71%	2.87[0.12,70.16]
Subtotal (95% CI)	420	398		100%	2.78[0.29,26.49]
Total events: 2 (Higher omega 3), 0 (Lower omega 3)					
Heterogeneity: $\text{Tau}^2=0; \text{Chi}^2=0, \text{df}=1(P=0.98); I^2=0\%$					
Test for overall effect: $Z=0.89(P=0.37)$					
Favours high ALA 0.01 0.1 1 10 100 Favours low ALA					

Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for subgroup differences: $\chi^2=1.19$, $df=1$ ($P=0.55$), $I^2=0\%$					
Favours high ALA 0.01 0.1 1 10 100 Favours low ALA					


Analysis 4.7. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 7 All cause mortality - ALA - subgroup by intervention type.


Study or subgroup	Higher omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
4.7.1 Dietary advice					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
4.7.2 Supplemental foods					
AlphaOmega - ALA 2010	182/2409	188/2428		81.74%	0.98[0.8,1.19]
FLAX-PAD 2013	1/58	0/52		0.31%	2.69[0.11,64.74]
MARGARIN 2002	3/109	1/157		0.62%	4.32[0.46,41]
WAHA 2016	1/362	0/346		0.31%	2.87[0.12,70.16]
Subtotal (95% CI)	2938	2983		82.98%	0.99[0.82,1.21]
Total events: 187 (Higher omega 3), 189 (Lower omega 3)					
Heterogeneity: $\tau^2=0$; $\chi^2=2.48$, $df=3$ ($P=0.48$); $I^2=0\%$					
Test for overall effect: $Z=0.06$ ($P=0.95$)					
4.7.3 Supplements (capsule)					
Norwegian 1968	43/6716	40/6690		17.02%	1.07[0.7,1.64]
Subtotal (95% CI)	6716	6690		17.02%	1.07[0.7,1.64]
Total events: 43 (Higher omega 3), 40 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: $Z=0.31$ ($P=0.75$)					
4.7.4 Any combination					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
Total (95% CI)	9654	9673		100%	1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)					
Heterogeneity: $\tau^2=0$; $\chi^2=2.57$, $df=4$ ($P=0.63$); $I^2=0\%$					
Test for overall effect: $Z=0.08$ ($P=0.94$)					
Test for subgroup differences: $\chi^2=0.1$, $df=1$ ($P=0.76$), $I^2=0\%$					
Favours high ALA 0.01 0.1 1 10 100 Favours low ALA					

Analysis 4.8. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 8 All-cause mortality - ALA - subgroup by duration.




Analysis 4.9. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 9 All-cause mortality - ALA - subgroup by primary or secondary prevention.







Analysis 4.10. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 10 All-cause mortality - ALA - subgroup by statin use.




Analysis 4.11. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 11 Cardiovascular mortality (overall) - ALA.




Analysis 4.12. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 12 CVD mortality - ALA - SA fixed-effect.




Analysis 4.13. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 13 CVD mortality - ALA - SA by summary risk of bias.







Analysis 4.14. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 14 CVD mortality - ALA - SA by compliance and study size.





Analysis 4.15. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 15 CVD mortality - ALA - subgroup by dose.






Analysis 4.16. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 16 CVD mortality - ALA - subgroup by replacement.







Analysis 4.17. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 17 CVD mortality - ALA - subgroup by intervention type.




Analysis 4.18. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 18 CVD mortality - ALA - subgroup by duration.




Analysis 4.19. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 19 CVD mortality - ALA - subgroup by primary or secondary prevention.







Analysis 4.20. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 20 CVD mortality - ALA - subgroup by statin uses.




Analysis 4.21. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 21 Cardiovascular events (overall) - ALA.







Analysis 4.22. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 22 CVD events - ALA - SA fixed-effect.




Analysis 4.23. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 23 CVD events - ALA - SA by summary risk of bias.







Analysis 4.24. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 24 CVD events - ALA - SA by compliance and study size.





Analysis 4.25. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 25 CVD events - ALA - subgroup by dose.







Analysis 4.26. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 26 CVD events - ALA - subgroup by replacement.






Analysis 4.27. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 27 CVD events - ALA - subgroup by intervention type.







Analysis 4.28. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 28 CVD events - ALA - subgroup by duration.





Analysis 4.29. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 29 CVD events - ALA - subgroup by primary or secondary prevention.






Analysis 4.30. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 30 CVD events - ALA - subgroup by statin use.







Analysis 4.31. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) - ALA.




Analysis 4.32. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 32 CHD mortality - ALA - SA fixed-effect.




Analysis 4.33. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 33 CHD mortality - ALA - SA by summary risk of bias.







Analysis 4.34. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 34 CHD mortality - ALA - SA by compliance and study size.





Analysis 4.35. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 35 CHD mortality - ALA - subgroup by dose.







Analysis 4.36. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 36 CHD mortality - ALA - subgroup by replacement.






Analysis 4.37. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 37 CHD mortality - ALA - subgroup by intervention type.







Analysis 4.38. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 38 CHD mortality - ALA - subgroup by duration.




Analysis 4.39. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 39 CHD mortality - ALA - subgroup by primary or secondary prevention.







Analysis 4.40. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 40 CHD mortality - ALA - subgroup by statin use.




Analysis 4.41. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 41 CHD mortality - ALA - subgroup by CAD history.




Analysis 4.42. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 42 Coronary heart disease events (overall) - ALA.




Analysis 4.43. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 43 CHD events - ALA - SA fixed-effect.




Analysis 4.44. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 44 CHD events - ALA - SA by summary risk of bias.




Analysis 4.45. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 45 CHD events - ALA - SA by compliance and study size.







Analysis 4.46. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 46 CHD events - ALA - subgroup by dose.




Analysis 4.47. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 47 CHD events - ALA - subgroup by replacement.




Analysis 4.48. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 48 CHD events - ALA - subgroup by intervention type.




Analysis 4.49. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 49 CHD events - ALA - subgroup by duration.







Analysis 4.50. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 50 CHD events - ALA - subgroup by primary or secondary prevention.




Analysis 4.51. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 51 CHD events - ALA - subgroup by statin use.




Analysis 4.52. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 52 CHD events - ALA - subgroup by CAD history.







Analysis 4.53. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 53 Stroke (overall) - ALA.




Analysis 4.54. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 54 Stroke - ALA - SA fixed-effect.




Analysis 4.55. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 55 Stroke - ALA - SA by summary risk of bias.




Analysis 4.56. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 56 Stroke - ALA - SA by compliance and study size.




Analysis 4.57. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 57 Stroke - ALA - subgroup by dose.





Analysis 4.58. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 58 Stroke - ALA - subgroup by replacement.






Analysis 4.59. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 59 Stroke - ALA - subgroup by intervention type.







Analysis 4.60. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 60 Stroke - ALA - subgroup by duration.




Analysis 4.61. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 61 Stroke - ALA - subgroup by primary or secondary prevention.




Analysis 4.62. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 62 Stroke - ALA - subgroup by statin use.







Analysis 4.63. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 63 Stroke - ALA - subgroup by stroke type.




Analysis 4.64. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 64 Arrhythmia (overall) - ALA.






Analysis 4.65. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 65 Arrhythmia - ALA - SA fixed-effect.








Analysis 4.66. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 66 Arrhythmia - ALA - SA by summary risk of bias.



Study or subgroup	Favours high- er omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for overall effect: $Z=1.86(P=0.06)$ Test for subgroup differences: $\chi^2=0.75, df=1 (P=0.39), I^2=0\%$					
Favours higher omega 3 0.1 0.2 0.5 1 2 5 10 Favours lower omega 3					

Analysis 4.67. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 67 Arrhythmia - ALA - SA by compliance and study size.

Study or subgroup	Favours high- er omega 3 n/N	Lower omega 3 n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
4.67.1 SA - low risk of compliance bias					
AlphaOmega - ALA 2010	62/2409	79/2428		50%	0.79[0.57,1.1]
Subtotal (95% CI)	2409	2428		50%	0.79[0.57,1.1]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: $Z=1.4(P=0.16)$					
4.67.2 SA - 100+ randomised					
AlphaOmega - ALA 2010	62/2409	79/2428		50%	0.79[0.57,1.1]
Subtotal (95% CI)	2409	2428		50%	0.79[0.57,1.1]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)					
Heterogeneity: Not applicable					
Test for overall effect: $Z=1.4(P=0.16)$					
Total (95% CI)	4818	4856		100%	0.79[0.63,1]
Total events: 124 (Favours higher omega 3), 158 (Lower omega 3)					
Heterogeneity: $\tau^2=0; \chi^2=0, df=1(P=1); I^2=0\%$					
Test for overall effect: $Z=1.98(P=0.05)$					
Test for subgroup differences: Not applicable					
Favours higher omega 3 0.5 0.7 1 1.5 2 Favours lower omega 3					

Comparison 5. High vs low ALA omega-3 fat (secondary outcomes)

Outcome or subgroup title	No. of studies	No. of parti- cants	Statistical method	Effect size
1 MACCES - ALA	1	110	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.32, 3.95]
2 Myocardial infarction (overall) - ALA	3	18353	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.76, 1.32]
3 Total MI - ALA - subgroup by fatality	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Fatal MI	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.62, 1.46]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.2 Non-fatal MI	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.15, 1.77]
4 Angina - ALA	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.41 [0.75, 2.64]
5 Revascularisation - ALA	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 CABG - ALA	1	266	Risk Ratio (M-H, Random, 95% CI)	0.29 [0.01, 5.93]
5.2 Angioplasty - ALA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Any revascularisation - ALA	1	266	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.07, 7.84]
6 Peripheral arterial disease - ALA	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
7 Body weight, kg - ALA	4	664	Mean Difference (IV, Random, 95% CI)	-1.49 [-4.17, 1.18]
8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect	4	664	Mean Difference (IV, Fixed, 95% CI)	0.17 [-0.61, 0.96]
9 Weight, kg - ALA - SA by summary risk of bias	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 Low risk of bias	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
9.2 Moderate/high risk of bias	4	664	Mean Difference (IV, Random, 95% CI)	-1.49 [-4.17, 1.18]
10 Weight, kg - ALA - SA by compliance and study size	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
10.1 SA - low risk of compliance bias	3	629	Mean Difference (IV, Random, 95% CI)	-1.59 [-4.47, 1.30]
10.2 SA - 100+ randomised	3	629	Mean Difference (IV, Random, 95% CI)	-1.59 [-4.47, 1.30]
11 Weight, kg - ALA - subgroup by dose	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
11.1 ALA low < 5 g/d	3	485	Mean Difference (IV, Random, 95% CI)	-0.71 [-3.31, 1.90]
11.2 ALA high > 5 g/d	1	179	Mean Difference (IV, Random, 95% CI)	-4.20 [-7.61, -0.79]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12 Weight, kg - ALA - subgroup by intervention type	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
12.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
12.2 Supplemental foods	3	526	Mean Difference (IV, Random, 95% CI)	-1.23 [-5.27, 2.80]
12.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
12.4 Any combination	1	138	Mean Difference (IV, Random, 95% CI)	-1.98 [-5.89, 1.92]
13 Weight, kg - ALA - subgroup by replacement	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
13.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.2 ALA replacing MUFA	1	138	Mean Difference (IV, Random, 95% CI)	-1.98 [-5.89, 1.92]
13.3 ALA replacing n-6	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	-0.30 [-10.57, 9.97]
13.6 Replacement unclear	2	491	Mean Difference (IV, Random, 95% CI)	-1.43 [-6.26, 3.39]
14 Weight, kg - ALA - subgroup by duration	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
14.1 Medium duration 1 to < 2 years in study	4	664	Mean Difference (IV, Random, 95% CI)	-1.49 [-4.17, 1.18]
14.2 Medium-long duration: 2 to < 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
14.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
15 Weight, kg - ALA - subgroup by statin use	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
15.1 ALA - ≥ 50% of control group on statins	1	35	Mean Difference (IV, Random, 95% CI)	-0.30 [-10.57, 9.97]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
15.2 ALA - < 50% of control group on statins	1	138	Mean Difference (IV, Random, 95% CI)	-1.98 [-5.89, 1.92]
15.3 ALA - use of statins unclear	2	491	Mean Difference (IV, Random, 95% CI)	-1.43 [-6.26, 3.39]
16 Weight, kg - ALA - subgroup by primary or secondary prevention	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
16.1 Low CVD risk	3	629	Mean Difference (IV, Random, 95% CI)	-1.59 [-4.47, 1.30]
16.2 Moderate CVD risk	1	35	Mean Difference (IV, Random, 95% CI)	-0.30 [-10.57, 9.97]
16.3 High CVD risk	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17 Body mass index, kg/m ² - ALA	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
18 BMI, kg/m ² - ALA - SA fixed-effect	3	1581	Mean Difference (IV, Fixed, 95% CI)	0.12 [-0.06, 0.30]
19 BMI, kg/m ² - ALA - SA by summary risk of bias	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
19.1 Low risk of bias	2	1402	Mean Difference (IV, Random, 95% CI)	0.15 [-0.04, 0.33]
19.2 Moderate/high risk of bias	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
20 BMI, kg/m ² - ALA - SA by compliance and study size	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
20.1 SA - low risk of compliance bias	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
20.2 SA - 100+ randomised	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
21 BMI, kg/m ² - ALA - subgroup by dose	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
21.1 ALA low < 5 g/d	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
21.2 ALA high > 5 g/d	2	321	Mean Difference (IV, Random, 95% CI)	-1.12 [-2.24, 0.01]
22 BMI, kg/m ² - ALA - subgroup by intervention type	3		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
22.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
22.2 Supplemental foods	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
22.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
22.4 Any combination	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23 BMI, kg/m² - ALA - subgroup by replacement	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
23.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23.2 ALA replacing MUFA	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
23.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	-0.3 [-2.29, 1.69]
23.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23.5 ALA replacing nil/low n-3 placebo	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23.6 Replacement unclear	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
24 BMI, kg/m² - ALA - subgroup by duration	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
24.1 Medium duration 1 to < 2 years in study	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
24.2 Medium-long duration: 2 to < 4 years in study	2	1402	Mean Difference (IV, Random, 95% CI)	0.15 [-0.04, 0.33]
24.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
25 BMI, kg/m² - ALA - subgroup by statin use	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
25.1 ALA - ≥ 50% of control group on statins	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
25.2 ALA - < 50% of control group on statins	1	142	Mean Difference (IV, Random, 95% CI)	-0.3 [-2.29, 1.69]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
25.3 ALA - use of statins unclear	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
26 BMI, kg/m ² - ALA - subgroup by primary or secondary preventionA	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
26.1 Primary prevention of CVD	2	321	Mean Difference (IV, Random, 95% CI)	-1.12 [-2.24, 0.01]
26.2 Secondary prevention of CVD	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
27 Other measures of adiposity - ALA	4		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
27.1 Visceral adipose tissue, cm ²	1	35	Mean Difference (IV, Fixed, 95% CI)	27.0 [-21.28, 75.28]
27.2 Subcutaneous adipose tissue, cm ²	1	35	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.3 Waist circumference, cm	3	629	Mean Difference (IV, Fixed, 95% CI)	-1.59 [-3.10, -0.07]
28 Total cholesterol, serum, mmol/L - ALA	6	2164	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.23, 0.05]
29 TC, mmol/L - ALA - SA fixed-effect	6	2164	Mean Difference (IV, Fixed, 95% CI)	-0.10 [-0.17, -0.03]
30 TC, mmol/L - ALA - SA by summary risk of bias	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
30.1 Low risk of bias	3	1436	Mean Difference (IV, Random, 95% CI)	0.00 [-0.13, 0.14]
30.2 Moderate/high risk of bias	3	728	Mean Difference (IV, Random, 95% CI)	-0.19 [-0.36, -0.01]
31 TC, mmol/L - ALA - SA by compliance and study size	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
31.1 SA - low risk of compliance bias	4	2045	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.25, 0.05]
31.2 SA - 100+ randomised	4	2045	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.25, 0.05]
32 TC, mmol/L - ALA - subgroup by dose	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
32.1 ALA low < 5 g/d	3	1759	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.24, 0.09]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
32.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	-0.13 [-0.47, 0.21]
33 TC, mmol/L - ALA - subgroup by intervention type	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
33.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
33.2 Supplemental foods	6	2164	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.23, 0.05]
33.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
33.4 Any combination	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
34 TC, mmol/L - ALA - subgroup by replacement	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
34.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
34.2 ALA replacing MUFA	1	1210	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.13, 0.09]
34.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	0.14 [-0.10, 0.38]
34.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
34.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	0.30 [-0.30, 0.90]
34.6 Replacement unclear	3	777	Mean Difference (IV, Random, 95% CI)	-0.21 [-0.31, -0.11]
35 TC, mmol/L - ALA - subgroup by duration	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
35.1 Medium duration 1 to < 2 years in study	4	812	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.33, -0.07]
35.2 Medium-long duration: 2 to < 4 years in study	2	1352	Mean Difference (IV, Random, 95% CI)	0.02 [-0.12, 0.16]
35.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
36 TC, mmol/L - ALA - subgroup by statin use	6		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
36.1 ALA - \geq 50% of control group on statins	3	1329	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.15, 0.11]
36.2 ALA - < 50% of control group on statins	1	142	Mean Difference (IV, Random, 95% CI)	0.14 [-0.10, 0.38]
36.3 ALA - use of statins unclear	2	693	Mean Difference (IV, Random, 95% CI)	-0.21 [-0.30, -0.11]
37 TC, mmol/L - ALA - subgroup by primary or secondary prevention	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
37.1 Primary prevention of CVD	4	870	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.30, 0.12]
37.2 Secondary prevention of CVD	2	1294	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.14, 0.08]
38 Triglycerides, fasting, serum, mmol/L - ALA	6	1776	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.11, 0.05]
39 TG, fasting, mmol/L - ALA - SA fixed-effect	6	1776	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.11, 0.05]
40 TG, fasting, mmol/L - ALA - SA by summary risk of bias	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
40.1 Low risk of bias	3	1436	Mean Difference (IV, Random, 95% CI)	0.03 [-0.13, 0.19]
40.2 Moderate/high risk of bias	3	340	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.18, 0.09]
41 TG, fasting, mmol/L - ALA - SA by compliance and study size	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
41.1 SA - low risk of compliance bias	4	1657	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.13, 0.04]
41.2 SA - 100+ randomised	4	1657	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.13, 0.04]
42 TG, fasting, mmol/L - ALA - subgroup by dose	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
42.1 ALA low < 5 g/d	3	1371	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.16, 0.03]
42.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	0.05 [-0.09, 0.19]
43 TG, fasting, mmol/L - ALA - subgroup by intervention type	6		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
43.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
43.2 Supplemental foods	5	1650	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.10, 0.07]
43.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
43.4 Any combination	1	126	Mean Difference (IV, Random, 95% CI)	-0.12 [-0.33, 0.09]
44 TG, fasting, mmol/L-AL - subgroup by replacement	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
44.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
44.2 ALA replacing MUFA	2	1336	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.17, 0.02]
44.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	0.13 [-0.16, 0.42]
44.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
44.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	0.30 [-0.39, 0.99]
44.6 Replacement unclear	2	263	Mean Difference (IV, Random, 95% CI)	0.04 [-0.15, 0.23]
45 TG, fasting, mmol/L- ALA - subgroup by duration	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
45.1 Medium duration 1 to < 2 years in study	4	424	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.15, 0.12]
45.2 Medium-long duration: 2 to < 4 years in study	2	1352	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.17, 0.15]
45.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
46 TG, fasting, mmol/L - ALA - subgroup by statin use	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
46.1 ALA - ≥ 50% of control group on statins	3	1329	Mean Difference (IV, Random, 95% CI)	0.03 [-0.17, 0.23]
46.2 ALA - < 50% of control group on statins	2	268	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.26, 0.23]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
46.3 ALA - use of statins unclear	1	179	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.20, 0.16]
47 TG, fasting, mmol/L - ALA - subgroup by primary or secondary prevention	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
47.1 Primary prevention	4	482	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.14, 0.11]
47.2 Secondary prevention	2	1294	Mean Difference (IV, Random, 95% CI)	0.02 [-0.22, 0.25]
48 High-density lipoprotein, serum, mmol/L - ALA	6	1776	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.08, 0.03]
49 HDL, mmol/L - ALA - SA fixed-effect	6	1776	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.05, 0.00]
50 HDL, mmol/L - ALA - SA by summary risk of bias	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
50.1 Low risk of bias	3	1436	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.06, 0.00]
50.2 Moderate/high risk of bias	3	340	Mean Difference (IV, Random, 95% CI)	0.04 [-0.14, 0.22]
51 HDL, mmol/L - ALA - SA by compliance and study size	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
51.1 SA - low risk of compliance bias	4	1657	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.08, 0.04]
51.2 SA - 100+ randomised	4	1657	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.08, 0.04]
52 HDL, mmol/L - ALA - subgroup by dose	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
52.1 ALA low < 5 g/d	3	1371	Mean Difference (IV, Random, 95% CI)	0.06 [-0.08, 0.19]
52.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.12, -0.01]
53 HDL, mmol/L - ALA - subgroup by intervention type	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
53.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
53.2 Supplemental foods	5	1650	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.06, -0.00]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
53.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
53.4 Any combination	1	126	Mean Difference (IV, Random, 95% CI)	0.15 [0.01, 0.29]
54 HDL, mmol/L - ALA - subgroup by replacement	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
54.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.2 ALA replacing MUFA	2	1336	Mean Difference (IV, Random, 95% CI)	0.05 [-0.11, 0.22]
54.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.11, 0.03]
54.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	0.10 [-0.17, 0.37]
54.6 Replacement unclear	2	263	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.17, -0.02]
55 HDL, mmol/L - ALA - subgroup by duration	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
55.1 Medium duration 1 to < 2 years in study	4	424	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.13, 0.13]
55.2 Medium-long duration: 2 to < 4 years in study	2	1352	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.05, 0.00]
55.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
56 HDL, mmol/L - ALA - subgroup by statin use	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
56.1 ALA - ≥ 50% of control group on statins	3	1329	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.09, 0.03]
56.2 ALA - < 50% of control group on statins	2	268	Mean Difference (IV, Random, 95% CI)	0.05 [-0.14, 0.23]
56.3 ALA - use of statins unclear	1	179	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.20, 0.02]
57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention	6		Mean Difference (IV, Random, 95% CI)	Subtotals only


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
57.1 Low CVD risk	2	305	Mean Difference (IV, Random, 95% CI)	0.03 [-0.21, 0.26]
57.2 Moderate CVD risk	2	177	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.10, 0.04]
57.3 High CVD risk	2	1294	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.11, 0.03]
58 Low-density lipoprotein, serum, mmol/L - ALA	7	2201	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.15, 0.04]
59 LDL, mmol/L - ALA - SA fixed-effect	7	2201	Mean Difference (IV, Fixed, 95% CI)	-0.05 [-0.11, 0.00]
60 LDL, mmol/L - ALA - SA by summary risk of bias	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
60.1 Low risk of bias	3	1350	Mean Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.10]
60.2 Moderate/high risk of bias	4	851	Mean Difference (IV, Random, 95% CI)	-0.14 [-0.22, -0.06]
61 LDL, mmol/L - ALA - SA by compliance and study size	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
61.1 SA - low risk of compliance bias	5	2085	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.16, 0.06]
61.2 SA - 100+ randomised	5	2085	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.16, 0.06]
62 LDL, mmol/L - ALA - subgroup by dose	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
62.1 ALA low < 5 g/d	4	1796	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.17, 0.05]
62.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.28, 0.19]
63 LDL, mmol/L - ALA - subgroup by intervention type	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
63.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
63.2 Supplemental foods	6	2075	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.17, 0.05]
63.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
63.4 Any combination	1	126	Mean Difference (IV, Random, 95% CI)	0.0 [-0.25, 0.25]
64 LDL, mmol/L - ALA - subgroup by replacement	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
64.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
64.2 ALA replacing MUFA	2	1250	Mean Difference (IV, Random, 95% CI)	0.01 [-0.07, 0.09]
64.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	0.14 [-0.08, 0.36]
64.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
64.5 ALA replacing nil/low n-3 placebo	1	32	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.59, 0.39]
65 LDL, mmol/L - ALA - subgroup by duration	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
65.1 Medium duration 1 to < 2 years in study	5	935	Mean Difference (IV, Random, 95% CI)	-0.14 [-0.22, -0.06]
65.2 Medium-long duration: 2 to < 4 years in study	2	1266	Mean Difference (IV, Random, 95% CI)	0.03 [-0.06, 0.13]
65.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
66 LDL, mmol/L - ALA - subgroup by statin use	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
66.1 ALA - ≥ 50% of control group on statins	3	1240	Mean Difference (IV, Random, 95% CI)	0.00 [-0.08, 0.08]
66.2 ALA - < 50% of control group on statins	2	268	Mean Difference (IV, Random, 95% CI)	0.08 [-0.09, 0.24]
66.3 ALA - use of statins unclear	2	693	Mean Difference (IV, Random, 95% CI)	-0.16 [-0.25, -0.07]
67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
67.1 Primary prevention of CVD	5	993	Mean Difference (IV, Random, 95% CI)	-0.08 [-0.20, 0.05]
67.2 Secondary prevention of CVD	2	1208	Mean Difference (IV, Random, 95% CI)	0.01 [-0.08, 0.09]


Analysis 5.1. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 1 MACCEs - ALA.




Analysis 5.2. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 2 Myocardial infarction (overall) - ALA.




Analysis 5.3. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 3 Total MI - ALA - subgroup by fatality.







Analysis 5.4. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 4 Angina - ALA.




Analysis 5.5. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 5 Revascularisation - ALA.




Analysis 5.6. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 6 Peripheral arterial disease - ALA.




Analysis 5.7. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 7 Body weight, kg - ALA.




Analysis 5.8. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect.




Analysis 5.9. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 9 Weight, kg - ALA - SA by summary risk of bias.







Analysis 5.10. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 10 Weight, kg - ALA - SA by compliance and study size.




Analysis 5.11. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 11 Weight, kg - ALA - subgroup by dose.







Analysis 5.12. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 12 Weight, kg - ALA - subgroup by intervention type.




Analysis 5.13. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 13 Weight, kg - ALA - subgroup by replacement.







Analysis 5.14. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 14 Weight, kg - ALA - subgroup by duration.







Analysis 5.15. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 15 Weight, kg - ALA - subgroup by statin use.




Analysis 5.16. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 16 Weight, kg - ALA - subgroup by primary or secondary prevention.**Analysis 5.17. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 17 Body mass index, kg/m² - ALA.****Analysis 5.18. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 18 BMI, kg/m² - ALA - SA fixed-effect.**



Analysis 5.19. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 19 BMI, kg/m² - ALA - SA by summary risk of bias.








Analysis 5.20. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 20 BMI, kg/m² - ALA - SA by compliance and study size.








Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI			
	N	Mean(SD)	N	Mean(SD)						
Test for subgroup differences: Not applicable										
Favours higher omega 3					-20	-10	0	10	20	Favours lower omega 3

Analysis 5.21. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 21 BMI, kg/m² - ALA - subgroup by dose.








Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
5.21.1 ALA low < 5 g/d							
AlphaOmega - ALA 2010	630	0.1 (1.5)	630	-0.1 (1.8)		100%	0.15[-0.03,0.33]
Subtotal ***	630		630			100%	0.15[-0.03,0.33]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.61(P=0.11)							
5.21.2 ALA high > 5 g/d							
Dodin 2005	85	25.9 (4.5)	94	27.4 (4.8)		68.08%	-1.5[-2.86,-0.14]
MARGARIN 2002	49	0.2 (1.4)	93	0.5 (9.6)		31.92%	-0.3[-2.29,1.69]
Subtotal ***	134		187			100%	-1.12[-2.24,0.01]
Heterogeneity: Tau ² =0; Chi ² =0.95, df=1(P=0.33); I ² =0%							
Test for overall effect: Z=1.95(P=0.05)							
Test for subgroup differences: Chi ² =4.75, df=1 (P=0.03), I ² =78.96%							
<div><div></div><div>Favours higher omega 3</div><div>-20-1001020</div><div>Favours lower omega 3</div></div>							

Analysis 5.22. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 22 BMI, kg/m² - ALA - subgroup by intervention type.


Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
5.22.1 Dietary advice							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
5.22.2 Supplemental foods							
AlphaOmega - ALA 2010	630	0.1 (1.5)	630	-0.1 (1.8)		51.23%	0.15[-0.03,0.33]
Dodin 2005	85	25.9 (4.5)	94	27.4 (4.8)		29.23%	-1.5[-2.86,-0.14]
MARGARIN 2002	49	0.2 (1.4)	93	0.5 (9.6)		19.54%	-0.3[-2.29,1.69]
Subtotal ***	764		817			100%	-0.42[-1.53,0.69]
Heterogeneity: Tau ² =0.62; Chi ² =5.7, df=2(P=0.06); I ² =64.93%							
Test for overall effect: Z=0.74(P=0.46)							
5.22.3 Supplement (capsule)							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
5.22.4 Any combination							
<div><div></div><div>Favours higher omega 3</div><div>-20-1001020</div><div>Favours lower omega 3</div></div>							

Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
							


Analysis 5.23. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 23 BMI, kg/m² - ALA - subgroup by replacement.

Study or subgroup	Higher omega 3		Lower omega 3		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
5.23.1 ALA replacing SFA							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
5.23.2 ALA replacing MUFA							
AlphaOmega - ALA 2010	630	0.1 (1.5)	630	-0.1 (1.8)		100%	0.15[-0.03,0.33]
Subtotal ***	630		630			100%	0.15[-0.03,0.33]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.61(P=0.11)							
5.23.3 ALA replacing n-6							
MARGARIN 2002	49	0.2 (1.4)	93	0.5 (9.6)		100%	-0.3[-2.29,1.69]
Subtotal ***	49		93			100%	-0.3[-2.29,1.69]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.3(P=0.77)							
5.23.4 ALA replacing carbs/sugars							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
5.23.5 ALA replacing nil/low n-3 placebo							
Subtotal ***	0		0				Not estimable
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
5.23.6 Replacement unclear							
Dodin 2005	85	25.9 (4.5)	94	27.4 (4.8)		100%	-1.5[-2.86,-0.14]
Subtotal ***	85		94			100%	-1.5[-2.86,-0.14]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.16(P=0.03)							
Test for subgroup differences: Chi ² =5.7, df=1 (P=0.06), I ² =64.93%							
							


Analysis 5.24. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 24 BMI, kg/m² - ALA - subgroup by duration.




Analysis 5.25. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 25 BMI, kg/m² - ALA - subgroup by statin use.




Analysis 5.26. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 26 BMI, kg/m² - ALA - subgroup by primary or secondary preventionA.




Analysis 5.27. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 27 Other measures of adiposity - ALA.




Analysis 5.28. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 28 Total cholesterol, serum, mmol/L - ALA.




Analysis 5.29. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 29 TC, mmol/L - ALA - SA fixed-effect.




Analysis 5.30. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 30 TC, mmol/L - ALA - SA by summary risk of bias.







Analysis 5.31. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 31 TC, mmol/L - ALA - SA by compliance and study size.




Analysis 5.32. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 32 TC, mmol/L - ALA - subgroup by dose.







Analysis 5.33. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 33 TC, mmol/L - ALA - subgroup by intervention type.




Analysis 5.34. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 34 TC, mmol/L - ALA - subgroup by replacement.







Analysis 5.35. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 35 TC, mmol/L - ALA - subgroup by duration.







Analysis 5.36. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 36 TC, mmol/L - ALA - subgroup by statin use.




Analysis 5.37. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 37 TC, mmol/L - ALA - subgroup by primary or secondary prevention.**Analysis 5.38. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 38 Triglycerides, fasting, serum, mmol/L - ALA.****Analysis 5.39. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 39 TG, fasting, mmol/L - ALA - SA fixed-effect.**




Analysis 5.40. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 40 TG, fasting, mmol/L- ALA - SA by summary risk of bias.




Analysis 5.41. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 41 TG, fasting, mmol/L- ALA - SA by compliance and study size.







Analysis 5.42. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 42 TG, fasting, mmol/L - ALA - subgroup by dose.





Analysis 5.43. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 43 TG, fasting, mmol/L- ALA - subgroup by intervention type.






Analysis 5.44. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 44 TG, fasting, mmol/L-AL - subgroup by replacement.







Analysis 5.45. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 45 TG, fasting, mmol/L- ALA - subgroup by duration.




Analysis 5.46. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 46 TG, fasting, mmol/L - ALA - subgroup by statin use.







Analysis 5.47. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 47 TG, fasting, mmol/L- ALA - subgroup by primary or secondary prevention.




Analysis 5.48. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 48 High-density lipoprotein, serum, mmol/L - ALA.




Analysis 5.49. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 49 HDL, mmol/L - ALA - SA fixed-effect.




Analysis 5.50. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 50 HDL, mmol/L - ALA - SA by summary risk of bias.







Analysis 5.51. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 51 HDL, mmol/L - ALA - SA by compliance and study size.




Analysis 5.52. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 52 HDL, mmol/L - ALA - subgroup by dose.







Analysis 5.53. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 53 HDL, mmol/L - ALA - subgroup by intervention type.




Analysis 5.54. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 54 HDL, mmol/L - ALA - subgroup by replacement.




Analysis 5.55. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 55 HDL, mmol/L - ALA - subgroup by duration.







Analysis 5.56. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 56 HDL, mmol/L - ALA - subgroup by statin use.




Analysis 5.57. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention.




Analysis 5.58. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 58 Low-density lipoprotein, serum, mmol/L - ALA.




Analysis 5.59. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 59 LDL, mmol/L - ALA - SA fixed-effect.




Analysis 5.60. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 60 LDL, mmol/L - ALA - SA by summary risk of bias.




Analysis 5.61. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 61 LDL, mmol/L - ALA - SA by compliance and study size.







Analysis 5.62. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 62 LDL, mmol/L - ALA - subgroup by dose.




Analysis 5.63. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 63 LDL, mmol/L - ALA - subgroup by intervention type.




Analysis 5.64. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 64 LDL, mmol/L - ALA - subgroup by replacement.







Analysis 5.65. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 65 LDL, mmol/L - ALA - subgroup by duration.



Analysis 5.66. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 66 LDL, mmol/L - ALA - subgroup by statin use.




Analysis 5.67. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention.




Comparison 6. High vs low ALA omega-3 fats (tertiary outcomes)


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Blood pressure, mmHg - ALA	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Systolic BP - ALA	4	1671	Mean Difference (IV, Random, 95% CI)	-0.87 [-4.48, 2.75]
1.2 Diastolic BP - ALA	4	1671	Mean Difference (IV, Random, 95% CI)	-1.42 [-4.40, 1.57]
2 Serious adverse events - ALA	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Any serious adverse events	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Bleeding	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Serious GI effects	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.4 Pulmonary embolus or DVT	1	708	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.01, 7.80]
2.5 Thrombophlebitis	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.59 [0.72, 3.51]
2.6 Urolithiasis	1	13406	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.47, 1.36]
3 Side effects - ALA	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Dropouts due to side effects	5	3480	Risk Ratio (M-H, Random, 95% CI)	2.10 [0.66, 6.71]
3.2 Abdominal pain or discomfort	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 Diarrhoea	1	708	Risk Ratio (M-H, Random, 95% CI)	3.82 [0.82, 17.88]
3.4 Nausea	1	110	Risk Ratio (M-H, Random, 95% CI)	6.29 [0.33, 118.93]
3.5 Any gastrointestinal side effect - ALA	4	3450	Risk Ratio (M-H, Random, 95% CI)	2.06 [0.62, 6.80]
3.6 Pain (joint, lumbar, muscle pain)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3.7 All side effects combined	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Dropouts - ALA	6	3663	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.92, 1.25]

Analysis 6.1. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - ALA.





Analysis 6.2. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - ALA.






Analysis 6.3. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 3 Side effects - ALA.





Analysis 6.4. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - ALA.



ADDITIONAL TABLES

Table 1. Risk of bias assessment methods in greater detail

Risk of bias element	Criteria for low risk of bias	Criteria for unclear	Criteria for high risk of bias
Selection bias: random sequence generation	The trial authors needed to have described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. For example "the randomisation sequence was computer generated". We allowed that a good method of randomisation was strongly implied if the authors discussed stratification and/or blocking. Therefore, if the authors were not explicit about their randomisation method but did describe stratification or blocking we assessed this as corresponding to low risk.	The trial authors have not described their method in sufficient detail for the assessment of whether it would produce comparable groups. For example, the authors state "the trial was randomised" and provide no further information.	The randomisation method was assessed as not truly random, and may not produce comparable groups.
Selection bias: allocation concealment	The trial authors needed to have described the method used to conceal allocation sequence in sufficient detail to determine whether the allocations could have been foreseen in advance of, or during, enrolment. Good methods included putting allocation codes in opaque sealed envelopes (ideally prepared by someone outside the treatment or assessment teams and sequentially numbered), using a telephone allocation system after the participants had consented to participate or providing a random number that links to a specific set of capsules prepared and distributed centrally or by an arms-length pharmacist.	The trial authors gave insufficient detail as to method.	The allocation was known in advance of participants consenting to take part in the trial.
Performance bias: blinding of participants and personnel	The trial authors needed to have described all measures used, if any, to blind trial participants and personnel from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say "both the intervention and placebo capsules looked and tasted the same." However, if the trial authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding, then we assumed that the blinding was effective and the risk of bias was low.	Insufficient methodological details were provided e.g. "the trial was blinded."	The trial was unblinded or where blinding was broken, e.g. "the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only."
Detection bias: blinding of outcome assessment	Trial authors needed to have described measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say "the outcome assessors had no knowledge of the group allocation, and both the intervention and placebo capsules looked and tasted the same so the self-assessment scales were also blinded." However if the trial authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding of the assessors, then we assumed that the blinding was effective and the risk of bias is low. All bio-	Insufficient methodological details were provided e.g. "the trial was blinded."	The trial was unblinded or blinding was broken, e.g. for a self-assessment measure "the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only." Because the level of blinding could vary by outcome, assessment of risk of bias was based on blinding of the review's primary outcome(s). Where primary out-

Table 1. Risk of bias assessment methods in greater detail *(Continued)*

	chemical assessment (lipids, glucose, CRP, insulin, PSA, etc.) were considered at low risk of detection bias if outcome assessor blinding or double-blinding was stated.		comes had different assessments we opted for the higher risk of bias but noted that risk of bias was lower for other outcomes.
Attrition bias: incomplete outcome data	The trial authors needed to describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. They needed to report the number of attrition/exclusions, the numbers in each group at each time point, reasons for attrition/exclusion and any re-inclusions in analyses. Ideally, they would report how they imputed any missing data e.g. last observation carried forward. There needed to be a reasonable balance of attrition/exclusions between trial arms and $\leq 20\%$ of the sample should be lost over a year.	The authors didn't state reasons for attrition/exclusion, or were unclear about the numbers lost to attrition/exclusion in each trial arm.	The authors demonstrated a substantial difference in the rates of attrition/exclusions between the trial arms and/or $> 20\%$ of the baseline sample was lost over a year ($> 10\%$ over 6 months).
Reporting bias: selective outcome reporting	The trial authors needed to have published their trial protocol or trials registry entry before the end of the trial's recruitment period, i.e. prospectively. They needed to have reported on all of the primary and secondary outcomes listed in the protocol/registry entry. We deemed reporting additional secondary outcomes in the results paper(s), although not ideal, to still be low risk.	No trial protocol or trials registry entry was found, it was registered retrospectively, or the dates of registration and participant recruitment were unclear.	The trial authors did not report at least one primary or secondary outcome listed in the protocol/registry entry or the results paper(s) reported a primary outcome that was not listed at all in the protocol or not listed as a primary outcome in the protocol.
Other sources of bias: attention bias	The trial authors needed to have reported that participants in all trial arms received the same amount of attention and time from researchers and clinical teams. For example, "All participants attended the clinic for a baseline assessment which took 2 hours. They were then followed with monthly telephone calls, and finally attended for a 6 month assessment at the clinic which took 1 hour." If the trial only differed by the content of the capsules, and the assessment schedule was not stated to differ between the two arms, we assumed it to be at low risk.	The authors did not state the attention each arm received.	Participants in different arms received different amounts of attention. For example "the intervention group only attended for additional assessments at months 2, 4, and 6" or "the rates of relapse differed substantially between the groups which led to differing amounts of treatment time and attention," or "the intervention group received a 40 minute dietary education session."
Other sources of bias: limited compliance	The trial authors needed to have reported on the level of compliance in all arms in sufficient detail to determine whether the trial results were robust. We followed a flow chart to make this determination. A statistically significant difference between the intervention and control groups in a body measure of at least 50% of the test fatty acids. Where no body measures were reported then estimated compliance needed to be greater than 64% (proportion complying multiplied by compliance threshold).	Compliance not reported or not in a way that could be interpreted.	Measures of compliance were reported but fell below the appropriate thresholds.
Other sources of bias: other	In the absence of any additional issues this item was coded "low risk of bias"	—	If fraud concerns had been raised and the paper had been withdrawn, or the author had been

Table 1. Risk of bias assessment methods in greater detail (Continued)

found guilty of fraud by a legal or medical entity the paper was excluded from the review. However if fraud concerns were raised, but the journal had not withdrawn the paper, and the author had not been formally sanctioned; then the trial was included in the review, but concerns were raised here, and the risk of bias for this item was high.

CRP: C-reactive protein; **PSA:** prostate specific antigen

Table 2. Meta-regression results for cardiovascular mortality^a

Variable assessed	P value
LCn3 dose	0.21
ALA dose	0.88
Omega-6 dose	0.71
Total PUFA dose	0.78
Duration, months	0.78
Primary or secondary CVD prevention	0.82
Food or capsule	0.27
Risk of bias	0.91
Food or capsule	0.72
+ LCn3 dose	0.37
+ n6 dose	0.99

ALA: alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** polyunsaturated fatty acids

^aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular mortality. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews ([Hooper 2018](#) and [Abdelhamid 2018b](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when $P < 0.10$). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

Table 3. Meta-regression results for cardiovascular events^a

Variable assessed	P value	Coefficient sign where $P < 0.10$
-------------------	---------	-----------------------------------

Table 3. Meta-regression results for cardiovascular events^a (Continued)

LCn3 dose	0.02	Negative (lower CVD event risk with higher LCn3 dose)
ALA dose	0.67	
Omega-6 dose	0.38	
Total PUFA dose	0.29	
Duration, months	0.16	
Primary or secondary CVD prevention	0.76	
Food or capsule	0.30	
Risk of bias	0.17	
Risk of bias	0.19	Negative (lower CVD event risk with higher LCn3 dose)
+ LCn3 dose	0.07	
+ duration	0.19	
LCn3 dose - analysis omitting REDUCE-IT 2019 data	0.99	

ALA: alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** polyunsaturated fatty acids

^aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular events. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews ([Hooper 2018](#) and [Abdelhamid 2018b](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when $P < 0.10$). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

Table 4. Meta-regression results for coronary heart disease deaths^a

Variable assessed	P value
LCn3 dose	0.89
ALA dose	0.94
Omega-6 dose	0.61
Total PUFA dose	0.59
Duration, months	0.79
Primary or secondary CVD prevention	0.97
Food or capsule	0.59
Risk of bias	0.41
Risk of bias	0.60

Table 4. Meta-regression results for coronary heart disease deaths^a (Continued)

+ Food or capsule	0.81
+ PUFA dose	0.68

ALA: alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** polyunsaturated fatty acids

^aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on coronary heart disease mortality. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (Hooper 2018 and Abdelhamid 2018b). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when $P < 0.10$). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

Table 5. Metaregression results for coronary heart disease events^a

Variable assessed	P value	Coefficient sign where $P < 0.10$
LCn3 dose	0.02	Negative (risk of CHD events falls as LCn3 dose increases)
ALA dose	0.18	
Omega-6 dose	0.51	
Total PUFA dose	0.57	
Duration, months	0.16	
Primary or secondary CVD prevention	0.82	
Food or capsule	0.22	
Risk of bias	0.71	
ALA dose	0.36	Negative (risk of CHD events falls as LCn3 dose increases)
+ duration	0.35	
+ LCn3 dose	0.06	
LCn3 dose - analysis omitting REDUCE-IT data	0.81	

ALA: alpha-linolenic acid; **CHD:** coronary heart disease; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** polyunsaturated fatty acids

^aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD events. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (Hooper 2018 and Abdelhamid 2018b). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when $P < 0.10$). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

Table 6. Metaregression results for stroke^a

Variable assessed	P value	Coefficient sign where $P < 0.10$
-------------------	---------	-----------------------------------

Table 6. Metaregression results for stroke^a (Continued)

LCn3 dose	0.12	—
ALA dose	0.73	—
Omega-6 dose	0.23	—
Total PUFA dose	0.09	Negative (lower risk with higher dose)
Duration, months	0.03	Negative (smaller risk with longer duration)
Primary or secondary CVD prevention	0.44	-
Food or capsule	0.36	—
Risk of bias	0.26	—
Duration	0.03	—
+ LCn3 dose	0.06	
+ total PUFA dose	0.15	

ALA: alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** polyunsaturated fatty acids

^aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on stroke. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews ([Hooper 2018](#) and [Abdelhamid 2018b](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when $P < 0.10$). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

Table 7. Meta-regression results for arrhythmia^a

Variable assessed	P value	Coefficient sign where $P < 0.10$
LCn3 dose	0.52	-
ALA dose	0.45	—
Omega-6 dose	0.56	—
Total PUFA dose	0.99	—
Duration, months	0.03	Positive (higher risk with longer duration)
Primary or secondary CVD prevention	0.03	Negative (greater effect with primary prevention)
Food or capsule	1.00	—
Risk of bias	0.65	—
ALA dose	0.33	—
+ Primary secondary prevention	0.42	

Table 7. Meta-regression results for arrhythmia^a (Continued)

+ duration	0.42
------------	------

ALA: alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** polyunsaturated fatty acids

^aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on arrhythmia. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews ([Hooper 2018](#) and [Abdelhamid 2018b](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when $P < 0.10$). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

Table 8. Comparison of the results of long-chain omega-3 interventions in this review with other major recent reviews^a

Systematic review	Balk 2016		Aung 2018		Hu 2019		This review	
Outcome	Number of people experiencing events	RR (95% CI)	Number of people experiencing events	RR (95% CI)	Number of people experiencing events	RR (95% CI)	Number of people experiencing events	RR (95% CI)
All-cause mortality	8480	0.97 (0.92 to 1.03)	-	Not assessed	-	Not assessed	11,297	0.97 (0.93 to 1.01)
Cardiovascular deaths	3799	0.92 (0.82 to 1.02)	-	Not assessed	4630	0.93 (0.88 to 0.99)	5658	0.92 (0.86 to 0.99)
CVD events (MAC-CEs in Balk 2016)	8085	0.96 (0.91 to 1.02)	12,001	0.97 (0.93 to 1.01)	14,694	0.97 (0.94 to 0.99)	17,619	0.96 (0.92 to 1.01)
CHD deaths	-	Not pooled	2695	0.93, (0.83 to 1.03)	2934	0.92 (0.86 to 0.98)	3598	0.90 (0.81 to 1.00)
CHD events	-	Not assessed	6273	0.96, (0.90 to 1.01)	7536	0.95 (0.91 to 0.99)	8791	0.91 (0.85 to 0.97)
Stroke	1467	0.98 (0.88 to 1.09)	1713	1.03 (0.93 to 1.13)	2459	1.05 (0.98 to 1.14)	2850	1.02 (0.94, 1.12)
Arrhythmia	-	Not pooled	-	Not assessed	-	Not assessed	4586	0.99 (0.92 to 1.06)
CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; MACCE: major adverse cerebrovascular or cardiovascular event; RCT: randomised controlled trial; RR: risk ratio								

^aMeta-analysis of effects of long-chain omega-3 in three recent systematic reviews, [Balk 2016](#), [Aung 2018](#) and [Hu 2019](#), comparing their findings with our findings for our primary outcomes.

APPENDICES

Appendix 1. Search strategy 2019

CENTRAL

- #1 MeSH descriptor: [Fish Oils] explode all trees
- #2 MeSH descriptor: [Linseed Oil] this term only
- #3 MeSH descriptor: [Linolenic Acids] this term only
- #4 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
- #5 (fish near/3 oil*)
- #6 (oil* near/3 (cod* or marin*))
- #7 (omega-3 or omega3 or (omega* near/5 fat*))
- #8 eicosapentaen*
- #9 docosahexaen*
- #10 (oil* near/3 (flax* or rapeseed* or canola*))
- #11 (Linolen* or alpha-linolen* or alphalinolen*)
- #12 (perilla* or linseed* or maxepa*)
- #13 (oil* near/3 (rape or colza))
- #14 (marin* near/3 lipid*)
- #15 (naudicelle* or herring* or sild)
- #16 (clupe* near/3 hareng*)
- #17 (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*)
- #18 (salmo* near/3 trut*)
- #19 (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish)
- #20 (thunnus* or swordfish* or xiphias* or dogfish or scyliorhinus*)
- #21 (crab or crabs or (cancer pagarus))
- #22 (DHA or EPA)
- #23 MeSH descriptor: [Salmoniformes] explode all trees
- #24 MeSH descriptor: [Tuna] this term only
- #25 MeSH descriptor: [alpha-Linolenic Acid] this term only
- #26 MeSH descriptor: [Flax] this term only
- #27 (fish near/3 (diet* or capsul* or nutrit* or supplement*))
- #28 (icosapentaen* or docosapentaen*)
- #29 (oil* near/3 (purslane or mustard* or candlenut* or stillingia or walnut*))
- #30 (laks or lax)
- #31 (ALA or DPA)

#32 (algal near oil*)

#33 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 Publication Year from 2017 to 2019

MEDLINE Ovid

1. exp Fish Oils/
2. Linseed Oil/
3. linolenic acids/ or alpha-linolenic acid/
4. Flax/
5. exp Fatty Acids, Omega-3/
6. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
7. (oil* adj3 (cod* or marin*)).ti,ab.
8. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
9. eicosapentaen*.ti,ab.
10. docosahexaen*.ti,ab.
11. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
12. (Linolen* or alpha-linolen* or alphaslinolen*).ti,ab.
13. (perilla* or linseed* or maxepa*).ti,ab.
14. (oil* adj3 (rape or colza)).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorhinus* or laks or lax).ti,ab.
22. (crab or crabs or cancer pagarus).ti,ab.
23. exp salmoniformes/ or tuna/
24. (fish adj3 capsul*).ti,ab.
25. icosapentaen*.ti,ab.
26. docosapentaen*.ti,ab.
27. (oil* adj3 (purslane or mustard* or candlenut* or stillingia or walnut*)).ti,ab.
28. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. randomized.ab.

32. placebo.ab.
33. clinical trials as topic.sh.
34. randomly.ab.
35. trial.ti.
36. 29 or 30 or 31 or 32 or 33 or 34 or 35
37. exp animals/ not humans.sh.
38. 36 not 37
39. 28 and 38
40. limit 39 to ed=20170427-20190213
41. 39 not (1* or 2*).ed.
42. 40 or 41

Embase Ovid

1. exp salmoniformes/ or tuna/
2. fish oil/
3. linseed oil/
4. linolenic acid/
5. Flax/
6. omega 3 fatty acid/
7. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
8. (oil* adj3 (cod* or marin*)).ti,ab.
9. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
10. (eicosapentaen* or icosapentaen*).ti,ab.
11. docosahexaen*.ti,ab.
12. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
13. (Linolen* or alpha-linolen* or alphaslinolen*).ti,ab.
14. (perilla* or linseed* or maxepa*).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorhinus* or laks or lax).ti,ab.
22. (crab or crabs or (cancer adj3 pagarus)).ti,ab.
23. exp salmonine/

24. (fish adj3 capsul*).ti,ab.
25. docosapentaen*.ti,ab.
26. (ALA or DHA or DPA or EPA).ti,ab.
27. (algal adj oil*).ti,ab.
28. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. random\$.tw.
30. factorial\$.tw.
31. crossover\$.tw.
32. cross over\$.tw.
33. cross-over\$.tw.
34. placebo\$.tw.
35. (doubl\$ adj blind\$).tw.
36. (singl\$ adj blind\$).tw.
37. assign\$.tw.
38. allocat\$.tw.
39. volunteer\$.tw.
40. crossover procedure/
41. double blind procedure/
42. randomized controlled trial/
43. single blind procedure/
44. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. (animal/ or nonhuman/) not human/
46. 44 not 45
47. 28 and 46
48. limit 47 to dd=20160721-20170427

ClinicalTrials.com

1. Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation, Suspended, Terminated, Withdrawn, Unknown status Studies | Interventional Studies | omega-3 or "omega 3" OR EPA OR DHA OR eicosapentaen* OR docosahexaen* OR docosapentaen* | Adult, Older Adult | Studies that accept healthy volunteers | Phase 1, 2, 3, 4 | First posted from 09/20/2016 to 08/01/2019.
2. This search was re-run using the term "eicosapentaenoic" in place of the omega-3 string.
3. This search was re-run using the term "fish oil*" in place of the omega-3 string.

ICTRP

(omega-3 or "omega 3" OR EPA OR DHA OR eicosapentaen* OR docosahexaen* OR docosapentaen* OR fish oil*) for intervention (title and condition not limited, including any recruitment status, all phases though run separately, limited to date of registration 20th Sept 2016 to 1st August 2019).

Appendix 2. Medline search strategy 2002 (for the previous version of this review)

1 exp Fish Oils/

2 exp Linseed Oil/
 3 linolenic acids/ or exp alpha-linolenic acid/
 4 exp Fatty Acids, Omega-3/
 5 (fish adj5 (diet\$ or nutrit\$ or oil\$ or supplement\$)).tw.
 6 (oil\$ adj3 (cod\$ or marin\$ or rapeseed\$ or canola\$)).tw.
 7 (omega-3 or omega3).tw.
 8 (eicosapentaen\$ or icosapentaen\$).tw.
 9 docosahexaen\$.tw.
 10 (Linolen\$ or alpha-linolen\$ or alphalinolen\$).tw.
 11 (maxepa\$ or omacor\$).tw.
 12 (trout or kipper\$ or salmon or mackerel\$ or tuna or tunafish or sardine\$ or pilchard\$ or herring\$).tw.
 13 flax\$.tw.
 14 rapeseed\$.tw.
 15 canola\$.tw.
 16 alphalinolen\$.tw.
 17 perilla\$.tw.
 18 linolen\$.tw.
 19 linseed\$.tw.
 20 maxepa\$.tw.
 21 (oil\$ adj3 colza).tw.
 22 (marin\$ adj3 (lipid\$ or oil\$)).tw.
 23 naudicelle\$.tw.
 24 sild.tw.
 25 (clupe\$ adj3 hareng\$).tw.
 26 whitebait\$.tw.
 27 sprat\$.tw.
 28 brisling\$.tw.
 29 (salmo adj3 trut\$).tw.
 30 bloater.tw.
 31 scomb\$.tw.
 32 conger\$.tw.
 33 tunny.tw.
 34 tuna-fish.tw.
 35 thunnus\$.tw.
 36 swordfish\$.tw.
 37 xiphias\$.tw.
 38 dogfish.tw.
 39 scyliorhinus\$.tw.
 40 (crab or crabs).tw.
 41 (cancer adj3 pagurus).tw.
 42 (laks or lax).tw.
 43 exp Flax/
 44 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
 45 randomized controlled trial.pt.
 46 controlled clinical trial.pt.
 47 randomized.ab.
 48 placebo.ab.
 49 clinical trials as topic.sh.
 50 randomly.ab.
 51 trial.ti.
 52 50 or 47 or 51 or 46 or 45 or 48 or 49
 53 (animals not (human and animals)).sh.
 54 52 not 53
 55 44 and 54
 56 (20\$ not (2000\$ or 2001\$)).ed.
 57 55 and 56

Appendix 3. Search strategy 2016 (to update the omega-3 review)

CENTRAL

- #1 MeSH descriptor: [Fish Oils] explode all trees
- #2 MeSH descriptor: [Linseed Oil] this term only
- #3 MeSH descriptor: [Linolenic Acids] this term only
- #4 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
- #5 (fish near/3 oil*)
- #6 (oil* near/3 (cod* or marin*))
- #7 (omega-3 or omega3 or (omega* near/5 fat*))
- #8 eicosapentaen*
- #9 docosahexaen*
- #10 (oil* near/3 (flax* or rapeseed* or canola*))
- #11 (Linolen* or alpha-linolen* or alphalinolen*)
- #12 (perilla* or linseed* or maxepa*)
- #13 (oil* near/3 (rape or colza))
- #14 (marin* near/3 lipid*)
- #15 (naudicelle* or herring* or sild)
- #16 (clupe* near/3 hareng*)
- #17 (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*)
- #18 (salmo* near/3 trut*)
- #19 (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish)
- #20 (thunnus* or swordfish* or xiphias* or dogfish or scyliorhinus*)
- #21 (crab or crabs or (cancer pagarus))
- #22 (DHA or EPA)
- #23 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 Publication Year from 2002 to 2016
- #24 MeSH descriptor: [Salmoniformes] explode all trees
- #25 MeSH descriptor: [Tuna] this term only
- #26 MeSH descriptor: [alpha-Linolenic Acid] this term only
- #27 MeSH descriptor: [Flax] this term only
- #28 (fish near/3 (diet* or capsul* or nutrit* or supplement*))
- #29 (icosapentaen* or docosapentaen*)
- #30 (oil* near/3 (purslane or mustard* or candlenut* or stillingia or walnut*))
- #31 (laks or lax)
- #32 (ALA or DPA)
- #33 (algal near oil*)
- #34 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33

#35 #23 or #34

MEDLINE Ovid

1. exp Fish Oils/
2. Linseed Oil/
3. linolenic acids/ or alpha-linolenic acid/
4. Flax/
5. exp Fatty Acids, Omega-3/
6. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
7. (oil* adj3 (cod* or marin*)).ti,ab.
8. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
9. eicosapentaen*.ti,ab.
10. docosahexaen*.ti,ab.
11. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
12. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
13. (perilla* or linseed* or maxepa*).ti,ab.
14. (oil* adj3 (rape or colza)).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorhinus* or laks or lax).ti,ab.
22. (crab or crabs or cancer pagarus).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. randomized.ab.
27. placebo.ab.
28. clinical trials as topic.sh.
29. randomly.ab.
30. trial.ti.
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animals/ not humans.sh.
33. 31 not 32

34. 23 and 33
35. limit 34 to ed=20020201-20160721
36. exp salmoniformes/ or tuna/
37. (fish adj3 capsul*).ti,ab.
38. icosapentaen*.ti,ab.
39. docosapentaen*.ti,ab.
40. (oil* adj3 (purslane or mustard* or candlenut* or stillingia or walnut*)).ti,ab.
41. 36 or 37 or 38 or 39 or 40
42. 33 and 41
43. 35 or 42

Embase Ovid

1. exp salmoniformes/ or tuna/
2. fish oil/
3. linseed oil/
4. linolenic acid/
5. Flax/
6. omega 3 fatty acid/
7. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
8. (oil* adj3 (cod* or marin*)).ti,ab.
9. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
10. (eicosapentaen* or icosapentaen*).ti,ab.
11. docosahexaen*.ti,ab.
12. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
13. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
14. (perilla* or linseed* or maxepa*).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorhinus* or laks or lax).ti,ab.
22. (crab or crabs or (cancer adj3 pagarus)).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. random\$.tw.

25. placebo\$.tw.
26. (doubl\$ adj blind\$).tw.
27. (singl\$ adj blind\$).tw.
28. double blind procedure/
29. randomized controlled trial/
30. single blind procedure/
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. (animal/ or nonhuman/) not human/
33. 31 not 32
34. 23 and 33
35. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016*).dd,em.
36. 34 and 35
37. exp salmonine/
38. (fish adj3 capsul*).ti,ab.
39. docosapentaen*.ti,ab.
40. (ALA or DHA or DPA or EPA).ti,ab.
41. (algal adj oil*).ti,ab.
42. 37 or 38 or 39 or 40 or 41
43. 33 and 42
44. 36 or 43

Appendix 4. Search strategy 2017 (for allied reviews)

These searches were developed and run to collect relevant trials for the systematic reviews on omega-6 fats (the update of [Hooper 2018](#)) and on total polyunsaturated fatty acid (PUFA) fats ([Abdelhamid 2018b](#)) on health. They are shown here as these searches were run with the searches for this review, the identified titles and abstracts de-duplicated and combined, so that we assessed titles and abstracts for all three reviews together. These searches were each run from database inception, due to the widening of the inclusion criteria, then de-duplicated with each other. The RCT filter for MEDLINE is the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, we applied terms as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Lefebvre 2011](#)).

CENTRAL

- #1 MeSH descriptor: [Fatty Acids, Essential] explode all trees
- #2 MeSH descriptor: [Fatty Acids, Unsaturated] this term only
- #3 ((polyunsaturat* or poly-unsaturat*) near/3 fat*)
- #4 (poly* adj4 unsat* near/4 fatty acid*)
- #5 PUFA
- #6 MeSH descriptor: [Fatty Acids, Omega-6] explode all trees
- #7 omega-6
- #8 (n-6 near/4 acid*) or ("n 6" near/4 acid*)

#9 linoleic acid*

#10 MeSH descriptor: [Corn Oil] this term only

#11 MeSH descriptor: [Cottonseed Oil] this term only

#12 MeSH descriptor: [Olive Oil] this term only

#13 MeSH descriptor: [Safflower Oil] this term only

#14 MeSH descriptor: [Sesame Oil] this term only

#15 MeSH descriptor: [Soybean Oil] this term only

#16 ((corn or maize or mazola) near/4 oil*)

#17 (cottonseed* or (cotton next seed*))

#18 (olive near/4 oil*)

#19 (safflower near/4 oil*)

#20 (sesame near/4 oil*)

#21 ((soy bean or soybean) near/4 (oil* or fat*))

#22 (so?a near/4 oil*)

#23 so?aoil*

#24 (soy near/4 oil*)

#25 (sunflower near/4 oil*)

#26 helianth*

#27 (grapeseed near/4 oil*)

#28 (canola near/4 oil*)

#29 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28

MEDLINE Ovid

1. exp fatty acids, essential/

2. fatty acids, unsaturated/

3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.

4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.

5. PUFA.ti,ab.

6. exp fatty acids, omega-6/

7. omega-6.ti,ab.

8. (n-6 adj4 acid*).ti,ab.

9. linoleic acid*.ti,ab.

10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/

11. ((corn or maize or mazola) adj4 oil*).ti,ab.

12. (cottonseed* or (cotton adj seed*)).ti,ab.

13. (olive adj4 oil*).ti,ab.
14. (safflower adj4 oil*).ti,ab.
15. (sesame adj4 oil*).ti,ab.
16. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
17. (so?a adj4 oil*).ti,ab.
18. so?aoil*.ti,ab.
19. (soy adj4 oil*).ti,ab.
20. (sunflower adj4 oil*).ti,ab.
21. helianth*.ti,ab.
22. (grapeseed adj4 oil*).ti,ab.
23. (canola adj4 oil*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34

Embase Ovid

1. exp essential fatty acid/
2. unsaturated fatty acid/ or docosapentaenoic acid/ or omega 6 fatty acid/ or polyunsaturated fatty acid/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. omega-6.ti,ab.
7. (n-6 adj4 acid*).ti,ab.
8. linoleic acid*.ti,ab.
9. edible oil/ or canola oil/ or corn oil/ or cotton seed oil/ or olive oil/ or safflower oil/ or safflower oil plus soybean oil/ or sesame seed oil/ or soybean oil/ or sunflower oil/
10. ((corn or maize or mazola) adj4 oil*).ti,ab.

11. (cottonseed* or (cotton adj seed*)).ti,ab.
12. (olive adj4 oil*).ti,ab.
13. (safflower adj4 oil*).ti,ab.
14. (sesame adj4 oil*).ti,ab.
15. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
16. (so?a adj4 oil*).ti,ab.
17. so?aoil*.ti,ab.
18. (soy adj4 oil*).ti,ab.
19. (sunflower adj4 oil*).ti,ab.
20. helianth*.ti,ab.
21. (grapeseed adj4 oil*).ti,ab.
22. (canola adj4 oil*).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. double blind procedure/
25. single blind procedure/
26. randomized controlled trial/
27. ((double* or single*) adj blind*).ti,ab.
28. (random* or placebo*).ti,ab.
29. 24 or 25 or 26 or 27 or 28
30. (animal/ or nonhuman/) not human/
31. 29 not 30
32. 23 and 31

FEEDBACK

Interpretation of effect estimates, 18 July 2018

Summary

I am not clear how the quoted RRs and CIs in the abstract support statements of no effect in one part but statements of effect in another part. It seems that throughout the CIs comprehensively span unity. For example, how is a statement of 'probably reduces risk of CHD mortality' supported by the metrics '(1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs)? That seems like an entirely null result.

Reply

Thank you for your query.

We described the process of deciding whether there was "little or no effect", or a positive or negative effect, in the methods section of the review (under "Summary of findings table").

It was agreed with the World Health Organization (WHO) Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health, who commissioned this review as part of a wider set that an effect size of 8% (either way, so $RR > 1.08$ or < 0.92) in the point estimate of the risk ratio would suggest benefit or harm. Presence or absence of effect is decided on the basis of the pre-stated outcome measure, here RR. This certainty of this finding was assessed through the GRADE process (which is represented in the Summary of Findings tables).

- Wide confidence intervals lead to downgrading for imprecision,

- changes in results in sensitivity analyses lead to downgrading for risk of bias,
- skewed funnel plots or knowledge of quantities of missing data lead to downgrading for publication bias,
- heterogeneity of results (high I^2) lead to downgrading for inconsistency, and
- limited representativeness of included populations lead to downgrading for indirectness.

We used absolute risk or NNTB to describe the scale of effect where an effect was suggested – this could be large or small (all in this review were very small).

You are absolutely correct in pointing out that this means that ALA intake probably makes little or no difference to CHD mortality. We apologise for this confusion, which resulted from us using an earlier cut-off of 7% to consider effectiveness. The effect for CV events is still “ALA intake may reduce the risk of cardiovascular events but by a very small amount (from 4.8 to 4.7%)” even though the effect is RR 0.95 (95% CI 0.83 to 1.07) as the sensitivity analysis limiting to studies at low summary risk of bias suggested a 9% reduction in risk (RR 0.91, 95% CI 0.79 to 1.04, $I^2 = 0\%$). Effects of ALA on arrhythmia are clearer (main analysis suggests RR 0.79, 95% CI 0.57 to 1.10, moderate-certainty evidence).

This finding has now been corrected in the review.

Thank you for your keen eye! We hope this clarifies how decisions were made and effects expressed within the review (and the review series).

Contributors

Feedback submitted by: Bruce Neal

Response by Lee Hooper, contact author of review, and Bill Cayley, feedback editor of Cochrane Heart

Dosing and conclusions, 19 July 2018

Summary

Most of the CVD OR ranges listed for LCn3 data showed zones of significant OR benefit. No dosing information was included. I question the study's "conclusions", and believe that a more sensitive analysis of the data could easily show benefit in terms of CVD risk reduction.

Reply

Thank you for your comments, and your attention to the question of dosing. While with any intervention it certainly might seem plausible that a higher dose would be more likely to show benefit than a lower dose, this was not borne out in the studies that met inclusion criteria for this Review. As outlined in the Summary of Findings Tables, and summarized in the Abstract, the authors “found no evidence of dose-response or duration effects for any primary outcome, but there was a suggestion of greater protection in participants with lower baseline omega-6 intake across outcomes.”

Contributors

Feedback submitted by: TR Morris

Response by Lee Hooper, contact author of review, and Bill Cayley, feedback editor of Cochrane Heart

Effect of study duration, 26 November 2019

Summary

I think it's incorrect to determine mortality as the percentage of patients who died during the considered studies (e.g., 9% for patients taking long chain omega 3, according to the article). Since those studies have different lengths (from 12 to 72 months), patients from long studies are expected to die with much higher rate, than patients from short studies. Long studies will contribute toward increasing the mortality metric, while short studies will decrease it. Instead, I suggest normalizing mortality by study duration. For example, let's take 1 month as a unit of duration. Then, if a study lasted 24 months and had mortality rate 3%, that is living rate of 97%, or 0.97, you calculate average living rate per month as $0.97^{(1/24)} \approx 0.99875 = 99.875\%$, and you use $100\% - 99.875\% = 0.125\%$ as average mortality rate per month in this study.

Reply

Thank you for your comments on the duration of our included trials. Outcome risk does differ between included trials and depends on baseline risk as well as trial duration, but this is not necessarily true of relative risk, our outcome measure. To assess duration effects, as well as effects of dose, baseline risk, intervention type, replacement, statin use, baseline triglyceride levels or diabetic status, we carried out extensive sub-grouping and meta-regression. We found no suggestion of consistent duration effects in either sub-grouping or meta-regression for either LCn3 or ALA except for effects of LCn3 on stroke, where longer trials suggested a smaller effect size in meta-regression (this was not clear in sub-grouping), and longer trials showed increased risk of arrhythmia with increased LCn3 in sub-grouping and meta-

regression. These sub-grouping and meta-regression results are all discussed in the results section of the review. We believe that this accounts appropriately and fully for duration effects within the systematic review.

Contributors

Feedback submitted by: Philip Blagoveschensky, Data Science Masters student, Skoltech

Response by Lee Hooper, contact author of review, and Bill Cayley, feedback editor of Cochrane Heart

WHAT'S NEW

Date	Event	Description
11 October 2019	New citation required and conclusions have changed	Seven new trials (six of LCn3, one of ALA) added to included trials (of which six were moved from ongoing trials), and seven new ongoing trials added. Addition of these included trials boosts numbers of included participants by over 30%. The 86 included RCTs randomised 162,796 participants to trials of at least 12 months' duration. The updated evidence suggests that increasing LCn3 slightly reduces CHD mortality and CHD events (previously the evidence suggested little or no effect). Our understanding of effects of LCn3 on other outcomes, and of ALA on all outcomes, has not altered.
21 September 2019	New search has been performed	Electronic searches updated to February 2019, trials registry searches to July 2019.

HISTORY

Protocol first published: Issue 2, 1999

Review first published: Issue 4, 2004

Date	Event	Description
28 November 2018	New citation required but conclusions have not changed	The amendments did not change our conclusions.
28 November 2018	Feedback has been incorporated	We have responded to feedback by two parties.
28 November 2018	Amended	Effects of alpha-linolenic acid on coronary heart disease mortality now correctly interpreted as "little or no effect" as effect size was < 8%. Effects of long-chain omega-3 and alpha-linolenic acid on serum high-density lipoprotein reinterpreted as "little or no effect" as changes were < 5% of baseline. Study flow corrected.
13 March 2018	New citation required and conclusions have changed	This update now reports arrhythmia (atrial fibrillation) and cardiovascular mortality data. Data now included from 79 RCTs (112,059 participants) lasting at least one year, of which 25 were at low summary risk of bias. We added the following outcomes to the list of primary outcomes upon the request of World Health Organization (WHO) Nu-

Date	Event	Description
		<p>trition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health.</p> <ol style="list-style-type: none"> 1. Cardiovascular mortality. 2. Arrhythmia (new and recurrent). <p>We altered inclusion criteria to include only RCTs of at least 12 months' duration (rather than 6 months as previously), and we excluded cohort studies.</p> <p>We are assessing effects of long-chain omega-3 fats separately from effects of alpha-linolenic acid (as planned in the previously published version).</p>
27 April 2017	New search has been performed	Electronic searches updated to 27 April 2017
14 March 2012	Amended	Additional tables re-numbered
16 October 2011	New search has been performed	<p>Searches updated to July 2011.</p> <p>Cohort studies not included in this update, and previously included cohort studies and related text have been removed.</p> <p>Previously included trials where we know that no deaths or primary or secondary health events occurred were removed.</p> <p>New secondary outcomes added (fatal and non-fatal arrhythmias, and diabetes)</p> <p>Cardiovascular mortality added as a primary outcome.</p>
9 September 2008	Amended	Converted to new review format.
1 August 2004	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

LH and CDS conceived and led the original version of this review; LH, CDS, HM and HWV were authors of the original version of this review. LH designed the searches, and CB developed, refined, ran and de-duplicated them. ASA, TJB, JSB, PB, GCT, KHOD, HWV, FS and LH screened titles and abstracts; ASA, JSB, PB, GCT and LH assessed full-text papers for inclusion; LH, PB and JSB searched trials registers and assessed entries for inclusion; LH and ASA located full texts, managed assessment and collection of titles, abstracts and full texts, data extraction and 'Risk of bias' assessment. All authors carried out data extraction and assessed risk of bias. LH, KHOD and JSB designed 'Risk of bias' assessment; JSB, KHOD, TJB, ASA and LH wrote to trial authors; LH, KHOD, JSB, TJB and ASA carried out data checks; JSB, TJB, LH and ASA tabulated intake and status data. FS, KHOD, JSB, HWV, CDS and LH provided methodological support. ASA, FKA and LH entered data into Review Manager 5 and ran meta-analyses, ASA and LH carried out sensitivity and subgroup analyses, and LH the meta-regression. ASA wrote the first draft of the review and LH the WHO NUGAG Subgroup on Diet and Health report; both carried out GRADE assessment and interpretation. All authors critically read and commented on the final draft and agreed on it for submission.

DECLARATIONS OF INTEREST

ASA: none known
TJB: none known
JSB: none known
PB: none known
GCT: none known
HJM: none known
KHOD: none known
FKA: none known

CDS: none known
HVW: none known
FS: none known
LH: none known

SOURCES OF SUPPORT

Internal sources

- University of East Anglia, UK.

External sources

- World Health Organization Nutrition Guidance Expert Advisory Group (NUGAG), Other.
WHO NUGAG Subgroup on Diet and Health requested and funded the update and extension of this review.
- This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Heart. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health and Social Care, UK.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The differences between the protocol and this update were detailed in the previous update ([Abdelhamid 2018a](#)).

We have also added two sets of post-hoc subgroups recently requested by the World Health Organization (WHO), assessing whether baseline triglyceride or baseline diabetes status affect the primary outcomes. This is in response to a current debate (following publication of [REDUCE-IT 2019](#)) on whether beneficial effects are specifically seen in participants with raised triglycerides. We carried out these new subgroups for effects of long-chain omega-3 on primary outcomes, and we would have carried them out for effects of alpha-linolenic acid on primary outcomes, except that no included trials of alpha-linolenic acid were of people with raised triglycerides or with diabetes or risk factors.

INDEX TERMS

Medical Subject Headings (MeSH)

*Dietary Supplements; Arrhythmias, Cardiac [epidemiology]; Cardiovascular Diseases [diet therapy] [mortality] [*prevention & control]; Cause of Death; Coronary Disease [mortality]; Docosahexaenoic Acids [therapeutic use]; Eicosapentaenoic Acid [therapeutic use]; Fatty Acids, Omega-3 [adverse effects] [*therapeutic use]; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke [epidemiology]; Treatment Outcome; alpha-Linolenic Acid [therapeutic use]

MeSH check words

Adult; Humans